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Abstract   
ABSTRACT 
 
The Ireland-Claisen rearrangement is a powerful synthetic tool which allows predictable 
diasterocontrol and chirality transfer in the synthesis of γ,δ-unsaturated carboxylic 
acids. Previous work within the Carbery group has developed a novel protocol for the 
synthesis of β-alkoxy- and aryloxy-α-amino acids. 
 
Chapter 2 covers the initial volume of work on developing this methodology further to 
allow the synthesis of sterically congested α-quaternary carbon centres in β-alkyoxy- 
and aryloxy-α-amino acids. Individual substrate optimisation allowed improvement of 
both the yields and diastereoselectivity of this rearrangement, along with the isolation of 
a key degradation product. A series of heteroproline-based rearrangements laid the 
groundwork for remote chirality transfer within this Ireland-Claisen rearrangement. 
 
The principle of self-regeneration of stereocentres is applied in an Ireland-Claisen 
context in Chapter 3. Showing exceptional levels of remote stereocontrol the 
rearrangement is shown to be general, offering almost exclusively diastereoselectivities 
of >99:1. Allylic enol ether amino esters saw yields of 47 – 83% and provided 
functional handles allowing for further synthetic manipulations.  Carbon substituted 
allyl amino esters allowed facile access into β-hydroxy-α-amino acid derivatives of 
proteinogenic amino acids leucine and isoleucine (amongst others) with excellent 
selectivity. 
 
The synthesis of both enantiomers of mycestericin G in Chapter 4 highlights the 
synthetic utility of this methodology, in addition to allowing a revision of absolute 
configuration of this natural product. The synthesis of a mycestericin G analogue, 
derived from threonine, is also presented. 
 
Finally, Chapter 5 exploits these rearrangement products as chiral diene ligands in 
rhodium-catalysed conjugate addition reactions. Both ligand and reaction condition 
optimisation led to a range of aryl boronic acids used in the 1,4-addition to 2-
cyclohexenone with yields of 24 – 100% and enantioselectivities of 74 – 93% observed. 
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Chapter 1  Introduction 
1. INTRODUCTION 
1.1 β-Hydroxy-α-Amino Acids 
 
Compounds that contain both amine and carboxylic acid functional groups are classed 
as amino acids. They can vary in the number of carbon linkers between the functional 
groups, and are typically identified by this linkage; α-amino acids feature the amine and 
carboxylic acid bonded to the same α-carbon, whilst β-amino acids feature a chain of 
two carbons separating these groups (Figure 1). 
 
 
Figure 1 - α- and β-Amino acids 
There are twenty natural proteinogenic amino acids that are found within proteins that 
are coded for in the genetic code.1 Proteinogenic means ‘protein-building’, and it is 
these twenty amino acids that make up the proteins and peptides that are vital for life.1-2 
Two of these proteinogenic amino acids (threonine and serine, Figure 2)  can be further 
classified as β-hydroxy-α-amino acids.3 
 
 
Figure 2 - L-Threonine and L-serine 
Threonine is one of eight essential amino acids. These eight amino acids are so called 
because their synthesis can’t occur within the body, but must be obtained through food 
or other sources.4-5 Serine meanwhile is considered to be a non-essential amino acid, as, 
in healthy adults, it can be synthesised in the body via a condensation reaction between 
glycine and activated formaldehyde. However, this is not the case for patients with poor 
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kidney function, where synthesis may not cover serine requirements, and hence 
supplements are needed.4 
  
Natural products in their own right, β-hydroxy-α-amino acids are also found as 
components of more complex compounds, a significant number of which have 
noteworthy biological activity.6-7 For example, vancomycin and lysobactin demonstrate 
considerable antibiotic activity, while cyclosporine acts as an immunosuppressant 
commonly used clinically to suppress the rejection of transplanted human organs.8-10 
 
 
Figure 3 - Lysobactin11 
Of recent interest is lysobactin (Figure 3), a cyclic depsipeptide which features several 
β-hydroxy-α-amino acid units.  First isolated from a species of Lysobacter 
(ATCC53042), lysobactin shows strong antibacterial activity against methicillin-
resistant Staphylococcus aureus (MRSA).12-13 Although the mode of action for 
lysobactin is not precisely known, data suggests that it may be due to inhibition of 
transglycosylation and its preceding steps of cell wall peptidoglycan synthesis. This 
mode of action is different to that of vancomycin, the usual last resort antibiotic. Indeed, 
the minimum inhibitory concentrations (MICs) ranged between 0.39 to 0.78 μg/mL for 
MRSA and vancomycin-resistant enterococci (VRE), greater than 50-fold lower than 
those reported for vancomycin itself.14 
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1.1.1 Synthesis of β-Hydroxy-α-Amino Acids 
 
Due to their biological importance much effort has been directed towards the synthesis 
of β-hydroxy-α-amino acids.  As a result there are many strategies for their synthesis, 
including Sharpless asymmetric epoxidations15-17, Strecker synthesis18, aza-Claisen 
rearrangements19, Wittig rearrangements8, and a number of aldol reactions20-24, 
including some catalysed enzymatically.6-7, 25 
 
The aldol reaction has received much attention as an efficient route to asymmetric β-
hydroxy-α-amino acids.  One of the simplest strategies involves the use of threonine 
aldolases and serine hydroxymethyl transferases in the enzyme-catalysed asymmetric 
aldol reaction.  Wong et al. were able to exploit L-threonine aldolase (LTA) and D-
threonine aldolase (DTA) with the use of pyridoxal phosphate (PLP) coenzyme to 
activate glycine to react with a range of aldehydes (Scheme 1).6 
 
 
Scheme 1 - Enzymatic synthesis of β-hydroxy-α-amino acids based on D- and L-threonine aldolases 
The kinetically controlled products from LTA were erythro-β-hydroxy-α-L-amino acids 
from aliphatic aldehydes, and the threo isomer with aromatic aldehydes, whilst DTA 
formed threo-β-hydroxy-α-D-amino acids with both aliphatic and aromatic aldehydes.  
A series of studies with respect to the enzyme’s kinetics, specificity and stability, 
among others, found that the enzymes were stable with little loss of activity over a 
period of one week. Overall it was demonstrated that the enzymes accept an extensive 
range of aldehydes as acceptors, allowing a route to either L- or D-α-amino acids, albeit 
with an epimeric mixture at the β-carbinol centre. 
 
A group from Eli Lilly demonstrated the enantioselective synthesis of the oral 
carbacephalosporin antibiotic loracarbef (Lorabid®) from L-erythro-2-amino-3-hydroxy-
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6-heptenoic acid, synthesised by the serine hydroxymethyltransferase (SHMT) 
catalyzed condensation between glycine and 4-pentenaldehyde (Scheme 2).25 
 
 
Scheme 2 - SHMT catalyzed synthesis of β-hydroxy-α-amino acids in the total synthesis of antibiotic 
loracarbef 
The success of enzyme-catalyzed aldol reactions has prompted many groups to examine 
other forms of catalytic aldol reactions as routes into β-hydroxy-α-amino acids.  One 
such group is that of Barbas III et al., where efficient asymmetric aldol reaction of a 
glycine aldehyde derivative utilising organocatalysis using L-proline has been 
developed (Scheme 3).22 
 
 
Scheme 3 - Direct organocatalytic synthesis of enantiometically enriched β-hydroxy-α-amino acids 
Good yields, high diastereoselectivity and excellent enantioselectivity were seen in this 
reaction.  The use of phthalimidoacetaldehyde 1 was key for the reaction, as it allowed 
selective reactivity of the enamine intermediate. For analytical purposes the methyl ester 
was synthesised using trimethylsilyl diazomethane immediately after the oxidation of 
the aldehyde 2 with sodium chlorite. However, the free amino acid was able to be 
synthesised by deprotection of the phthalimide with hydrazine as opposed to 
methylation. 
 
Another highly explored area within aldol based chemistry is using glycinate Schiff 
bases as donors.  
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N
Ph
Ph CO2tBu
nBuLi (1.2 eq)
-sparteine (1.2 eq)
H
O
toluene, -78 °C NH
O
CO2tBu
PhPh OH
N
CO2tBu
Ph
Ph
+
44% threo, 60% ee
5a
22% erythro, 56% ee
5b
4
 
Scheme 4 - Synthesis of β-hydroxy-α-amino acids by (–)-sparteine-mediated aldol addition 
Demonstrated by Molinski et al., addition of isobutyraldehyde to the lithium enolate of 
4 produced a mixture of threo-oxazolidine 5a and erythro-imine 5b (Scheme 4).23  After 
separation by chromatography, analysis by chiral HPLC showed enantioselectivities of 
60% and 56% respectively. These were readily converted to the corresponding β-
hydroxyleucines by hydrolysis-hydrogenolysis. These optically active amino acids were 
required for the configurational analysis of lobocyclamide B, a novel antifungal 
cyclododecapeptide, isolated from Lyngbya confervoides in the Bahamas. 
 
In 1993, Satoshi Omura presented an efficient asymmetric synthesis of all four 
stereoisomers of 3-hydroxyleucine, utilising a Sharpless asymmetric epoxidation and 
benzyl isocyanate-induced epoxide opening as the key steps (Scheme 5).17 
 
OH
PhC(Me)2O2H
Ti(OiPr)4, (+)-(DIPT)
OH
O
6 82%, >95% ee(-)7
NaH
BnNCO
THF,
N
Bn
O
OH
O
+
OH
O
NBn
O
NaH, THF,
(+)8 75%
(+)9
CO2H
O
NBn
O
100%
(-)10
CH2N2
CO2Me
O
NBn
O
KOH
EtOH
CO2H
O
NBn
O
1) 2N KOH
2) H2, Pd(OH)2
OH
NH2
CO2H
87%
(-)11
96%
(-)12
(50% overall yield)
(+)-13
CrO3
H2SO4
H2O
 
Scheme 5 - Synthesis of (2R,3S)-3-hydroxyleucine (+)-13 
The synthetic strategy started with the Sharpless asymmetric epoxidation of 6, affording 
epoxide 7 in 82% yield and greater than 95% ee. A mixture of regioisomeric 
oxazolidinones were formed after treatment with benzyl isocyanate and sodium hydride.  
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After exposure to additional sodium hydride, heterocycle 9 was formed as a single 
product, and subsequent Jones oxidation yielded carboxylic acid 10. The (2S,3S)-isomer 
was synthesised by carbamate deprotection and hydrogenolysis of 10.  Synthesis of the 
(2R,3S)-isomer however required two more steps; diazomethane esterification, followed 
by epimerization and saponification before finishing the synthesis with carbamate 
deprotection and hydrogenolysis to afford (2R,3S)-3-hydroxyleucine in 50% overall 
yield.  The opposite enantiomers were synthesised through the same methodology, 
simply replacing (+)-DIPT with (−)-DIPT in the epoxidation of 6. 
 
The Strecker reaction was employed by Cativiela et al. in their synthesis of (2S,3S)- and 
(2R,3S)-2-amino-3,4-dihydroxybutyric acid (18 and 22 respectively), however they 
required the use of two alternate routes to obtain the two diastereomers (Scheme 6 and 
Scheme 7 respectively).18 
 
 
Scheme 6 - Synthesis of (2S,3S)-2-amino-3,4-dihydroxybutyric acid 18 
Schiff base 15 was prepared by condensation between aldehyde 14 and benzylamine, 
preceding a Strecker reaction to afford 16 in an 88:12 diastereomeric ratio.  The 
diastereomers were readily separable by column chromatography allowing the synthesis 
to continue. Nitrile hydrolysis with simultaneous O-benzyl deprotection with 
hydrochloric acid afforded the N-benzyl amino acid after purification by ion-exchange 
chromatography. Hydrogenolysis in the presence of Pearlman’s catalyst yielded the 
required (2S,3S)-2-amino-3,4-dihydroxybutyric acid 18, with the absolute configuration 
and optical purity being confirmed by literature comparison (Scheme 6). 
  | 6 
Chapter 1  Introduction 
 
Scheme 7 - Synthesis of (2R,3S)-2-amino-3,4-dihydroxybutyric acid 22 
Synthesis of the (2R,3S)- isomer was achieved by diastereoselective cyanide addition to 
14 utilising tin tetrachloride as a Lewis acid. Treatment with trifluoromethanesulfonic 
anhydride, sodium azide and then hydrogenolysis with Pd/C afforded the amino nitrile 
21. Following separation of diastereomers by flash chromatography, acid hydrolysis and 
ion exchange chromatography afforded the (2R,3S)-2-amino-3,4-dihydroxybutyric acid 
22 with a specific rotation matching that in the literature (Scheme 7). 
 
1.2 Sphingosine and Sphingosine-related Metabolites 
 
The term sphingolipid was proposed by Herb Carter in 1947 to describe a complex 
range of lipids in which fatty acids have a simple amide bond to a sphingoid base 
backbone.26-27 This sphingoid base can be further phosporylated, acylated, glycosylated 
or bridged to various headgroups to create the thousands of sphingolipids that have been 
elucidated to this date. The most common long-chain base is sphingosine, first 
discovered by Johann Thudichum in 1884 on the hydrolysis of the three lipids 
sphigomyelin, cerebroside, and cerebrosulfatide.28  
 
OH
NH
O
O
P
O
O O
N
Black: Sphingosine
Red: Phosphocholine
Blue: Fatty acid
Sphingomyelin
 
Figure 4 - Sphingomyelin 
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Sphingolipids are important components of all mammalian membranes, of which 
sphingomyelin is the most abundant (Figure 4). The basic structural units of 
sphingolipids in the human cell typically start from dihydrosphingosine (more 
commonly known as sphinganine); which is synthesised in nature from serine and 
palmitoyl-CoA by serine palmitoyltransferase (SPT). From here it can follow a myriad 
of pathways until the desired sphingolipid is formed.29 Not only do sphingolipids play a 
structural role, but they are also important in cellular regulation and signal 
transmission.29-31 It is now known that sphingolipids are involved in almost every type 
of disease, from being the binding target for bacteria32, to causing the toxicity of 
fumonisins33-34 (a common food contaminant worldwide) through disruption of de novo 
sphingolipid biosynthesis. They are known to be used by cells to coordinate cell 
division and survival in cases of cancer – they even showed chemotherapeutic potential 
in experimental human clinical trials.35-36 The list continues with implications in 
Alzheimer’s disease37-39, and also acting as immunosuppressants.40 As such, 
sphingolipid-based therapeutics is an ever increasing area of interest to researchers who 
are trying to steer a course through the complex mechanisms – and occasional 
contradictory findings –  presented from such a large number of structurally and 
metabolically interrelated bioactive species.29 
 
1.2.1 Isolation and Biology of Sphingosine Analogues 
 
Since sphingosine was discovered by Thudichum, a host of related compounds have 
been isolated. In the early 1970s one such metabolite was discovered almost 
simultaneously by two research groups. In 1971, Dieter Kluepfel isolated the novel 
antifungal compound, myriocin 23 (Figure 5), from Myriococcum albomyces, a 
thermophilic fungus.41-42 They demonstrated that myriocin showed no significant 
antimicrobial activity, but that it did however, show strong antifungal activity in vitro. 
Meanwhile, in 1972, Fabrizio Aragozzini reported the isolation of thermozymocidin, a 
metabolite of the thermophilic mould Mycelia sterilia.43 The structure and properties of 
thermozymocidin were identical to 23. More recently, the culture broths of Melanconis 
flavovirens and Isaria sinclairii have also been found to contain 23.44-45 This family of 
fungi have been used in traditional Chinese medicine as a drug for ‘eternal youth’.46  
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Figure 5 - Potent immunosuppressant, myriocin 
It was however, Fujita et al. who, on isolating 23, realised its potential as a potent 
immunosuppressive agent.45 They found that it suppressed the proliferation of 
lymphocytes in mouse allergeneic mixed lymphocyte reaction, and was 10- to 100-fold 
more potent than cyclosporine A; an immunosuppressive drug approved for use in the 
1980s.47-48 
 
On further analysis of the culture broth of Mycelia sterilia, Fujita et al. were also able to 
isolate and elucidate the structures of a new class of 7 metabolites which they termed 
the mycestericins.49-50 Mycestericin A 24, B 25, and C 26 were reported to be congruent 
to 23 with respect to their polar head group, featuring the same hydroxy group 
substitution and stereochemistry. Mycestericins D 27 through to G 30 lack the 
secondary γ-hydroxy group, and form two pairs of diastereomers. 
 
Figure 6 - Mycestericins A-G 
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Structure activity relationships (SAR) between myriocin 23 and the mycestericins (24-
30) using mouse allogenic mixed lymphocyte reaction in vitro were built to evaluate the 
influence of the structural features of these immunosuppressants.51 It is from similar 
SARs that allowed the derivative fingolimod 31 to be identified (Figure 7). 
 
 
Figure 7 - Fingolimod 
Originally in phase III clinical trials for use in kidney transplants, fingolimod was found 
to have no advantages over the existing standard of care.52-53 However, in two phase III 
trials, it was seen to reduce the rate of relapses in relapse-remitting multiple sclerosis.54 
Now marketed by Novartis as Gilenya™, it is advertised as the “first once-daily pill for 
relapsing forms of multiple sclerosis”.55 Whilst its mode of action in humans is not fully 
understood, it is believed to sequester lymphocytes in the lymph nodes, reducing the 
number that can move to the central nervous system which cause the auto-immune 
responses seen in multiple sclerosis.56 
 
1.2.2 Synthesis of Sphingosine Analogues 
 
Soon after the discovery of myriocin, two groups accomplished the synthesis of chiral γ-
lactones derived from myriocin.57-59 However, it wasn’t until 1982 when Scolastico et 
al. published the first total synthesis of myriocin.60-61 Completed in 15 linear steps D-
fructose 32 was utilised as the chiral synthon (Scheme 8). The key aim was to achieve 
the synthesis of 2-amino-2-deoxy-2-hydroxymethyl-D-mannonic acid 37, from which 
all the key stereocentres would be installed. Hydrocyanation of fructosyl p-tolylimine 
33 afforded two diastereomers, in a 7:2 mixture. Unfortunately the desired (2S)-epimer 
35 was the minor component in this mixture. By subjecting (2R)-epimer 34 to an excess 
of hydrogen cyanide in ethanol-water, partial conversion to the desired diastereomer 
was achieved.  
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Scheme 8 – First total synthesis of myriocin 
Hydrolysis with concentrated hydrochloric acid, before removal of the N-tolyl 
protecting group by hydrogenolysis afforded key amino acid 37. Schotten-Baumann 
conditions gave a poor yield of 38, whereas treatment with excess benzoyl chloride in 
pyridine, followed by methanolysis of the benzoyl ester gave the lactone 38 in 60% 
yield. Initial attempts to perform a sodium periodate oxidation gave rise to an undesired 
hemiacetal dimer. To avoid this dimer, 38 was treated with acetone and catalytic 
sulphuric acid, followed by esterification with benzoyl chloride, before final hydrolysis 
of the isopropylidene acetal afforded the diol 39. Sodium periodate oxidation, 
subsequent sodium cyanoborohydride reduction and tosylation yielded the tosyl lactone 
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41 necessary for coupling to the lithium divinylcuprate 42. This cuprate was synthesised 
in 9 steps from 1-morpholinocyclohexene and, with the use of HMPA as a co-solvent, 
successfully coupled with 41 to afford the protected anhydromyriocin in a relatively low 
yield of 28%. Final hydrolysis of the benzoyl protecting groups provided synthetic (+)-
myriocin 23, indistinguishable from the naturally obtained compound. 
 
Since this initial total synthesis there have been many other attempts to synthesis both 
(+)-myriocin 23, and it’s enantiomer (−)-myriocin.62 Yoshikawa and co-workers also 
looked to utilise a natural carbohydrate as an optically pure starting material, opting to 
start with 2-deoxy-D-glucose, and featuring a modified Darzens reaction as one of their 
key steps.63-64 Highly diasteroselective aldol reactions were employed by both Nagao 
and Lee, with the former using D-valine to synthesise a chiral bislactim ether, and the 
latter using an oxazoline framework as the basis of their approach.65-66 Many 
approaches have focused on epoxide opening, with Hatakeyama et al. using Katsuki-
Sharpless catalytic asymmetric epoxidation to synthesise an enantiomerically pure 
epoxide, opened using Red-Al®.67 Both Deloisy and Rao have also featured epoxide 
opening in their formal synthesis of myriocin.68-69 Chida et al. took D-mannose and 
constructed the quaternary centre using an Overman rearrangement in a 7:1 ratio of 
diastereomers. The most recent synthesis, by Marsden and Jones features the synthesis 
of a quaternary (E)-vinylglycine using an asymmetric deconjugative alkylation of a 
dehydroamino acid, with complete diasteroselective control. The subsequent 
dihydroxylation also proceeded with excellent diastereoselectivities, yielding a 90:10 
mixture of diastereomers. These two key reactions allowed not only the synthesis of 
(+)-myriocin, but also its analogue 2-epi-myriocin.70  
 
To date there have only been a limited number of total syntheses of the mycestericins 
(24-30), with the main interest in the diastereomeric pairs mycestericin D/E (27/28) and 
F/G (29/30). The sole total synthesis of (−)-mycestericin A 24 is by Chida et al. in 
which the Overman rearrangement is utilised to allow access to the key stereochemistry 
required (Scheme 9). This methodology is also applied to the synthesis of 14-epi-
mycestericin A71-72, myriocin 2373 and other sphingosine analogues such as 
lactacystin74-75 and sphingofungin E76).  
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Scheme 9 - The Overman rearrangement in the synthesis of mycestericin A 
Starting from dimethyl L-tartrate 43 the acetonide 44 was formed over 8 steps, with the 
penultimate step a Wittig reaction installing the E-alkene as a single isomer. Treatment 
with trichloroacetonitrile and DBU afforded the trichloroacetimide 45, which was used 
without any further purification. The subsequent Overman rearrangement proceeded 
after heating to 140 °C in xylene in the presence of potassium carbonate. After 48 hours 
the desired trichloroamide 46 was formed in 62% yield, along with its epimer epi-46. 
The desired compound 46 was then used to complete the total synthesis in a further 15 
linear steps. 
 
Whilst there are currently no syntheses for either mycestericin B or C (25 and 26 
respectively), (−)-mycestericin D 27 has been synthesised using an L-threonine aldolase 
catalysed aldol reaction of glycine with 4-benzyloxybutanol (Scheme 10).77-78 This aldol 
reaction gave mixed ratios of the threo- and erythro-β-hydroxy-α-amino acids 
depending on the reaction time. The erythro isomer was the major product when 
reaction times were kept short (90:10 after 5 mins – albeit with a low yield of 18%, 
compared with 40:60 favouring the threo isomer after 15 hours, in 70% yield). A 
compromise was made between selectivity and yield settling on a 68:32 erythro:threo 
ratio, with a 75% yield. In order to affect separation of these diastereoisomers, 
protection by acetylation of the amino group and subsequent methylation of the 
carboxylic acid afforded the separable derivatives 48e and 48t. The enantiomerically 
pure cis-oxazoline 50 was formed in 83% yield, prior to treatment with 
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paraformaldehyde and DBU, followed by acetylation to stereoselectively produce the 
desired acetate 51 in 88% yield.  
 
 
Scheme 10 - L-Threonine aldolase catalysed synthesis of mycestericin D 
The synthesis of mycestericin D was completed in 7 steps. The formal synthesis of 
mycestericin F 29 was also presented, since the catalytic hydrogenation of a natural 
sample of 27 has been previously reported by Fujita et al. to give mycestericin F 29.50 
 
 
Scheme 11 - Hatakeyama's approach towards the synthesis of mycestericin E 
The first reported total synthesis of the mycestericins E and G (28 and 30) was by Fujita 
et al. using a stereoselective acylation based on Seebach’s self regeneration of 
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stereocentres as the key step in forming the quaternary centre.79-80 Hatakeyama et al. 
approached the synthetic challenge of 28 via a cinchona alkaloid-catalysed asymmetric 
Baylis-Hillman reaction and a Lewis acid-promoted cyclisation of an 
epoxytrichloroacetimidate 56 as their key steps (Scheme 11).81 With oxazoline 57 in 
hand a further 5 steps was required to complete the synthesis of (−)-mycestericin E 28 
with an overall yield of 4.7% starting from the achiral aldehyde 52. 
 
Shibasakai et al. used a lanthanum/amide-based ligand system for an asymmetric 
amination as their key step in the synthesis of diastereomers mycestericin F and G (29 
and 30).82  
 
 
Scheme 12 - Shibasaki's synthesis of mycestericin F and G 
After many unsatisfactory attempts at performing the catalytic asymmetric amination, 
and from previous studies, Shibasaki came to the conclusion that a trans-N-H proton as 
seen in the lactam type compound 59 was required for a successful reaction. Stable 
under both acidic and basic conditions, 59 isn’t amenable to β-elimination. 
Consequently the amination proceeded smoothly at room temperature. Decreasing the 
temperature to 0 °C further improved the transformation, affording 61 in 96% yield and 
96% ee. With the aliphatic tail installed, conditions were found to effect the 
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diastereoselective reduction to both 63a and 63b, in both cases with complete 
stereocontrol. The total syntheses were completed by catalytic hydrogenation followed 
by acid hydrolysis, to afford mycestericin F and G (29 and 30) in 10% and 11 % overall 
yield respectively. 
 
1.3 Self-Regeneration of Stereocentres 
 
One of the foundations of organic chemistry rests on the concept that a reaction 
involving an achiral molecule with a prochiral trigonal centre at the site of reactivity 
will result, if none of the reactants or surroundings are chiral, in the formation of a 
statistical mix of enantiomeric products.  That is, a racemic molecule will be produced.  
Even if the intermediate is radical, or anionic, and has a trigonal-pyrimidal geometry it 
will be capable of rapid inversion – especially in acyclic systems.80  
 
 
Scheme 13- Transition states associated with an SN1 reaction. 
Take the example of the sec-butyl free radical reacting with chlorine (Scheme 13).  The 
reaction can take place on either side of the molecule, with the relative rates of the two 
competing reactions the same. Indeed, the two transition states A and B are 
enantiomeric, leading to identical physical properties; including bond angles, lengths 
and also the free energies of formation.  Because of this, the energy of activation will be 
identical with a 50:50 mixture of (R)- and (S)-2-chlorobutane (64a and 64b) being 
formed (Figure 8).83 
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Figure 8 - An achiral intermediate gives enantiomeric transition states with equal activation energies83 
There are examples which, on the face of it, appear to contradict this rule.  The SNi 
substitution of a hydroxyl group with chlorine using thionyl chloride is one illustration 
of this (Scheme 14a).84  In this case, the ion pair does not completely dissociate before 
the concomitant loss of sulphur dioxide to allow the nucleophilic attack of the chloride 
on the same face.  There are even examples of enolates, whereby the only centre of 
chirality is destroyed, which provide exceptions to the rules.  Some of these cases can 
be ascribed to suitably stable enolate intermediates which possess axes of chirality 
(Scheme 14b), whilst others can form aggregates with chiral components in the reaction 
mixture.85-86 
 
 
Scheme 14 - Retention of stereochemistry. a) Decomposition of alkyl chlorosulphites in an SNi manner.84 b) 
Stereoselective trapping of an enolate by a diazooxoketo group with retention of stereochemistry85 
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With the aim to incorporate readily available, simple, chiral compounds into complex 
target molecules, Dieter Seebach developed a method of producing inherently pro-chiral 
enolates of α-amino or α-hydroxy acids which would nonetheless react with 
electrophiles in a manner that afforded enantiomerically enriched products. This 
straightforward but widely applicable principle is known as the self-regeneration of 
stereocentres (SRS) (Scheme 15).87-90  
 
 
Scheme 15 - The principle of self-regeneration of stereocentres. 
SRS follows a highly simple process: the chiral starting material must possess two 
functional groups capable of forming an acetal (or equivalent functional group), and 
contain a single chiral centre.  Acetal formation must occur stereoselectively, as the 
original stereogenic centre is lost during the creation of the intermediate trigonal centre.  
The ensuing reaction with the intermediate is performed diastereoselectively due to the 
existence of chirality in the temporary acetal moiety.  The final stage of the process is 
removal of the acetal leaving the desired product which has undergone a “dissociative, 
enantioselective substitution at a centre of chirality without the need for a chiral 
auxiliary”.80  Whilst obviously requiring an auxiliary in the form of the aldehyde, the 
simplicity and ingenuity of this principle is that it is not a chiral auxiliary, but a 
common, cheap and readily available aldehyde that simply utilises the original chirality 
present in the starting material. 
 
1.3.1 Endocyclic Enolates in SRS 
 
The twenty proteinogenic amino acids and their related α-hydroxy acids, along with 
other similar natural compounds of this class, provide a substantial set of chiral building 
blocks which can be utilised in synthesis using SRS. 
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The acetalisation of α-amino-, α-hydroxy- and α-sulphanylcarboxylic acids generally 
results in the thermodynamic synthesis of the cis-substituted oxazolidinone, 
dioxolanone and thioxolanone.91  Furthermore an imidazolidinone can be synthesised 
from a relevant amino acid amide 65, again under thermodynamic control yielding the 
cis-isomer cis-67.  However, under kinetic control it is also possible to synthesise the 
trans-imidazolidinone trans-67, allowing access to either enantiomeric product from the 
naturally occurring amino acids (Scheme 16).92  Pivalaldehyde is the preferred choice of 
auxiliary, for several reasons. Primarily, the bulky tBu group affords excellent 
diastereoselectivity in both formation of the acetal and subsequent reactions at the 
newly created trigonal centre. Secondly, it creates an unobtrusive singlet in the 1H NMR 
spectra which doesn’t overlay with any other key spectral areas, and thirdly, it is a 
readily available reagent. 
 
 
Scheme 16 - Synthesis of cis- and trans-2-(tert-butyl)-3-methylimidazolidin-4-ones 
With the transient chiral centre now in place the reactive centre can be created.  The 
favoured method for this is using LDA or LHMDS to form the lithium enolate, which 
can subsequently react with a range of electrophiles (Scheme 17).  The imidazolidinone 
enolates are typically stable at temperatures above 0 °C, whereas those of the 
dioxolanones must be kept at low temperatures.  The high diastereoselectivity of the 
reactions are due to the bulky tert-butyl group at the acetal centre shielding one face of 
the enolate, and therefore preventing any reaction with an electrophile from that face. 
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Scheme 17 - α-Alkylation of α-amino, α-hydroxy and α-sulphanylcarboxylic acids and their derivatives using 
SRS 
The final step in the process is hydrolysis to furnish the α,α-disubstituted carboxylic 
acid.  Due to the stability of the new stereocentre it is possible to submit the alkylation 
products to fairly forcing conditions without fear of racemisation. 
 
Whilst typical electrophiles are alkylation reagents, where the only new stereocentre is 
formed at the trigonal centre, symmetrical ketones have also been used (Scheme 18).  
However, the enolate generated has also been used in aldol reactions and with 
unsymmetrical ketones or aldehydes, which introduces a new chiral centre.93 Seebach 
found that moderate to high levels of diastereoselectivity were possible for both 
aromatic and aliphatic aldehydes and unsymmetrical ketones, and that the same pattern 
observed with alkylations is followed, in that the t-butyl group controls the facial 
selectivity. 
 
 
Scheme 18 – Benzylation and reaction with acetone of a dioxolanone through an endocyclic enolate 
The use of SRS with endocyclic enolates has seen use in a variety of total syntheses, the 
first of which was reported by Seebach et al. in 1983 for the total synthesis of (+)- and 
(–)-frontalin in 5 linear steps and an overall yield of 73% starting from lactic acid 
(Scheme 19).94 
 
  | 20 
Chapter 1  Introduction 
 
Scheme 19 - Total synthesis of (R)-(+)-frontalin. 
With cis-72 isolated cleanly, the enolate was reacted with iododimethoxypentane 70 to 
afford the alkylated product 74 as a single diastereomer. The synthesis of (+)-frontalin 
was completed in a further 2 steps 
 
There are many more complex and involved syntheses, such as the synthesis of (+)-
eremantholide (Figure 9).95 The first step in the synthesis is the reaction of the same 
lactic acid enolate 73 with 2,3-dibromopropene, creating a key stereocentre that is 
maintained throughout the rest of the synthesis, which included a novel use of the 
Ramberg-Bäcklund sequence to effect a medium-sized ring contraction.  SRS is also 
used in the total synthesis of (+)-indicine N-oxide by Yamada et al. where by a 
stereochemical illustration was put forward for the outcome of the aldol reaction 
between the dioxolanone and acetaldehyde (Scheme 20).96 
 
 
Figure 9 – Natural products synthesised using SRS. 
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In this instance, once 1,3-allylic strain has been minimised, and approach of the 
acetaldehyde is considered to be opposite to the tert-butyl group, there are two possible 
transition states. Transition state A features a large steric interaction between the 
acetaldehyde and the iso-propyl group of the dioxolanone. This interaction is no longer 
present in transition state B, and as a result is favoured leading to lactone alcohol 79 in a 
52% yield.  Yamada also saw a small amount of product 80 resulting from approach of 
the aldehyde on the same face as the bulky tert-butyl group.  However, the desired 
lactone alcohol 79 was isolatable from its diastereomers after repeated chromatography. 
 
Scheme 20 -Diastereoselectivity seen in the synthesis of (+)-indicine N-oxide 
1.3.2 Bicyclic Enolates in SRS 
 
Another application of the SRS principle is the formation of a bicyclic acetal, with 
subsequent enolisation and then either alkylation, or aldol reaction.  This approach has 
been favoured by many, including Seebach, and has been used in the total synthesis of 
brevianamide B by Williams et al. (Scheme 22), whilst Baldwin et al. used a highly 
erudite refinement of the SRS principle in the total synthesis of (+)-lactacystin (Scheme 
23).97-98 
 
Williams et al. used allylated proline derivative 83, previously reported by Seebach, as 
the starting point for the synthesis of brevianamide B (Scheme 21).88  The condensation 
reaction between proline and pivalaldehyde yields a single isomer of the N,O-acetal 82.  
Subsequent LDA promoted enolisation and reaction with allyl bromide furnished the α-
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substituted proline derivative 83 as a single diastereomer.  Selectivity is due to approach 
of the electrophile on the re face, leaving the electrophile cis to the tert-butyl group, on 
the exo side of the 1-aza-3-oxabicyclo[3.3.0]octane system.  This is in contrast to the 
anti selectivity prevalent in the mono-endocyclic enolates discussed previously. This 
demonstrates the efficiency of the SRS principle, such that it can be used as the formal 
starting material in the total synthesis of natural products. 
 
Scheme 21 - Re facial selectivity in the allylation of a bicyclic N,O-acetal 
Further derivatisation by Williams led to the formation of allylic chloride 84 that was 
then subjected to the key stereoselective intramolecular SN2’ cyclisation which provided 
the remaining stereogenic centre necessary for the completion of brevianamide B. 
 
 
Scheme 22 - Total synthesis of (−)-brevianamide B. 
Baldwin’s synthesis of lactocystin featured an aldol reaction between isobutyraldehyde 
and a bicyclic siloxypyrrole.  The bicyclic oxazolidine 88 was prepared from (R)-
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glutamic acid 87 in three steps following previously reported procedures.99-100 Next 
followed a sophisticated series of elaborations to yield the unsaturated derivative 89 
using methylation and selenenylation/ozonolysis.  Finally, treatment with TBSOTf and 
2,6-lutidine afforded the key siloxypyrrole 90. An aldol reaction led to a 9:1 mixture of 
diastereomers, however, after chromatography the major isomer 91 was isolated in 55% 
yield.  Further derivitisation led to (+)-lactacystin 92 in an overall yield of 7.5% (from 
88) 
 
 
Scheme 23 – Baldwin’s total synthesis of (+)-lactacystin 
1.3.3 Exocyclic Enolates in SRS 
 
All the previous examples of SRS have involved enolates formed within the cyclic 
structure.  However, it is possible, and indeed desirable, to form a system that allows an 
exocyclic enolate to be created whilst retaining the principles of SRS. 
 
It is practical to protect 2,3-diaminopropanoic acid, serine, cysteine and glyceric acid as 
seen in Figure 10. 
 
 
Figure 10 - Protected forms of 1,3-diaminopropanoic acid, serine, cysteine and glyceric acid 
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Treatment with a lithium base allows formation of an exocyclic enolate, which, despite 
the presence of an endocyclic β-leaving group, is relatively stable.  This stability isn’t 
however absolute, and in the case of cysteine the character of the N-acyl group is 
paraamount to its stability; only the enolate formed for the formyl derivative 96 is stable 
enough to undergo alkylation (Scheme 24).101-103 
 
 
Scheme 24 - a) N-ester derivative undergoes facile β-elimination. b) N-formyl derivative successfully undergoes 
alkylation 
Pattenden et al. have made use of these N-formyl thiazolidines in the total synthesis of 
many natural products, such as didehydromirabazole A 99; a cytotoxic alkaloid, and 
(S)-desferrithiocin 100; a ferric ion chelator (Figure 11).102, 104-106 One of their targets, 
thiangazole 101, shows a 100% inhibition of HIV-1 at 4.7 pM, along with no cell 
toxicity.107 Furthermore, it is able to discriminate between HIV-1 and HIV-2. 
 
 
Figure 11 - Didehydromirabazole A, (S)-desferrithiocin and thiangazole 
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These three natural products are all derived from either (R)- or (S)-2-methylcysteine, or 
indeed, feature core segments derived from both. It was essential for these total 
syntheses that a suitable large-scale synthesis of this chiral building block was achieved. 
 
 
Scheme 25 - Large-scale synthesis of (R)-2-methylcysteine 
Thiazolidine 102 was derived from (R)-cysteine methyl ester hydrochloride and 
pivalaldehyde. After formylation, a single diastereomer 103 was formed, allowing for 
stereoselective alkylation using LDA in the presence of DMPU. This methylated 
thiazolidine 104 had an exclusive anti relationship between the methyl and tert-butyl 
groups. Acid hydrolysis furnished the (R)-2-methylcysteine 105, which, for use in the 
total synthesis was methylated and used as methyl ester 106.  
 
As is seen for the endocyclic enolates, high levels of diastereocontrol are seen in the 
exocyclic derivatives. The control provided can be explained using stereochemical 
models (Figure 12).90 
 
 
Figure 12 - Stereochemical model of exocyclic enolates in SRS 
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The N-formyl oxazolidine 107 forms a planar enolate, with the electrophilic attack 
occurring opposite the bulky tert-butyl group giving rise to the trans-oxazolidine 108. 
However, the dioxolane ring 109 is puckered on enolisation allowing the tert-butyl 
group to be equatorial. Now, the dioxolane ring, and the S-tert-butyl group are shielding 
the bottom face of the enolate, hence accounting for the more unusual cis- 
stereochemistry seen in 110. 
 
Whilst there are many examples of the use of alkylations and aldol reactions with 
exocyclic enolates, their use in total synthesis is more limited. However, Corey et al. 
demonstrated its potential in the synthesis of lactacystin (Scheme 26).108 N-Benzylserine 
was used as the chiral starting material to synthesise oxazolidine 111. This was 
deprotonated using LDA with the lithium enolate-lithium bromide complex reacting 
with isobutyraldehyde to afford the enantiomerically pure aldol product 112 in 51% 
yield after recrystallisation. It is worth noting that, in the absence of lithium bromide, 
poor yields and selectivities were seen. The synthesis was completed in a further 13 
steps with an overall yield of 6.2%.  
 
 
Scheme 26 - Corey’s total synthesis of (+)-lactacystin 
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1.3.4 α,β-Unsaturated Carbonyl Compounds in SRS 
 
It is also possible to add new substituents at the position β or γ to the carbonyl in 
addition to those at the α position seen in the previous sections. The same five 
membered acetals are prepared using an aldehyde and the prerequisite chiral starting 
material. These resulting compounds can then be brominated using a radical process 
that shows a preference for the C-H bond adjacent to the carbonyl group over the acetal 
centre. Elimination of HBr then leads to an exocyclic double bond in the case of 
dioxolanones, imidazolidinones and oxazolidinones (Scheme 27a) and endocyclic 
double bonds for oxazolidine and thiazolidine substrates (Scheme 27b). 
 
 
Scheme 27 - Preparation of chiral α,β-unsaturated carbonyl compounds 
These unsaturated compounds are now amenable to a variety of processes, such as the 
Michael addition of nucleophiles, addition of radicals, and cycloadditions. In some 
cases, it is also possible to react with electrophiles via the formation of dienolates. 
 
The oxazoline 117 derived from threonine presents the opportunity for reaction at both 
the β- and the γ-position. Michael addition allows creation of a new quaternary centre as 
a single diastereomer, in a good yield (Scheme 28).109 
 
 
Scheme 28 - Michael addition of a nucleophile to an α,β-unsaturated carbonyl compound 
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Rather than react the oxazoline with a nucleophile, it is also possible for it to undergo γ-
deprotonation to form the dienolate 119. It will now act as a nucleophile itself and 
reaction with benzaldehyde proceeds with a high regioselectivity, along with good 
yields and diastereoselectivity.109 
 
 
Scheme 29 - Dienolate formation and reaction with benzaldehyde 
Roush et al. have used SRS with a Diels-Alder approach in the total synthesis of (−)-
chlorothricolide.110 With proof of principle showing that high diastereoselectivities can 
be obtained, this was applied to the final synthesis in a challenging tandem inter-
intramolecular Diels-Alder reaction under reflux in toluene for 20 hours. HPLC analysis 
of the reaction mixture showed four predominate cycloadducts, in a ratio of 
67:13:10:10. This closely matched the expectations drawn from previous separate 
attempts; with 93:7 observed for the intermolecular reaction111, and 72:19:9 selectivity 
for the intramolecular reaction.112 
 
 
Scheme 30 - Tandem inter-intramolecular Diels-Alder reaction in the synthesis of (−)-chlorothricolide 
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1.4 Pericyclic Reactions 
 
Pericyclic reactions occur through a concerted mechanism via a cyclic transition 
state.113  During pericyclic reactions no intermediates are formed, nor is there any 
change in formal charge.  There are four main classes of pericyclic reactions: 
cycloadditions, electrocyclic reactions, group transfer reactions and sigmatropic 
rearrangements (Figure 13). 
 
 
Figure 13 - Examples of pericyclic reactions 
Pericyclic reactions are described according to the change in σ-bonds in the system.  
Cycloadditions; such as the well known Diels-Alder sees the formation or loss of two σ-
bonds, electrocyclic reactions have a change of one σ-bond, whilst sigmatropic 
rearrangements see the migration of a single σ-bond, with no change in the number of 
σ-bonds. Group transfer reactions are similar to sigmatropic rearrangements in that σ-
bond migration is observed. However, the process is bimolecular, and forms one new σ-
bond, and is hence classified as a separate entity.  
 
1.4.1 Sigmatropic Rearrangements 
 
In a sigmatropic reaction a single σ-bond migrates from one location in a molecule to 
another.  They are assigned a numerical [i,j] classification referring to the number of 
atoms that each sigma terminus has moved.  An example of a [3,3] sigmatropic 
rearrangement is the Cope rearrangement, whilst the rearrangement of 1,3-pentadiene is 
an example of a [1,5] sigmatropic rearrangement (Figure 14). 
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Figure 14 - Numbering of an [i,j] Sigmatropic Rearrangement 
The numbering system starts from either side of the bond being broken or formed.  In a 
sigmatropic rearrangement the molecular formula of the starting material is retained, 
hence complete atom economy is achieved. 
 
1.4.2 Claisen Rearrangement 
 
The Claisen rearrangement was the first example of a [3,3] sigmatropic rearrangement.  
Published in 1912, Rainer Ludwig Claisen showed that heating an allyl aryl ether 121 
produced allyl phenols 122 without any intermediates (Scheme 31).114  The Claisen 
rearrangement is often referred to in the literature as a 3-oxa-Cope rearrangement, 
despite the fact that the first Cope rearrangement wasn’t reported until 1940, 28 years 
after Claisen’s seminal paper.115-116 The Claisen rearrangement, as a “suprafacial, 
concerted, nonsynchronous pericyclic process”, is occasionally considered as an 
intramolecular SN2 alkylation.117   
 
 
Scheme 31 – The aromatic Claisen rearrangement 
There are two categories of the Claisen rearrangement, the aromatic Claisen 
rearrangement, the main focus of the seminal paper, and the aliphatic Claisen 
rearrangement, touched upon briefly in the first paragraph of Claisen’s original paper.  
It is argued that it is the understated aliphatic Claisen rearrangement which has 
stimulated more interest from both a synthetic and mechanistic viewpoint. The aliphatic 
Claisen rearrangement proceeds after heating of an allyl vinyl ether 123 to around 200 
°C, leading to the formation of γ,δ-unsaturated aldehydes 124. 
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Scheme 32 - The aliphatic Claisen rearrangement 
Synthetically the Claisen rearrangement has found good use in total syntheses due to its 
high stereoselectivity, and is used in key steps of such syntheses. The rearrangement can 
proceed through two conformational types of transition states to produce opposite 
diastereomers (Scheme 33).  As the transition states differ in energy, the ratio of 
products obtained reflects the transition state geometry.  Schmid et al. has examined the 
stereochemistry (and rate) of the rearrangement, and found that all 4 of the 
conformational isomers he studied proceeded via the chair-like transition state.118 
 
 
Scheme 33 - Transition States in the Claisen Rearrangement 
Therefore the E,E and Z,Z isomers rearrange to yield the syn diastereomer, whilst both 
the E,Z and Z,E isomers afford the anti diastereomer. 
 
Hurd and Pollack first suggested a cyclic mechanism119 whilst Gajewski and Conrad 
used secondary kinetic deuterium isotope effects to suggest an earlier, reactant-like 
transition state.120-121 This more recent study suggested that the transition state had more 
bond-breaking than bond-making character, with the transition state more closely 
resembling the diradical as opposed to the 1,4-diyl (Scheme 34).  
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Scheme 34 - Nature of the transition state in the aliphatic Claisen rearrangement postulated by Gajewski and 
Conrad 
The Claisen rearrangement has found many uses in organic synthesis, with Paquette et 
al. employing it as their central strategy in the total synthesis of (±)-precapnelladiene 
130 (Scheme 35).122 
 
 
Scheme 35 – Final steps in the total synthesis of precapnelladiene including a key Claisen rearrangement 
They completed the total synthesis in 11 steps, with an overall yield of 20% achieved 
starting from 8α-methyl-bicyclo[3.3.0]octan-2-one.  Conversion of lactone 125 to enol 
ether 126 via the Tebbe reagent, followed by the aliphatic Claisen rearrangement 
proceeded efficiently in 87% yield over the two steps.  The synthesis was concluded by 
forming tosylhydrazone 128, before allowing it to decompose under carbenoid 
conditions based on those developed by Friedman.123  The resultant isomeric mixture 
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was separable by chromatography on silica gel infused with 2% silver nitrate. 
Subsequent isomerisation of 129 allowed final isolation of precapnelladiene 130. 
 
Nature also utilises the aliphatic Claisen rearrangement, in the enzyme-catalysed 
rearrangement of chorismate 131 into prephenate 132 (Scheme 36); a precursor for the 
essential amino acids tyrosine and phenylalanine.124  Chorismate mutase is the key 
enzyme which is responsible for the rate enhancement of approximately one million 
fold compared to the uncatalysed (yet still facile) rearrangement.125  This reaction, is 
one of the few pericyclic reactions in biology and has provided a rare opportunity for an 
understanding to be gained in how such transformations are promoted and accomplished 
in nature. 
 
 
Scheme 36 - Enzyme catalysed rearrangement of chorismate into prephenate 
The aromatic Claisen rearrangement (as seen in Scheme 31) sees the rearrangement of 
allylic aryl ethers to o-allylphenols on heating.  In this rearrangement an allylic shift is 
seen for any substituent α to the ether oxygen, whereby it will finish γ to the ring.  If a 
proton is present in the ortho position then tautomerisation will follow, with the driving 
force being re-aromatisation of the ring.126 
 
 
Scheme 37 - Secondary Cope rearrangement in the aromatic Claisen rearrangement 
If both ortho positions on the ring are substituted (133), then re-aromatisation in this 
fashion is not possible.  Instead, migration of the allylic group to the para position is 
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observed (135).  This second [3,3] sigmatropic rearrangement is an example of the Cope 
rearrangement (Scheme 37). 
 
As is seen for the aliphatic Claisen rearrangement, the aromatic version also finds 
widespread use in total syntheses.  It was used by Vyvyan et al. in the total synthesis of 
(±)-heliannuol C and E, both in 7 steps, with overall yields of 15% and 9% 
respectively.127 The heliannuols, extracted from Helianthus annuus, are a group of 
phenolic allelochemicals that are active against dicotyledon plant species.128  This gives 
them the potential to be used in the agricultural industry for germination inhibition of 
crops such as lettuce and cress.  
 
 
Scheme 38 - Total synthesis of (±)-heliannuol C and E 
Aryl ether 139 required for the aromatic Claisen rearrangement was synthesised in good 
yield via Mitsunobu etherification (70-98%).  The rearrangement itself proceeded 
regioselectively in high yield (81%) at low temperature.  Epoxidation led to a mixture of 
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inseparable diastereomers with a quantitative yield (~1:1.5 dr), which was then used in 
both cyclization reactions.  The first of these, a regioselective 7-endo-cyclization from 
treatment of the epoxide with SnCl4 provided separable benzoxepanes, of which 142 
was the correct diastereomer.  Subsequent deprotection yielded heliannuol C 143.  
Heliannuol E 145 was synthesised using a 6-exo-cyclization, to form 144 followed by 
demethylation.  Use of a stronger base led to problems, with migration of the olefin into 
conjugation with the aromatic ring being observed.  The same demethylation seen for 
heliannuol C was employed as the final step. 
 
1.4.3 Variants of the Claisen Rearrangement 
 
Since the initial publication of the Claisen rearrangement there have been many 
variations reported. Many of these now have their own sub-classes present in the 
literature. Some key examples of these include: 
 
Meerwein-Eschenmoser Claisen rearrangement 
In the Meerwein-Eschenmoser Claisen rearrangement 2-amino allyl vinyl ethers are 
transformed into γ,δ-unsaturated amides.116 First discovered in 1961 by Meerwein it was 
Eschenmoser et al. who first introduced a practical procedure for this rearrangement.129 
In 1964 they described the conversion of allylic and benzylic carbinols to ketene N,O-
acetal intermediates, which then underwent facile [3,3] sigmatropic rearrangement.130-
131 The rearrangement of allenylic carbinol systems has also been reported.132 The 
neutral conditions typically required allows the use of sensitive substrates, provided 
they are thermally stable. 
 
 
Scheme 39 - The first catalytic enantioselective Meerwein-Eschenmoser Claisen rearrangement 
Kozlowski and Linton have recently described the first catalytic enantioselective 
rearrangement, using palladium(II) catalysis (Scheme 39).133  
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Johnson-Claisen rearrangement 
The Johnson-Claisen rearrangement is closely related to the Meerwein-Eschenmoser 
Claisen rearrangement, and proceeds via condensation of an ortho-ester and an allylic or 
propargylic alcohol.134-135 The ketene acetal intermediate 152 rearranges through a [3,3] 
sigmatropic rearrangement to afford a γ,δ-unsaturated ester 153.  
 
 
Scheme 40 - The Johnson-Claisen rearrangement 
Carroll rearrangement 
There are two potential pathways through which the Carroll rearrangement can proceed. 
Both involve the [3,3] sigmatropic rearrangement of β-keto allylic esters into β-
ketocarboxylic acids. Subsequent decarboxylation furnishes γ,δ-unsaturated ketones.  
 
 
Scheme 41 - The Carroll rearrangement 
The first pathway takes place in the presence of base with a high reaction temperature. 
The intermediate enol reacts in a Claisen rearrangement, with subsequent 
decarboxylation.136-137 The second pathway is milder and proceeds through the use of 
palladium(0). In this route, an intermediate allyl cation/carboxylic acid anion 
organometallic complex is formed which undergoes decarboxylation and then addition 
into the π-allylic system.138 By introducing suitable chiral ligands, this pathway allows 
the reaction to proceed in an enantioselective fashion.139 
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Overman rearrangement 
The Overman rearrangement involves either the thermal, or transition metal catalysed 
rearrangement of allylic trichloroacetimidates to afford the corresponding 
trichloroacetamides.140 
 
 
Scheme 42 - The Overman rearrangement 
The allylic trichloroacetimides are easily prepared by treating an allylic alcohol 154 
with trichloroacetonitrile in the presence of catalytic amounts of base. 
 
Aza-Claisen rearrangement 
The aza-Claisen rearrangement sees the replacement of the oxygen atom in a Claisen 
rearrangement for a nitrogen atom. The rearrangement itself is a thermal process, and 
both aromatic and aliphatic substrates can be used. In the aromatic rearrangement some 
product distribution can be seen due to subsequent Cope rearrangement, similar to that 
seen in the Claisen rearrangement. 
 
 
Scheme 43 - The aza-Claisen rearrangement 
A major disadvantage of this rearrangement is the harsh conditions required. However, 
a zwitterionic aza-Claisen variant has been introduced, which allows for a reduction in 
temperature through the use of ammonium or amide enolates (Scheme 44).141-142 
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Scheme 44 - The zwitterionic aza-Claisen rearrangement 
Treatment of allylamine 159 with propionyl chloride results in the formation of an 
acylammonium salt, which is deprotonated to generate the zwitterionic intermediate 
160. Subsequent [3,3] sigmatropic rearrangement generates the desired γ,δ-unsaturated 
pyrrolidine amide 161 in good yield and excellent diastereoselectivity.  
 
1.5 Ireland-Claisen Rearrangement 
 
Introduced in 1972, the Ireland-Claisen rearrangement is a variant of the Claisen 
rearrangement.  It is a [3,3] sigmatropic rearrangement of silyl ketene acetals formed 
from the enolization of allylic esters with a lithium dialkylamide base.143  The resulting 
products are δ,γ-unsaturated carboxylic acids.  As with the Claisen rearrangement, it is 
used towards the synthesis of a diverse range of natural products.  Whilst the first report 
of an ester enolate rearrangement was in 1937 by Tseou and Wang, this, and other 
scattered reports were beset with low yields and the need for high reaction 
temperatures.144-145 Hence none had the success and potential synthetic application as 
the Ireland-Claisen rearrangement.  
 
Ireland and Mueller were able to overcome these previously seen difficulties with the 
use of a lithium dialkylamide base. This allowed efficient enolization at low 
temperatures, whilst silylation of the ester enolate suppressed side reactions such as 
ketene decomposition and Claisen-type condensations. The applicability of the reaction 
was demonstrated in the synthesis of dihydrojasmone (Scheme 45).143 
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Scheme 45 - Synthesis of dihydrojasmone incorporating the first example of the Ireland-Claisen 
rearrangement 
The synthesis of dihydrojasmone featured in Ireland’s seminal paper saw lactone 165 
produced in 70% yield from the allylic ester 162.  Subsequent reduction and then base 
treatment followed to yield the dihydrojasmone 167 with an overall yield of 57%. 
 
The Ireland-Claisen rearrangement is a dynamic tool for the organic chemist due to the 
number of advantages it possesses.  Such benefits include: ease of preparation of the 
allylic esters, allowing for facile access to the reaction substrates; control of the E/Z 
geometry of both the alkene and enolate, allowing for a high level of diastereoselectivity 
(vide infra 1.5.1 Diastereocontrol in the Ireland-Claisen Rearrangement); the high level 
of chirality transfer seen between the allylic stereocentre of the silyl ketene acetal and 
the newly formed stereocentres; and the ability to perform the reaction at low 
temperatures and under basic conditions. In essence, it is a more facile and synthetically 
viable reaction than the analogous Claisen rearrangement. 
 
Ireland has demonstrated numerous total syntheses of natural products using the 
Ireland-Claisen rearrangement as one of the key steps.146-151 In the synthesis of lasalocid 
A, two separate Ireland-Claisen rearrangements were employed with great success. 
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Scheme 46 - Total synthesis of lasalocid A 
The initial rearrangement installed a tertiary centre α to the furan oxygen. This resultant 
dihydrofuran 169 was transformed to furanyl pyran 170.  The second rearrangement, 
under the same conditions as previously used, produced the α-carboxyl quaternary 
centre 171 with good diastereoselectivity and yield.  Further elaboration led to ketone 
172, which was subsequently used in the aldol reaction with the previously prepared 
aldehyde 173. Subsequent hydrogenation furnished the desired lasalocid A 174.  
 
1.5.1 Diastereocontrol in the Ireland-Claisen Rearrangement 
 
The Ireland-Claisen rearrangement proceeds via a highly ordered transition state.  As a 
result of this, there is a preferential stereochemical outcome in favour of either syn 
(threo), or anti (erythro) pentenoic acids from pertinently substituted substrates.  Such 
stereochemistry can be controlled by the geometry of the alkene, and that of the silyl 
ketene acetal.  It is also dependant on the nature of the transition state – namely whether 
it proceeds via a chair-like or boat-like transition state.  It is generally accepted that 
acyclic allyl silyl ketene acetals favour the chair-like transition state, whilst cyclic 
variants tend to prefer the boat-like structure.152-153 
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Whilst the control of the alkene geometry is dealt with during the substrate synthesis, 
the enolate (and hence silyl ketene acetal) geometry is developed in situ.  Ireland 
reported that the ester enolate could be stereoselectively generated based on the 
character of the solvent used.154 Subsequent trapping with a silyl agent (in this case 
TBSCl) produces the silyl ketene acetal. Due to changes in substituent priority between 
the ester enolate and the silyl ketene acetal, all geometries are assigned with respect to 
their silyl ketene acetal derivative. When THF was used as solvent, the E-silyl ketene 
acetal 176 was formed preferentially. However, on using a 23 vol% HMPA/THF 
mixture the Z-silyl ketene acetal 177 was preferentially obtained with the exception of 
phenyl acetates (Table 1). 
 
Table 1 - Solvent control of silyl ketene acetals 
 
Entry R R’ E/Z (THF) E/Z (23 vol% HMPA, THF) 
1 Et Me 91:9 16:84 
2 tBu Me 97:3 9:91 
3 Et tBu 95:5 23:77 
4 Ph Me 29:71 5:95 
 
With the ability to control the conformation of both the alkene and silyl ketene acetal, it 
is possible to predict the stereochemical outcome of rearrangements of acyclic silyl 
ketene acetals. As shown by Ireland, the anti 2,3-dimethyl pentenoic acid isomer 184 
can be obtained in one of two ways: either by the rearrangement of the E-silyl ketene 
acetal of E-crotyl propionate 179; or from the Z-silyl ketene acetal of the Z-crotyl 
propionate 182 with similar levels of diastereoselectivity. The corresponding syn 2,3-
dimethyl pentenoic acid isomer 185 can be achieved from the Z-silyl ketene acetal of E-
crotyl propionate 180; or from the E-silyl ketene acetal of the Z-crotyl propionate 183.  
Diastereoselectivities reported by Ireland ranged from 5:1 to 8:1 (Scheme 47). 
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Scheme 47 - Diastereoselection in the Ireland-Claisen rearrangement 
1.5.2 Glycinates in the Ireland-Claisen Rearrangement 
 
Table 2 - Influence of N-protecting group on glycinate rearrangements 
O
O
N
R' LDA, TMSCl
THF, -75 °C O
O
TMS
N
R
-75 °C to reflux CO2H
N
R
R'R
186a-d 187a-d
60-65%, 9:1 dr
188a-d  
Entry Substrate R R’ Yield (%) dr 
1 186a Boc H 60-65 9:1 
2 186b Cbz H 65 4:1 
3 186c Bz H 65 5.4:1 
4 186d TFA H 58 1.5:1 
 
The Ireland-Claisen rearrangement has been used in the synthesis of α-amino acids by 
Bartlett and Barstow.155  They explored a variety of N-protected crotyl glycinates (186a-
d) using Ireland’s optimized conditions152 (2.1 eq LDA with 2.1 eq TMSCl added at -75 
°C after 10 mins), and whilst both Cbz and benzoyl derivatives rearranged in 
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comparable yield, their diastereoselectivity was generally lower than that observed for 
the Boc analogue (Table 2). 
 
Chiral glycinates have also been utilised in an approach by Saigo and co-workers to 
achieve absolute asymmetric induction.156  The use of an aminoindanol auxiliary in allyl 
glycinate 189 in conjunction with the unusual silylating agent HSiMe2Cl produced a 
98:2 diastereomeric ratio. 
 
 
Scheme 48 - Use of chiral glycinates in the Ireland-Claisen rearrangement 
It was postulated that the E-silyl ketene acetal 190 formed the chair conformation 
shown in order to minimise dipolar interactions.  The allylic alkene can then rearrange 
from the less sterically congested face of the oxazolidine to yield the observed product 
192.  However, based on previous precedent set by related carbamates, it is suggested 
that chelation favours the formation of a Z-silyl ketene acetal 191.157-158  Formation of 
the least sterically hindered conformation would also lead to the observed product 
(Scheme 48). 
 
Chelate Enolate Claisen Rearrangement 
The ester enolate Claisen rearrangement (the Ireland-Claisen rearrangement) found its 
success based on its ability to limit side reactions such as enolate decomposition.  
However, if heteroatoms with free electron pairs (such as oxygen, nitrogen, sulphur) are 
present as either α- or β-substituted esters then chelation to the enolate metal is 
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possible, giving rise to five- (193) and six-membered (194) chelate rings respectively 
with high selectivities with respect to the Z-(O)-enolate formation (irrespective of 
HMPA addition) (Figure 15). 
 
 
Figure 15 - Chelate enolates 
The formation of the chelate results in the stabilisation of the enolate and therefore 
allows a direct rearrangement of the metal enolate.159 Ireland’s silylation and subsequent 
rearrangement is still possible too, albeit with the geometry set up by the chelated 
enolate. 
 
When the allylic esters of N-protected amino acids undergo rearrangement, γ,δ-
unsaturated amino acids are attained.  The first such synthesis was reported by Steglich 
et al. in 1975 (Scheme 49).160 When N-benzoyl amino acid allylic esters 195 were 
treated with dehydrating agents (in this case phosgene) the oxazole intermediate 196 
rearranged readily to the resulting allyloxazolinone 197, with ensuing hydrolysis 
affording the α-alkylated allylic amino acid 198.  As a result of the fixed geometry in 
the oxazole ring, a strong preference for the chair-like transition state is observed, with 
high diastereoselectivity seen as a consequence. 
 
 
Scheme 49 - First synthesis of allylic amino acids by Ireland-Claisen rearrangement 
Kazmaier has been prolific in the area of chelate enolate Ireland-Claisen 
rearrangements.159, 161-169  In 1994 an investigation into the addition of several salts to 
the rearrangement of N-benzyloxycarbonylglycine crotyl ester 199 was conducted 
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(Table 3).166  Rearrangement of the lithiated glycine allyl esters directly was 
unsuccessful, since the rearrangement itself occurs at temperatures at which the enolate 
decomposes.  However addition of metal salts forms stable glycine enolate chelates 
which do not decompose upon warming to room temperature.  Kazmaier found that 
copper(II) and nickel(II) salts formed such stable chelates that the corresponding 
enolates were not reactive enough to undergo the rearrangement (Table 3). 
 
Table 3 - Rearrangements of chelate-bridged glycine ester enolates in the presence of metal salts 
 
Entry MXn Yield (%) dr (syn:anti) 
1 ZnCl2 90 95:5 
2 CoCl2 78 93:7 
3  MgCl2 85 91:9 
4 Al(OiPr)3 75 90:10 
5 Ti(OiPr)4 50 90:10 
6 Me2SiCl2 50 85:15 
7 Me3SiCl 60 83:17 
 
Zinc dichloride (entry 1) proved to afford the best results both with respect to yield and 
diastereoselectivity. The lower yield obtained with the use of tetraisopropylorthotitanate 
(entry 5) was reasoned to be caused by the crotyl ester being transesterified by 
titanium(IV) catalysis.  It is worthwhile also noting the advantage that the metal salts 
provide over the silyl ketene acetals (entries 6 and 7) with increased yields and 
diastereoselectivity observed. 
 
1.5.3 Quaternary Centres in the Ireland-Claisen Rearrangement 
 
Kazmaier et al. extended their research into the formation of α-amino acids using the 
chelate version of the Ireland-Claisen rearrangement by investigating the formation of 
quaternary centres. 
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There are two potential sites for formation of a new quaternary centre in Kazmaier’s 
chelate rearrangement protocol; at the α-carbon (Table 4), and the β-carbon (Table 5). 
 
Table 4 – Synthesis of α-quaternary carbon centers 
 
Entry X R1 R2 R3 Yield (%) de (%) 
1 Cbz H H Me 90 90 
2 TFA Me H Me 84 96 
3 Cbz Et Me H 87 N/A 
4 Cbz iPr Me H 39 N/A 
5 Boc iBu Me H 62 N/A 
6 Cbz CH2Ph Me H 63 N/A 
7 TFA Ph H Me 94 95 
 
α-Alkylated amino acids, containing quaternary centres are an interesting class of 
compounds, chiefly because of their activity as enzyme inhibitors.170  Whilst Steglich’s 
oxazole-based rearrangement is suitable for the synthesis of α-alkylated amino acids, 
Kazmaier furthered the chelate-based rearrangement with an investigation into the 
synthesis of these sterically demanding compounds (Table 4).163, 167 A range of N-
protected amino acids 203 were subjected to Kazmaier’s conditions, and little 
dependence on the protecting group was found. With the exception of the phenylglycine 
derivative (entry 7) the yields are lower than found for the original, unsubstituted 
glycine (entry 1).  These results start to show some of the additional substitution that 
can be applied to the substrates, providing a vast array of potential substitution patterns. 
 
In particular, di-substitution of the olefin provides access to amino acids containing β-
quaternary centres; themselves useful building blocks in the synthesis of natural 
products such as bottromycin A.171  Kazmaier has shown that utilising such olefin 
substitution does indeed provide β-quaternary centres in moderate to good yield (Table 
5).168 
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Table 5 - Synthesis of β-quaternary carbon centres 
 
Entry X R1 R2 MXn 
Yield[a] 
(%) 
ds[b] 
(%) 
ee[b] 
(%) 
1[c] Cbz Me Me ZnCl2 81 N/A N/A 
2[c] Boc               -(CH2)4- ZnCl2 64 N/A N/A 
3[d] TFA Naphthyl Me Al(OiPr)3 70 50 N/A 
4[d],[e] TFA (CH2)2-CH=C(CH3)2 Me Al(OiPr)3 51 98 85 
5[d],[e] TFA Cyclohexyl Me Al(OiPr)3 30 90 86 
6[d],[e] TFA               -(CH2)5- Al(OiPr)3 70 N/A 86 
[a] after methylation   [b] Determined by GC   [c]  3.5 eq LDA   [d]  5.5 eq LHMDS   [e]  2.5 eq Quinine 
 
It has also been shown that by coordinating chiral ligands to the metal centre of the 
intermediate complex it is possible to develop an asymmetric chelate enolate Claisen 
rearrangement (entries 4-6).169 Both acyclic and cyclic substrates were amenable to the 
rearrangement with the six-membered ring affording a good ee when a chiral ligand was 
used (entry 6).  Excellent diastereoselectivity was seen with the geranyl ester (entry 4), 
again with good enantioselectivity when quinine was present.  The addition of the 
quinine results in the formation of a chiral chelated enolate which subsequently 
undergoes rearrangement imparting enantioselectivity in the product.   
 
These results show that by changing the substitution pattern of the substrate both α- and 
β-quaternary centres can be synthesised using the Ireland-Claisen rearrangement and 
that good diastereoselectivities and enantioselectivities are attainable. 
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2. α-QUATERNARY CENTRES IN β-HYDROXY-α-AMINO ACIDS 
2.1 Background 
 
The use of the Ireland-Claisen rearrangement as the key reaction in the synthesis of β-
alkoxy- and aryloxy-α-amino acids has previously been shown by this research 
group.172-173 The rearrangement provides control of the stereocentres formed via the 
geometries of the enolate and alkene, and the tolerance of a large number of 
functionalities allows the final product to be used as a building block in the synthesis of 
natural products and other complex structures.174 
 
The choice of substrate class was derived from two pertinent rearrangements.  The first 
was Ireland’s allylic enol ether 207 which rearranged to give an anti-β-alkoxy acid 
208.153  The second rearrangement was reported by Kazmaier, where he demonstrated 
the rearrangement of allylic amino ester 209 to the syn-allylic amino ester 210 via a 
chelated zinc enolate.166  Subsequent optimisation followed to secure a reliable and 
efficient route to a range of β-alkoxy- and β-aryloxy-α-amino acids 212. 
 
 
Scheme 50 - New Ireland-Claisen route to β-alkoxy- and β-aryloxy-α-amino acids 
It is envisioned that this method can be extended to allow the synthesis of sterically 
congested α-quaternary carbon centres in β-hydroxy-α-amino acids 214 (Scheme 51).  
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This is appealing as the α-substituted β-hydroxy-α-amino acid moieties seen in a 
number of important natural products, such as lactacystin and salinosporamide A, could 
be synthesised from simple substrates using this method. 
 
A range of substrates will be synthesised for an investigation into the effect of 
substituents in the α-position. Furthermore the effect of nitrogen protecting group will 
also be investigated. 
 
 
Scheme 51 - Ireland-Claisen synthesis of α-quaternary centres in β-hydroxy-α-amino acids 
2.2 Phthaloyl Protected Substrates 
 
Based on the initial work towards the synthesis of β-hydroxy-α-amino acids the 
decision to use a phthaloyl protecting group was a natural one.172  It has been shown to 
be effective under the established conditions, and protects both available sites on the 
nitrogen simultaneously.  With an electron withdrawing nature and the ability for 
chelation between the carbonyls and the lithium enolate it should aid in the selective 
silyl ketene acetal formation. 
 
2.2.1 Retrosynthetic Analysis 
 
With a clearly defined aim, and a suitable substrate chosen, it was necessary to establish 
a suitable route to prepare the substrate. It is therefore necessary to apply a 
retrosynthesis back to an easily obtainable precursor and then employ the forward 
synthesis to obtain a suitable quantity of the substrate, and subsequently orchestrate the 
rearrangement to identify the optimum conditions. 
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Figure 16 - Retrosynthetic analysis of phthaloyl protected substrate 
The retrosynthesis takes us to three readily available commercial compounds, where 
variation of the R-substituent is achieved through the use of a variety of α-amino acids.  
Enol ether 218 is prepared via reduction of the vinylogous carbonate 217, which will be 
subjected to carbodiimide coupling conditions with the phthaloyl protected amino acid 
to provide a short route into the desired substrate 220. 
 
2.2.2 Forward Synthesis 
 
Enol ether 218a was synthesised by the DIBAL-H reduction of commercially available 
methyl trans-methoxyacrylate. The methyl ether was chosen due to its simplicity, and 
the commercial availability of the starting vinylogous carbonate.  There have been many 
papers published reporting this synthesis, however, they all state the sensitivity of the 
product, noting that it was difficult to store, hard to purify, and that it was normally used 
in its crude form.153, 175-177 
 
 
Scheme 52 - Reduction of methyl trans-methoxyacrylate 
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Numerous methods of quenching the reaction were detailed across the publications; 
however, quenching at 0 °C with an ethyl acetate and Rochelle’s salt solution afforded 
us the highest yield. 
 
With the enol ether in hand it was necessary to synthesise a range of protected α-amino 
acids 219a-g.  Commercially available α-amino acids 216a-g were protected by 
refluxing in toluene with phthalic anhydride 215 under Dean Stark conditions.  It was 
found that reducing the equivalents of phthalic anhydride used by Jurczak et al. to 1.01 
helped increase the purity and yield of the resultant products.178 Attempts to protect 
serine with phthalimide were, however unsuccessful and resulted in multiple spots by 
TLC, from which the desired product was unable to be isolated. 
 
Table 6 - Synthesis of N-phthaloyl protected Ireland-Claisen substrates 
 
Entry Substrate R Yield of 219 (%) Yield of 220 (%) 
1 216a H N/A[a] 74 
2 216b Me 79 82 
3 216c Et 77 100 
4 216d iPr 94 94 
5 216e nPr 81 70 
6 216f iBu 78 75 
7 216g CH2OH 0 N/A 
[a] Commercially available 
 
Carbodiimide promoted coupling of protected α-amino acids 219 with methoxy enol 
ether 218a lead to the desired substrates 220 in good to excellent yields.  Optimised 
conditions for the coupling reaction proved to be a 2:1 ratio of N-phthaloyl α-amino 
acid to methoxy enol ether, with 2 equivalents of 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDCi.HCl) and triethylamine and a catalytic quantity (≈10 
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mol%) of DMAP.  Increase in the amount of N-phthaloyl α-amino acid used led to a 
small quantity of its anhydride formed which was inseparable from the desired product 
220. 
 
2.2.3 Initial Rearrangement Attempts 
 
With the substrates in hand, the Ireland-Claisen rearrangement was attempted.  It was 
envisaged that the conditions employed for the Ireland-Claisen rearrangement of glycine 
based systems (Scheme 53) would have the same effect with these α-substituted 
derivatives. 
 
N
O
O
O
O
H
OMe
1) TMSCl (1.3 eq), LHMDS (1.3 eq)
THF, -95 °C to 0 °C, 90 mins
2) CH2N2, Et2O
MeO
O OMe
NPhth
220a
74%, 11:1 dr
221a  
Scheme 53 - Rearrangement conditions for non-quaternary centres 
This proved to be the case for the alanine derived substrate 220b only.  It rearranged in 
71% yield with a diastereoselectivity of 24:1.  This promising result showed that 
increasing the size of the group at the α-position (from a proton to a methyl group) had 
a dramatic effect on the selectivity of the reaction (Table 7 entry 1 and 2). 
 
Table 7 - Initial rearrangment attempts 
 
Entry Substrate R Conversion (%)[c] dr (syn:anti) 
1[a] 220a H 100 (74) 11:1 
2[a] 220b Me 100 (71) 24:1 
3[b] 220c Et 44 2.4:1 
4[b] 220d iPr 0 N/A 
5[b] 220e nPr 40 1.1:1 
6[b] 220f iBu 0 N/A 
[a] 90 mins   [b] 18 hours   [c] Product against starting material. Isolated yields in parenthesis. 
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On increasing the steric bulk around the α-position problems started to arise. 
Rearrangement of linear 2-aminobutyric derivative 220c (entry 3) and norvaline 
derivative 220e (entry 5) showed only moderate conversion, even after extended 
reaction times of 18 hours. In addition to the disappointing conversions, the 
diastereoselectivity fell when compared to the glycine (220a, entry 1) and alanine 
(220b, entry 2) rearrangements, with 2.4:1 and 1.1:1 seen respectively. On attempting 
rearrangement of branched substrates no product was seen, with starting material 
returned for both valine derivative 220d (entry 4) and leucine derivative 220f (entry 6). 
It can be proposed that the branched substrates sterically crowd the α-position such that 
either deprotonation, or rearrangement cannot take place. The linear nature of 220c and 
220e are such that whilst affecting the outcome of the reaction, they do not prevent it 
from occurring. 
 
These results, whilst not showing the same success as seen previously still has the 
potential to achieve a successful rearrangement.  A series of optimisations are necessary 
to develop the route further. 
 
2.2.4 Rearrangement Optimisation 
 
2.2.4.1 Optimisation for N-Phthaloyl (E)-3-methoxyallyl 2-aminobutanoate 
 
Methoxyallyl 2-aminobutyric acid derived 220c showed potential for optimisation when 
rearranged under the initial conditions, with a 44% conversion and diastereoselectivity 
of 2.4:1 observed (Table 8, entry 1). Extending the reaction time led to a slight increase 
in conversion (entry 2), as did raising the initiation temperature to -78 °C (entry 4). The 
largest gains were, however, found by increasing the equivalents of LHMDS and 
TMSCl from 1.3 to 2 (entries 2 and 4 compared to entries 3 and 5). High conversions 
were observed, with a diastereomeric ratio of 2.7:1 when conducted at -78 °C.  After 
purification this resulted in a yield of 20%.  A small amount of the parent amino acid 
219c was also observed, isolated as its methyl ester, as an additional 2% of the mass 
returned. The additional mass lost can be postulated to be caused by degredation of the 
enolate prior to silylation. 
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Table 8 - Optimisation for N-phthaloyl 2-aminobutyric acid allyl ester 
 
Entry Temp TMSCl (eq) 
LHMDS 
(eq) 
Time 
(hrs) 
Conversion 
(%)[a] 
dr 
(syn:anti) 
1 -95 °C 1.3 1.3 3 44 2.4:1 
2 -95 °C 1.3 1.3[b] 18 56 2.3:1 
3 -95 °C 2 2 18 96 (19) 2.4:1 
4 -78 °C 1.3 1.3 18 69 2.4:1 
5 -78 °C 2 2 18 95 (20) 2.7:1 
 [a] Product against starting material. Isolated yields in parenthesis.   [b] LHMDS added by hand 
 
2.2.4.2 Optimisation for N-Phthaloyl (E)-3-methoxyallyl 2-amino-3-methylbutanoate 
 
After the initial rearrangement attempt, an optimisation study was undertaken to 
improve rearrangement of the valine derived substrate 220d (Table 9).   
 
Table 9 - Optimisation for N-phthaloyl valine allyl ester 
 
Entry Temp TMSCl (eq) LHMDS (eq) Time (hrs) Conversion (%)[a]
1 -95 °C 1.3 1.3 3 0 
2 -95 °C 2 2 3 0 
3 -95 °C 3 3 3 0 
4 -95 °C then RT 1.3 
1.3          
then 1 18 50 (11) 
5 -78 °C 1.3 1.3 6 15 
6 0 °C 1.3 1.3 6 18 
7 0 °C 4 4 72 100 (12) 
 [a] Conversion stated as product against starting material. Isolated yields in parenthesis. 
 
Increasing the amount of base and TMSCl used, to both 2, and 3 equivalents, had no 
bearing on the outcome of the reaction, with only starting material recovered. On 
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attempting the rearrangement at -95 °C with 1.3 eq, after 3 hours, when TLC showed no 
sign of reaction, a further equivalent of LHMDS was added to the reaction mixture at 
room temperature. This was left to stir overnight, where a conversion of 50% was seen, 
with an isolated yield of 11% (entry 4). The diastereoselectivity of this reaction was 
unable to be determined due to the lack of resolution between the diastereomers in the 
1H NMR.  Further rearrangement attempts were made at -78 °C and 0 °C, and whilst a 
yield of 12% was seen when four equivalents of LHMDS and TMSCl were used, there 
was an additional 27% mass of the parent amino acid (isolated as the methyl ester), 
present as an inseparable mixture. 
 
This investigation into the rearrangement of α-substituted substrates has, so far, only 
used LHMDS. Since a key element in all Ireland-Claisen rearrangements is the base 
used a short study was initiated to investigate further.   
 
 
Scheme 54 - Effect of base on rearrangement of N-phthaloyl valine allyl ester 
The use of KHMDS saw starting material returned, with only a trace amount of product 
seen after several days of stirring.  nBuLi meanwhile returned only starting material 
after stirring for 18 hours, without any sign of product whatsoever (Scheme 54). These 
observations bear some resemblance to the optimisation study previously conducted 
within the group, on the phthaloyl glycine substrate 220a. In those studies, it was found 
that switching from LHMDS to NaHMDS or KHMDS resulted in a significant drop in 
both yields and diastereoselectivity. Furthermore, it was discovered that use of non-
ethereal solvents such as toluene led to an intractable mixture of products.179 
 
During the course of these studies, a publication by Collum et al. detailed LHMDS-
mediated enolization, including the influence of triethylamine on the E/Z selectivity.180 
The conditions detailed in his article have been put to good use in the synthesis of β2,3-
  | 56 
Chapter 2  Results & Discussion   
amino acids within our group, where the standard conditions were failing to provide 
adequate results (Scheme 55).181 
 
 
Scheme 55 - Collum's enolization conditions 
Unfortunately, after attempting these conditions in our rearrangement the complex 
NMR that resulted after work up showed no sign of the desired product, whilst 
significant quantities of starting material could be discerned (Scheme 56). 
 
 
Scheme 56 - Attempted Collum rearrangement of N-phthaloyl valine allyl ester 
Despite many failed rearrangement attempts, we have progressed from a rearrangement 
protocol which saw no sign of any product, and have been able to optimise these 
conditions to synthesise the desired α-quaternary β-hydroxy-α-amino acid in 11% 
yield. However, it appears that the increase in steric bulk is preventing a successful 
reaction from occurring. 
  
2.2.4.3 Optimisation for N-Phthaloyl (E)-3-methoxyallyl 2-aminopentanoate 
 
Norvaline derivative 220e showed some promise for optimisation, with initial 
conditions producing a conversion of 40% and an approximate diastereoselectivity of 
1.1:1 (Table 10, entry 1).  Prolonging the reaction time to 72 hours doubled the 
conversion, with a small increase in diastereoselectivity (entry 2).  A subsequent 
increase in the equivalents of LHMDS and TMSCl further increased the conversion, and 
affords a dr almost double that first seen (entry 3).  Increasing the temperature to -78 °C 
led to an improvement in the conversion and isolated yield when compared to the 
comparative rearrangements at -95 °C (entries 5 and 6 against entry 3). 
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Table 10 - Optimisation for N-phthaloyl norvaline allyl ester 
 
Entry Temp TMSCl (eq) 
LHMDS 
(eq) 
Time 
(hrs) Conversion (%)
[a] dr (syn:anti) 
1 -95 °C 1.3 1.3 3 40 1.1:1 
2 -95 °C 1.3 1.3[b] 72 80 1.4:1 
3 -95 °C 2 2[b] 72 95 (23) 2:1 
4 -78 °C 1.3 1.3 72 95 1.9:1 
5 -78 °C 2 2 72 100 (41) 3:1 
6 -78 °C 2 2[b] 72 100 (45) 2:1 
7 -78 °C 3 3 72 100 1.9:1 
[a] Conversion stated as product against starting material. Isolated yields in parenthesis.   [b] LHMDS added 
via syringe pump at a rate of 3mL/min 
 
On workup and subsequent purification it becomes apparent that a side product is 
present. Identified as the parent amino acid (isolated as the methyl ester PhthN-Nva-
OMe) it is found to have an Rf highly similar to the desired product 221e, which made 
purification difficult. Unfortunately this side product was observed in all rearrangement 
attempts. 19% of PhthN-Nva-OMe was recovered from the rearrangement at -95 °C 
(entry 3), along with 23% of the desired product. On increasing the temperature, and 
adding LHMDS dropwise by hand, 41% of product was obtained, along with 24% of 
PhthN-Nva-OMe (entry 5). Due to the lack of resolved peaks in the 1H NMR it was not 
possible to obtain an accurate diastereomeric ratio from the crude reaction mixture, 
nonetheless, the two diastereomers were separable by column chromatography, whereby 
a ratio of 3:1 was obtained. When a syringe pump was used for the addition, with an 
addition rate of 3mL/min, 45% of rearranged product was obtained, with a much 
reduced 11% of PhthN-Nva-OMe (entry 6).  This time it was possible to obtain a 
diastereomeric ratio of 2:1, from the crude 1H NMR. 
 
2.2.4.4 Optimisation for N-Phthaloyl (E)-3-methoxyallyl 2-amino-4-methylpentanoate 
 
All rearrangement attempts of leucine derivative 220f failed to show any sign of desired 
product. However, along with unreacted starting material, significant quantities of the 
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parent amino acid 219f were recovered (isolated as the methyl ester after treatment with 
diazomethane). These results were seen when using either 2, or 3 equivalents of 
LHMDS at -78 °C, and with reaction times of both 18 and 48 hours. 
 
 
Scheme 57 - Postulated mechanisms for decomposition to parent amino acid 
Whilst there is no conclusive evidence for the mechanism for the formation of the 
parent amino acid, two plausible mechanisms are shown in Scheme 57.  Such 
decomposition was originally seen when a simple N-Boc glycine derivative was being 
used, under Kazmaier’s chelate enolization conditions (LHMDS and ZnCl2).  The 
rationale in the chelate example was the dianionic nature of the intermediate enolate 
(Figure 17). It was argued that the C-Oσ* orbital is overlapped by two highly electron 
rich π-systems, which allow a significant level of electron density to be donated into the 
σ* orbital.173 
 
 
Figure 17 - Possible enolate instability under chelate enolization 
In our scenario however, the additional substitution present may provide enough 
electron density to cleave this C-O single bond. Furthermore, it is likely to help stabilise 
the ketene intermediate. Presumably this decomposition route occurs rapidly, such that 
silylation is unable to take place and prevent it. 
 
2.2.5 Optimal Rearrangements 
 
During the course of the investigation into the rearrangement of N-phthaloyl-α-
substituted-amino acids we have found that as the substituent size is increased the 
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rearrangement becomes far less facile, up to leucine, whereby no rearrangement is seen, 
but rather a complete decomposition of the substrate to the parent amino acid.  It has 
been necessary to acquire different conditions for each amino acid, to obtain optimal 
results (Table 11). 
 
Table 11 - Optimal rearrangement results 
 
Entry Substrate R Temp TMSCl (eq) 
LHMDS 
(eq) Yield (%)
[a] dr 
(syn:anti) 
1 220a H -95 °C 1.3 1.3 74 (100) 11:1 
2 220b Me -95 °C 1.3 1.3 71 (100) 24:1 
3 220c Et -78 °C 2 2 20 (95) 2.7:1 
4 220d iPr -95 °C 1.3 1.3 & 1 11 (50) N/A 
5 220e nPr -78 °C 2 2 45 (100) 2:1 
6 220f iBu -78 °C 2 2 0 N/A 
 [a] Conversions in parenthesis, stated as product against starting material. 
 
There are two potential reasons for the poor results achieved with the larger groups.  
The first of these is the inability of the base to deprotonate the α-proton and hence form 
the silyl ketene acetal.  The second is the inability for the rearrangement to take place 
once the silyl ketene acetal has been formed. The reasoning behind both these 
possibilities lie with steric crowding; it can be seen that the branched chains (entries 4 
and 6) offer poor rearrangements, whilst improved results are obtained with the linear 
substrates (entries 2, 3 and 5), which would present less steric hindrance around the α-
position, hence improving deprotonation, or the ability for the allyl group to approach in 
order to undergo rearrangement. A 3D representation of the silyl ketene acetal for 
substrate 220d shows the iso-propyl substituent crowding the key reaction site (Figure 
18). 
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Figure 18 - 3D representation of the silyl ketene acetal for N-phthaloyl valine allyl ester 
2.3 Boc-N-Me Protected Substrates 
 
It is known, both from within the group and from other Ireland-Claisen rearrangements 
that the nitrogen protecting group can have a large bearing on the success of the 
rearrangement.  As part of an investigation into derivatives of glycine-based substrates 
it has been demonstrated that Boc-sarcosine-methoxyallyl ester 224a undergoes 
rearrangement in 73% yield with a diastereomeric ratio of 2:1 (Scheme 58).173  In the 
course of this previous study Boc-N-Me-alanine derivative 224b had also been found to 
rearrange satisfactorily, in 65% yield and a diastereomeric ratio of 9:1.182  Consequently 
we wanted to attempt the rearrangement with other α-substituted amino acids. 
 
N
O
O
OMe
1) TMSCl (1.3 eq), LHMDS (1.3 eq)
THF, -95 °C to RT
2) CH2N2, Et2O O
MeO
OMe
R N
224a R = H
224b R = Me
Boc
Me
Boc
Me
225a R = H, 73% 2:1 dr
225b R = Me, 65% 9:1 dr
R
 
Scheme 58 - Rearrangement of Boc-N-Me-glycine allyl esters 
2.3.1 Retrosynthetic Analysis 
 
With the new series of substrates identified a new route was needed to prepare them.  
Whilst the synthesis of the allylic enol ether remains the same, protection of the amino 
acid needs to be established. 
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Figure 19 - Retrosynthetic Analysis of Boc- N-Me Protected Substrate 
The forward route requires the protection to take place in two steps, namely Boc 
protection of the amino acids, followed by N-methylation. 
 
2.3.2 Forward Synthesis 
 
With the proposed route in place the first step – Boc protection – took place in 
quantitative yield. N-Boc valine 226d was carried forward in its crude form to the 
alkylation using methyl iodide and sodium hydride, in DMF.  However, despite 
following a literature procedure, the result was an intractable mixture of starting 
material and impurities (Scheme 59).183 
 
 
Scheme 59 - Initial synthetic attempt 
It was reasoned that the methylation might proceed more successfully if the carboxylic 
acid was protected as the methyl ester.  A new synthesis was therefore designed 
(Scheme 60 and Scheme 61).  Initial esterification proceeded in an excellent yield of 
90%.  A variety of conditions were investigated for the subsequent Boc protection.  
Using sodium hydroxide as the base resulted in hydrolysis of the methyl ester, so 
triethylamine was used instead.  By performing the reactions in water, lower yields were 
seen, in part due to partial water solubility of the product, requiring multiple extractions.  
Performing the reaction in THF presented a simple workup; concentration in vacuo, and 
then purification by flash chromatography.  The single disadvantage was long reaction 
times of 96 hours to attain high yields of the Boc protected amino esters 229d and 229e. 
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Scheme 60 - Revised synthetic route 
The methylation that followed occurred in good yield when using sodium hydride and 
methyl iodide in DMF.  This route avoided the large amounts of both sodium hydride 
and methyl iodide that were used in the previous unsuccessful attempt.  Ensuing 
hydrolysis with lithium hydroxide afforded the desired Boc-N-Me-valine 227d and Boc- 
N-Me-norvaline 227e in 96% and 86% yields respectively.  
 
 
Scheme 61 - Synthesis of N-Boc N-Me protected amino acids 
The final stage of the synthesis was carbodiimide promoted coupling of protected amino 
acids 227d-e with allylic enol ether 218a, which proceeded in good yield for valine 
derived substrate 231d (Scheme 62). It did however give a disappointing yield of N-
Boc-N-Me-norvaline allyl ester 231e. This was however, in part, due to partial 
decomposition whilst undergoing purification by flash chromatography. 
 
 
Scheme 62 – Completion of substrate synthesis 
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2.3.3 Rearrangement Attempts 
 
Initial efforts concentrated on Boc-N-Me-valine allyl ester 111a.  As was the case with 
N-phthaloyl valine, the original conditions resulted only in starting material being 
recovered. 
 
Table 12 - Optimisation of N,N-Boc,Me valine allyl ester 
 
Entry Substrate Temp TMSCl (eq) 
LHMDS 
(eq) Base 
Time 
(hrs) 
Conversion 
(%)[a] 
1 231d -95 °C 1.3 1.3 LHMDS 3 0 
2 231d -78 °C 2 2 LHMDS 3 0 
3 231d 0 °C 2 2 LHMDS 3 0 
4 231d -78 °C 2 2 KHMDS 5 0 
5 231e -78 °C 2 2 & 1 LHMDS 18 0 
 [a] Conversion stated as product against starting material. Isolated yields in parenthesis.    
 
Increasing the temperature and the equivalents of base and TMSCl had no effect, and 
switching to the base KHMDS made no difference to the overall result (Table 12). 
 
Since more success had been seen for the rearrangement of the N-phthaloyl norvaline 
allyl ester 220e over the valine derivative 220d, it was decided to attempt the 
rearrangement of the analogous Boc-N-Me-norvaline allyl ester 231e (Table 12).  
However, this failed to rearrange at -78 °C with 2 equivalents of LHMDS, and even an 
additional equivalent of base at room temperature failed to provide any conversion. 
 
Since this series was showing little potential it was decided to focus on other areas of 
chemistry which showed more signs of promise. 
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2.4 Heteroproline Derived Substrates 
 
Earlier attempts to protect serine with phthalimide had been unsuccessful; however, due 
to its ubiquitous nature it is a highly desirable substrate where the α-substituted serine 
that results from the rearrangement can be used as a building block for natural products. 
 
 
Scheme 63 - Synthetic attempts towards N-phthaloyl serine 
2.4.1 Substrate Genesis 
 
Whilst investigating alternative methods of protecting serine we were drawn to the 
success seen when rearranging the proline-derived substrate 233. Under modified 
rearrangement conditions – the same used when rearranging the N-phthaloyl protected 
substrates 220c and 220e – a highly successful rearrangement was observed (Scheme 
64). A single diastereomer was recovered in a near quantitative yield.179 
 
 
Scheme 64 - Rearrangement of L-proline methoxyallyl ester 
This observation led us to postulate that serine could be protected with formaldehyde to 
form a cyclic N,O-acetal, such that structurally it would be very similar to proline 
(Figure 20).  Furthermore, this has the potential to allow cysteine, and threonine to be 
protected in the same manner, and hence allow more structurally diverse building 
blocks to be created. 
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Figure 20 - Protection of L-serine analogous to L-proline 
With a clear idea of the substrate required for the Ireland-Claisen rearrangement a 
synthetic route is needed for its synthesis. As with the retrosyntheses from the previous 
sections the first retrosynthetic step is disconnection at the acyl bond to provide 
protected amino acid 237 and enol ether 218a. Serine 235a can be used to synthesise the 
oxazolidine 236, which, after Boc protection will afford the protected amino acid ready 
for coupling with 218a.  
 
 
Scheme 65 - Retrosynthetic analysis of oxaproline substrate 
2.4.2 Forward Synthesis of Heteroproline Allyl Esters 
 
The retrosynthetic scheme (Scheme 65) can, in practice, be readily shortened.  It has 
previously been demonstrated that N-Boc-4-carboxy-1,3-oxazolidine (4-oxaproline) 
237a can be synthesised in high yields, in a one-pot procedure.184 Serine is dissolved in 
an aqueous solution of sodium hydroxide and paraformaldehyde, and left in the fridge 
overnight. Boc anhydride and a catalytic amount of hydroxylamine hydrochloride are 
subsequently added at room temperature and left to stir for three hours to furnish the 
desired oxaproline in excellent yield. 
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Table 13 - Synthesis of N-Boc heteroprolines 
 
Entry Substrate X R Yield of 237 (%) 
1 235a O H 93 
2 235b S H 77 
3 235c O Me 97 
 
This method was also used with great success with cysteine and threonine, in addition to 
serine, to afford three newly protected amino acids ready for esterification (Table 13). 
 
Carbodiimide promoted esterification occurred in moderate yield (Table 14); this can be 
partly explained by the sensitivity of the products. The threonine substrates were 
particularly sensitive, and where further purification was necessary a short pad of base-
treated silica was used (see 3.3.1 Substrate Synthesis for an in-depth discussion on the 
synthesis of enol ethers 218 and subsequent esterification). 
 
Table 14 - Synthesis of N-Boc heteroproline allyl esters 
 
Entry Product X R R1 Yield (%) 
1 238a O H Me 67 
2 238b S H Me 63 
3 238c O Me Me 56 
4 238d O Me Et 45 
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2.4.3 Rearrangement of Heteroproline Allyl Esters 
 
The proline allyl esters that have been previously subjected to the Ireland-Claisen 
rearrangement have required higher temperatures and more base than the N-phthaloyl 
glycinates to achieve complete conversion.  Due to the similarity of our current 
substrates to these it was foreseen that similar conditions would be necessary. Initial 
attemps using 2 equivalents of both LHMDS and TMSCl showed promising signs of 
reactivity. However, after 18 hours there was still residual starting material. By 
increasing the number of equivalents to 3 the reaction was able to go to completion. 
 
Table 15 - Rearrangement of heteroproline allyl esters 
 
Entry Product X R R1 Yield (%) dr (syn:anti)
1 239a O H Me 50 6:1 
2 239b S H Me 44 12:1 
3 239c O Me Me 47 >99:1 
5 239d O Me Et 70 >99:1 
 
The initial findings show that whilst the yields are moderate to good, the diastereomeric 
ratios are very positive.  Both the serine 239a and cysteine 239b rearrangement 
products show good diastereoselectivity, whilst the threonine derivatives 239c and 239d 
rearrange as single diastereomers (Table 15).  For compound characterisation variable 
temperature (VT) NMR was necessary to ensure that the rotameric peaks were not 
screening any diastereomeric peaks. 
 
Due to the use of enantiomerically pure threonine, the additional methyl group present 
on the oxazolidine ring creates a chiral centre. This shows that there is the potential for 
enantiomeric control with this reaction, with transfer of chirality controlled by this 
stereocentre. 
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3. SRS IN AN IRELAND-CLAISEN REARRANGEMENT 
3.1 Concept Development 
 
The success seen in the rearrangement of threonine allyl esters 239c and 239d led us to 
the belief that we could induce similar chirality control with serine. However, any such 
attempts would require – as is the case in the rearrangements of 239c (Figure 21) – the 
asymmetric transfer to be outside the cyclic transition state. 
 
 
Figure 21 - The exopericyclic nature of the directing group in the heteroproline Ireland-Claisen 
rearrangement 
Whilst the transfer of chirality within the cyclic framework is well documented, this is 
not the case for the consequences of chirality sited outside such a framework.185 There 
are scattered examples in the literature that show limited efficacy in asymmetric 
synthesis. For the subsequent discussion, the stereocentres will be assigned based on 
their relative location to the silyl ketene acetal. Carbons α to the C1 carbon will be 
designated C1′, α to C5, C5′ and so on. 
 
Gilbert et al. showed that the rearrangement of a prenyl cyclopentyl ester with a methyl 
substituent at C1′ gave high facial selectivity (Scheme 66).186 This selectivity was due to 
the approach of the prenyl group anti to the C1′ methyl group in the transition state. The 
same diastereomer would be achieved regardless of the geometry of the silyl ketene 
acetal, or rearrangement through either a chair or boat transition state. 
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Scheme 66 - Influence of a remote stereocentre at C1′ 
On the use of either E- or Z-crotyl esters (rather than the prenyl ester seen in Scheme 
66) the same stereoselectivity was seen at the newly created quaternary centre, however, 
the diastereoselectivity at C3 was low. This was presumed to be due to a lack of 
selectivity in the formation of the silyl ketene acetal rather than the rearrangement 
proceeding through a combination of chair and boat transition states. 
 
Ishizaki et al. used the diastereoselective Ireland-Claisen rearrangement of the C5′ 
triisopropylsilyl ether 242 to afford the trans-carboxylic acid 243 with a 
diastereoselectivity of 10.5:1 (Scheme 67).187 A range of silyl protecting groups were 
trialled, with the TIPS group providing the highest level of selectivity. It can be 
envisaged that attack of the silyl ketene acetal will be anti to the O-silyl group. In this 
case – whilst a chair transition state is most likely – both the chair and boat transition 
states would yield the same product. 
 
TIPSO
O
O
TIPSO
O
OTBS
TIPSO
HO
O
242
61%, 10.5:1 dr
243
LDA (1.4 eq)
TBSCl (1.4 eq)
HMPA (1.2 eq)
-78 °C rt
 
Scheme 67 - Influence of a remote stereocentre at C5′ 
Whilst the examples above show a small selection of asymmetric induction from a 
chiral centre one atom removed from the cyclic transition state there are even fewer 
examples of selective rearrangements when the remote stereocentre is two atoms 
exopericyclic. We have already seen one such example (see 1.5.2 Glycinates in the 
Ireland-Claisen Rearrangement, Scheme 48) where the use of chiral glycinates afforded 
asymmetric induction. Gould and Kallmerten have also reported an auxiliary-directed 
glycolate Ireland-Claisen rearrangement where modest selectivities were induced 
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(Scheme 68).188 They highlighted the synthetic utility of their method in a short 
synthesis of (R)-(−)-pantolactone. 
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Scheme 68 - Glycolates as a chiral auxiliary in the Ireland-Claisen rearrangement 
Their protocol sees two alternative transition states, such that one is favoured over the 
other. This allows the external auxiliary to direct the facial selectivity of addition to the 
enolate π-system, allowing for a preferential outcome. In this case, the best 
diastereoselectivity seen was with the cinnamyl glycolates, which was rationalised due 
to a favourable π-stacking interaction. 
 
We conceived that it would be possible to apply the principle of self-regeneration of 
stereocentres with an Ireland-Claisen rearrangement.  
 
 
Scheme 69 - Introduction of SRS to an Ireland-Claisen rearrangement 
The prerequisite substrate bears a large similarity to the heteroproline compounds that 
were successfully rearranged previously. However, in this novel application of SRS the 
directing group is now two atoms exopericyclic to the chair transition state, and to the 
developing C-C bond. 
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3.2 Reaction Development 
 
3.2.1 Forward Synthesis of Chiral Oxazolidine 
 
Seebach has published many papers on the use of pivalaldehyde to protect serine as an 
N,O-acetal, which will install a chiral tert-butyl group on the oxazolidine ring.89-90, 189-
190  Furthermore, Ghosez et al. have demonstrated that it is possible to protect the 
oxazolidine with a Boc group, rather than the formyl group most commonly used by 
Seebach.191 
 
During the course of this investigation it was necessary to synthesise both enantiomers 
in addition to the racemic series. The yields for all three parallel series are shown in the 
relevant schemes. For a successful cyclisation of serine 246 with pivalaldehyde, it is 
necessary to synthesise the serine methyl ester hydrochloride salt 247. Condensation 
with pivalaldehyde proceeded under Dean-Stark conditions to give the desired 
oxazolidine in a 64% yield after 24 hours. However, extending the reaction time by a 
further 24 hours afforded the methyl 2-tert-butyloxaxolidine-4-carboxylate 248 in 95% 
yield, with a diastereomeric ratio of 63:37.  
 
 
Scheme 70 - Oxazolidine Synthesis 
Boc protection as reported by Ghosez et al. required the use of an ultrasonic bath at 55 
°C. This worked well, yielding a single diastereomer of oxazolidine 249 in 70%. 
However, the practicalities of this method were not ideal, since it was not conducive to 
scale, due to the limitations in size of our sonicator. To circumnavigate this issue, a 
solely thermal reaction, with vigorous stirring was attempted. Again, a single 
diastereomer was isolated, although the yields were variable from reaction to reaction, 
but were always in the range of 50-70%. Despite the occasional reduction in yield, this 
allowed us to bring through larger quantities of starting material. 
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Scheme 71 - Boc protection of 2-tert-butyloxazolidine-4-carboxylate 
Ester hydrolysis of 249 affords the free acid in good yield, ready for carbodiimide 
promoted coupling to enol ether 218a. Esterification proceeds smoothly to synthesise 
the desired rearrangement substrate 251a in 91% after purification through a short pad 
of base treated silica. 
 
 
Scheme 72 - Synthetic completion of rearrangement substrate 
3.2.2 Rearrangement Optimisation 
 
With the route to the desired substrate 251a in hand, the rearrangement was 
investigated. The conditions used in the heteroproline rearrangements (2.4.3 
Rearrangement of Heteroproline Allyl Esters) were an excellent starting point. 
 
 
Scheme 73 - Initial Ireland-Claisen rearrangement attempt 
The rearrangement pleasingly proceeds with a high yield, and furthermore, as a single 
diastereomer (Scheme 73). Polarimetry produces an [α]D of -13, showing optical 
activity that is comparable to similar compounds in the literature (Figure 22).192 
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Figure 22 - Literature Precedence For Optical Activity 
Before we progressed any further into developing the scope of this rearrangement, we 
wanted to ensure the rearrangement was fully optimised. For this purpose, a small 
screen of conditions was conducted. 
  
Table 16 - Optimisation of oxazolidine rearrangement 
 
Entry Temp (°C) TMSCl (eq) 
LHMDS 
(eq) Yield (%)
 Comments 
1 -95 1.3 1.3 - SM returned 
2 -95 2 2 - Trace product 
3 -78 1.3 1.3 - Intractable mixture
4 -78 2 2 - Intractable mixture
5 -78 3 3 78 >99:1 dr 
 
The findings from this optimisation screen show that our initial conditions (Table 16, 
entry 5) show complete consumption of starting material, with an isolated yield of 78%. 
On reducing the number of equivalents of TMSCl and LHMDS there is an increase in 
the quantity of residual starting material present. This forms an intractable mixture with 
the desired product, and isn’t amenable to separation by flash chromatography. On 
lowering the temperature to -95 °C the reaction is stopped, and only trace amounts of 
product can be seen, whilst large quantities of starting material can be seen in the 1H 
NMR. 
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3.3 Reaction Scope of Enol Ethers 
 
With the optimal reaction conditions successfully identified the scope of the 
rearrangement can be investigated further. The initial rearrangement product 252a 
features a β-methoxy group. It was hoped to establish the generality of this 
rearrangement, and show that a range of β-alkoxy and β-aryloxy compounds can be 
synthesised. Included in these will be protecting groups, which should allow easy access 
to β-hydroxy groups, a more common motif in natural products than their protected 
derivatives. 
 
3.3.1 Substrate Synthesis 
 
With the chiral oxazolidine synthesis already completed, attention was focused on the 
enol ether portion of the substrate. For all our previous investigations (E)-3-
methoxyprop-2-en-1-ol (or methoxy enol ether) 218a has been used due to the 
commercial availability of its precursor methyl trans-3-methoxyacrylate. However, for 
substitution other than methyl it is necessary to synthesise these vinylogous esters. 
Work into this synthesis has already been conducted within the laboratory, where 
several reagents were investigated as catalysts in the 1,4-addition of oxygen 
nucleophiles to activated acetylenes (Table 17).179 
 
Table 17 - 1,4-Addition optimization179 
 
Entry Catalyst Time Yield Comments 
1 NMM 4 hrs 65% Homo coupling observed 
2 P(nBu)3 24 hrs 74% Purification by distillation 
3 DABCO 0.5 hrs 73% Purification by chromatography 
 
Of these previously reported methods,193-195 the DABCO-mediated reaction provided 
the desired products in good yields, along with short reaction times, and required the 
simplest purification techniques. For these reasons this was the method of choice. 
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With a suitable route developed, several alcohols were reacted with methyl propiolate to 
afford a range of vinylogous esters 217b-p (Table 18). 
 
Table 18 - DABCO catalysed 1,4-addition into methyl propiolate 
 
Entry OR Product Yield Entry OR Product Yield 
1 OEt 217b 88% 9 O  
217j 86% 
2 OiPr 217c 73% 10 
 
217k 93% 
3  217d 85% 11 
 
217l 62% 
4  217e 86% 12 
 
217m 91% 
5 
 
217f 98% 13 
 
217n 86% 
6 
 
217g 91% 14 
 
217o 36% 
7 
 
217h 93% 15  217p 81% 
8 
 
217i 93%     
 
The range of alcohols reacted with methyl propiolate 253 successfully, to afford the 
desired vinylogous carbonates in good to excellent yields (62-93%). The only low 
yielding reaction was with cyclohexanol, where 36% yield was observed. Steric effects 
can be reasonably discounted, since iso-propyl 217c and 217p, both synthesised from 
secondary alcohols, are formed in good yields. 
 
Having already established the optimum conditions and work-up procedure for the 
DIBAL-H reduction of these class of vinylogous carbonates using methyl trans-3-
methoxyacrylate (Scheme 52), all the vinylogous carbonates were subjected to these 
reaction conditions (Table 19). 
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Table 19 - DIBAL-H reduction of vinylogous carbonates 
 
Entry OR Product Yield Entry OR Product Yield 
1 OMe 218a 77% 9 
 
218i 82% 
2 OEt 218b 88% 10 O  
218j 80% 
3 OiPr 218c 76% 11 
 
218k 90% 
4  218d 71% 12 
 
218l 91% 
5  218e 83% 13 
 
218m 89% 
6 
 
218f 53% 14 
 
218n 86% 
7 
 
218g 64% 15 
 
218o 74% 
8 
 
218h 95% 16  218p 72% 
 
Despite the sensitivity of these compounds generally good yields were seen across the 
board, and, providing they were stored below 0 °C and under nitrogen gas, storage was 
possible for several months without decomposition. 
 
Carbodiimide promoted esterification allowed the successful synthesis of the desired 
allylic oxazolidine esters 251a-p (Table 20). The same optimized conditions were used 
as have been seen for both the phthalimide protected substrates, and the heteroproline 
derivatives. In the majority of cases purification was through a short pad of either base 
treated silica, or basic alumina. However, three of the substrates proved to be 
particularly sensitive, and were not amenable to further purification. For this reason, the 
ortho-iodobenzyl-, iso-butyl-, and cyclohexyl- substrates (217m, 217n, 217o 
respectively) were taken forward into the rearrangement without any purification, and 
used in their crude form. A fourth, the iso-propyl 217c suffered heavy decomposition on 
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the column, however, it was possible to isolate sufficient pure product to be used in the 
rearrangement. 
 
Table 20 - Allylic oxazolidine ester synthesis 
 
Entry OR Product Yield 
1 OMe 251a 91% 
2 OEt 251b 93% 
3 OiPr 251c 36% 
4 251d 75% 
5 251e 79% 
6 251f 83% 
7 251g 84% 
8 251h 95% 
9 251i 72% 
10 O 251j 74% 
11 251k 51% 
12 251l 60% 
13 251m - 
14 251n - 
15 251o - 
16  251p 83% 
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3.3.2 Substrate Rearrangement 
 
With a wide variety of allylic oxazolidine esters prepared, the scope of the 
rearrangement could be investigated, following the optimised rearrangement protocol. 
 
Table 21 - Rearrangement scope: alkoxy enol ether variation 
 
Entry OR Product Yield dr[a] 
1 OMe 252a 78% >99:1 
2 OMe rac-252a[b] 81% >99:1 
3 OMe ent-252a[c] 83% >99:1 
4 OEt 252b 84% >99:1 
5 OiPr 252c 70% >99:1 
6 252d 71% >99:1 
7  252e
[d] 76% >99:1 
[a] Measured by 1H NMR (500 MHz) analysis of crude reaction mixture.   [b] Oxazolidine 
derived from DL-serine.   [c] Oxazolidine derived from D-serine.   [d] Isolated as TMS alkyne. 
 
The rearrangement protocol is seen to be general, with yields between 47-84%, and 
excellent diastereoselectivity seen for all examples. A large variety of O-functionality 
has been examined, with simple alkyl substrates (Table 21 entries 1-4) rearranging with 
the highest yields. Increasing the substitution on these alkyl groups (entry 5) lowers the 
yield slightly, but importantly doesn’t alter the diastereoselectivity. Functionalised alkyl 
groups are tolerated well, with the allyl ether 251d rearranging in good yield (entry 6). 
Rearrangement of the propargyllic substrate 251e results in the silylation of the terminal 
alkyne, with the TMS alkyne isolated (entry 7). This silylation can be accounted for by 
the excess levels of both base, and TMSCl present in the reaction mixture. 
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Table 22 - Rearrangement scope: aryl enol ether variation 
 
Entry OR Product Yield dr[a] 
1 252f 77% >99:1 
2 252g 68% >99:1 
3 252h 73% >99:1 
4 252i 58% >99:1 
5 O 252j 73% >99:1 
6 O rac-252j
[b] 73% >99:1 
7 O ent-252j
[c] 72% >99:1 
8 252k 75% >99:1 
9 
 
252l 70% 93:7 
[a] Measured by 1H NMR (500 MHz) analysis of crude reaction mixture.   [b] Oxazolidine 
derived from DL-serine.   [c] Oxazolidine derived from D-serine. 
 
The rearrangement can also be successfully applied to aryl and benzyl based enol ethers, 
which allows easy access to a range of β-aryloxy-α-amino acids. A wide range of 
hydroxyl protecting groups (Table 22 entries 2, 5-8) can be successfully incorporated 
into the rearrangement, hence allowing a range of deprotection options. Gratifyingly 
this rearrangement has also shown good tolerance to O-functional handles (Table 22 
entry 4 & Table 23 entry 1), which shows the potential for further synthetic elaboration.  
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Table 23 - Rearrangement scope: sensitive substrates – 2 step reactions 
 
Entry OR Product Yield dr[a] 
1 252m 51%[b] >99:1 
2 252n 55%[b] >99:1 
3 
 
252o 47%[b] >99:1 
[a] Measured by 1H NMR (500 MHz) analysis of crude reaction mixture.   [b] Yields based on 
218m-o. 
 
In the case of the iso-butyl- and cyclohexyl ethers, in addition to the ortho-iodo benzyl 
ether the yields shown are over two steps; the first being the carbodiimide esterification. 
Taking into account the yield of ester formation these rearrangements have been shown 
to rearrange as efficiently as the other examples (70-80%). 
 
The only substrate not to furnish a single diastereomer is dichlorobenzyl ether 252l 
(Table 22 entry 9). Here, we see a slight drop in diastereoselectivity to 93:7. A potential 
explanation for this is that the di-substituted nature of the aromatic ring is starting to 
disfavour the chair transition state (Figure 23). 
 
 
Figure 23 - Proposed chair transition state 
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The absolute and relative stereochemistry obtained in this Ireland-Claisen 
rearrangement has been confirmed by X-ray diffraction of the iodoaryl ether 252i 
(Figure 24). The sense of stereochemistry observed is consistent with the expected 
transition state, where the enol ether portion approaches the silylketene acetal anti to the 
tert-butyl group of the oxazolidine. Furthermore, this approach is consistent with other 
stereochemical transformations that utilise Seebach’s self-regeneration of stereocentres 
method.90, 196-202  
 
  
ON
O
O
O
SiMe3
O
O
H
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Figure 24 - ORTEP plot of XRD analysis of 252i with proposed Ireland-Claisen rearrangement geometry 
Whilst technically isolated as a 1:1 mixture of diastereomers, rearrangement of the 
substituted methallyl substrate 251p proceeds as a single diastereomer with respect to 
the new stereocentres being formed (Scheme 74).  
 
 
Scheme 74 - Rearrangement of racemic enol ether 
In an analogous rearrangement, utilising an N-diboc glycine derived substrate, this ether 
substitution has been used in the formal synthesis of L-(+)-furanomycin (Scheme 75).174 
It follows that this would allow 252p to present a novel analogue to this natural 
antibiotic.203-204 
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Scheme 75 - Synthesis of L-(+)-furanomycin 
Diazomethane esterification has been an integral part of the rearrangement protocol, 
allowing for ease of isolation and characterisation as the methyl ester. However, whilst 
it is quick, efficient, and easy to incorporate into the experimental procedure there are 
times when alternative ester groups could be required. A benzyl ester would offer the 
potential for rapid removal under hydrogenation conditions, and, in conjunction with the 
benzyl ether 252j allows for global deprotection. As an alternative to diazomethane, 
benzyl bromide can be used to synthesise this desired ester (Table 24). 
 
Table 24 - Rearrangement scope: benzyl ester synthesis 
O
N
Boc
O
O
OR
1) TMSCl (3 eq)
LHMDS (3 eq)
THF, -78 °C to RT
2) BnBr (2.5 eq)
K2CO3 (1 eq)
Et2O
O
N
Boc
CO2Bn
OR
tButBu
251j-k 254j-k  
Entry OR Product Yield dr[a] 
1 O 254j 72% >99:1 
2 O ent-254j
[b] 60% >99:1 
3 254k 58% >99:1 
4 
 
ent-254k[b] 60% >99:1 
[a] Measured by 1H NMR (500 MHz) analysis of crude reaction mixture.   [b] Oxazolidine 
derived from D-serine. 
 
In general, there is a small decrease in yield in forming the benzyl ester when compared 
to the methyl ester. This suggests that the esterification is not as efficient when using 
benzyl bromide instead of diazomethane.  
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With a range of enol ethers demonstrating the reliability of this rearrangement, we 
wanted to test the limits. All previous examples use E-enol ethers. If the transition state 
geometry holds, use of a Z-enol ether should give rise to the alternate diastereomer. 
Whilst the route to the required Z-substrate is broadly similar as seen for the trans 
olefins, the addition to methyl propiolate is now conducted using a catalytic amount of 
silver(I) trifluromethanesulfonate (Scheme 76).205 Reduction with DIBAL-H in toluene 
follows the same procedure used with the E-enol ethers. 
 
 
Scheme 76 - Synthesis of (Z)-3-methoxyprop-2-en-1-ol 
Subsequent carbodiimide esterification with the oxazolidine acid 250 proceeded in 
moderate yield (Scheme 77). Substrate 257 proved to be more sensitive than the trans 
derivative, and this can account for the lost mass during purification. 
 
 
Scheme 77 - Carbodiimide promoted synthesis of Z-methoxyallyl oxazolidine ester 257 
The substrate was subjected to the rearrangement conditions, with the expectation that 
formation of the opposite diastereomer would be seen. However, this was not fully the 
case. Instead, a mixture of diastereomers were seen, with the major diastereomer the 
same as observed in the rearrangement of the trans-substrate, in an 80:20 diastereomeric 
ratio (Scheme 78). 
 
 
Scheme 78 - Rearrangement of Z-enol ether 
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We can hypothesise that the Z-enol ether is now sitting in an axial position in the chair 
transition state (Figure 25), increasing 1,3-allylic strain, and consequently reducing the 
rate of the reaction. Due to the high electron density around the enol ether, it is possible 
that a significant quantity of substrate is undergoing isomerisation to the E-enol ether, 
which, when formed, reacts faster than its Z-isomer to produce the diastereoselectivity 
seen. 
 
 
Figure 25 - Postulated transition state for the Z-enol ether 
To probe how this 1,3-allylic strain effects the rearrangement 1,2,2’-trisubstituted enol 
ether 261 was synthesised and coupled to the oxazolidine acid 250. 
 
 
Scheme 79 - Synthesis of (E)-methyl 3-methoxybut-2-enoate 
The trisubstituted vinylogous carbonate 259 was obtained in a 60% yield, along with a 
small quantity of side product 260 (Scheme 79).206  
 
 
Scheme 80 - Synthesis of trisubstituted oxazolidine allyl ester 
This was then reduced using DIBAL-H to afford the enol ether 261 in excellent yield 
(Scheme 80). The final step in the substrate synthesis was carbodiimide coupling to 
afford 262 in a quantitative yield. Due to the stability of the substrate, attempts at 
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purification were abandoned, and the substrate was taken forward to the rearrangement 
in a crude form. 
 
 
Scheme 81 - Unsuccessful rearrangement of (2R,4S)-3-tert-butyl 4-((E)-3-methoxybut-2-enyl) 2-tert-
butyloxazolidine-3,4-dicarboxylate 
Attempts at rearranging this trisubstituted substrate proved ineffective. The standard 
conditions failed to show any sign of product, with just starting material seen by TLC. 
Extended reaction times, and increasing the final reaction temperature to 40 °C failed to 
produce any conversion. 
 
Whilst the rearrangement itself was ultimately unsuccessful, it does allow further 
insight into the course of the reaction, and help to demonstrate the effect that a Z-
substituted olefin has on the reaction; that the 1,3-allylic strain is such that the 
rearrangement is not favourable. In the case of the Z-enol ether rearrangement (Scheme 
78), this helps to corroborate the hypothesis that isomerisation to the E-enol ether after 
slow rearrangement of the Z-enol ether is the cause of the low level of 
diastereoselectivity seen. 
 
3.4 Reaction Scope of Crotyl Esters207 
 
With a range of enol ether derived substrates (251a-p) successfully rearranged, 
highlighting the synthetic applicability of this rearrangement protocol, efforts turned to 
developing this reaction further. It is known that the increased electron density provided 
by the oxygen in the enol ether helps to promote rearrangement, and increase the rate of 
rearrangement.153, 208-209 Despite this, it was hoped that the rearrangement procedure was 
robust enough to be applicable to carbon substituted allyl groups. This would present an 
enantiomeric approach to β-hydroxy-α-amino acid derivatives of proteinogenic amino 
acids leucine and isoleucine – alongside more unnatural amino acids – from the 
abundant amino acid serine. 
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3.4.1 Substrate Synthesis 
 
Featuring the same chiral oxazolidine core, a range of commercially available alcohols 
were used to synthesise the required allyl esters for the Ireland-Claisen rearrangement. 
In all previous carbodiimide promoted esterification reactions, two equivalents of the 
oxazolidine carboxylic acid were used to one equivalent of the enol ether. However, 
since commercial alcohols are now being used, it was desirable to conserve as much of 
the synthetically produced acid as possible. For this reason, the equivalents were 
dropped from 2 to just 1.1 in all cases.210 
 
Table 25 - Synthesis of oxazolidine allylic ester rearrangement substrates 
 
Entry R1 R2 Product Yield 
1 H H 265a 84% 
2 H Me 265b 84% 
3 Me H 265c 97% 
 
All three substrates were successfully synthesised, without the need for further 
purification, and in excellent yields. Whilst the E-crotyl alcohol 264b is readily 
available, the same cannot be said for its isomer Z-crotyl alcohol. In order to synthesise 
the Z-crotyl substrate, a new approach was necessary. 
 
 
Scheme 82 – Carbodiimide coupling of oxazolidine and 2-butyn-1-ol 
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Carbodiimide coupling of 2-butyn-1-ol with the oxazolidine 250 furnished alkyne 
substrate 265d in good yield (Scheme 82). Whilst this allows entry into the Z-crotyl 
substrate through hydrogenation using Lindlar’s catalyst (Scheme 83), it also presents 
an opportunity to test the rearrangement protocol on an alkyne rather than the typical 
allyl esters seen in Ireland-Claisen rearrangements.  
 
O
NtBu
Boc
O
O
57%
265e
O
NtBu
Boc
O
O
H2 (1 atm)
EtOAc, RT, 90 min
265d
Lindlar's Catalyst (5 wt%)
Quinoline (5 mol%)
Me
Me
 
Scheme 83 - Lindlar hydrogenation of 2-butyne oxazolidine ester 
3.4.2 Substrate Rearrangement 
 
With the Ireland-Claisen rearrangement substrates prepared they were subjected to the 
conditions previously optimised for the enol ether based substrates. 
 
Table 26 - Rearrangement scope: carbon substitution 
 
Entry OR1 R2 Product Yield dr[a] 
1  266a 57% >99:1 
2  266b 44% >99:1 
3  266c 26%
[b] >99:1 
4  266d 56% >99:1 
5   
266e 0%[b] - 
[a] Measured by 1H NMR (500 MHz) analysis of crude reaction mixture.    [b] Reactions stirred for an 
additional 72 hours at 65 °C. 
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It can immediately be seen that the yields are much lower, and reaction times longer, 
than those for the enol ether rearrangements, which is consistent with the electronic 
effects predicted. Nonetheless, the rearrangement does work, and single diastereomers 
are produced in each instance. That is, the reaction is consistent with the approach of the 
silylketene acetal anti to the oxazolidine tert-butyl group. The additional stereocentre 
created in the case of the E-crotyl rearrangement is also formed stereoselectively. This 
indicates that silylketene acetal formation occurs stereroselectively. To achieve any 
conversion for the 2-methyl propen-ester 266c it was necessary to extend the reaction 
time by 72 hours in conjunction with heating to 65 °C.  The only substrate which does 
not undergo rearrangement (even after heating) is the Z-crotyl ester. This mirrors the 
results seen in the rearrangements of the E- and Z-methoxy enol ether substrates (252a 
and 257), whereby the 1,3-allylic strain appears to significantly retard the rate of 
reaction. In this case it completely stops any reaction from taking place. 
 
Rearrangement of the alkyne ester presents an intriguing product. Allene 266d formed 
large translucent crystals which enabled a crystal structure to be obtained allowing 
confirmation of the stereochemical outcome of the rearrangement (Figure 26). Allenes 
are a very versatile functional group, and are found in many natural products.211-212 Not 
only can they act as either an electrophile213, or a nucleophile214, but are also commonly 
used in cycloaddition reactions.215-216 
 
 
Figure 26 - XRD analysis of allene 266d 
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3.5 Rearrangement Product Derivatisation 
 
The products obtained through this rearrangement protocol allow plenty of scope for 
further synthetic elaboration. Whilst the products obtained from the enol ether 
containing substrates allow deprotection, in addition to elaboration of the ether 
functionality, the products obtained from the rearrangement of the carbon substituted 
allyl esters allow for the synthesis of β-hydroxy-α-amino acid derivatives of some 
natural proteinogenic amino acids. 
 
3.5.1 Derivatisation of Enol Ether Rearrangement Products 
 
Whilst the potential for synthetic elaboration on the range of compounds 252a-p is quite 
vast, the initial principle which forms the basis of the self-regeneration of stereocentres 
methodology is the ability to remove the temporary stereocentre that provided the 
control of chirality. In this case, this means acid hydrolysis of the oxazolidine with 
concomitant deprotection of the Boc group (Scheme 84).217 Gratifyingly, there is no 
loss of diastereoselectivity under the reaction conditions. 
 
 
Scheme 84 - Acid hydrolysis of N-Boc oxazolidine rearrangement product 
With successful hydrolysis of the oxazolidine, the principle of SRS has been upheld. 
That is, a temporary stereocentre has been installed, creation of an achiral sp2 reactive 
site has resulted in a diastereoselective reaction, and removal of the temporary 
stereocentre has been completed. Knowing that the process has gone full circle a range 
of synthetic manipulations can be conducted to highlight the potential that these 
substrates hold. 
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Reduction of Ester Functionality 
The methyl ester that results after diazomethane esterification is amenable to reduction 
through the use of lithium aluminium hydride to afford the primary alcohol in a 
quantitative yield. As was observed in the hydrolysis of 252a, there was no loss of 
diastereoselectivity in the reaction with a single diastereomer seen for the primary 
alcohol 268. 
 
 
Scheme 85 - Lithium aluminium hydride reduction of oxazolidine methyl ester 
An attempt was made at the selective DIBAL-H reduction of the oxazolidine methyl 
ester 252a to the methyl ketone, however after 4 hours at -78 °C there was no indication 
by TLC analysis of any reduction products. The reaction was allowed to warm to 0 °C 
where it was stirred for a further 3 hours. There being no sign of any product formation, 
the reaction mixture was quenched with an ethyl acetate/Rochelle Salt solution and 
starting material 252a was recovered. 
 
 
Scheme 86 - Attempted DIBAL-H reduction to oxazolidine methyl ketone 
Ring Closing Metathesis 
Ring closing metathesis is a key C-C bond forming reaction, which has become an 
essential tool in the synthesis of natural products over the last quarter of a century.218 
Robert Grubbs has been instrumental in the development of this field, and it was his 
group which developed a series of air-stable ruthenium-based carbene catalysts that, 
whilst less active than other systems, exhibit far greater functional group tolerance, 
allowing for new synthetic applications.219-220 
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Figure 27 - Structures of ruthenium-based metathesis catalysts 
On subjecting the allyl ether 252d to the second generation Hoveyda-Grubbs catalyst in 
dichloromethane for 24 hours, 2,5-dihydrofuran 270 was obtained in good yield.  
 
 
Scheme 87 - 2,5-Dihydrofuran synthesis via ring closing metathesis 
Such dihydrofurans and their derivatives can be found in polyether antibiotics and 
mycotoxinsand can therefore be seen to be an important class of compounds.221-225   
 
Enyne Metathesis 
Enyne metathesis bears the same mechanistic rationale as alkene metathesis, and can be 
considered to be a bond reorganisation of an alkene and an alkyne to produce 1,3-
dienes.226 
 
 
Scheme 88 - Attempted enyne metathesis on trimethylsilyl alkyne 252e 
Alkyne 252e is the perfect substrate on which to attempt an enyne metathesis. The 
metathesis was attempted with both Grubbs II and Hoveyda-Grubbs II catalysts, 
  | 92 
Chapter 3  Results & Discussion   
however unfortunately with the trimethylsilane group present there is no reaction, and 
the starting alkyne is the sole compound isolated from the reaction mixture. 
 
It is possible that the presence of the silyl group on the alkyne is preventing the 
metathesis from taking place. Removal of the silyl group through the use of potassium 
carbonate in methanol afforded the desired terminal alkyne 272 in excellent yield. 
 
 
Scheme 89 - Deprotection of TMS alkyne 
In 1998 Mori reported the dramatic effect ethylene can have on the yield of ruthenium 
catalysed enyne RCM reactions.227 Furthermore, Smulik and Diver have previously 
shown that alkynes that undergo poor enyne metathesis perform better when the second 
generation of Grubbs’ ruthenium catalyst is used.228 
 
Table 27 - Initial optimisation screen for enyne metathesis catalysts 
 
Entry Catalyst Additive Yield 273 (%)  Yield 274 (%)
1 Grubbs I - 0 0 
2 Grubbs I allyl alcohol (5 mol%) 0 0 
3 Grubbs I ethylene (1 atm) trace trace 
4 Grubbs II ethylene (1 atm) 50 50 
5 Hoveyda-Grubbs II ethylene (1 atm) 50 50 
   6[a] Hoveyda-Grubbs II ethylene (1 atm) 50 50 
[a] Reaction complete after 10 hours. 
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An initial screen of ruthenium catalysts, along with a selection of additives (Table 27) 
mirrored that seen by Smulik and Diver; that the first generation catalyst showed only a 
trace amount of conversion, and only when in the presence of ethylene. When the 
carbene based 1,3-dimesityl-4,5-dihydroimidazol-2-ylidene-substituted ruthenium 
complex (Grubbs II) was used complete consumption of starting material was seen after 
20 hours. However, in addition to seeing the desired 1,3-diene 273, the dimer 274 was 
also isolated, in a 1:1 mass ratio. The Hoveyda-Grubbs II catalyst showed the ratio and 
yields between the monomer and dimer as seen with the Grubbs II catalyst, however the 
rate of the reaction was quicker.  
 
Attempts were made to limit the amount of dimer being produced from the cross-
metathesis of the initially formed monomer. Unfortunately, whilst lowering the catalyst 
loading increased the ratio slightly in favour of the monomer, it left a considerable 
quantity of starting material present. 
 
Table 28 - Effect of catalyst loading on monomer:dimer ratio 
 
Entry Catalyst Loading      (x mol%) Yield 273 (%)  Yield 274 (%) 
1 Hoveyda-Grubbs II 5 50 50 
2 Hoveyda-Grubbs II 2.5 31 25 
3 Hoveyda-Grubbs II 1.25 10 6 
 
Heck Reaction 
The intramolecular Heck reaction of the ortho-iodophenyoxy rearrangement product 
252i has the potential for three products to be formed; that is for either a 5-endo, 5-exo, 
  | 94 
Chapter 3  Results & Discussion   
or 6-endo reaction to take place to afford the benzofuran 275, dihydrobenzofuran 276, 
or the benzopyran 277 structures respectively (Scheme 90). 
 
 
Scheme 90 - Three possible outcomes from the intramolecular Heck reaction of 252i 
The initial attempt at the Heck reaction, conducted at reflux in acetonitrile resulted in 
several close running spots by TLC. However, by repeating at room temperature a more 
controlled reaction took place. Whilst a single spot was observed by TLC, the initial 1H 
NMR showed there to be a mixture of two products (275 and 276). Fortunately, upon 
standing in deuterated chloroform for 2 hours, prior to a 13C NMR being run, 
isomerisation had occurred to leave the 5-endo product 275 as the sole product from the 
reaction, in a quantitative yield (Scheme 91). 
 
 
Scheme 91 - Synthesis of a benzofuran moiety by a 5-endo Heck reaction 
Benzofuran moieties are often found in natural products and can exhibit biological 
activity of interest to pharmaceutical application.229-230 As such, new routes to these, and 
other heterocyclic compounds provide a constant challenge to the organic chemist.231  
 
Dihydroxylation 
Dihydroxylation of para-methoxybenzyl ether ent-254k, using literature conditions232, 
occurs with subsequent lactonisation forming either spiro-lactone 278 or 279 in 
quantitative yield, and as a single diastereomer. 
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Scheme 92 - Dihydroxylation to afford the γ-lactone 
To assess the precise stereochemistry of the dihydroxylation the para-nitrobenzoate 
ester 280 was synthesised and subjected to single-crystal crystallography to obtain a 
definitive structure (Figure 28). From this the observed anti configuration of the alkene 
osmylation relative to the PMB ether could be assigned, and shows that spiro-lactone 
278 was the sole product from the dihydroxylation. 
 
 
Scheme 93 - Synthesis of para-nitrobenzoate derivative for XRD analysis 
 
Figure 28 - XRD analysis of para-nitrobenzoate 280 
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3.5.2 Derivatisation of Crotyl Rearrangement Products 
 
Hydrogenation of the rearrangement products enables access to the amino acid side 
chains that feature on some proteinogenic amino acids. 
 
Table 29 – Hydrogenation of crotyl rearrangement products 
 
Entry R1 R2 Product Yield 
1 H H 281a 87% 
2 Me H 281b 78% 
3 H Me 281c 66% 
 
All reactions went to completion in under 90 minutes with catalytic palladium on 
carbon under 1 atmosphere of hydrogen. Hydrogenation of the allene proceeded in just 
20 minutes, to selectively afford the Z-alkene 281d in an 80% yield (Scheme 94). Use 
of a 2D NOESY experiment allowed assignment as the Z- geometry (See 8.2.1 2D-NOE 
Spectra for 281d). Considerable interest has been shown towards vinyl glycines, due to 
their use as antibiotics233-234, enzyme inhibitors235, as well as synthetic intermediates236. 
Whilst there are many outstanding methods for the synthesis of non-proteinogenic 
amino acids, vinyl glycines are one highly important class for which many of these 
techniques cannot generally be applied.237 Hence the ability to afford the asymmetric 
synthesis of analogues of this class of compounds is an important development. 
 
 
Scheme 94 - Z- Selective allene hydrogenation 
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With a selection of both saturated and unsaturated protected β-hydroxy-α-amino esters 
synthesised, acid hydrolysis is necessary to remove the N,O-acetal and the Boc 
protecting group. The same conditions that were seen previously were also applicable to 
this class of compounds.  
 
Table 30 – Concomitant deprotection of N-O-acetal and Boc protecting groups 
 
Entry Substrate R1 Product Yield 
1 266a 282a 80% 
2 266b 282b 45% 
3 266d 282c 44% 
4 281a 282d 73% 
5 281b 282e 59% 
6 281c  282f 71% 
 
Acid hydrolysis shows moderate to good yields across the range of substrates. Whilst 
the methyl ester aids isolation of these compounds, they exhibit partial solubility in 
aqueous solution, and this presents an area where mass could be lost in the work-up 
procedure. 
 
3.6 Conclusions 
 
The principle of self-regeneration of stereocentres has been shown to be successfully 
employed in an Ireland-Claisen rearrangement to allow a highly stereospecific reaction. 
Not only can this novel protocol be applied to a variety of enol ether based substrates, 
but also those bearing carbon substitution on the allyl ester. This allows the synthesis of 
both β-hydroxy-α-amino acid substituted proteinogenic amino acid derivatives as well 
as β,β′-dihydroxy-α-amino acid structures that feature in a number of biologically 
active natural products.  
  | 98 
Chapter 3  Results & Discussion   
There are a very limited number of Ireland-Claisen rearrangements that feature such 
remote transfer of chirality.116 A chiral glycinate rearrangement mentioned earlier 
(Scheme 48) showed good levels of diastereoselectivity, whilst rearrangement of a 
chiral 2-mesityl-1,3-dioxolane substrate by Parsons et al. showed no selectivity 
(Scheme 95).238 It can be speculated that this lack of selectivity may be due to poor E/Z 
control during silylketene acetal formation, or the lack of a ‘relay’ strategy between the 
two tert-butyl groups present in the oxazolidines featured here.  
 
 
Scheme 95 - Parsons' Ireland-Claisen rearrangement of 283 
Importantly, aldol reactions performed on an oxazolidine framework similar to that 
shown in this work, with simple achiral aldehydes, exhibit very low levels of 
diastereoselectivity (Scheme 96).192 Furthermore, the ability to further functionalise 
such aldol products is expected to be limited due to the potential for base mediated 
retro-aldol reaction, in addition to limited nucleophilicity of the alcohol due to the 
proximity of sterically imposing oxazolidine moiety. 
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Scheme 96 - Aldol reaction of simple achiral aldehydes with oxazolidine esters 
Shown in this context the power of this rearrangement stands out, offering exceptional 
stereocontrol through a self-regeneration of stereocentres strategy allowing integration 
of functional handles with the potential for subsequent stereoselective synthetic 
elaboration. As such, a range of biologically relevant natural products can now be 
synthesised through use of this rearrangement protocol. 
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4. SYNTHESIS OF MYCESTERICIN G 
4.1 Background 
 
Rearrangement products 252a-p feature a polar β,β′-dihydroxy-α-amino acid head 
group (267) of the kind that have been implicated by structure activity relationships as 
the crucial structural feature in myriocin 23, mycestericin G 30 and other related natural 
products. 
 
 
Figure 29 – Mycestericin G and β,β′-dihydroxy-α-amino acid derived from the Ireland-Claisen rearrangement 
The syn stereochemistry obtained in our rearrangement (as confirmed by XRD analysis 
of 252i) matches that seen in mycestericin G. The challenge posed by the compact 
stereochemistry and juxtaposition of the polar head and lipophilic tail make this the 
perfect target to apply the Ireland-Claisen methodology seen in Chapter 3.  
 
4.2 Total Synthesis of Mycestericin G 
 
4.2.1 Retrosynthetic Analysis 
 
Initial examination of mycestericin G shows the potential union of the lipophilic tail, 
and the chiral head unit via cross-metathesis. The β,β′-dihydroxy-α-amino acid head 
unit will need to be synthesised from D-serine, to afford the correct enantiomer. 
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Figure 30 - Retrosynthetic analysis of mycestericin G 
By utilising the benzyl ether, hydrogenation of the olefin to afford the saturated chain 
seen in mycestericin G should also serve to remove the benzyl protecting group. The 
key stereochemistry required is introduced in the rearrangement of ent-251j to ent-252j. 
 
4.2.2 Initial Investigation 
 
Whilst the enantiomer required to complete the synthesis of (–)-mycestericin G is 
derived from D-serine, initial investigations were conducted using the cheaper, more 
readily available natural L-serine. 
 
With a key step in the total synthesis the cross-metathesis, the lipophilic tail needs to be 
synthesised. Fürstner et al. have reported a selective iron-catalysed cross-coupling 
reaction of Grignard reagents with, amongst others, acid chlorides.239 This provided a 
one step entry into a suitable cross-metathesis partner 286. 
 
 
Scheme 97 - Iron catalysed cross-coupling in the synthesis of ketone 286 
With the lipophilic coupling partner in hand, the methyl ether rearrangement product 
252a was chosen as a test substrate for the initial explorations of the cross-metathesis. 
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Table 31 - Initial cross-metathesis exploration 
 
Entry Catalyst Temp (°C) Time (hrs) Conversion (%)[a] 
1 Grubbs I 20 24 0 
2 Grubbs II 20 to 40 24 + 24 0 
3 Hoveyda-Grubbs II 40 24 50 (0) 
[a] Conversion stated as product against starting material. Isolated yields shown in parenthesis 
 
Early efforts proved unsuccessful, with neither Grubbs I nor Grubbs II catalysts 
showing any signs of product. It was noticed however, that a significant quantity of 
olefin was undergoing dimerisation, to form the homodimer 289. 
 
 
Figure 31 - Homodimer 289 
Whilst there was an improvement on utilising the Hoveyda-Grubbs II catalyst, with a 
conversion of 50% seen, this was unable to be isolated due to co-elution of 252a due to 
a highly similar Rf, in addition to homodimer 289 contaminating most fractions due to 
partial solubility in the eluent causing a slow release during chromatography. 
 
The tolerance of cross-metathesis reactions on sterically congested olefin moieties has 
previously been described.240-241 These reports correlate our observation that the higher 
activity seen in second generation [Ru]-carbenes often aids the progress of cross-
metathesis reactions. However, even the use of the Hoveyda-Grubbs II catalyst proved 
unable to produce a clean reaction pathway.  Grubbs has also demonstrated improved 
cross-metathesis reactions when using symmetric internal olefins.242 Many cases were 
reported where a two-step cross-metathesis procedure whereby a terminal olefin was 
dimerised prior to undergoing the desired cross-metathesis reaction. 
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With the observation that homodimer 289 formation was facile it was decided to isolate 
it prior to re-attempting the desired cross-metathesis reaction (Scheme 98). 
 
83%
289
O
8 5
O
85
O
85
Grubbs II (2.5 mol%)
286
DCM, 40 °C, 72 h
 
Scheme 98 - Synthesis of homodimer 289 
The initial attempt utilising the homodimer proved successful, with 48% isolated after 
72 hours (Table 32 entry 1). With a set of conditions in hand, an attempt at the cross-
metathesis was made using the substrate identified in the retrosynthetic analysis, namely 
the benzyl ether 252j. Disappointingly, the yield is drastically reduced, and the product 
is unable to be cleanly isolated. Attempts were made to optimise the cross-metathesis of 
the benzyl ether, however, on increasing the temperature either in toluene, or, to a lesser 
extent in dichloroethane, isomerisation of the homodimer is seen, and a multitude of 
products are seen with varying lengths of carbon in the lipophilic tail. 
 
Table 32 - Cross-metathesis development 
 
Entry Substrate R Solvent Temp (°C) Time (hrs) Yield (%) 
1 252a Me DCM 40 72 48 
2 252j Bn DCM 40 96 22[a]
3 252j Bn Toluene 110 72 0[b]
4 ent-252j Bn DCE 60 72 0[b] 
[a] Product unable to be isolated cleanly.    [b] Isomerisation of 289 observed. 
 
From this set of results it can be proposed that the steric bulk of the ether moiety is 
having a substantial effect on the outcome of the cross-metathesis. If this presumption 
were to hold true, then a new approach using the free hydroxyl would be expected to 
undergo metathesis more readily.  
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To this end, para-methoxylbenzyl ether 252k can be deprotected via DDQ-mediated 
oxidation in excellent yield. Whilst para-anisaldehyde 290a, produced as a side 
product, proved challenging to remove by conventional methods, use as the crude 
reaction mixture led to no reduction in yields in subsequent synthetic steps.  
 
 
Scheme 99 - DDQ deprotection of PMB ether 252k 
With the free hydroxyl synthesised it could be subjected to the optimised conditions 
obtained for the cross-metathesis reaction. Gratifyingly a more efficient cross-
metathesis is seen to occur, with the reaction time cut by a third, and a vastly superior 
yield observed. 
 
 
Scheme 100 - Cross-metathesis of allylic alcohol 290 
4.2.3 Completion of the Synthesis of Mycestericin G 
 
With a proficient cross-metathesis protocol established, a preparative scale synthesis of 
ent-254k was initiated. 
 
 
Scheme 101 - Preparative scale rearrangement 
With gram quantities of ent-254k needed a streamlined procedure was performed with 
carbodiimide mediated coupling of 250 and 218k, Ireland-Claisen rearrangement and 
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carboxyl benzylation conducted on a 4 mmol scale without intermediate purification. In 
addition to shortening the laboratory procedure this served to increase the overall yield 
across the three synthetic steps. 
 
 
Scheme 102 - DDQ deprotection of PMB ether ent-254k 
DDQ deprotection of the PMB group occurs in excellent yield. As seen in the synthesis 
of 290 (Scheme 99) p-anisaldehyde is present after initial workup. Removal by sodium 
borohydride reduction of aldehyde 290a and subsequent flash chromatography results in 
a slight loss of yield to 74% (See 7.3 Compound Characterisation for further details), 
however, this additional layer of purification isn’t required since the presence of the 
aldehyde bears no impact on the result of the ensuing cross-metathesis reaction. 
 
 
Scheme 103 - Cross-metathesis towards the synthesis of mycestericin G 
The cross-metathesis proceeds well (Scheme 103), albeit with a slightly reduced yield 
when compared to the analogous methyl ester 291. This continues the observations that 
steric bulk around the olefin serves to reduce the activity, and subsequent performance 
in the metathesis reaction. 
 
With a successful cross-metathesis the two key structural features – the chiral head 
group and lipophilic tail – have been amalgamated with just two proposed steps 
remaining to synthesise mycestericin G.  The first step, acidic hydrolysis of oxazolidine 
ent-293, formed amino diol ent-294 in good yield (Scheme 104). 
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Scheme 104 - Acid hydrolysis of oxazolidine ent-292 
Final hydrogenolysis of the benzyl ester and alkene however proved problematic. An 
initial attempt using 5 wt% palladium on carbon under an atmosphere of hydrogen 
failed to generate any sign of product. However, significant decomposition of the 
starting material was observed. 
 
 
Scheme 105 - Attempted hydrogenation of amino diol ent-293 
For the hydrogenation of a natural sample of mycestericin E, Fujita et al. utilised 200 
wt% palladium on carbon to afford mycestericin G.50 It can be reasoned that by using 
small catalytic quantities of palladium on carbon any desired hydrogenation is reacting 
at a far slower rate than decomposition of the starting material. By increasing the 
catalytic loading to near stoichiometric amounts it was hoped that the desired 
hydrogenation would occur more rapidly. Whilst trace amounts of mycestericin G could 
be discerned from the 1H NMR spectrum, decomposition was still the dominating result 
from the reaction. 
 
To circumnavigate this problem, the order of these transformations was reversed. 
Oxazolidine ent-293 was now subjected to hydrogenation allowing rapid reduction of 
the alkene, and cleavage of the benzyl ester in near quantitative yield (Scheme 106). 
 
 
Scheme 106 - Hydrogenation of ent-292 
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Acid hydrolysis followed by basification of the subsequent hydrochloride salt afforded 
mycestericin G as a white powder (Scheme 107).  
 
 
Scheme 107 - Completion of mycestericin G synthesis 
Whilst all spectroscopic data was in accordance with previously published reports, the 
optical rotation of the synthetic compound was, however, opposite in sign, but of 
similar magnitude to that reported for the natural product (Figure 32).50 
 
 
Figure 32 - Comparison of optical rotation between natural and synthetic mycestericin G 
To further understand and analyse this discrepancy the synthetic sequence was repeated 
starting from L-serine with the aim of synthesising the opposite enantiomer (Scheme 
108). 
 
The spectroscopic data for ent-30 was identical to that observed for the synthetic 
sequence derived from D-serine. However, the optical rotation was now not only similar 
in magnitude, but also of the same sign of rotation as the natural sample of mycestericin 
G. 
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Scheme 108 - Synthesis of mycestericin G starting from L-Serine 
This discrepancy can be explained by analysis of the literature of similar sphingosine 
natural products. Hydrogenation of myriocin 23, forms dihydromyriocin (mycestericin 
C 26). The key realisation in this transformation is that hydrogenation leads to a reversal 
in the sense of optical rotation; i.e., myriocin 23 is dextrorotatory, whilst mycestericin C 
26 is levorotory (Scheme 109). 
 
 
Scheme 109 - Hydrogenation of myriocin 23, with inherent reversal in sense of optical rotation 
Whilst the absolute configuration of mycestericin E 28 has been confirmed through its 
total synthesis, this is not the case for mycestericin G 30, its saturated derivative.79 The 
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same report obtains mycestericin G 30 from synthetic mycestericin E 28, and provides 
identical spectroscopic data when compared with a natural sample. However, no optical 
rotation data was reported for this synthetic mycestericin G. As a result, there is no 
unequivocal evidence that the configuration of the stereocentres in mycestericin E is the 
same as those in mycestericin G. Furthermore, the optical rotation observed for 
synthetically obtained mycestericin G in this body of work parallels the switch in sense 
of rotation between the unsaturated and saturated analogues.  
 
 
Scheme 110 - Hydrogenation of mycestericin E, with contrasting optical rotation between natural and 
synthetic mycestericin G 
Of particular interest when assessing this inconsistency with the optical rotations is the 
recent synthesis of mycestericin G by Kumagai and Shibasaki.82 Synthesis of the 
originally reported structure resulted with an opposite sense of optical rotation to that in 
the original isolation paper (ሾαሿDଶ଴ +12.8 (c 0.05, MeOH)). This discrepancy was 
attributed to the poor solubility of mycestericin G in methanol.  
 
These findings offer firm credence to a reassignment in the configuration of 
mycestericin G, such that it is enantiomeric to the original assignment (Figure 33). 
 
 
Figure 33 - (+)- and (−)-Mycestericin G: determination of configuration 
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4.3 Total Synthesis of Threonine Analogue of Mycestericin G 
 
Drug discovery has long used the process of structure-activity relationships to develop a 
lead compound into a safer, and more effective clinical agent. Bioisosterism and other 
structural changes have regularly been used to accomplish the desired enhancement in 
efficacy, or to reduce levels of toxicity.243 
 
With the successful synthesis and reassignment of mycestericin G, the heteroproline 
rearrangements conducted in section 2.4.3 Rearrangement of Heteroproline Allyl Esters 
offer an efficient route into (2S,3R)-2-amino-3-hydroxy-2-((R)-1-hydroxyethyl)-14-
oxoicosanoic acid 296; an analogue of mycestericin G with a chiral head group derived 
from threonine, rather than serine. It can be envisaged that the same synthetic route will 
be applicable for the mycestericin G analogue. 
 
 
Figure 34 - A potential analogue of mycestericin G 
p-Methoxybenzyl enol ether 218k was coupled with the 5-methyloxazolidine 237c in 
good yield, to afford the substrate required for the key Ireland-Claisen rearrangement 
(Scheme 111). 
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Scheme 111 - Carbodiimide promoted esterification of 5-methyloxazolidine 
An efficient rearrangement was seen to occur under the standard conditions used for 
these oxazolidine class of compounds (Scheme 112). With a single diastereomer 
observed, in good yield, the contiguous stereocentres of the chiral head group are now 
installed. 
 
 
Scheme 112 - Rearrangement of p-methoxybenzyl oxazolidine ester 
DDQ deprotection of the PMB group occurs in excellent yield, and, gratifyingly, 
separation of the anisaldehyde from the desired product is achievable by flash 
chromatography (Scheme 113). 
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Scheme 113 - DDQ deprotection 
The cross-metathesis suffers from a lower yield when compared to the 2-t-butyl 
oxazolidine cross-metathesis. As has been observed across the range of substrates used 
in this cross-metathesis, any increase in steric congestion appears to severely hinder the 
reaction. In this case, the proximity of the methyl group on the oxazolidine must be 
hindering the reaction. When followed by a hydrogenation over palladium on carbon, a 
yield of 34% is obtained over the two steps (Scheme 114). 
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Scheme 114 - Cross-metathesis and hydrogenation 
Acid hydrolysis completes the synthesis, albeit, in a low yield. The poor yield can be 
explained due to partial solubility of the amino acid in water. The nature of the work up 
involved basification with aqueous sodium hydroxide, concentration in vacuo and then 
dissolution of the residue in water, from which the desired product precipitated as a 
white solid. In the case of mycestericin G, a significant quantity precipitates. The 
threonine analogue was observed to have a higher affinity to the water, and as a result, a 
decrease in yield was obtained.  
 
 
Scheme 115 - Completion of the synthesis of the threonine analogue of mycestericin G, 296 
4.4 Conclusion 
 
Both enantiomers of mycestericin G have been synthesised in a concise 10 step 
synthesis starting from the readily available serine methyl ester hydrochloride salt. The 
natural product (−)-mycestericin G (ent-30) first isolated from Mycelia sterilia was 
obtained in an 9.7% overall yield after its enantiomer was first synthesised in 13.5% 
overall yield. Key steps in the synthesis were the Ireland-Claisen rearrangement (the 
methodology for which has been previously discussed in Chapter 3), and the cross-
metathesis. These steps allowed the synthesis of the chiral head group, and it’s coupling 
to the lipophilic tail seen in the natural product. 
 
Synthesis of both enantiomers of the natural product, allowed a revision of the 
stereochemistry to be made. Confidence in this reassignment is augmented by the XRD 
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analysis obtained from a rearrangement product (Figure 24), which verified the 
predicted outcome of the Ireland-Claisen rearrangement, along with the optical rotation 
for mycestericin G seen by Kumagai and Shibasaki. 
 
The synthetic route used in the synthesis has been shown to be applicable not only to 
mycestericin G, but also allows for synthetic derivations to be made, of which the 
threonine analogue 296 has successfully been synthesised over 9 linear steps. Whilst 
increased steric interactions lower the yield of the cross-metathesis, and solubility issues 
affect the acid hydrolysis a quick, and efficient synthesis is still obtained. 
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5. CHIRAL DIENE LIGANDS IN CONJUGATE ADDITIONS 
5.1 Introduction 
 
Transition metal-catalysed conjugate addition of organometallic reagents to activated 
alkenes has become a powerful method in organic synthesis.244 Part of the power of this 
chemistry stems from the ability to tune reactivity with countless ligand and metal 
combinations.245 In 1997 Miyaura et al. published the first report on the rhodium-
catalysed conjugate addition of both aryl and alkenyl boronic acids to methyl vinyl 
ketone (Scheme 116).246  
 
 
Scheme 116 - Rhodium-catalysed conjugate addition of phenyl boronic acid and methyl vinyl ketone 
In collaboration with Hiyashi et al., the first asymmetric rhodium-catalysed conjugate 
addition was observed with the addition of a range of electron-donating and electron-
withdrawing aryl boronic acids to 2-cyclohexenone (Scheme 117).247 The excellent 
yields and enantioselectivities observed in this reaction have become the benchmark for 
rhodium-catalysed conjugate addition.248 
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Scheme 117 - First enantioselective rhodium-catalysed conjugate addition 
5.1.1 Mechanism of Rhodium-Catalysed Conjugate Additions 
 
The discovery by Miyaura et al. that the addition of base accelerated the conjugate 
addition to α,β-unsaturated amides contributed to the discussion that the active 
precursor is a hydroxy-rhodium species 305.249 Such a species was confirmed by 
Hayashi et al. in their mechanistic study with 31P NMR spectra.250 
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The first step of the mechanism involves the formation of the active rhodium-hydroxyl 
precursor 305 by loss of ligands (such as acac or Cl). This reactive species then 
undergoes transmetallation with the desired organoboron reagent to form the aryl-
rhodium species 306 (Scheme 118). It is usual to use an excess of organoboron reagent 
due to a competitive protodeboronation pathway. Coordination and insertion of the 
unsaturated carbon-carbon double bond leads to the η3-oxa-π-allylrhodium complex 
307. Enantioselectivity in the product is obtained from the facial selectivity of the chiral 
ligand. Hydrolysis of the rhodium-enolate with water regenerates the active catalyst 
along with the conjugate-addition product 308. 
 
 
Scheme 118 - The mechanism of rhodium-catalysed conjugate addition 
Rhodium-catalysed conjugate addition reactions aren’t confined solely to organoboron 
reagents; many other organometallics participate in transmetallation to rhodium. Whilst 
other organometallic donors can offer different advantages and reaction pathways, they 
will not be discussed further here, but can be found in a review by Frost et al.251 
 
5.1.2 Chiral Diene Ligands in Rhodium-Catalysed Conjugate Additions 
 
Since these reports, the application and range of organoboron reagents has grown 
exponentially. In particular, the development of chiral diene ligands have found this 
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class of ligand to be superior to many other types of chiral ligands, such as 
bisphosphines. Not only can they show enhanced catalytic activity, but also 
enantioselectivity, particularly in rhodium-catalysed asymmetric transformations.252 
 
Achiral chelating ligands such as 1,5-cyclooctadiene (cod) and norbornadiene (nbd) 
were known to be stable ligands in transition metal complexes253, however, it wasn’t 
until 2003 when a chiral diene ligand was developed by Hayashi et al.254 Derived from 
norbornadiene in 9 steps, (R,R)-Bn-nbd 309 was successfully utilised in the conjugate 
addition of arylboronic acids to α,β-unsaturated ketones and esters with high yields and 
excellent enantioselectivities (Scheme 119). 
 
 
Scheme 119 - First use of a chiral diene ligand in a rhodium-catalysed conjugate addition 
The 309-rhodium complex is able to recognise the enantioface of the enone due to steric 
repulsion of the benzyl group on the diene, and the carbonyl moiety. The implication of 
this is the α-re-face being favoured over the α-si-face for both cyclic and linear enones 
(Scheme 120). 
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Scheme 120 - Enantioselectivity in a rhodium-catalysed conjugate addition 
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Since this first publication, bicyclic diene frameworks have been further developed.252 
Noteworthy amongst these is Carreira’s diene 311, readily derived from (−)-carvone in 
a seven step synthesis (Figure 35).255-256 
 
O
Me
Me
( )-carvone, 310
Me OMe
311  
Figure 35 - Carreira's diene, dervived from (−)-carvone 
Despite such bicyclic ligands offering excellent substrate scope and high 
enantioselectivities, there is a need to increase ligand availability.257 To this end simple 
chiral dienes have been reported by Du et al., and Trost et al. which lack the rigidity of 
the bicyclic ligands.257-258 
 
Du described a simple chain diene 312 that achieved moderate enantioselectivities as a 
starting point for a new and practical direction in the design of future chiral diene 
ligands. Further modifications by Du saw ligand 313 achieve higher selectivities, up to 
95% ee.259 Whilst seeing improvements in enantioselectivity, this new ligand requires a 
longer, six step synthesis from 1,5-hexadiene. 
 
MsHN NHMsHO OH
312
3 steps to prepare
products up to 85% ee
313
6 steps to prepare
products up to 95% ee  
Figure 36 - Du's chiral chain diene ligand development 
Trost’s aims were specifically to create “a more convenient synthetic approach towards 
chiral dienes for use in transition metal catalysis”.257 Furthermore he felt it was 
desirable to produce a structurally diverse library of ligands from a common 
intermediate. By using palladium-catalysed asymmetric allylic alkylation (Pd-AAA) on 
meso- and d,l-divinylethylene carbonate with a variety of nucleophiles, a series of 
potential ligands were synthesised (Scheme 121). 
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Scheme 121 - Synthesis of chiral diene ligands via a Pd-AAA 
Ligand 316a prepared from the Pd-AAA using phthalimide gave superior 
enantioselectivity and yield over the other ligands synthesised, and was subsequently 
utilised to show the general applicability of this chiral diene ligand (Scheme 122). 
 
 
Scheme 122 - Application of Trost's chiral diene ligand in Rh-catalysed conjugate addition 
5.1.3 Hybrid Olefin Ligands in Rhodium-Catalysed Conjugate Additions 
 
In the attempt to achieve ever higher catalytic activity and selectivity 
phosphourous/olefin260-262 and nitrogen/olefin263 hybrid ligands have been developed, 
and successfully utilised in many transition-metal-catalysed asymmetric reactions. 
However, recent advances have seen a rise in interest in chiral sulphur-containing 
ligands, due to their availability, high stability, metal affinity, and in particular, S-
stereogenic control.264 The use of chiral sulphur-olefin hybrid ligands in rhodium-
catalysed conjugate additions was simultaneously reported by Knochel,265 Xu,266-267 and 
Du,268 with promising activity and selectivity observed (see ligands 317, 318, and 319 
respectively, Figure 37). 
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Figure 37 - Recent chiral sulphur/olefin ligand development 
Du et al. have developed a series of chiral N-tert-butanesulfinyl α,β-unsaturated 
ketimines through a one step condensation of α,β-unsaturated ketones with tert-
butanesulfinamide.269 Ligand 320, obtained from chalcone showed both the highest 
reactivity and enantioselectivity in a rhodium-catalysed conjugate addition (Scheme 
123). 
 
N
S
O
Ph
O
+
[RhCl(C2H4)2]2 (1.5 mol%)
320 (3.6 mol%) O
K3PO4•3H2O (7.5 mol %)
MeOH, 30 °C
303 321
96%, 98% ee
322
Ph
B(OH)2
Ph
 
Scheme 123 - Rhodium-catalysed conjugate addition using a sulphur/olefin ligand 
The diverse range of ligand structures this one step procedure allows, along with the 
high yields and enantioselectivities shown make this class of ligands highly attractive to 
a variety of transition-metal-catalysed asymmetric reactions. 
 
5.2 Rhodium-Catalysed Conjugate Addition 
 
5.2.1 Ligand Synthesis 
 
With such interest in new ligand systems for rhodium-catalysed conjugate addition 
reactions, it was felt that the rearrangement products seen in Chapter 3 can be 
transformed into chiral diene ligands with just a few functional group interconversions. 
It was envisaged that reduction of the methyl ester to an aldehyde, followed by a Wittig 
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reaction would furnish the desired diene in a quick synthetic sequence (Figure 38). 
Unfortunately, as previously discussed, selective reduction to the aldehyde is not 
amenable, therefore it is necessary to proceed via the primary alcohol with subsequent 
oxidation to the aldehyde. 
 
 
Figure 38 - Chiral diene ligands from rearrangement products 
A selection of rearrangement products were chosen to allow a broad range of ligands to 
be screened in the rhodium-catalysed conjugate addition (Table 33). 
 
Table 33 - Lithium aluminium hydride reduction of tert-butyloxazolidine methyl esters 
LiAlH4 (2 eq)
THF, 0 °C to RT
O
NtBu
Boc
CO2Me
R
O
NtBu
Boc
R
OH
323a-d  
Entry Substrate R Product Yield 
1 252b OEt 323a 100% 
2 252g OPMP 323b 89% 
3 266a H 323c 100% 
4 266b Me 323d 98% 
 
In addition to these four examples based on the tert-butyloxazolidine core, a single 
example based on the threonine-derived oxazolidine was desired to allow a comparison 
in the conjugate addition. As was seen with the tert-butyloxazolidine reductions, an 
excellent yield was obtained (Scheme 124). 
 
 
Scheme 124 - Lithium aluminium hydride reduction of methyloxazolidine methyl ester 
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Pleasingly, subsequent Swern oxidation proceeded with very good yields across all four 
tert-butyloxazolidine substrates (Table 34). It should be noted, that neither the 
reduction, nor oxidation steps required purification by flash chromatography, making 
these operationally simple reactions to perform. 
 
Table 34 - Swern oxidation of tert-butyloxazolidine primary alcohols 
 
Entry Substrate R Product Yield 
1 323a OEt 325a 78% 
2 323b OPMP 325b 80% 
3 323c H 325c 75% 
4 323d Me 325d 82% 
 
The threonine derived methyloxazolidine also oxidised cleanly to obtain the desired 
aldehyde with an excellent yield (Scheme 125). 
 
 
Scheme 125 - Swern oxidation of methyloxazolidine primary alcohol 
The final step of the synthesis is to install the olefin by a Wittig reaction. Initial efforts 
focused on the ethoxy aldehyde 325a, with a range of conditions attempted before 
successfully obtaining any sign of the desired diene. Use of either nBuLi or tBuOK at 
room temperature failed to show any sign of conversion (Scheme 126). 
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Scheme 126 - Attempted Wittig reaction 
However, on heating to reflux, an 87% yield was gratifyingly obtained. These 
conditions allowed a successful reaction for all tert-butyloxazolidine aldehydes with 
high yields for all four substrates (Table 35).  
 
Table 35 - Wittig reaction of tert-butyloxazolidine aldehydes 
 
Entry Substrate R Product Yield 
1 325a OEt 327a 87% 
2 325b OPMP 327b 74% 
3 325c H 327c 78% 
4 325d Me 327d 69% 
 
Methyloxazolidine 326 was also amenable to the Wittig reaction, with the desired diene 
328 formed in 73% yield (Scheme 127). 
 
 
Scheme 127 - Wittig reaction of methyloxazolidine aldehyde 326 
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5.2.2 Ligand Screening 
 
With a range of chiral diene ligands now synthesised, the rhodium-catalysed conjugate 
addition can be attempted. Yu et al. had recently reported the use of an α,β-divinyl 
tetrahydropyrrole 329 as a chiral chain diene ligand (Scheme 128), and these optimised 
conditions were used as a starting point in this investigation.270  
 
 
Scheme 128 - Yu's α,β-divinyl tetrahydropyrrole in a rhodium-catalysed conjugate addition 
An initial reaction using ethoxyallyl ligand 327a (Scheme 129) showed, by TLC, that 
some starting material was still present after 18 hours. The reaction was subsequently 
concentrated in vacuo where the crude 1H NMR showed no sign of starting material. 
Indeed, TLC analysis now also showed that there was no starting material present. After 
purification by flash chromatography, a quantitative yield was obtained with an 83% ee. 
From this observation, it appeared that any residual starting material was being 
consumed whilst in the rotary evaporator. 
 
 
Scheme 129 - Initial conjugated addition of phenylboronic acid to 2-cyclohexenone, using 327a 
To probe this interesting observation further, two additional reactions were conducted. 
Firstly, an aqueous workup was conducted on the reaction mixture in place of rotary 
evaporation; whilst the second saw the reaction mixture immediately transferred to the 
rotary evaporator on addition of 2-cyclohexenone 303. After 18 hours and an aqueous 
workup, there was still starting material present by TLC. An isolated yield of 64% was 
obtained, along with a slightly improved ee of 87%. Meanwhile, the second test reaction 
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saw a near quantitative yield of 98% returned, with a near identical enantioselectivity 
seen to the initial reaction (that is 84% ee). These results confirm the belief that the 
reaction is being driven to completion whilst under rotary evaporation. It is worth 
noting, that on conducting these experiments on the rotary evaporator, if less water was 
used relative to 1,4-dioxane, then the reactions could fail to go to completion. 
 
To explore this effect further a solvent swap was conducted. The initial coordination of 
the rhodium and chiral ligand was conducted in dichloromethane, before removal under 
reduced pressure, and then addition of water, potassium hydroxide and 2-
cyclohexenone. An aqueous work up followed, to avoid any further reaction in vacuo. 
Whilst a quantitative conversion, and isolated yield were obtained, there was no 
improvement in enantioselectivity (Scheme 130). 
 
 
Scheme 130 - Solvent swap investigation into the effect of water on the conjugated addition 
With two conditions acquired that allows complete consumption of the starting material, 
the decision was made to use the more operationally simple procedure, and to 
immediately place the reaction mixture on the rotary evaporator. With the experimental 
conditions now chosen, ligands 327a-d, and 328 (Figure 39) were compared in the 
conjugate addition of phenylboronic acid to 2-cyclohexenone. 
 
 
Figure 39 - Chiral diene ligands 
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It can be seen that both the ethoxyallyl, and allyl substituted ligands (327a and 327c 
respectively) proceed in quantitative yield, with good enantioselectivity (Table 36, 
entries 1 and 3). There is a slight drop off in both activity and enantioselectivity with 
para-methoxyphenyl ligand 327b (entry 2), falling to 49% yield and 68% ee for methyl 
ligand 327d (entry 4). Threonine derived ligand 328 fails to offer much conversion, 
with a poor yield of 13%, and a moderate 51% ee (entry 5). 
 
Table 36 - Chiral diene ligand screening 
 
Entry Ligand Yield (%) ee (%)[a] 
1 327a 100 83 
2 327b 86 72 
3 327c 100 87 
4 327d 49 68 
5 328 13    51[b] 
[a] ee was determined by HPLC (Chiralpak AD column) [b] Opposite 
enantiomer (i.e. 304) obtained 
 
5.2.3 Ligand Development 
 
With allyl ligand 327c showing the highest enantioselectivity, along with a quantitative 
yield, further alkyl based ligands were desired to investigate effects of substitution on 
the olefin itself. With new ligands 327e and 327f identified, a route was required for 
their synthesis. 
 
 
Figure 40 - Additional chiral diene ligands 
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Alkylation of oxazolidine 249 was anticipated to provide the quickest synthetic access 
to these desired ligands. It was also envisaged that alkylation with allyl bromide would 
provide an alternative method for the synthesis of ligand 327c. 
 
 
Scheme 131 - Alkylation of formyl oxazolidine 329 
Following a procedure by Colombo and Giacomo, which reported the alkylation of 
analogous formyl oxazolidine 330 with a large excess of alkyl halide (Scheme 131),198 a 
selection of conditions were attempted using allyl bromide as a test electrophile. This 
showed a significant drop in yield when 4 equivalents of alkylating agent was used, 
compared to the 15 equivalents used by Colombo et al. However, reducing the number 
of equivalents to 10, an increase in yield to 81% was observed. Further changes made 
were to use LHMDS, and the removal of additional additives and co-solvents from the 
reaction. With these modifications in place a range of electrophiles were reacted with 
the enolate of oxazolidine 249 (Table 37). With 3-chloro-2-methylprop-1-ene failing to 
react, the iodoalkane was synthesised using a Finkelstein reaction.271 
 
Table 37 - Alkylation of oxazolidine 249 
 
Entry E R1 R2 x (eq) Product Yield (%) 
1  H H 4 266a 50 
2  H H 10 266a 81
3  H H 15 266a 75 
4  H Me 10 333a 90 
5  Me H 10 333b 0
 
6  Me H 10 333b 76 
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With alkylation now successful, addition products 333a-b were subjected to the same 
functional group interconversions to obtain the desired chiral diene. Both reduction and 
oxidation steps proceeded smoothly and, without the requirement for column 
chromatography, allow facile access to aldehydes 327e-f. The Wittig reaction proceeds 
in similar high yields as seen previously (Scheme 132). 
 
 
Scheme 132 - Synthetic steps towards chiral diene ligands 
With these substituted allyl ligands now synthesised. A comparison could be made 
against allyl ligand 327c (Table 38, entry 1). Unfortunately, whilst diene ligand 327e 
shows high enantioselectivity, it fails to improve upon that seen for 327c. Furthermore, 
the additional substitution appears to limit reactivity, and a moderate yield of 40% is 
obtained (entry 2). Whilst not appearing to affect the reactivity as severely as diene 
327e, 327f suffers a large decrease in enantioselectivity (entry 3). 
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Table 38 - Additional ligand screening 
 
Entry Ligand Yield (%) ee (%)[a] 
1 327c 100 87 
2 327e 40 84 
3 327f 78 49 
[a] ee was determined by HPLC (Chiralpak AD column) 
 
5.2.4 Reaction Optimisation 
 
With allyl ligand 327c showing excellent enantioselectivity and yields after the ligand 
screening, further optimisation was conducted to ensure maximum enantioselectivity 
was being achieved (Table 39). 
Table 39 - Reaction optimisation using allyl ligand 327c 
 
Entry Temp Time Yield (%) ee (%)[c] 
1 50 °C to RT 1 min[a] 100 87 
2 RT 1 min[a] 100 88 
3 RT 2.5 hrs[b] 17 83 
4 RT 24 hrs[b] 16 88 
5 RT to 100 °C 2.5 hrs[b] 97 82 
[a] Reaction transferred immediately to rotary evaporator on addition of 303. [b] Reaction 
subjected to aqueous work-up [c] ee was determined by HPLC (Chiralpak AD column) 
 
Most literature reports specify 50 °C as the optimum temperature to allow 
catalyst/ligand exchange. However, it can be seen that this can be done at room 
temperature with no loss in yield, and a slight increase in enantioselectivity (entries 1 & 
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2). Moreover, this removes the need to allow the reaction mixture to cool prior to 
addition of 2-cyclohexenone 303. It can be seen that under normal reaction conditions 
(that is, stirring under an inert atmosphere), the reactions proceed sluggishly, even with 
extended reaction times (entries 3 and 4). However, on heating to 100 °C, it is driven to 
completion, and a near quantitative yield is obtained (entry 5). Unfortunately, the 
enantioselectivity is lower than that seen under rotary evaporation. 
 
5.2.5 Reaction Scope 
 
With a suitable chiral diene ligand and optimised set of reaction conditions identified, 
the scope of the conjugate addition could be investigated. 
 
Generally excellent yields are seen for all substrates, with 4-acetylphenyl 333d the sole 
exception with a poor yield of 24% (entry 5). The highest enantioselectivities are seen 
for the smallest substituents (entries 1 and 2), with the largest substituent, 1-
naphthalenyl 333c, showing a decrease in selectivity to 73% ee. Whilst the 4-
chlorophenyl 333e (entry 6) is afforded in excellent yield, it was not possible to obtain 
an accurate ee, due to the lack of resolution of the enantiomeric peaks by chiral HPLC. 
  
Table 40 - Scope of rhodium-catalysed conjugate addition 
 
Entry R Product Yield (%) ee (%)[a] 
1 H ent-304 100 88 
2 4-F 334a 95 91 
3 4-OMe 334b 93 84 
4 1-Naphth 334c 100 73 
5 4-Acetyl 334d 24 79 
6 4-Cl 334e 87    ND[b]
[a] ee was determined by HPLC (Chiralpak AD, OD-H, or OJ column) [b] Unable to effect 
resolution of enantiomeric peaks by chiral HPLC 
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5.3 Conclusions 
 
This short investigation into rhodium-catalysed conjugate addition reactions has 
afforded a promising series of results. A series of chiral diene ligands have been 
synthesised based on both tert-butyloxazolidine and methyloxazolidine cores. These 
have demonstrated excellent enantioselectivity in rhodium-catalysed conjugate addition 
reactions, with tert-butyloxazolidine allyl ligand 327c showing the highest 
enantioselectivities. A series of aryl boronic acids have been successfully employed in 
the conjugate addition to 2-cyclohexenone, showing this catalyst-ligand system to be 
general, with good to excellent enantioselectivities obtained. 
 
 
Chapter 6  Conclusions & Future Work   
6. CONCLUSIONS & FUTURE WORK 
6.1 Conclusions 
 
Efforts towards the synthesis of α-quaternary centres in β-alkoxy-α-amino acids 
through an Ireland-Claisen rearrangement have shown the considerable effects that 
substituent size has on the reaction. Nonetheless, a series of individual optimisations 
allowed formation of the desired β-alkoxy-α-amino acids in 11-74% yield, and with 
diastereomeric ratios of 2:1 up to 24:1. 
 
NPhth
O
O
R1
OMe
1) TMSCl (X eq), LHMDS (X eq)
THF, Temp °C to RT
2) CH2N2, Et2O O
MeO
OMe
R1 NPhth
220a-f
11-74%, 2:1 to 24:1 dr
221a-f  
Scheme 133 - Synthesis of α-quaternary β-methoxy-α-amino acids 
In the course of this study, attempts had failed to protect serine with phthalic anhydride. 
However, using the rearrangement of proline methoxyallyl ester 233 as inspiration, 
serine, threonine and cysteine were protected using formaldehyde to form a series of 
heteroprolines. These all underwent rearrangement to give good to excellent 
diastereoselectivities, with moderate to good yields. 
 
 
Scheme 134 – Rearrangement of heteroproline allyl esters 
Of particular interest was the level of remote transfer of chirality seen in the 
rearrangements of the threonine derived substrates. The methyl group located on the 
oxazolidine acts to selectively direct the rearrangement from a single face. 
 
This investigation has sought to combine an Ireland-Claisen rearrangement with the 
self-regeneration of stereocentres strategy pioneered by Seebach. The difficulties 
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involved with such remote levels of stereocontrol can be inferred from the relatively 
scattered literature reports, with limited efficacy, of asymmetric rearrangements with 
chirality outside the cyclic transition state. In this novel rearrangement protocol, the 
chiral directing group is two atoms exopericyclic to the developing C-C bond (Figure 
41). 
 
 
Figure 41 - Exopericyclic nature of the directing group in an Ireland-Claisen rearrangement 
Significantly, the rearrangement showed outstanding levels of diastereoselectivity, with 
complete transfer of chirality achieved. The generality of this reaction has shown to be 
impressive, with both enol ether substrates undergoing facile rearrangement (Scheme 
135), and also those bearing carbon substitution on the allyl ester. A range of functional 
handles have been incorporated into the products, along with protecting groups, 
allowing access to dihydrofurans, benzofurans, spiro-lactones in addition to β,β′-
dihydroxy-α-amino acid derivatives. 
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Scheme 135 - Rearrangement scope: enol ether variation 
When shown in comparison to aldol reactions performed on a similar oxazolidine 
framework, the importance of this reaction can be clearly identified. Allowing 
considerable improvements in selectivity, along with a wide reaction scope, this 
rearrangement shows considerable potential for synthetic utility. 
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The ability to access chiral β,β′-dihydroxy-α-amino acid head groups with such high 
selectivity has allowed the total synthesis of the potent immunosuppressant 
mycestericin G (Figure 42). Both enantiomers of this natural product have been readily 
synthesised, which, along with XRD analysis of o-iodophenoxy rearrangement product 
252i, allowed for a revision in stereochemistry to that previously reported. Using the 
synthetic route developed in the synthesis of mycestericin G, the threonine analogue, 
(2S,3R)-2-amino-3-hydroxy-2-((R)-1-hydroxyethyl)-14-oxoicosanoic acid 296, was also 
successfully synthesised. A key observation from these syntheses, was the effect steric 
interactions made on the success of the cross-metathesis. 
 
 
Figure 42 - Total synthesis of mycestericin G 
Finally, a series of chiral diene ligands were synthesised based around the tert-
butyloxazolidine core. From an extensive ligand screen, it was observed that 
substitution of the allyl olefin reduced either the reactivity, or the enantioselectivity of 
the conjugate addition, whilst the methyloxazolidine core suffered both from both poor 
reactivity and a decrease in enantioselectivity. With the allyl ligand 327c chosen to 
explore the substrate scope, excellent enantioselectivities were obtained in the rhodium-
catalysed conjugate addition reaction of 2-cyclohexenone with a variety of aryl boronic 
acids. 
 
6.2 Future Work 
 
There are several viable areas of research that this body of work could continue to 
explore. Whilst the SRS/Ireland-Claisen methodology has shown its synthetic 
applicability with the total synthesis of mycestericin G, there are several more natural 
products that remain a key target. 
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Figure 43 - Lactacystin 
One particular target, lactacystin (Figure 43), would require further development in two 
key areas of the rearrangement. Firstly, the effects of internal olefin substitution would 
need to be probed. It can be seen from the retrosynthetic analysis that rearrangement of 
a 3-benzyloxy-2-methallyl ester would provide the core chirality required to complete 
the synthesis of 9-epi-lactacystin (Figure 44). However, no attempts have been made in 
this body of work to rearrange tri-substituted olefins of that nature. Secondly, to 
complete the synthesis of lactacystin itself, access to the alternative diastereomer is 
required. Since use of Z-enol ethers were unsuccessful in our attempts to obtain the 
alternative diastereomer, it would be desirable to develop a facile route, perhaps through 
use of a Mitsunobu reaction, to invert the stereochemistry. 
 
 
Figure 44 - Retrosynthesis of 9-epi-lactacystin 
The logical continuation of the rhodium-catalysed conjugate addition is to continue to 
explore the scope of the reaction. Currently, with the sole exception of the 1-
naphthaleneboronic acid, only para-substituted arylboronic acids have been 
investigated. To fully demonstrate the applicability of our catalyst/ligand system, a wide 
range of ortho-/meta-/para- substituted systems, containing both electron rich, and 
electron deficient systems need to be examined. Furthermore, it would be desirable to 
vary the α,β-unsaturated ketone used as the acceptor in this reaction protocol. Not only 
would this incorporate variation in the cyclic ring size, but also attempt the conjugate 
addition on an acyclic substrate. There has been limited success to date in the conjugate 
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addition to an acyclic substrate utilising terminal diene ligands, so this would be a 
useful benchmark for the efficacy of our system.257 
 
Rhodium-catalysed addition reactions of arylborons with aldehydes have recently been 
shown to be an attractive transformation.272-273 The use of ketones has, however, largely 
been limited to activated ketones, such as the trifluoromethyl ketones used by Minnaard 
et al. (Scheme 136). 
 
R
CF3
O Rh(C2H4)2(acac) (3-5 mol%)
ligand (7.5-12.5 mol%)
ArB(OH)2 (3 eq)
MTBE, R
CF3
HO Ar
 
Scheme 136 - Addition of arylboronic acids to trifluoromethyl ketones 
Unactivated ketones, meanwhile, have only been reported to be suitable substrates 
under special conditions. However, Hu et al. have recently reported a rhodium(I)/diene-
catalysed addition reaction of arylborons with ketones.273 With 23 examples they have 
shown this to be a general reaction, with moderate to good enantioselectivities obtained. 
 
 
Scheme 137 - Rh(I)/chiral diene-catalysed addition reactions of arylboronic acids with ketones 
These literature reports provide a vast scope with which to benchmark our tert-
butyloxazolidine diene ligand 327c against, and to hopefully push the boundaries of the 
current synthetic limitations.  
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7. EXPERIMENTAL 
7.1 General Experimental Information 
 
All reactions were carried out using anhydrous solvents and under an inert atmosphere 
of nitrogen.  All reaction vessels were flame dried before use.  Solvents were obtained 
by passing through anhydrous alumina columns using an Innovative Technology Inc. 
PS-400-7 solvent purification system.  All reagents were purchased from commercial 
suppliers: Acros Organics, Alfa Aesar, Sigma Aldrich or Novabiochem and used 
without further purification.  Triethylamine was freshly distilled prior to use and 
chlorotrimethylsilane was freshly distilled from 10 % quinoline.  All distilled materials 
were stored under nitrogen in a fridge.  All reactions were monitored by thin layer 
chromatography (TLC) using pre-coated MN Alugram Sil G/UV254 silica gel 60 
aluminium backed plates.  Plates were developed using standard techniques, UV light 
followed by a chemical dip, usually KMnO4 and gentle heating.  Flash chromatography 
was performed on chromatography grade, silica 60Å particle size 35-70 micron from 
Fisher Scientific using the solvent system as stated. 
 
1H and 13C NMR was performed on Brüker Avance 250 (1H 250 MHz), Brüker Avance 
300 (1H 300 MHz and 13C 75 MHz), Brüker Avance 400 (1H 400 MHz and 13C 100 
MHz) and Brüker Avance 500 (1H 500 MHz and 13C 125 MHz) as stated.  Chemical 
shifts are reported in parts per million (ppm) relative to tetramethylsilane (TMS) (δ = 
0.00). Coupling constants are reported in Hertz (Hz) and signal multiplicity is denoted 
as singlet (s), doublet (d), triplet (t), quartet (q), quintet (quin.), sextet (sex.), septet 
(sept.), multiplet (m), and broad (br). Mass spectroscopy was performed on a Brüker 
μTOF using electrospray ionisation (ESI) in either positive or negative ionisation as 
stated.  Infra-red spectroscopy was carried out using a Perkin Elmer Spectrum RX FT-
IR system with KBr plates, using a thin film. Melting points were determined using a 
Bibby Scientific Melting point apparatus Stuart SMP10 digital. X-ray data was 
collected at 150 K on a Nonius KappaCCD area diffractometer using Mo-Kα radiation 
(λ = 0.71073 Å) and all structures were solved by direct methods and refined on all F2 
data using SHELXL-97 suite of programs. Hydrogen atoms included in idealised 
positions and refined using the riding model. 
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7.2 General Experimental Procedures 
 
General Procedure I for the preparation of Vinylogous Carbonates172 
 
ROH (1.1 eq)
DABCO (10 mol%)
THF, RT, 30 min
OR
MeO2C MeO2C  
 
To a stirred solution of 1,4-diazabicyclo[2.2.2]octane (10 mol%) and alcohol (1.1 eq) in 
THF (150 ml) at room temperature was added methyl propiolate (1.0 eq) via syringe 
pump over 10 minutes, before stirring at room temperature for a further 30 minutes. 
Sodium hydroxide (10% solution, 200 ml) was added and the aqueous was extracted 
with DCM (4 × 100 ml), combined, washed with brine (3 × 150 ml), dried over Na2SO4, 
filtered and concentrated in vacuo. Product ester was isolated after subsequent 
purification by flash chromatography. 
 
General Procedure II for the preparation of Synthesis of Enol Ethers172 
 
 
 
To a stirred solution of trans-methyl 3-alkoxyacrylate (1.0 eq) in toluene (10 mL) at -78 
°C was added DIBAL-H (1M in tol., 2.5 eq) at a rate of 1 mL min-1.  After addition the 
reaction was stirred at -78 °C for 4-8 hrs before being poured into an ice-cold solution 
of saturated Rochelle salt (150 mL) and EtOAc (150 mL).  The biphasic mixture was 
stirred vigorously at room temperature for 2 hours before extracting with EtOAc (3 × 75 
mL).  The organics were combined, dried over Na2SO4, filtered and concentrated in 
vacuo to afford the enol ether without the need for further purification. 
 
General Procedure III for the preparation of N-Phthaloyl Amino Acids 
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To a stirred solution of amino acid (1.0 eq) and phthalic anhydride (1.01 eq) in toluene 
was added triethylamine (1.0 eq) and refluxed under Dean-Stark conditions until the 
heterogeneous mixture went into solution and sufficient water had been evolved (~ 24 
hrs).  The solution was allowed to cool to room temperature and washed with 10% citric 
acid (aq) (3 × 75 mL), back extracted with EtOAc (1 × 100 mL), dried and concentrated 
in vacuo to afford the N-phthaloyl amino acid without the need for further purification. 
 
General Procedure IV for Carbodiimide Promoted Coupling Reactions 
 
 
 
To a stirred solution of N-protected amino acid (2.0 eq) in DCM was added EDCi.HCl 
(2.0 eq), triethylamine (2.0 eq), catalytic DMAP (5 mol%) and the enol ether (1.0 eq).  
The reaction is stirred at room temperature until consumption of enol ether was 
observed by TLC.  The reaction mixture was diluted with DCM (30 mL) before 
washing with NaHCO3 (sat) (3 × 50 mL), 10% citric acid (3 × 50 mL), brine (1 × 50 
mL) and dried over Na2SO4.  Concentration in vacuo afforded the enol amino esters 
without the need for further purification. 
 
General Procedure V for the preparation of Amino Acid Methyl Esters 
Hydrochloride 
 
 
 
To a solution of amino acid (1.0 eq) in MeOH (350 mL) at 0 °C was added thionyl 
chloride (2.0-7.0 eq) dropwise.  The reaction mixture was allowed to warm to room 
temperature and stirred for 18 hours. Solvent was removed in vacuo and crude solid was 
re-dissolved in acetone (50 mL) and concentrated in vacuo to afford amino acid methyl 
esters without the need for further purification. 
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General Procedure VI for the preparation of N-Boc Heteroprolines184  
 
 
 
A solution of amino acid (1.0 eq) and formaldehyde (37% aq, 1.2 eq) in 2N NaOH (15 
mL) was allowed to stand in the fridge overnight.  Then NH2OH.HCl (0.1 eq), NaOH 
(0.1 eq) in H2O (2.5 mL) and acetone (17.5 mL) was added at 0 °C.  Boc2O (1.1 eq) was 
added at room temperature and the reaction mixture stirred for a further 3 hours.  The 
reaction mixture was diluted with water (50 mL) and washed with Et2O (1 × 50 mL).  
The aqueous phase was acidified to pH 3 with 20% citric acid and extracted with EtOAc 
(3 × 50 mL), dried over Na2SO4 and concentrated in vacuo to afford N-Boc 
heteroproline. 
 
General Procedure VII for the Ireland-Claisen Rearrangement of Oxazolidine 
Allyl Esters 
 
 
 
To a stirred solution of oxazolidine allyl ester (1.0 eq) in THF at -78 °C was added 
TMSCl (3.0 eq).  After 10 mins LHMDS (1M, 3.0 eq) was added via syringe pump at 
an addition rate of 10 mL hr-1 and the reaction mixture allowed to warm to room 
temperature after a period of 30 mins, and stirred for 18 hours.  The reaction was 
quenched by the addition of 1N HCl and brine solution (1:1) and extracted with DCM 
(3 × 15 mL) and EtOAc (1 × 15 mL). The organic layers were dried over Na2SO4 and 
concentrated in vacuo to afford the crude acid.  Treatment with diazomethane 
(according to general procedure VIII) affords the crude amino ester. 
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General Procedure VIII for the Diazomethane Methylation of Carboxylic Acids 
 
 
 
To a solution of the crude acid (1.0 eq) in diethyl ether at 0 °C was added an ethereal 
solution of diazomethane generated from N-nitrosomethyl urea (2.0 eq) and KOH 
(37%) using sigma aldrich’s mini diazald kit. Once esterification was complete (yellow 
colour persists), the mix was quenched with glacial acetic acid then basified with 
NaHCO3 (sat). The organics were extracted with EtOAc (5 × 15 ml), dried over MgSO4, 
filtered and concentrated in vacuo. 
 
General Procedure IX for the Deprotection and Acid Hydrolysis of N-Boc 
Oxazolidines 
 
 
 
To a solution of N-Boc oxazolidine (1.0 eq) in MeOH was added 6N HCl (20 eq) and 
the reaction mixture refluxed until consumption of starting material was observed by 
TLC.  The reaction mixture was allowed to cool to room temperature and concentrated 
in vacuo to afford the crude hydrochloride salt. This was treated with saturated sodium 
bicarbonate (20 mL) and extracted with DCM (3 × 10 mL), dried over anhydrous 
magnesium sulphate and concentrated in vacuo to afford the crude amino esters. 
 
General Procedure X for Rhodium-Catalysed Conjugate Additions 
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A solution of boronic acid (1.5 eq), bis(ethylene)rhodium(I) chloride dimer (2.5 mol%) 
and ligand (6 mol%) in 1,4-dioxane (0.9 mL) was allowed to stir at room temperature 
for 15 minutes. 2-Cyclohexenone and potassium hydroxide (aq) (0.075M, 10 mol%) 
were added and the reaction mixture immediately concentrated in vacuo and purified by 
flash chromatography to afford the pure arylcyclohexanones. 
 
7.3 Compound Characterisation 
 
(E)-Methyl 3-ethoxyacrylate (217b) 
 
 
 
DABCO (270 mg, 2.38 mmol) in THF (200 mL), ethanol (1.21 g, 26.2 mmol) and 
methyl propiolate (2.12 mL, 23.8 mmol) were combined according to general procedure 
I (reaction time: 45 minutes). Purified by flash chromatography (10:1 Pet/EtOAc) to 
afford the pure vinylogous carbonate as a colourless oil (2.72 g, 88%). 1H NMR 
(500MHz, CDCl3) δH 1.31 (3H, t, J = 7.0 Hz), 3.66 (3H, s), 3.88 (2H, q, J = 7.0 Hz), 
5.17 (1H, d, J = 12.6 Hz), 7.56 (1H, d, J = 12.6 Hz); 13C NMR (125MHz, CDCl3) δC 
14.4, 51.0, 66.7, 96.0, 162.4, 168.3. All analytical data is in accordance with reported 
literature values.172 
 
(E)-Methyl 3-isopropoxyacrylate (217c)  
 
 
 
DABCO (270 mg, 2.38 mmol) in THF (200 mL), propan-2-ol (1.57 g, 26.2 mmol) and 
methyl propiolate (2.12 mL, 23.8 mmol) were combined according to general procedure 
I (reaction time: 30 minutes). Purified by flash chromatography (10:1 Pet/EtOAc) 
followed by distillation under vacuum to afford the pure vinylogous carbonate as a 
colourless oil (2.27 g, 73%).  1H NMR (500MHz, CDCl3) δH 1.24 (6H, d, J = 6.2 Hz), 
3.63 (3H, s), 4.18 (1H, sept, J = 6.2 Hz), 5.18 (1H, d, J = 12.5 Hz), 7.47 (1H, d, J = 12.5 
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Hz); 13C NMR (125MHz, CDCl3) δC 21.9, 50.8, 75.5, 96.8, 161.6, 168.4. All analytical 
data is in accordance with reported literature values.173 
 
 (E)-Methyl 3-(allyloxy)acrylate (217d) 
 
 
 
DABCO (270 mg, 2.38 mmol) in THF (100 mL), allyl alcohol (1.37 g, 23.6 mmol) and 
methyl propiolate (2.12 mL, 23.8 mmol) were combined according to general procedure 
I (reaction time: 40 minutes). Purified by flash chromatography (10:1 Pet/EtOAc) to 
afford the pure vinylogous carbonate as a colourless oil (2.85 g, 85%).  1H NMR 
(500MHz, CDCl3) δH 3.60 (3H, s), 4.30 (2H, dt, J = 5.3, 1.5 Hz), 5.16 (1H, d, J = 12.6 
Hz), 5.22 (1H, dq, J = 10.3, 1.5 Hz), 5.28 (1H, dq, J = 17.2, 1.5 Hz), 5.85 (1H, ddt, J = 
17.2, 10.3, 5.3 Hz), 7.49 (1H, d, J = 12.6 Hz); 13C NMR (125MHz, CDCl3) δC 50.9, 
71.5, 96.8, 118.7, 131.7, 161.9, 167.9. All analytical data is in accordance with reported 
literature values.172  
 
(E)-Methyl 3-(prop-2-ynyloxy)acrylate (217e) 
 
 
 
DABCO (204 mg, 1.82 mmol) in THF (250 mL), propargyl alcohol (1.16 mL, 20.0 
mmol) and methyl propiolate (1.62 mL, 18.2 mmol) were combined according to 
general procedure I (reaction time: 45 minutes). Purified by flash chromatography (10:1 
Pet/EtOAc) to afford the pure vinylogous carbonate as a colourless oil (2.19 g, 86%).  
1H NMR (500MHz, CDCl3) δH 2.60 (1H, t, J = 2.6 Hz), 3.71 (3H, s), 4.53 (2H, d, J = 
2.6 Hz), 5.35 (1H, d, J = 12.7 Hz), 7.58 (1H, d, J = 12.7 Hz); 13C NMR (125MHz, 
CDCl3) δC 51.2, 58.1, 76.6, 77.0, 98.3, 160.6, 167.6. All analytical data is in accordance 
with reported literature values.173  
 
 
 
  | 142 
Chapter 7  Experimental   
(E)-Methyl 3-phenoxyacrylate (217f) 
 
 
 
DABCO (270 mg, 2.38 mmol) in THF (200 mL), phenol (2.46 g, 26.2 mmol) and 
methyl propiolate (2.12 mL, 23.8 mmol) were combined according to general procedure 
I (reaction time: 45 minutes). Purified by flash chromatography (10:1 Pet/EtOAc) to 
afford the pure vinylogous carbonate as a colourless oil (4.34 g, 98%).  1H NMR 
(500MHz, CDCl3) δH 3.74 (3H, s), 5.58 (1H, d, J = 12.4 Hz), 7.08 (2H, d, J = 8.4 Hz), 
7.21 (1H, t, J = 7.5 Hz), 7.39 (2H, t, J = 7.5 Hz), 7.83 (1H, d, J = 12.4 Hz);  13C NMR 
(125MHz, CDCl3) δC 51.3, 101.8, 118.0, 125.0, 130.0, 155.9, 159.2, 167.6. All 
analytical data is in accordance with reported literature values.172 
 
(E)-Methyl 3-(4-methoxyphenoxy)acrylate (217g) 
 
 
 
DABCO (270 mg, 2.38 mmol) in THF (200 mL), 4-methoxyphenol (3.25 g, 26.2 mmol) 
and methyl propiolate (2.12 mL, 23.8 mmol) were combined according to general 
procedure I (reaction time: 45 minutes). Purified by flash chromatography (6:1 
Pet/EtOAc) to afford the pure vinylogous carbonate as a colourless oil (4.49 g, 91%).  
1H NMR (500MHz, CDCl3) δH 3.73 (3H, s), 3.81 (3H, s), 5.48 (1H, d, J = 12.6 Hz), 
6.89 (2H, m), 7.00 (2H, m), 7.76 (1H, d, J = 12.6 Hz); 13C NMR (125MHz, CDCl3) δC 
51.7, 56.1, 101.3, 115.3, 119.8, 149.9, 157.3, 160.8, 168.2. All analytical data is in 
accordance with reported literature values.172 
 
(E)-Methyl 3-(4-(trifluoromethyl)phenoxy)acrylate (217h) 
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DABCO (135 mg, 1.19 mmol) in THF (200 mL), 4-(trifluoromethyl)phenol (2.12 g, 
13.1 mmol) and methyl propiolate (1.06 mL, 11.9 mmol) were combined according to 
general procedure I (reaction time: 45 minutes). Purified by flash chromatography (15:1 
Pet/EtOAc) to afford the pure vinylogous carbonate as a colourless oil (2.72 g, 93%).  
Mpt: 60-61 °C; 1H NMR (500MHz, CDCl3) δH 3.74 (3H, s), 5.66 (1H, d, J = 12.2 Hz), 
7.16 (2H, m), 7.64 (2H, m), 7.80 (1H, d, J = 12.2 Hz); 13C NMR (125MHz, CDCl3) δC 
51.4, 103.6, 117.8, 122.7, 124.9, 127.4 (q, J = 3.6 Hz), 157.2, 158.1, 167.1. All 
analytical data is in accordance with reported literature values.172 
 
(E)-Methyl 3-(2-iodophenoxy)acrylate (217i) 
 
 
 
DABCO (116 mg, 1.03 mmol) in THF (200 mL), 2-iodophenol (2.50 g, 11.4 mmol) and 
methyl propiolate (916 μL, 10.3 mmol) were combined according to general procedure I 
(reaction time: 45 minutes). Purified by flash chromatography (6:1 Pet/EtOAc) to afford 
the pure vinylogous carbonate as a colourless oil (2.91 g, 93%).  1H NMR (500MHz, 
CDCl3) δH 3.74 (3H, s), 5.52 (1H, d, J = 12.4 Hz), 6.96 (1H, t, J = 7.5 Hz), 7.07 (1H, d, 
J = 7.5 Hz), 7.38 (1H, t, J = 7.8 Hz), 7.72 (1H, d, J = 12.4 Hz), 7.85 (1H, d, J = 7.8 Hz); 
13C NMR (125MHz, CDCl3) δC 51.4, 87.8, 102.3, 119.1, 127.0, 130.0, 140.0, 155.1, 
159.0, 167.3. All analytical data is in accordance with reported literature values.172 
 
(E)-Methyl 3-(benzyloxy)acrylate (217j) 
 
 
 
DABCO (110 mg, 0.970 mmol) in THF (40 mL), benzyl alcohol (1.08 g, 9.99 mmol) 
and methyl propiolate (890 μL, 9.99 mmol) were combined according to general 
procedure I (reaction time: 40 minutes). Purified by flash chromatography (10:1 
Pet/EtOAc) followed by distillation under vacuum to afford the pure vinylogous 
carbonate as a colourless oil (1.65 g, 86%).  1H NMR (500MHz, CDCl3) δH 3.71 (3H, 
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s), 4.91 (2H, s), 5.34 (1H, d, J = 12.7 Hz), 7.34–7.42 (5H, m), 7.69 (1H, d, J = 12.7 Hz); 
13C NMR (125MHz, CDCl3) δC 51.1, 72.9, 97.2, 127.7, 128.5, 128.7, 135.2, 162.1, 
168.0. All analytical data is in accordance with reported literature values.172 
 
(E)-Methyl 3-(4-methoxybenzyloxy)acrylate (217k) 
 
  
 
DABCO (270 mg, 2.38 mmol) in THF (200 mL), 4-methoxybenzyl alcohol (3.25 mL, 
26.2 mmol) and methyl propiolate (2.12 mL, 23.8 mmol) were combined according to 
general procedure I (reaction time: 30 minutes). Purified by flash chromatography (10:1 
Pet/EtOAc) to afford the pure vinylogous carbonate as a colourless oil (4.92 g, 93%).  
1H NMR (500MHz, CDCl3) δH 3.71 (3H, s), 3.83 (3H, s), 4.84 (2H, s), 5.32 (1H, d, J = 
12.5 Hz), 6.92 (2H, m), 7.28 (2H, m), 7.67 (1H, d, J = 12.5 Hz); 13C NMR (125MHz, 
CDCl3) δC 51.1, 55.3, 72.8, 97.0, 114.1, 127.2, 129.6, 159.9, 162.2, 168.1. All analytical 
data is in accordance with reported literature values.172 
 
(E)-Methyl 3-(2,6-dichlorobenzyloxy)acrylate (217l) 
 
 
 
DABCO (270 mg, 2.38 mmol) in THF (300 mL), 2,6-dichlorobenzyl alcohol (4.63 g, 
26.2 mmol) and methyl propiolate (2.12 mL, 23.8 mmol) were combined according to 
general procedure I (reaction time: 30 minutes). Purified by flash chromatography (10:1 
Pet/EtOAc) to afford the pure vinylogous carbonate as a colourless oil (3.82 g, 62%).  
1H NMR (500MHz, CDCl3) δH 3.73 (3H, s), 5.16 (2H, s), 5.39 (1H, d, J = 12.6 Hz), 
7.25–7.28 (1H, m), 7.35 (1H, s), 7.37 (1H, s), 7.71 (1H, d, J = 12.6 Hz); 13C NMR 
(125MHz, CDCl3) δC 51.2, 67.5, 97.1, 128.5, 130.7, 131.0, 137.0, 162.1, 167.9. All 
analytical data is in accordance with reported literature values.173 
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(E)-Methyl 3-(2-iodobenzyloxy)acrylate (217m) 
 
 
 
DABCO (270 mg, 2.38 mmol) in THF (200 mL), 2-iodobenzyl alcohol (6.12 g, 26.2 
mmol) and methyl propiolate (2.12 mL, 23.8 mmol) were combined according to 
general procedure I (reaction time: 45 minutes). Purified by flash chromatography (6:1 
Pet/EtOAc) to afford the pure vinylogous carbonate as a colourless oil (6.85 g, 91%).  
1H NMR (500MHz, CDCl3) δH 3.73 (3H, s), 4.91 (2H, s), 5.37 (1H, d, J = 12.5 Hz), 
7.04–7.07 (1H, m), 7.36–7.40 (2H, m), 7.71 (1H, d, J = 12.5 Hz), 7.87 (1H, d, J = 8.1 
Hz); 13C NMR (125MHz, CDCl3) δC 51.2, 76.4, 97.4, 97.5, 128.5, 128.8, 130.1, 137.5, 
139.5, 161.7, 167.9. All analytical data is in accordance with reported literature 
values.172 
 
(E)-Methyl 3-isobutoxyacrylate (217n) 
 
 
 
DABCO (270 mg, 2.38 mmol) in THF (200 mL), 2-methyl-1-propanol (2.42 g, 26.2 
mmol) and methyl propiolate (2.12 mL, 23.8 mmol) were combined according to 
general procedure I (reaction time: 45 minutes). Purified by flash chromatography (6:1 
Pet/EtOAc) to afford the pure vinylogous carbonate as a colourless oil (3.24 g, 86%).  
1H NMR (500MHz, CDCl3) δH 0.91 (6H, d, J = 6.7 Hz), 1.95 (1H, oct, J = 6.7 Hz), 3.56 
(2H, d, J = 6.7 Hz), 3.64 (3H, s), 5.14 (1H, d, J = 12.7 Hz), 7.55 (1H, d, J = 12.7 Hz); 
13C NMR (125MHz, CDCl3) δC 18.8, 28.0, 50.9, 77.4, 95.8, 162.8, 168.2. All analytical 
data is in accordance with reported literature values.172 
 
(E)-Methyl 3-(cyclohexyloxy)acrylate (217o) 
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DABCO (270 mg, 2.38 mmol) in THF (400 mL), cyclohexanol (2.62 g, 26.2 mmol) and 
methyl propiolate (2.12 mL, 23.8 mmol) were combined according to general procedure 
I (reaction time: 1 hour). Purified by flash chromatography (15:1 Pet/EtOAc) to afford 
the pure vinylogous carbonate as a colourless oil (1.58 g, 36%).  FTIR (film/cm-1) υmax: 
2937, 2861, 1707, 1638, 1619; 1H NMR (500MHz, CDCl3) δH 1.23–1.56 (6H, m), 1.71–
1.76 (2H, m), 1.89–1.93 (2H, m), 3.69 (3H, s), 3.93 (1H, sept, J = 4.1 Hz), 5.25 (1H, d, 
J = 12.7 Hz), 7.56 (1H, d, J = 12.7 Hz); 13C NMR (125MHz, CDCl3) δC 23.4, 25.2, 
31.8, 51.0, 81.0, 96.8, 161.8, 168.6; HRMS (ESI, +ve) m/z calcd. for C10H16O3Na 
207.0997, found: 207.0994 (M+Na)+. 
 
(E)-Methyl 3-(but-3-en-2-yloxy)acrylate (217p) 
 
  
 
DABCO (204 mg, 1.82 mmol) in THF (200 mL), 3-buten-2-ol (1.44 g, 20.0 mmol) and 
methyl propiolate (1.62 mL, 18.2 mmol) were combined according to general procedure 
I (reaction time: 30 minutes). Purified by flash chromatography (10:1 Pet/EtOAc) to 
afford the pure vinylogous carbonate as a colourless oil (2.30 g, 81%).  FTIR (film/cm-
1) υmax: 2986, 2952, 1708, 1639, 1621; 1H NMR (500MHz, CDCl3) δH 1.26 (3H, d, J = 
6.4 Hz), 3.56 (3H, s), 4.39 (1H, app. quin, J = 6.4 Hz), 5.09–5.18 (3H, m), 5.70 (1H, 
ddd, J = 17.1, 10.5, 6.4 Hz), 7.40 (1H, d, J = 12.5 Hz); 13C NMR (125MHz, CDCl3) δC 
20.5, 50.7, 79.4, 97.5, 116.9, 137.5, 161.2, 168.0; HRMS (ESI, +ve) m/z calcd. for 
C8H12O3Na 179.0684, found: 179.0676 (M+Na)+. 
 
(E)-3-(Methoxy)prop-2-enol (218a) 
 
 
 
Methyl trans-3-methoxyacrylate (1.85 mL, 17.2 mmol) was reduced according to 
general procedure II (reaction time: 4 hours) to afford the product as a yellow oil (1.17 
g, 77%).  1H NMR (500 MHz, d6-acetone ) δH 3.35 (1H, t, J = 5.7 Hz), 3.51 (3H, s), 
3.96 (2H, app. t, J = 7.0 Hz), 4.96 (1H, dt, J = 12.7, 7.0 Hz), 6.51 (1H, d, J = 12.7 Hz); 
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13C NMR (125 MHz, d6-acetone ) δC 55.1, 59.1, 102.9, 149.5. All analytical data is in 
accordance with literature precedence.172 
 
(E)-3-Ethoxyprop-2-en-1-ol (218b) 
 
 
 
(E)-methyl 3-ethoxyacrylate (1.59 g, 12.2 mmol) was reduced according to general 
procedure II (reaction time: 6 hours) to afford the product as a colourless oil (1.10 g, 
88%).  1H NMR (500MHz, DMSO) δH 1.19 (3H, t, J = 7.1 Hz), 3.70 (2H, q, J = 7.1 
Hz), 3.83 (2H, ddd, J = 5.6, 4.7, 1.3 Hz), 4.40 (1H, t, J = 5.6 Hz), 4.86 (1H, dt, J = 12.9, 
6.9 Hz), 6.42 (1H, d, J = 12.9 Hz); 13C NMR (125MHz, DMSO) δC 15.1, 59.0, 64.6, 
104.4, 148.5. All analytical data is in accordance with literature precedence.172 
 
(E)-3-Isopropoxyprop-2-en-1-ol (218c) 
 
 
 
(E)-Methyl 3-isopropoxyacrylate (2.08 g, 14.4 mmol) was reduced according to general 
procedure II (reaction time: 4 hours) to afford the product as a colourless oil (1.41 g, 
76%).  1H NMR (500MHz, d6-acetone) δH 1.15 (6H, d, J = 6.2 Hz), 3.81 (2H, app. t, J = 
6.5 Hz), 4.00 (1H, quin, J = 6.2 Hz), 4.36 (1H, t, J = 5.4 Hz), 4.88 (1H, dt, J = 12.5, 6.5 
Hz), 6.33 (1H, d, J = 12.5 Hz); 13C NMR (125MHz, d6-acetone) δC 22.4, 59.0, 72.3, 
105.7, 147.6. All analytical data is in accordance with literature precedence.173 
 
(E)-3-(Allyloxy)prop-2-en-1-ol (218d) 
 
 
 
(E)-Methyl 3-(allyloxy)acrylate (1.38 g, 12.1 mmol) was reduced according to general 
procedure II (reaction time: 6 hours) to afford the product as a yellow oil (0.78 g, 71%).  
1H NMR (500 MHz, d6-DMSO) δH 3.83 (2H, ddd, J = 7.0, 5.5, 1.2 Hz), 4.21 (2H, dt, J 
= 5.3, 1.7 Hz), 4.43 (1H, t, J = 5.5 Hz), 4.92 (1H, dt, J = 13.8, 7.0 Hz), 5.20 (1H, dq, J = 
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10.4, 1.7 Hz), 5.31 (1H, dq, J = 17.3, 1.7 Hz), 5.94 (1H, ddt, J = 17.3, 10.4, 5.3 Hz), 
6.44 (1H, d, J = 13.8 Hz); 13C NMR (125 MHz, d6-DMSO) δC 58.5, 69.9, 105.1, 117.6, 
134.3, 148.2. All analytical data is in accordance with literature precedence.172 
 
(E)-3-(Prop-2-ynyloxy)prop-2-en-1-ol (218e) 
 
 
 
(E)-methyl 3-(prop-2-ynyloxy)acrylate (2.07 g, 14.8 mmol) was reduced according to 
general procedure II (reaction time: 6 hours) to afford the product as a colourless oil 
(1.37 g, 83%).  1H NMR (500MHz, d6-acetone) δH 2.60 (1H, dt, J = 2.4, 0.8 Hz), 4.06 
(2H, d, J = 7.2 Hz), 4.43 (2H, d, J = 2.4 Hz), 5.17 (1H, dt, J = 12.7, 7.2 Hz), 6.52 (1H, 
d, J = 12.7 Hz); 13C NMR (125MHz, d6-acetone) δC 57.0, 60.1, 75.3, 78.5, 105.4, 148.1. 
All analytical data is in accordance with literature precedence.173 
 
(E)-3-Phenoxyprop-2-en-1-ol (218f) 
 
 
 
(E)-Methyl 3-(phenyloxy)acrylate (1.02 g, 6.79 mmol) was reduced according to 
general procedure II (reaction time: 6 hours) to afford the product as a colourless oil 
(0.60 g, 53%). 1H NMR (500 MHz, d6-acetone ) δH 3.70 (1H, t, J = 5.4 Hz), 4.11 (2H, 
app. t, J = 6.6 Hz), 5.49 (1H, dt, J = 12.3, 6.6 Hz), 6.81 (1H, d, J = 12.3 Hz), 7.04 (2H, 
d, J = 8.4 Hz), 7.08 (1H, t, J = 7.5 Hz), 7.36 (2H, d, J = 7.5 Hz); 13C NMR (125 MHz, 
d6-acetone ) δ: 58.4, 112.5, 116.4, 122.8, 129.7, 143.8, 157.2. All analytical data is in 
accordance with literature precedence.172 
 
(E)-3-(4-Methoxyphenoxy)prop-2-en-1-ol (218g) 
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(E)-Methyl 3-(4-methoxyphenoxy)acrylate (1.15 g, 5.52 mmol) was reduced according 
to general procedure II (reaction time: 6 hours) to afford the product as a colourless oil 
(0.64 g, 64%).  1H NMR (500MHz, d6-acetone) δH 4.10 (1H, t, J = 5.6 Hz), 4.28 (3H, s), 
4.58 (2H, app. t, J = 5.6 Hz), 5.88 (1H, dt, J = 12.2, 6.7 Hz), 7.22 (1H, d, J = 12.2 Hz), 
7.42 (2H, m, ArH), 7.48 (2H, m, ArH); 13C NMR (125MHz, d6-acetone) δC 55.0, 58.5, 
111.0, 114.7, 117.9, 145.3, 150.9, 155.7. All analytical data is in accordance with 
literature precedence.172 
 
(E)-3-(4-(Trifluoromethyl)phenoxy)prop-2-en-1-ol (218h) 
 
 
 
(E)-Methyl 3-(4-(trifluoromethyl)phenoxy)acrylate (2.55 g, 10.4 mmol) was reduced 
according to general procedure II (reaction time: 6 hours) to afford the product as a 
colourless oil (2.14 g, 95%).  1H NMR (500MHz, d6-acetone) δH 3.76 (1H, br s), 3.96 
(2H, dd, J = 6.5, 1.3 Hz), 5.43 (1H, dt, J = 12.0, 6.5 Hz), 6.66 (1H, dt, J = 12.0, 1.3 Hz), 
6.98 (2H, m), 7.44 (2H, m); 13C NMR (125MHz, d6-acetone) δC 59.6, 116.0, 117.7, 
125.3, 127.6, 128.4 (q, J =4.0 Hz), 143.8, 161.1. All analytical data is in accordance 
with literature precedence.172 
 
(E)-3-(2-Iodophenoxy)prop-2-en-1-ol (218i) 
 
 
 
(E)-Methyl 3-(2-iodophenoxy)acrylate (1.34 g, 4.41 mmol) was reduced according to 
general procedure II (reaction time: 6 hours) to afford the product as a colourless oil 
(1.00 g, 82%).  1H NMR (500MHz, d6-acetone) δH 3.59 (1H, t, J = 5.7 Hz), 3.99 (2H, dt, 
J = 5.7, 1.4 Hz), 5.40 (1H, dt, J = 12.1, 6.6 Hz), 6.63 (1H, dt, J = 12.1, 1.4 Hz), 6.97 
(1H, dd, J = 7.5, 1.4 Hz), 7.25–7.31 (1H, m), 7.72 (1H, dd, J = 7.9, 1.4 Hz); 13C NMR 
(125MHz, d6-acetone) δC 59.6, 87.4, 115.0, 117.7, 126.2, 131.2, 141.0, 144.9, 157.6. All 
analytical data is in accordance with literature precedence.172 
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(E)-3-(Benzyloxy)prop-2-enol (218j) 
 
 
(E)-Methyl 3-(benzyloxy)acrylate (2.15 g, 11.2 mmol) was reduced according to 
general procedure II (reaction time: 4 hours) to afford the product as a colourless oil 
(1.56 g, 80%).  1H NMR (500 MHz, d6-DMSO) δH 3.86 (2H, t, J = 6.3 Hz), 4.47 (1H, t, 
J = 5.3 Hz), 4.75 (2H, s), 5.02 (1H, m), 6.55 (1H, d, J = 13.1 Hz), 7.32–7.39 (5H, m); 
13C NMR (125 MHz, d6-DMSO) δC 58.9, 71.0, 105.4, 126.9, 128.2, 128.8, 137.7, 148.4. 
All analytical data is in accordance with literature precedence.172 
 
(E)-3-(4-Methoxybenzyloxy)prop-2-en-1-ol (218k) 
 
 
 
(E)-Methyl 3-(4-methoxybenzyloxy)acrylate (4.88 g, 21.9 mmol) was reduced 
according to general procedure II (reaction time: 7 hours) to afford the product as a 
colourless oil (3.82 g, 90%).  1H NMR (500MHz, DMSO) δH 3.75 (3H, s), 3.84 (2H, t, J 
= 5.6 Hz), 4.45 (1H, t, J = 5.6 Hz), 4.66 (2H, s), 4.98 (1H, dt, J = 12.8, 7.1 Hz), 6.52 
(1H, d, J = 12.8 Hz), 6.93 (2H, m), 7.29 (2H, m);  13C NMR (125MHz, DMSO) δC 55.5, 
58.9, 70.8, 105.2, 113.9, 128.4, 129.6, 148.4, 159.4. All analytical data is in accordance 
with literature precedence.172 
 
(E)-Methyl 3-(2,6-dichlorobenzyloxy)acrylate (218l) 
 
 
 
(E)-Methyl 3-(2,6-dichlorobenzyloxy)acrylate (2.36 g, 9.03 mmol) was reduced 
according to general procedure II (reaction time: 4 hours) to afford the product as a 
colourless oil (1.93 g, 91%).  Mpt: 80–83 °C; 1H NMR (500MHz, d6-acetone) δH 3.46 
(1H, t, J = 5.9 Hz), 4.02 (2H, app. t, J = 6.8 Hz), 5.03 (2H, s), 5.34 (1H, dt, J = 12.4, 6.8 
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Hz), 6.63 (1H, d, J = 12.4 Hz), 7.41–7.51 (3H, m); 13C NMR (125MHz, d6-acetone) δC 
59.2, 65.5, 104.8, 128.6, 131.0, 132.4, 136.5, 148.2. All analytical data is in accordance 
with literature precedence.173 
 
(E)-3-(2-Iodobenzyloxy)prop-2-en-1-ol (218m) 
 
 
 
(E)-Methyl 3-(2-Iodobenzyloxy)acrylate 1.08 g, 3.72 mmol) was reduced according to 
general procedure II (reaction time: 6 hours) to afford the product as a colourless oil 
(0.88 g, 89%).  1H NMR (500MHz, d6-acetone) δH 3.44 (1H, t, J = 5.3 Hz), 4.01 (2H, t, 
J = 7.0 Hz), 4.78 (2H, s), 5.14 (1H, dt, J = 12.3, 7.0 Hz), 6.63 (1H, d, J = 12.3 Hz), 7.11 
(1H, td, J = 7.6, 1.7 Hz), 7.43–7.50 (2H, m), 7.91 (1H, dd, J = 7.6, 1.0 Hz); 13C NMR 
(125MHz, d6-acetone) δC 59.2, 74.6, 97.2, 105.2, 128.4, 129.0, 129.7, 139.3, 139.5, 
148.1. All analytical data is in accordance with literature precedence.172 
 
(E)-3-Isobutoxyprop-2-en-1-ol (218n) 
 
 
 
(E)-Methyl 3-isobutyloxyacrylate (1.38 g, 10.6 mmol) was reduced according to general 
procedure II (reaction time: 6 hours) to afford the product as a colourless oil (1.19 mg, 
86%).  1H NMR (500MHz, d6-acetone) δH 0.79 (6H, d, J = 6.7 Hz), 1.77 (1H, oct, J = 
6.7 Hz), 3.15 (1H, t, J = 5.5 Hz), 3.32 (2H, d, J = 6.7 Hz), 3.81 (2H, ddd, J = 7.0, 5.5, 
1.1 Hz), 4.82 (1H, dt, J = 12.6, 7.0 Hz), 6.35 (1H, d, J = 12.6 Hz); 13C NMR (125MHz, 
d6-acetone) δC 19.7, 29.3, 60.7, 76.5, 104.9, 150.3. All analytical data is in accordance 
with literature precedence.172 
 
(E)-3-(Cyclohexyloxy)prop-2-en-1-ol (218o) 
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(E)-Methyl 3-(cyclohexyloxy)acrylate (838 mg, 4.55 mmol) was reduced according to 
general procedure II (reaction time: 4 hours) to afford the product as a yellow oil (525 
mg, 74%). FTIR (film/cm-1) υmax: 3338, 2932, 2858, 1669, 1649; 1H NMR (500MHz, 
d6-acetone) δH 1.21–1.56 (6H, m), 1.67–1.77 (2H, m), 1.79–1.91 (2H, m), 3.27 (1H, t, J 
= 5.6 Hz), 3.71–3.79 (1H, m), 3.91–3.97 (2H, m), 5.01 (1H, dt, J = 12.4, 7.2 Hz), 6.39 
(1H, d, J = 12.4 Hz); 13C NMR (125MHz, d6-acetone) δC 23.3, 25.3, 31.8, 59.3, 77.4, 
105.1, 147.6. 
 
(E)-3-(But-3-en-2-yloxy)prop-2-en-1-ol (218p) 
 
 
 
(E)-Methyl 3-(but-3-en-2-yloxy)acrylate (2.27 g, 14.5 mmol) was reduced according to 
general procedure II (reaction time: 4 hours) to afford the product as a yellow oil (1.33 
g, 72%). FTIR (film/cm-1) υmax: 3393, 2979, 2931, 2872, 1670, 1652; 1H NMR 
(500MHz, d6-acetone) δH 1.26 (3H, d, J = 6.4 Hz), 3.33 (1H, t, J = 5.6 Hz), 3.93 (2H, 
app. t, J = 6.4 Hz), 4.35 (1H, app. p, J = 6.4 Hz), 5.03 (1H, dt, J = 12.4, 7.1 Hz), 5.13 
(1H, dt, J = 10.6, 1.4 Hz), 5.24 (1H, dt, J = 17.3, 1.4 Hz), 5.82 (1H, ddd, J = 17.3, 10.6, 
6.4 Hz), 6.37 (1H, d, J = 12.4 Hz); 13C NMR (125MHz, d6-acetone) δC 20.2, 59.3, 76.7, 
105.7, 114.9, 139.5, 147.4. 
 
2-(1,3-Dioxoisoindolin-2-yl)propanoic acid (219b) 
 
 
 
DL-Alanine (1.10 g, 12.3 mmol) in toluene (50 mL), phthalic anhydride (1.84 g, 12.4 
mmol) and triethylamine (1.74 mL, 12.3 mmol) were combined according to general 
procedure III (reaction time: 24 hours) to afford the title compound as a white powder 
(2.13 g, 79%). Mpt: 164-165 °C (lit.274 163 °C); FTIR (film/cm-1) υmax: 3050, 2922, 
2853, 1780, 1764, 1709; 1H NMR (300MHz, CDCl3) δH 1.66 (3H, d, J = 7.4 Hz3), 4.98 
(1H, q, J = 7.4 Hz), 7.62–7.71 (2H, m), 7.76–7.85 (2H, m), 10.02 (1H, bs); 13C NMR 
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(75MHz, CDCl3) δC 15.4, 47.6, 124.0, 132.2, 134.6, 167.8, 176.0; HRMS (ESI, -ve) m/z 
calc. for C11H8NO4 218.0459, found 218.0452 (M-H)-. 
 
2-(1,3-Dioxoisoindolin-2-yl)butanoic acid (219c) 
 
 
 
DL-2-Aminobutyric acid (2.76 g, 26.7 mmol) in toluene (100 mL), phthalic anhydride 
(4.00 g, 27.0 mmol) and triethylamine (3.74 mL, 26.7 mmol) were combined according 
to general procedure III (reaction time: 24 hours) to afford the title compound as an 
amorphous solid (4.77 g, 77%). Mpt: 95-96 °C (lit.275 95.5-96.5 °C); FTIR (film/cm-1) 
υmax: 3050, 2976, 2881, 1776, 1713, 1613; 1H NMR (500MHz, CDCl3) δH 0.92 (3H, t, J 
= 7.4 Hz), 2.20–2.33 (2H, m), 4.81 (1H, dd, J = 8.6, 7.1 Hz), 7.67–7.77 (2H, m), 7.80–
7.90 (2H, m), 11.47 (1H, bs); 13C NMR (125MHz, CDCl3) δC 10.9, 21.9, 53.5, 123.6, 
131.6, 134.3, 167.7, 175.2;  HRMS (ESI, +ve) m/z calc. for C12H11NO4Na 256.0586, 
found 256.0578 (M+Na)+. 
 
(S)-2-(1,3-Dioxoisoindolin-2-yl)-3-methylbutanoic acid (219d) 
 
 
 
L-Valine (2.50 g, 21.3 mmol) in toluene (80 mL), phthalic anhydride (3.18 g, 21.5 
mmol) and triethylamine (2.98 mL, 21.3 mmol) were combined according to general 
procedure III (reaction time: 24 hours) to afford the title compound as a white powder 
(4.93 g, 94%). Mpt: 112-114 °C (lit.276 112-113 °C); ሾαሿDଶ଴ -38 (c 1, MeOH), lit.
276 -51.4 
(c 1, CH2Cl2); 1H NMR (300MHz, CDCl3) δH 0.92 (3H, d, J = 6.8 Hz), 1.17 (3H, d, J = 
6.8 Hz), 2.68–2.85 (1H, m), 4.63 (1H, d, J = 8.5 Hz), 7.71–7.78 (2H, m), 7.84–7.91 
(2H, m, ArH), 9.89 (1H, bs, CO2H); 13C NMR (75MHz, CDCl3) δC 19.9, 21.3, 28.8, 
58.0, 124.1, 132.0, 134.7, 168.1, 174.8. All analytical data is in accordance with 
literature precedence.276 
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2-(1,3-Dioxoisoindolin-2-yl)pentanoic acid (219e) 
 
 
 
DL-Norvaline (5.00 g , 42.6 mmol) in toluene (180 mL), phthalic anhydride (6.36 g, 43 
mmol) and triethylamine (5.96 mL, 42.6 mmol) were combined according to general 
procedure III (reaction time: 24 hours) to afford the title compound as a white powder 
(8.52 g, 81%).  Mpt: 104-106 °C (lit.277 103-105°C);  FTIR (film/cm-1) υmax: 3031, 
2964, 2870, 1775, 1699, 1612;  1H NMR (500MHz, CDCl3) δH 0.94 (3H, t, J = 7.4 Hz), 
1.29–1.41 (2H, m), 2.13–2.21 (1H, m), 2.27–2.37 (1H, m), 4.94 (1H, dd, J = 11.1, 4.7 
Hz), 7.74 (2H, dd, J = 5.4, 3.1 Hz), 7.87 (2H, dd, J = 5.4, 3.1 Hz), 10.37 (1H, bs); 13C 
NMR (125MHz, CDCl3) δC 13.3, 19.5, 30.3, 51.6, 123.6, 131.7, 134.2, 167.6, 175.4;  
HRMS (ESI, +ve) m/z calc. for C13H13NO4Na 270.0742, found 270.0740 (M+Na)+. 
 
(S)-2-(1,3-Dioxoisoindolin-2-yl)-4-methylpentanoic acid (219f) 
 
 
 
L-Leucine (2.50 g, 19.1 mmol) in toluene (60 mL), phthalic anhydride (3.10 g, 21.0 
mmol) and triethylamine (2.67 mL, 19.1 mmol) were combined according to general 
procedure III (reaction time: 24 hours)  and recrystallised from EtOAc/Hexane to afford 
the title compound as white crystals (3.88 g, 78%).  Mpt: 125-128 °C (lit.278 124-125 
°C); ሾαሿDଶ଴ -21 (c 1, MeOH), lit.
279 -22.1 (c 1, EtOH); FTIR (film/cm-1) υmax: 3037, 
2962, 2936, 2874, 1779, 1708, 1611; 1H NMR (500MHz, CDCl3) δH 0.94 (3H, d, J = 
6.6 Hz), 0.96 (3H, d, J = 6.6 Hz), 1.45–1.57 (1H, m), 1.96 (1H, ddd, J = 14.3, 10.8, 4.9 
Hz), 2.38 (1H, ddd, J = 14.3, 10.8, 4.9 Hz), 5.01 (1H, dd, J = 11.6, 4.4 Hz),  5.68 (1H, 
bs), 7.72–7.77 (2H, m), 7.85–7.90 (1H, m); 13C NMR (125MHz, CDCl3) δC 21.0, 23.0, 
25.1, 37.0, 50.4, 123.6, 131.7, 134.2, 167.7, 175.1; HRMS (ESI, +ve) m/z calc. for 
C14H15NO4Na 284.0899, found 284.0897 (M+Na)+. 
 
  | 155 
Chapter 7  Experimental   
(E)-3-Methoxyallyl 2-(1,3-dioxoisoindolin-2-yl)acetate (220a)  
 
 
 
EDCi.HCl (433 mg, 2.26 mmol), triethylamine (319 μl, 2.26 mmol), N-phthaloyl 
glycine (464 mg, 2.26 mmol), DMAP (5 mol%), DCM (30 mL) and (E)-3-
(methoxy)prop-2-enol 218a (100 mg, 1.13 mmol) were combined according to general 
procedure IV (reaction time: 6 hours), to afford the title compound as a white solid (230 
mg, 74%). Mpt: 55 -58 °C (lit.172 55-58 °C); 1H NMR (500 MHz, CDCl3) δH 3.58 (3H, 
s), 4.43 (2H, s), 4.61 (2H, d, J = 8.2 Hz), 4.92 (1H, dt, J = 12.6, 8.2 Hz), 6.65 (1H, d, J 
= 12.6 Hz), 7.73–7.77 (2H, m), 7.88–7.91 (2H, m); 13C NMR (125 MHz, CDCl3) δC 
39.0, 56.2, 64.2, 96.3, 123.6, 132.1, 134.2, 154.0, 167.3, 167.5. All analytical data is in 
accordance with literature precedence.172 
 
(E)-3-Methoxyallyl 2-(1,3-dioxoisoindolin-2-yl)propanoate (220b) 
 
 
 
EDCi.HCl (479 mg, 2.50 mmol), triethylamine (353 μl, 2.50 mmol), phthalyl-DL-
alanine 219b (547 mg, 2.50 mmol), DMAP (5 mol%), DCM (30 mL) and (E)-3-
(methoxy)prop-2-enol 218a (110 mg, 1.25 mmol) were combined according to the 
general procedure IV (reaction time: 6 hours), to afford the title compound as a 
colourless oil (298 mg, 82%); 1H NMR (500MHz, CDCl3) δH 1.69 (3H, d, J = 7.3 Hz), 
3.55 (3H, s), 4.55–4.4.62 (2H, m), 4.85-4.92 (1H, m), 4.96 (1H, q, J = 7.3 Hz), 6.61 
(1H, d, J = 12.6 Hz), 7.72–7.77 (2H, m), 7.85-7.89 (2H, m); 13C NMR (125MHz, 
CDCl3) δC 15.3, 47.7, 56.1, 64.1, 96.5, 123.5, 132.0, 134.1, 153.7, 167.4, 169.7. All 
analytical data is in accordance with literature precedence.172 
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(E)-3-Methoxyallyl 2-(1,3-dioxoisoindolin-2-yl)butanoate (220c) 
 
 
 
EDCi.HCl (870 mg, 4.54 mmol), triethylamine (634 μl, 4.54 mmol), phthalyl-DL-2-
aminobutyric acid 219c (1.06 g, 4.54 mmol), DMAP (5 mol%), DCM (40 mL) and (E)-
3-(methoxy)prop-2-enol 218a (200 mg, 2.27 mmol) were combined according to 
general procedure IV (reaction time: 24 hours), to afford the title compound as a 
colourless oil (690 mg, 100%). FTIR (film/cm-1) υmax: 2974, 2840, 1776, 1714, 1654; 
1H NMR (500MHz, CDCl3) δH 0.89 (3H, t, J = 7.5 Hz), 2.17–2.28 (2H, m), 3.49 (3H, 
s), 4.53 (2H, d, J = 7.8 Hz), 4.71 (1H, dd, J = 9.7, 6.2 Hz), 4.83 (1H, dt, J = 12.6, 7.8 
Hz), 6.56 (1H, d, J = 12.6 Hz), 7.68–7.73 (2H, m), 7.80–7.84 (2H, m); 13C NMR 
(125MHz, CDCl3) δC 10.9, 22.1, 53.9, 56.0, 63.9, 96.5, 123.4, 131.8, 134.1, 153.6, 
167.7, 169.3; HRMS (ESI, +ve) m/z calcd. for C16H17NO5Na 326.1004, found 326.0997 
(M+Na)+. 
 
(S,E)-3-Methoxyallyl 2-(1,3-dioxoisoindolin-2-yl)-3-methylbutanoate (220d) 
 
 
 
EDCi.HCl (774 mg, 4.04 mmol), triethylamine (570 μl, 4.04 mmol), phthalyl-L-valine 
219d (1.00 g, 4.04 mmol), DMAP (5 mol%), DCM (40 mL) and (E)-3-(methoxy)prop-
2-enol 218a (178 mg, 2.02 mmol) were combined according to general procedure IV 
(reaction time: 24 hours), to afford the title compound as a colourless oil (600 mg, 
94%). FTIR (film/cm-1) υmax: 2967, 2935, 1774, 1715, 1715, 1655;  1H NMR (300MHz, 
CDCl3) δH 0.84 (3H, d, J = 6.8 Hz), 1.07 (3H, d, J = 6.7  Hz) 2.61–2.77 (1H, m), 3.45 
(3H, s), 4.41–4.56 (3H, m), 4.79 (1H, dt, J = 12.6, 7.8 Hz), 6.51 (1H, d, J = 12.6 Hz), 
7.61–7.72 (2H, m), 7.74–7.84 (2H, m); 13C NMR (75MHz, CDCl3) δC 19.9, 21.3, 29.0, 
56.5, 58.3, 64.1, 97.0, 123.9, 132.2, 134.5, 153.9, 168.2, 169.2; HRMS (ESI, +ve) m/z 
calcd. for C17H19NO5Na 340.1161, found 340.1157 (M+Na)+. 
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(E)-3-Methoxyallyl 2-(1,3-dioxoisoindolin-2-yl)pentanoate (220e) 
 
 
 
EDCi.HCl (1.30 g, 6.80 mmol), triethylamine (950 μl, 6.80 mmol), phthalyl-DL-
norvaline 219e (841 mg, 3.40 mmol), DMAP (5 mol%), DCM (60 mL) and (E)-3-
(methoxy)prop-2-enol 218a (300 mg, 3.40 mmol) were combined according to general 
procedure IV (reaction time: 24 hours), to afford the title compound as a colourless oil 
(746 mg, 70%). FTIR (film/cm-1) υmax: 2966, 1776, 1715, 1655; 1H NMR (300MHz, 
CDCl3) δH 0.94 (3H, t, J = 7.3 Hz), 1.23–1.42 (2H, m), 2.09–2.37 (2H, m), 3.55 (3H, s), 
4.58 (2H, d, J = 8.0 Hz), 4.81–4.96 (2H, m), 6.60 (1H, d, J = 12.6 Hz), 7.71–7.7.79 (2H, 
m), 7.84–7.91 (2H, m); 13C NMR (75MHz, CDCl3) δC 13.8, 20.0, 31.0, 52.6, 56.3, 64.4, 
97.0, 123.9, 132.3, 134.5, 154.0, 168.1, 169.9; HRMS (ESI, +ve) m/z calcd. for 
C17H19NO5Na 340.1161, found 340.1155 (M+Na)+. 
 
(S,E)-3-Methoxyallyl 2-(1,3-dioxoisoindolin-2-yl)-4-methylpentanoate (220f) 
 
 
 
EDCi.HCl (734 mg, 3.83 mmol), triethylamine (535 μl, 3.83 mmol), phthalyl-L-leucine 
219f (500 mg, 1.91 mmol), DMAP (5 mol%), DCM (40 mL) and (E)-3-(methoxy)prop-
2-enol 218a (1.91 mmol, 169 mg) were combined according to general procedure IV 
(reaction time: 24 hours), to afford the title product as a colourless oil (475 mg, 75%). 
FTIR (film/cm-1) υmax: 2960, 5874, 1776, 1714, 1655; 1H NMR (500MHz, CDCl3) δH 
0.94 (3H, d, J = 6.6 Hz), 0.96 (3H, d, J = 6.6 Hz), 1.45–1.55 (1H, m), 1.96 (1H, ddd, J = 
14.3, 11.0, 4.1 Hz), 2.35 (1H, ddd, J = 14.3, 11.0, 4.1 Hz), 3.56 (3H, s), 4.58 (2H, d, J = 
7.8 Hz), 4.85–4.90 (1H, m), 4.91–4.96 (1H, m), 6.61 (1H, d, J = 12.6 Hz), 7.73–7.77 
(2H, m), 7.85–7.90 (2H, m); 13C NMR (125MHz, CDCl3) δC 21.0, 23.2, 25.1, 37.2, 
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51.0, 56.1, 64.1, 96.6, 123.5, 131.9, 134.1, 153.7, 167.8, 169.8; HRMS (ESI, +ve) m/z 
calcd. for C18H21NO5Na 354.1317, found 354.1324 (M+Na)+. 
 
(±)-(syn)-Methyl 2-(1,3-dioxoisoindolin-2-yl)-3-methoxypent-4-enoate (221a)  
 
 
 
To a solution of (E)-3-methoxyallyl 2-(1,3-dioxoisoindolin-2-yl)acetate 220a (280 mg, 
1.03 mmol, 1.0 eq) in THF (2.8 mL) at -95 °C was added TMSCl (171 μL, 1.34 mmol, 
1.3 eq).  After 10 mins LHMDS (1M, 1.34 ml, 1.34 mmol, 1.3 eq) was added via 
syringe pump at an addition rate of 3 mL min-1 and reaction mixture allowed to warm to 
room temperature after a period of 30 mins, and stirred for 90 minutes.  The reaction 
was quenched by the addition of 1N HCl and brine solution (1:1, 5 mL) and extracted 
with DCM (3 × 15 mL), EtOAc (1 × 15 mL), dried over Na2SO4 and concentrated in 
vacuo to afford the crude acid.  Treatment with diazomethane according to general 
procedure VIII and purification by flash chromatography (4:1 Pet/EtOAc + 1% NEt3) 
affords the methyl ester as a colourless oil. (220 mg, 74%, dr 11:1). 1H NMR (500MHz, 
CDCl3) δH major diastereomer 3.15 (3H, s), 3.65 (3H, s),  4.47 (1H, app. t, J = 8.6 Hz), 4.81 
(1H, d, J = 8.6 Hz), 5.32 (1H, dt, J = 10.1, 1.3 Hz), 5.37(1H, dt, J = 17.1, 1.3 Hz), 5.79 
(1H, ddd, J = 17.1, 10.1, 1.3 Hz), 7.63–7.72 (2H, m), 7.75–7.85 (2H, m); δH minor 
diastereomer 3.33 (3H, s), 3.69 (3H, s), 4.61 (1H, t, J = 9.1 Hz), 4.94 (1H, d, J = 9.1 Hz), 
5.10 (1H, dt, J = 10.7, 1.2 Hz), 5.20 (1H, dt, J = 17.7, 1.2 Hz), 5.53 (1H, ddd, J = 17.7, 
10.7, 6.8 Hz), 7.72 – 7.75 (2H, m), 7.84 – 7.89 (2H, m); 13C NMR (75MHz, CDCl3) δC 
major diastereomer 52.9, 56.1, 57.1, 78.6, 120.3, 124.0, 132.3, 134.6, 135.4, 167.9, 168.2; δC 
minor diastereomer 53.1, 54.0, 57.3, 80.5, 121.2, 124.0, 132.5, 134.2, 134.8, 167.8, 168.1. All 
analytical data is in accordance with literature precedence.172 
 
(±)-(syn)-Methyl 2-(1,3-dioxoisoindolin-2-yl)-3-methoxy-2-methylpent-4- 
enoate  (221b)  
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To a solution of (E)-3-methoxyallyl 2-(1,3-dioxoisoindolin-2-yl)propanoate 220b (220 
mg, 0.74 mmol, 1.0 eq) in THF (2.2 mL) at -95 °C was added TMSCl (122 μL, 0.96 
mmol, 1.3 eq).  After 10 mins LHMDS (1M, 960 μl, 0.96 mmol, 1.3 eq) was added via 
syringe pump at an addition rate of 3 mL min-1 and reaction mixture allowed to warm to 
room temperature after a period of 30 mins, and stirred for 90 minutes.  The reaction 
was quenched by the addition of 1N HCl and brine solution (1:1, 5 mL) and extracted 
with DCM (3 × 15 mL), EtOAc (1 × 15 mL), dried over Na2SO4 and concentrated in 
vacuo to afford the crude acid.  Treatment with diazomethane according to general 
procedure VIII and purification by flash chromatography (6:1 Pet/EtOAc + 1% NEt3) 
affords the methyl ester as a colourless oil. (160 mg, 71%, dr 24:1). 1H NMR (500MHz, 
CDCl3) δH major diastereomer 1.84 (3H, s), 3.27 (3H, s), 3.75 (3H, s), 4.48 (1H, dt, J = 7.7, 
0.6 Hz), 5.31–5.38 (2H, m), 5.99 (1H, ddd, J = 17.1, 10.3, 7.7 Hz), 7.70–7.74 (2H, m), 
7.79–7.83 (2H, m); δH minor diastereomer 1.79 (3H, s), 3.32 (3H, s), 3.77 (3H, s), 4.60 (1H, 
dt, J = 8.0, 0.8 Hz), 5.26–5.30 (2H, m), 5.73 (1H, ddd, J = 17.1, 10.3, 8.0 Hz), 7.70–
7.74 (2H, m), 7.79–7.83 (2H, m); 13C NMR (125MHz, CDCl3) δC major diastereomer 19.3, 
52.4, 57.2, 65.6, 83.8, 120.5, 123.2, 131.7, 133.5, 134.0, 168.2, 170.6; δC minor diastereomer 
19.3, 52.5, 56.8, 65.2, 83.1, 121.1, 123.4, 131.9, 133.0, 134.2, 168.3, 169.7. All 
analytical data is in accordance with literature precedence.172 
 
(±)-(syn)-Methyl 2-(1,3-dioxoisoindolin-2-yl)-3-methoxy-2-ethylpent-4- 
enoate (221c) 
 
 
 
To a solution of (E)-3-methoxyallyl 2-(1,3-dioxoisoindolin-2-yl)butanoate 220c (50 mg, 
0.165 mmol, 1.0 eq) in THF (0.5 mL) at -78 °C was added TMSCl (42 μL, 0.330 mmol, 
2.0 eq).  After 10 mins LHMDS (1M, 330 μl, 0.330 mmol, 2.0 eq) was added and 
reaction mixture allowed to warm to room temperature after 30 mins, and stirred for 18 
hours.  The reaction was quenched by the addition of 1N HCl and brine solution (1:1, 5 
mL) and extracted with DCM (3 × 15 mL), EtOAc (1 × 15 mL), dried over Na2SO4 and 
concentrated in vacuo to afford the crude acid.  Treatment with diazomethane according 
to general procedure VIII and purification by flash chromatography (8:1 Pet/EtOAc + 
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1% NEt3) affords the methyl ester as a colourless oil (10.4 mg, 20%, dr 2.7:1).  FTIR 
(film/cm-1) υmax: 2997, 2957, 2829, 1784, 1753, 1718;  1H NMR (500MHz, CDCl3) δH 
major diastereomer 0.93 (3H, t, J = 7.4 Hz), 2.25–2.35 (1H, m), 2.60 (1H, dq, J = 14.6, 7.4 
Hz), 3.31 (3H, s), 3.80 (3H, s), 4.58 (1H, d, J = 8.2 Hz), 5.31–5.38 (2H, m), 5.98 (1H, 
app. dt, J = 17.3 Hz, 8.2 Hz), 7.70–7.75 (2H, m), 7.79–7.84 (2H, m); δH minor diastereomer 
0.93 (3H, t, J = 7.4 Hz), 2.13–2.22 (1H, m), 2.49 (1H, dq, J = 14.6, 7.4 Hz), 3.31 (3H, 
s), 3.80 (3H, s), 4.89 (1H, d, J = 8.2 Hz), 5.32–5.41 (2H, m), 5.67–5.78 (1H, m), 7.69–
7.74 (2H, m), 7.75–7.87 (2H, m); 13C NMR (125MHz, CDCl3) δC major diastereomer 9.0, 
26.5, 52.1, 57.3, 69.0, 84.1, 120.5, 123.2, 131.5, 133.5, 134.0, 168.4, 169.4; HRMS 
(ESI, +ve) m/z calcd. for C17H19NO5Na 340.1161, found: 340.1158 (M+Na)+. 
 
(±)-(syn)-Methyl 2-(1,3-dioxoisoindolin-2-yl)-2-isopropyl-3-methoxypent-4- 
enoate (221d) 
 
 
 
To a solution of (S,E)-3-methoxyallyl 2-(1,3-dioxoisoindolin-2-yl)-3-methylbutanoate 
220d (102 mg, 0.320 mmol, 1.0 eq) in THF (1.0 mL) at -95 C° was added TMSCl (54 
μL, 0.420 mmol, 1.3 eq).  After 10 mins LHMDS (1M, 420 μl, 0.420 mmol, 1.3 eq) was 
added and reaction mixture allowed to warm to room temperature after a period of 30 
mins, and stirred for 90 minutes.  LHMDS (0.320 mmol, 320 μL, 1.0 eq) was added and 
the reaction mixture stirred for 18 hours.  The reaction was quenched by the addition of 
1N HCl and brine solution (1:1, 5 mL) and extracted with DCM (3 × 15 mL), EtOAc (1 
× 15 mL), dried over Na2SO4 and concentrated in vacuo to afford the crude acid.  
Treatment with diazomethane according to general procedure VIII and purification by 
flash chromatography (8:1 Pet/EtOAc + 1% NEt3) affords the methyl ester as a 
colourless oil (12 mg, 11%, dr undeterminable).  FTIR (film/cm-1) υmax: 2993, 2957, 
2822, 1779, 1747, 1720;  1H NMR (250MHz, CDCl3) δH 0.93 (3H, d, J = 6.9 Hz), 1.04 
(3H, d, J = 6.9 Hz), 1.81–1.89 (1H, m), 3.27 (3H, s), 3.80 (3H, s), 4.61 (1H, d, J = 8.8 
Hz), 5.24–5.36 (2H, m), 5.77–5.94 (1H, m), 7.65–7.83 (4H, m);  13C NMR (75MHz, 
CDCl3) δC 18.5, 19.2, 30.1, 52.2, 57.3, 72.1, 84.9, 120.8, 123.6, 132.0, 133.8, 134.3, 
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168.9, 169.3; HRMS (ESI, +ve) m/z calcd. for C18H21NO5Na 354.1317, found: 
354.1319 (M+Na)+. 
 
(±)-(syn)-Methyl 2-(1,3-dioxoisoindolin-2-yl)-3-methoxy-2-propylpent-4- 
enoate (221e) 
 
 
 
To a solution of (E)-3-methoxyallyl 2-(1,3-dioxoisoindolin-2-yl)pentanoate 220e (50 
mg, 0.160 mmol, 1.0 eq) in THF (0.5 mL) at -78 °C was added TMSCl (41 μL, 0.320 
mmol, 2.0 eq).  After 10 mins LHMDS (1M, 320 μl, 0.320 mmol, 2.0 eq) was added via 
syringe pump at an addition rate of 3 mL min-1 and reaction mixture allowed to warm to 
room temperature after a period of 30 mins, and stirred for 18 hours.  The reaction was 
quenched by the addition of 1N HCl and brine solution (1:1, 5 mL) and extracted with 
DCM (3 × 15 mL), EtOAc (1 × 15 mL), dried over Na2SO4 and concentrated in vacuo 
to afford the crude acid.  Treatment with diazomethane according to general procedure 
VIII and purification by flash chromatography (8:1 Pet/EtOAc + 1% NEt3) affords the 
methyl ester as a colourless oil. (24 mg, 45%, dr 2:1). FTIR (film/cm-1) υmax: 2934, 
1779, 1743, 1715; 1H NMR (500MHz, CDCl3) δH major diastereomer 0.91 (3H, t, J = 7.3 Hz), 
1.13–1.23 (1H, m), 1.40–1.48 (1H, m), 2.19–2.27 (1H, m), 2.42–2.50 (1H, m), 3.29 
(3H, s), 3.79 (3H, s), 4.57 (1H, d, J = 8.2 Hz), 5.30–5.37 (2H, m), 5.93–6.02 (1H, m), 
7.69–7.74 (2H, m), 7.78–7.82 (2H, m); δH minor diastereomer 0.90 (3H, t, J = 7.3 Hz), 1.25–
1.38 (2H, m), 2.06–2.16 (1H, m), 2.33–2.42 (1H, m), 3.31 (3H, s), 3.78 (3H, s), 4.89 
(1H, d, J = 8.1 Hz), 5.34–5.40 (2H, m), 5.66–5.74 (1H, m), 7.69–7.74 (2H, m), 7.78–
7.82 (2H, m); 13C NMR (125MHz, CDCl3) δC major diastereomer 14.2, 21.0, 35.5, 52.1, 57.3, 
68.5, 84.3, 100.5, 123.2, 131.5, 133.6, 134.0, 168.3, 169.5; δC minor diastereomer 14.2, 17.3, 
34.9, 52.4, 56.5, 69.1, 81.4, 120.9, 123.1, 131.7, 132.9, 134.0, 168.7, 169.6; HRMS 
(ESI, +ve) m/z calcd. for C18H21NO5Na 354.1317, found: 354.1318 (M+Na)+. 
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(S)-2-(tert-Butoxycarbonylamino)-3-methylbutanoic acid (226d) 
 
 
 
To a solution of L-valine (1.00 g, 8.54 mmol, 1.0 eq) and 1N sodium hydroxide (10.3 
mL, 10.3 mmol, 1.2 eq) in dioxane (20 mL) was added Boc2O (1.86 g, 8.54 mmol, 1.0 
eq) in dioxane (10 mL) dropwise.  The reaction mixture was allowed to warm to room 
temperature and stirred for 18 hours.  Reaction mixture was acidified with 1N HCl and 
extracted with EtOAc (3 × 50 mL), washed with 1N HCl (1 × 50 mL), dried and 
concentrated in vacuo to afford the title compound as white crystals (1.86 g, 100%).  
Mpt: 78-80 °C (lit.280 77-78 °C); ሾαሿDଶ଴ -6 (c 1, acetic acid), lit.
280 -5.8 (c 1, acetic acid); 
1H NMR (300MHz, CDCl3) δH 0.87 (3H, d, J = 6.8 Hz), 0.94 (3H, d, J = 6.8 Hz), 1.38 
(9H, s), 1.99–2.22 (1H, m), 4.10–4.25 (1H, m), 4.94 (1H, app. d, J = 8.7 Hz), 8.61 (1H, 
bs);  13C NMR (75MHz, CDCl3) δC 17.9, 19.4, 27.8, 28.7, 31.4, 67.5, 156.9, 177.3. All 
analytical data is in accordance with literature precedence.281 
 
L-Valine methyl ester hydrochloride (228d) 
 
 
 
L-Valine (5.00 g, 42.7 mmol) in MeOH (350 mL) and thionyl chloride (20.2 mL, 278 
mmol, 7.0 eq) were combined according to general procedure V to afford L-valine 
methyl ester hydrochloride as a white powder (6.40 g, 90%). Mpt: 170 -173 °C (lit.282 
173-174 °C); ሾαሿDଶ଴ +24 (c 1, MeOH), lit.
283 +24.2 (c 1, MeOH); 1H NMR (500MHz, 
D2O) δ: 0.96 (6H, app t, J = 6.9 Hz), 2.23–2.33 (1H, m), 3.79 (3H, s), 3.97 (1H, d, J = 
4.7 Hz); 13C NMR (125MHz, D2O) δ: 16.9, 17.2, 29.3, 53.4, 58.4, 170.4. All analytical 
data is in accordance with literature precedence.283  
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DL-Norvaline methyl ester hydrochloride (228e) 
 
 
 
DL-Norvaline (6.00 g, 51.2 mmol) in MeOH (350 mL) and thionyl chloride (26.2 mL, 
359 mmol, 7.0 eq) were combined according to general procedure V to afford DL-
norvaline methyl ester hydrochloride as a white powder (8.55 g, 100%). Mpt: 109 -112 
°C (lit.284 114-115 °C); FTIR (film/cm-1) υmax: 3000, 2956, 2875, 1751; 1H NMR 
(500MHz, CDCl3) δH  0.87 (3H, t, J = 7.3 Hz), 1.27–1.44 (2H, m), 1.77–1.94 (2H, m), 
3.77 (3H, s), 4.08 (1H, t, J = 6.5 Hz); 13C NMR (125MHz, CDCl3) δC 12.7, 17.7, 31.7, 
52.7, 53.5, 171.0; HRMS (ESI, +ve) m/z calcd. for C6H14NO2 132.1025, found: 
132.1023 (M+H)+.   
 
(S)-Methyl 2-(tert-butoxycarbonylamino)-3-methylbutanoate (229d) 
 
 
 
To a solution of L-valine methyl ester hydrochloride 228d (6.38 g, 38.2 mmol, 1.0 eq) 
and triethylamine (16 mL, 114.6 mmol, 3.0 eq) in THF (130 mL) was added Boc2O 
(10.0 g, 45.8 mmol, 1.2 eq) in THF (20 mL).  Reaction mixture was allowed to stir at 
room temperature for 4 days. The solution was then concentrated in vacuo. Purification 
by flash chromatography (4:1 Pet/EtOAc) affords the title compound as a colourless oil 
(8.53 g, 97%). ሾαሿDଶ଴ -22.5 (c 2, MeOH), lit.
285 -21.9 (c 2.2, MeOH); 1H NMR (300MHz, 
CDCl3) δH  0.88 (3H, d, J = 6.9 Hz), 0.95 (3H, d, J = 6.9 Hz), 1.44 (9H, s), 2.02–2.20 
(1H, m), 3.73 (3H, s), 4.15–4.27 (1H, m), 4.90–5.09 (1H, m); 13C NMR (75MHz, 
CDCl3) δC  18.0, 19.4, 28.7, 31.7, 52.4, 58.9, 80.2, 156.0, 173.3. All analytical data is in 
accordance with literature precedence.285 
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Methyl 2-(tert-butoxycarbonylamino)pentanoate (229e) 
 
 
 
To a solution of DL-norvaline methyl ester hydrochloride 228e (8.35 g, 50.0 mmol, 1.0 
eq) and triethylamine (17.8 mL, 150 mmol, 3.0 eq) in THF (130 mL) was added Boc2O 
(13.1 g, 60.0 mmol, 1.2 eq) in THF (20 mL).  Reaction mixture was allowed to stir at 
room temperature for 4 days. The solution was then concentrated in vacuo. Purification 
by flash chromatography (4:1 Pet/EtOAc) affords the title compound as a colourless oil 
(11.56 g, 100%). FTIR (film/cm-1) υmax: 3361, 2962, 1741, 1716; 1H NMR (500MHz, 
CDCl3) δH  0.93 (3H, t, J = 7.3 Hz), 1.30-1.42 (2H, m), 1.45 (9H, s), 1.55–1.81 (2H, m), 
3.73 (3H, s), 4.24–4.34 (1H, m), 4.93-5.07 (1H, m); 13C NMR (125MHz, CDCl3) δC  
13.6, 18.6, 27.4, 28.3, 34.9, 52.1, 53.2, 155.4, 173.5; HRMS (ESI, +ve) m/z calcd. for 
C11H21NO4Na 254.1368, found: 254.1350 (M+Na)+. 
 
(S)-Methyl 2-(tert-butoxycarbonyl(methyl)amino)-3-methylbutanoate (230d) 
 
 
 
To a solution of N-Boc-L-valine methyl ester 229d (1.61 g, 6.96 mmol, 1.0 eq) and 
methyl iodide (650 μL, 10.4 mmol, 1.5 eq) in DMF (40 mL) at 0 °C was added sodium 
hydride (334 mg, 13.9 mmol, 2.0 eq) and the reaction mixture allowed to stir at room 
temperature overnight. The solution was then quenched with NH4Cl (sat) (50 mL) and 
extracted with EtOAc (3 × 50 mL), washed with brine (1 × 50 mL), dried over Na2SO4 
and concentrated in vacuo. Purification by flash chromatography (6:1 Pet/EtOAc) 
affords the title compound as a colourless oil (1.16 g, 68 %). ሾαሿDଶ଴ -87.5 (c 2, MeOH), 
lit.286 -88.1 (c 1.1, MeOH); 1H NMR (500MHz, CDCl3) δH rotamer A 0.89 (3H, d, J = 5.8 
Hz), 0.96 (3H, d, J = 6.6 Hz), 1.46 (9H, s), 2.12–2.24 (1H, m), 2.83 (3H, app. d, J = 
15.2 Hz), 3.70 (3H, s), 4.09 (1H, d, J = 10.3 Hz); δH rotamer B 0.89 (3H, d, J = 5.8 Hz), 
0.96 (3H, d, J = 6.6 Hz), 1.46 (9H, s), 2.12–2.24 (1H, m), 2.83 (3H, app. d, J = 15.2 
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Hz), 3.70 (3H, s), 4.46 (1H, d, J = 10.6 Hz); 13C NMR (125MHz, CDCl3) δC rotamer A 
18.7, 19.7, 28.3, 29.7, 30.3, 51.6, 63.0, 80.0, 155.6, 171.6; δC rotamer B 19.0, 20.0, 27.9,  
28.3, 30.7, 51.6, 65.0, 80.2, 156.3, 172.1. All analytical data is in accordance with 
literature precedence.286 
 
Methyl 2-(tert-butoxycarbonyl(methyl)amino)pentanoate (230e) 
 
 
 
To a solution of N-Boc-DL-norvaline methyl ester 229e (1.11 g, 4.80 mmol, 1.0 eq) and 
methyl iodide (448 μL, 7.20 mmol, 1.5 eq) in DMF (60 mL) at 0 °C was added sodium 
hydride (230 mg, 9.60 mmol, 2.0 eq) and the reaction mixture allowed to stir at room 
temperature overnight. The solution was then quenched with NH4Cl (sat) (50 mL) and 
extracted with EtOAc (3 × 50 mL), washed with brine (1 × 50 mL), dried over Na2SO4 
and concentrated in vacuo. Purification by flash chromatography (6:1 Pet/EtOAc) 
affords the title compound as a colourless oil (1.01 g, 86 %). FTIR (film/cm-1) υmax: 
2964, 2939, 2878, 1744, 1696;  1H NMR (500MHz, CDCl3) δH rotamer A 0.95 (3H, t, J = 
7.2 Hz), 1.25–1.41 (2H, m), 1.45 (9H, s), 1.61–1.93 (2H, m), 2.78 (3H, s), 3.71 (3H, s), 
4.41–4.49 (1H, m); δH rotamer B 0.95 (3H, t, J = 7.2 Hz), 1.25–1.41 (2H, m), 1.47 (9H, s), 
1.61–1.93 (2H, m), 2.83 (3H, s), 3.71 (3H, s), 4.75–4.83 (1H, m); 13C NMR (125MHz, 
CDCl3) δC rotamer A 13.6, 19.2, 28.3, 30.3, 30.9, 52.0, 57.3, 79.9, 156.4, 172.6; δC rotamer B 
13.6, 19.3, 28.3, 30.8, 31.2, 52.0, 58.8, 80.2, 156.4, 172.8;  HRMS (ESI, +ve) m/z calcd. 
for C12H23NO4Na 268.1525, found: 268.1501 (M+Na)+. 
 
(S)-2-(tert-Butoxycarbonyl(methyl)amino)-3-methylbutanoic acid (227d) 
 
 
 
N-Boc-N-Me-L-valine methyl ester 230d (990 mg, 4.04 mmol, 1.0 eq) was added to a 
solution of LiOH.H2O (509 mg, 12.1 mmol, 3.0 eq) in THF/H2O (30 mL, 1:1) at 0 °C 
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and allowed to stir for 5 hours.  The reaction mixture was acidified to pH 4 with glacial 
acetic acid and extracted with EtOAc.  The organics were washed with brine, dried over 
MgSO4 and concentrated in vacuo to afford the title compound as a colourless oil 
without the need for further purification (890 mg, 96%). ሾαሿDଶ଴ -89 (c 1, MeOH), lit.
287 -
85 (c 0.5, EtOH); 1H NMR (500MHz, CDCl3) δH 0.91 (3H, d, J = 6.7 Hz), 1.02 (3H, d, J 
= 6.7 Hz), 1.47 (9H, s), 2.14–2.39 (1H, m), 2.87 (3H, s), 4.04–4.17 (1H, m), 9.10 (1H, 
bs); 13C NMR (125MHz, CDCl3) δC 19.3, 27.4, 28.5, 32.0, 72.2, 79.9, 155.6, 175.8. All 
analytical data is in accordance with literature precedence.287 
 
2-(tert-Butoxycarbonyl(methyl)amino)pentanoic acid (227e) 
 
 
 
N-Boc-N-Me-DL-norvaline methyl ester 230e (967 mg, 3.94 mmol, 1.0 eq) was added to 
a solution of LiOH.H2O (496 mg, 11.8 mmol, 3.0 eq) in THF/H2O (20 mL, 1:1) at 0 °C 
and allowed to stir for 5 hours.  The reaction mixture was acidified to pH 4 with glacial 
acetic acid and extracted with EtOAc.  The organics were washed with brine, dried over 
MgSO4 and concentrated in vacuo to afford the title compound as a colourless oil 
without the need for further purification (911 mg, 100%). FTIR (film/cm-1) υmax: 3080, 
2965, 2935, 2877, 1698, 1673; 1H NMR (500MHz, CDCl3) δH rotamer A 0.97 (3H, t, J = 
7.4 Hz), 1.28–1.42 (2H, m), 1.46 (9H, s), 1.69–1.83 (2H, m), 2.82 (3H, s), 4.51 (1H, m); 
δrotamer B 0.97 (3H, t, J = 7.4 Hz), 1.28–1.42 (2H, m), 1.48 (9H, s), 1.84–1.99 (2H, m), 
2.85 (3H, s), 4.72 (1H, m); 13C NMR (125MHz, CDCl3) δC rotamer A 13.6, 19.4, 28.3, 
30.5, 30.9, 58.1, 80.6, 155.7, 176.8; δC rotamer B 13.6, 20.7, 28.3, 30.5, 31.0, 58.6, 80.6, 
156.8, 176.8; HRMS (ESI, -ve) m/z calcd. for C11H20NO4 230.2813, found: 230.1373 
(M-H)-. 
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(S,E)-3-Methoxyallyl 2-(tert-butoxycarbonyl(methyl)amino)-3-methylbutanoate 
(231d) 
 
 
 
EDCi.HCl (738 mg, 3.85 mmol), triethylamine (538 μl, 3.85 mmol), (S)-2-(tert-
butoxycarbonyl(methyl)amino)-3-methylbutanoic acid 227d (890 mg, 3.85 mmol), 
DMAP (5 mol%), DCM (40 mL) and (E)-3-(methoxy)prop-2-enol 218a (170 mg, 1.92 
mmol) were combined according to general procedure IV (reaction time: 24 hours), to 
afford the title compound as a yellow oil (443 mg, 77%).  FTIR (film/cm-1) υmax: 2967, 
2936, 1785, 1733, 1694, 1655; 1H NMR (500MHz, CDCl3) δH rotamer A 0.90 (3H, d, J = 
6.5 Hz), 0.98 (3H, d, J = 6.5 Hz), 1.45 (9H, s), 2.13-2.31 (1H, m), 2.82 (3H, s), 3.57 
(3H, s), 4.09 (1H, d, J = 10.5 Hz), 4.54 (2H, d, J = 7.7 Hz), 4.92 (1H, dt, J = 12.6, 7.7 
Hz), 6.64 (1H, d, J = 12.6 Hz); δH rotamer B 0.90 (3H, d, J = 6.5 Hz), 0.98 (3H, d, J = 6.5 
Hz), 1.45 (9H, s), 2.13-2.31 (1H, m), 2.86 (3H, s), 3.59 (3H, s), 4.43 (1H, d, J = 10.5 
Hz), 4.54 (2H, d, J = 7.7 Hz), 4.92 (1H, dt, J = 12.6, 7.7 Hz), 6.64 (1H, d, J = 12.6 Hz); 
13C NMR (125MHz, CDCl3) δC rotamer A 16.2, 18.8, 19.7, 27.8, 28.4, 56.1, 62.6, 63.3, 
65.1, 66.2, 96.9, 153.2, 171.1; δC rotamer B 17.3, 19.1, 20.0, 27.8, 28.4, 56.1, 62.8, 63.3, 
65.1, 66.2, 96.9, 153.5, 171.1; HRMS (ESI, +ve) m/z calcd. for C15H27NO5Na 324.1787, 
found: 324.1785 (M+Na)+. 
 
(E)-3-Methoxyallyl 2-(tert-butoxycarbonyl(methyl)amino)pentanoate (231e) 
 
 
 
EDCi.HCl (755 mg, 3.94 mmol), triethylamine (550 μL, 3.94 mmol), 2-(tert-
butoxycarbonyl(methyl)amino)pentanoic acid 227e (911 mg, 3.94 mmol), DMAP (5 
mol%), DCM (40 mL) and (E)-3-(methoxy)prop-2-enol 218a (174 mg, 1.97 mmol) 
were combined according to the general procedure IV (reaction time: 24 hours), to 
afford the title compound as a yellow oil (253 mg, 43%).  FTIR (film/cm-1) υmax: 2968, 
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2939, 1788, 1732, 1689, 1656; 1H NMR (500MHz, CDCl3) δH rotamer A 0.90–0.96 (3H, 
m), 1.25–1.42 (2H, m), 1.48 (9H, s), 1.81–1.97 (2H, m), 2.83 (3H, s), 3.59 (3H, s), 4.55 
(2H, d, J = 7.7 Hz), 4.76 (1H, dd, J = 10.9, 4.8 Hz), 4.88 (1H, m), 6.65 (1H, d, J = 6.5 
Hz); δH rotamer B 0.90–0.96 (3H, m), 1.25–1.42 (2H, m), 1.45 (9H, s), 1.64–1.80 (2H, m), 
2.79 (3H, s), 3.58 (3H, s), 4.44 (1H, dd, J = 10.9, 4.8 Hz), 4.51 (2H, d, J = 7.7 Hz), 4.88 
(1H, m), 6.63 (1H, d, J = 6.5 Hz); 13C NMR (125MHz, CDCl3) δC rotamer A 13.5, 19.2, 
28.2, 30.3, 30.6, 55.9, 62.9, 77.3, 79.7, 96.7, 153.2, 155.6, 171.8; δC rotamer B 13.5, 19.3, 
28.2, 30.4, 31.0, 56.0, 63.0, 77.3, 80.0, 96.8, 153.4, 156.3, 172.1; HRMS (ESI, +ve) m/z 
calcd. for C15H27NO5Na 324.1787, found: 324.1773 (M+Na)+. 
 
(S,E)-1-tert-Butyl 2-(3-methoxyallyl) pyrrolidine-1,2-dicarboxylate (233) 
 
 
 
EDCi.HCl (1.52 g, 7.95 mmol), triethylamine (1.10 ml, 7.95 mmol), Boc-L-Pro-OH 
(1.71 g, 7.95 mmol), catalytic DMAP and (E)-3-(methoxy)prop-2-enol 218a (350 mg, 
3.97 mmol) were combined according to general procedure 3. Purifcation was achieved 
by flash chromatography (4:1 Pet/EtOAc + 1% NEt3) to afford the title compound as a 
colourless oil (736 mg, 65%). ሾαሿDଶ଴ -89 (c 1, DCM); FTIR (film/cm
-1) υmax: 3072, 2976, 
2882, 1744, 1698, 1656; 1H NMR (300 MHz, CDCl3) δH rotamer A 1.35 (9H, s), 1.72 – 
2.23 (4H, m), 3.23 – 3.55 (2H, m), 3.50 (3H, s), 4.08 – 4.17 (1H, m), 4.44 – 4.55 (2H, 
m), 4.78 – 4.92 (1H, m), 6.56 (1H, d, J = 12.6 Hz); δH rotamer B 1.40 (9H, s), 1.72 – 2.23 
(4H, m), 3.23 – 3.55 (2H, m), 3.51 (3H, s), 4.19 – 4.27 (1H, m), 4.44 – 4.55 (2H, m), 
4.78 – 4.92 (1H, m), 6.58 (1H, d, J = 12.6 Hz); 13C NMR (75 MHz, CDCl3) δC rotamer A 
24.0, 28.7, 30.2, 46.7, 56.5, 59.3, 60.8, 80.1, 97.2, 153.7, 154.0, 173.3; δC rotamer B 24.7, 
28.8, 31.2, 46.9, 56.5, 59.6, 63.4, 80.2, 97.2, 154.0, 154.2, 173.6; HRMS (ESI, +ve) m/z 
calcd. for C14H23NO5Na 308.1474, found 308.1463 (M+Na)+. 
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anti-1-tert-Butyl 2-methyl 2-(1-methoxyallyl)pyrrolidine-1,2-dicarboxylate (234) 
 
 
 
To a solution of (S,E)-1-tert-butyl 2-(3-methoxyallyl) pyrrolidine-1,2-dicarboxylate 233 
(143 mg, 0.50 mmol, 1.0 eq) in THF (1.5 mL) at -78 °C was added TMSCl (186 μl, 
2.00 mmol, 2.0 eq). After 10 mins LHMDS (1M, 2.00 ml, 2.00 mmol, 2.0 eq) was 
added dropwise and reaction mixture allowed to warm to room temperature after a 
period of 30 mins, and stirred for 18 hours.  The reaction was quenched by the addition 
of 1N HCl and brine solution (1:1, 5 mL) and extracted with DCM (3 × 15 mL), EtOAc 
(1 × 15 mL), dried over Na2SO4 and concentrated in vacuo to afford the crude acid.  
Treatment with diazomethane according to general procedure VIII and purification by 
flash chromatography (15:1 Pet/EtOAc + 1% NEt3) affords the methyl ester as a 
colourless oil. (142 mg, 95%, 2:1 rotamers). FTIR (film/cm-1) υmax: 3001.2, 2988.4, 
2875.3, 1715.2, 1698.2; 1H NMR (500 MHz, CDCl3) δH rotamer A 1.35 (9H, s), 1.30 – 1.67 
(4H, m), 3.16 – 3.75 (2H, m), 3.23 (3H, s), 3.60 (3H, s), 4.28 – 4.36 (1H, m), 5.11 – 
5.33 (2H, m), 5.88 – 6.06 (1H, m); δH rotamer B 1.37 (9H, s), 1.30 – 1.67 (4H, m), 3.16 – 
3.75 (2H, m), 3.25 (3H, s), 3.61 (3H, s), 4.53 – 4.60 (1H, m), 5.11 – 5.33 (2H, m), 5.88 
– 6.06 (1H, m); 13C NMR (125 MHz, CDCl3) δC rotamer A 23.3, 28.8, 32.4, 48.8, 52.2, 
58.3, 70.2, 79.9, 82.0, 117.3, 135.6, 153.5, 173.7; δC rotamer B 23.9, 30.1, 33.9, 48.9, 52.2, 
58.6, 70.8, 80.5, 82.0, 117.3, 135.6, 154.3, 173.7; HRMS (ESI, +ve) m/z: calcd. for 
C15H26NO5 300.1811, found 300.1801 (M+H)+. 
 
(R)-3-(tert-Butoxycarbonyl)oxazolidine-4-carboxylic acid (237a) 
 
 
 
D-Serine (3.15 g, 30 mmol), formaldehyde (37% aq, 3.0 mL), 2N NaOH (15 mL, 30 
mmol), NH2OH.HCl (200 mg, 3.0 mmol), NaOH (120 mg, 3.0 mmol), H2O (2.5 mL), 
acetone (17.5 mL) and Boc2O (7.20 g, 33 mmol) were combined according to general 
procedure VI (reaction time: 24 hours), to afford the title compound as a colourless oil 
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which crystallises on standing to an amorphous white solid (6.05 g, 93%). ሾαሿDଶ଴ +70 (c 
1, MeOH), lit. (opp. ent)184 -81.8 (c 2.6, CHCl3); FTIR (film/cm-1) υmax: 3100, 2979, 
2884, 1752, 1704, 1684; 1H NMR (500MHz, CDCl3) δH rotamer A 1.42 (9H, s), 4.18 (2H, 
bs), 4.30–4.58 (1H, m), 4.78–5.05 (2H, m), 10.75 (1H, bs); δH rotamer B 1.44 (9H, s), 4.18 
(2H, bs), 4.30–4.58 (1H, m), 4.78–5.05 (2H, m), 10.75 (1H, bs); 13C NMR (125MHz, 
CDCl3) δC rotamer A 28.2, 56.8, 70.1, 79.4,  81.6, 152.3, 174.3; δC rotamer B 28.2, 57.2, 71.0, 
79.4,  82.0, 153.3, 175.4; HRMS (ESI, +ve) m/z calcd. for C9H15NO5Na 240.0848, 
found: 240.0839 (M+Na)+. 
 
(R)-3-(tert-Butoxycarbonyl)thiazolidine-4-carboxylic acid (237b) 
 
 
 
L-Cysteine (30 mmol, 3.63 g), formaldehyde (37% aq, 3.0 mL), NaOH (2N, 30 mmol, 
15 mL), NH2OH.HCl (200 mg, 3.0 mmol), NaOH (120 mg, 3.0 mmol), H2O (2.5 mL), 
acetone (17.5 mL) and Boc2O (7.20 g, 33 mmol) were combined according to general 
procedure VI (reaction time: 24 hours), to afford the title compound as a colourless oil 
which crystallises on standing to a white solid (5.41 g, 77%).  Mpt: 131-133 °C (lit.288 
132-133 °C);  ሾαሿDଶ଴ -117 (c 1, CH2Cl2), lit.
288 -114 (c 1, MeOH); 1H NMR (500MHz, 
CDCl3) δH rotamer A 1.45 (9H, s), 3.20–3.48 (2H, m), 4.35–4.98 (3H, m), 10.52 (1H, bs); 
δH rotamer B 1.49 (9H, s), 3.20–3.48 (2H, m), 4.35–4.98 (3H, m), 10.52 (1H, bs); 13C NMR 
(125MHz, CDCl3) δC rotamer A 28.3, 33.0, 48.4, 61.4, 81.8, 153.2, 175.1; δC rotamer B 29.1, 
34.4, 49.0, 61.4, 81.9, 153.9, 176.3. All analytical data is in accordance with literature 
precedence.289 
 
(4S,5R)-3-(tert-Butoxycarbonyl)-5-methyloxazolidine-4-carboxylic acid (237c) 
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L-Threonine (3.57 g, 30 mmol), formaldehyde (37% aq, 3.0 mL), 2N NaOH (15 mL, 30 
mmol), NH2OH.HCl (200 mg, 3.0 mmol), NaOH (120 mg, 3.0 mmol), H2O (2.5 mL), 
acetone (17.5 mL) and Boc2O (7.20 g, 33 mmol) were combined according to general 
procedure VI (reaction time: 24 hours), to afford the title compound as a colourless oil 
(6.76 g, 97%). ሾαሿDଶ଴ -103 (c 1, MeOH), lit.
184 -110.2 (c 2, CHCl3); 1H NMR (500MHz, 
CDCl3) δH rotamer A: 1.37–1.63 (12H, m), 3.83–4.06 (1H, m), 4.28 (1H, bs), 4.69–4.88 
(2H, m), 9.47 (1H, bs); δH rotamer B 1.37–1.63 (12H, m), 3.83–4.06 (1H, m), 4.28 (1H, bs), 
5.08–5.26 (2H, m), 9.47 (1H, bs); 13C NMR (125MHz, CDCl3) δC rotamer A 18.4, 28.2, 
63.2, 78.3, 78.9, 81.5, 152.2, 173.8; δC rotamer B 18.4, 28.2, 63.8, 78.8, 79.4, 82.1, 153.6, 
175.5. All analytical data is in accordance with literature precedence.184 
 
(R,E)-3-tert-Butyl 4-(3-methoxyallyl) oxazolidine-3,4-dicarboxylate (238a) 
 
 
 
EDCi.HCl (870 mg, 4.54 mmol), triethylamine (634 μL, 4.54 mmol), (R)-3-(tert-
butoxycarbonyl)oxazolidine-4-carboxylic acid 237a (986 mg, 4.54 mmol), DMAP (5 
mol%), DCM (40 mL) and (E)-3-(methoxy)prop-2-enol 218a (200 mg, 2.27 mmol) 
were combined according to general procedure IV (reaction time: 18 hours), to afford 
the title compound as a pale yellow oil (242 mg, 67%).  ሾαሿDଶ଴ +22 (c 1, CH2Cl2); FTIR 
(film/cm-1) υmax: 2977, 2881, 1747, 1702, 1654; 1H NMR (500MHz, CDCl3) δH 1.40 
(9H, s), 3.51 (3H, s), 4.01 (1H, dd, J = 8.8, 4.0 Hz), 4.10–4.46 (2H, m), 4.46–4.62 (2H, 
m), 4.77–4.99 (3H, m), 6.60 (1H, d, J = 12.3 Hz);  13C NMR (125MHz, CDCl3) δC rotamer 
A 27.9, 28.2, 56.1, 57.0, 63.7, 70.2, 79.5, 96.4, 152.0, 153.7, 170.5; δC rotamer B 27.9, 28.2, 
56.1, 57.5, 63.7, 71.1, 80.8, 96.4, 152.4, 153.9, 170.5; HRMS (ESI, +ve) m/z calcd. for 
C13H21NO6Na 310.1267, found: 310.1260 (M+Na)+. 
 
(R,E)-3-tert-Butyl 4-(3-methoxyallyl) thiazolidine-3,4-dicarboxylate (238b) 
 
 
  | 172 
Chapter 7  Experimental   
EDCi.HCl (782 mg, 4.08 mmol), triethylamine (570 μL, 4.08 mmol), (R)-3-(tert-
butoxycarbonyl)thiazolidine-4-carboxylic acid 237b (952 mg, 4.08 mmol), DMAP (5 
mol%), DCM (40 mL) and (E)-3-(methoxy)prop-2-enol 218a (180 mg, 2.04 mmol) 
were combined according to general procedure IV (reaction time: 18 hours), purified by 
flash chromatography (2:1 Pet/EtOAc + 1% NEt3) to afford the title compound as a 
colourless oil (389 mg, 63%). ሾαሿDଶ଴ -43 (c 1, CH2Cl2); FTIR (film/cm
-1) υmax: 2977, 
2933, 1747, 1702, 1655; 1H NMR (500MHz, CDCl3) δH rotamer A 1.36 (9H, s), 3.06–3.32 
(2H, m), 3.49 (3H, s), 4.30–4.44 (1H, m), 4.45–4.91 (5H, m), 6.52–6.63 (1H, m); δH 
rotamer B 1.41 (9H, s), 3.06–3.32 (2H, m), 3.49 (3H, s), 4.30–4.44 (1H, m), 4.45–4.91 (5H, 
m), 6.52–6.63 (1H, m); 13C NMR (125MHz, CDCl3) δC rotamer A 28.2, 33.1, 48.0, 56.0, 
61.6, 63.7, 81.0, 96.4, 153.0, 153.5, 170.3; δC rotamer B 28.2, 34.6, 49.0, 56.0, 61.6, 63.7, 
81.0, 96.4, 153.2, 153.8, 170.7; HRMS (ESI, +ve) m/z calcd. for C13H21NO5SNa 
326.1038, found: 326.1032 (M+Na)+. 
 
(4S,5R)-3-tert-Butyl 4-((E)-3-methoxyallyl) 5-methyloxazolidine-3,4-dicarboxylate 
(238c) 
 
 
 
EDCi.HCl (870 mg, 4.54 mmol), triethylamine (634 μL, 4.54 mmol), (4S,5R)-3-(tert-
butoxycarbonyl)-5-methyloxazolidine-4-carboxylic acid 237c (1.05 g, 4.54 mmol), 
DMAP (5 mol%), DCM (40 mL) and (E)-3-(methoxy)prop-2-enol 218a (200 mg, 2.27 
mmol) were combined according to general procedure IV (reaction time: 18 hours), 
purified by flash chromatography (2:1 Pet/EtOAc + 1% NEt3) to afford the title 
compound as a colourless oil (380 mg, 56%). ሾαሿDଶ଴ -70.3 (c 3.2, CH2Cl2); FTIR 
(film/cm-1) υmax: 2978, 2937, 2873, 1748, 1705, 1653; 1H NMR (500MHz, CDCl3) δH 
rotamer A 1.32 (9H, s), 1.37 (3H, bs), 3.47 (3H, s), 3.69–3.95 (1H, m), 4.05 (1H, dt, J = 
12.6, 6.3 Hz), 4.38–4.62 (2H, m), 4.62–4.90 (2H, m), 4.91–5.15 (1H, m), 6.50–6.62 
(1H, m); δH rotamer B 1.34 (9H, s), 1.37 (3H, bs), 3.47 (3H, s), 3.69–3.95 (1H, m), 4.05 
(1H, dt, J = 12.6, 6.3 Hz), 4.38–4.62 (2H, m), 4.62–4.90 (2H, m), 4.91–5.15 (1H, m), 
6.50–6.62 (1H, m); 13C NMR (125MHz, CDCl3) δC rotamer A 18.4, 28.1, 56.0, 63.5, 64.0, 
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78.8, 79.2, 80.6, 96.4, 152.0, 153.6, 170.0; δC rotamer B 18.6, 28.1, 56.0, 63.5, 64.0, 78.8, 
79.2, 80.6, 96.4, 152.4, 153.9, 170.2; HRMS (ESI, +ve) m/z calcd. for C14H23NO6Na 
324.1423, found: 324.1418 (M+Na)+. 
 
(4S,5R)-3-tert-Butyl 4-((E)-3-ethoxyallyl) 5-methyloxazolidine-3,4-dicarboxylate 
(238d) 
 
 
 
EDCi.HCl (1.15 g, 6.0 mmol), triethylamine (838 μL, 6.0 mmol), (4S,5R)-3-(tert-
butoxycarbonyl)-5-methyloxazolidine-4-carboxylic acid 237c (1.39 g, 6.0 mmol), 
DMAP (5 mol%), DCM (250 mL) and (E)-3-(ethoxy)prop-2-enol 218b (306 mg, 3.0 
mmol) were combined according to general procedure IV (reaction time: 2 hours), 
purified by flash chromatography (2:1 Pet/EtOAc + 1% NEt3) to afford the title 
compound as a colourless oil (427 mg, 45%). ሾαሿDଶ଴ -67.6 (c 2.9, CHCl3); FTIR 
(film/cm-1) υmax: 2979, 2936, 2880, 1749, 1703, 1653; 1H NMR (500MHz, CDCl3) δH 
rotamer A 1.27 (3H, t, J = 7.0 Hz), 1.40 (3H, d, J = 6.2 Hz), 1.42 (9H, s), 3.81 (2H, q, J = 
7.0 Hz), 3.83–3.92 (1H, m), 4.08–4.25 (1H, m), 4.49–4.58 (1H, m), 4.60 (1H, app. d, J 
= 7.7 Hz), 4.73 (1H, d, J = 4.0 Hz), 4.91–5.03 (1H, m), 5.06 (1H, d, J = 4.0 Hz), 6.72 
(1H, m); δH rotamer B 1.27 (3H, t, J = 7.0 Hz), 1.40 (3H, d, J = 6.2 Hz), 1.47 (9H, s), 3.81 
(2H, q, J = 7.0 Hz), 3.83–3.92 (1H, m), 4.08–4.25 (1H, m), 4.49–4.58 (1H, m), 4.60 
(1H, app. d, J = 7.7 Hz), 4.73 (1H, d, J = 4.0 Hz), 4.91–5.03 (1H, m), 5.06 (1H, d, J = 
4.0 Hz), 6.72 (1H, m); 13C NMR (125MHz, CDCl3) δC rotamer A 13.9, 17.9, 27.6, 63.3, 
63.5, 64.8, 78.4, 79.3, 79.9, 95.9, 151.7, 152.8, 169.7; δC rotamer B 14.1, 18.1, 27.6, 63.3, 
64.0, 66.8, 78.6, 79.3, 80.0, 97.4, 152.1, 153.1, 170.0; HRMS (ESI, +ve) m/z calcd. for 
C15H25NO6Na 338.1580, found: 338.1601 (M+Na)+. 
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(4S,5R)-3-tert-Butyl 4-((E)-3-(4-methoxybenzyloxy)allyl) 5-methyloxazolidine-3,4-
dicarboxylate (238e) 
 
 
 
EDCi.HCl (2.30 g, 12.0 mmol), triethylamine (1.68 mL, 12.0 mmol), (4S,5R)-3-(tert-
butoxycarbonyl)-5-methyloxazolidine-4-carboxylic acid 237c (2.78 g, 12.0 mmol), 
DMAP (5 mol%), DCM (250 mL) and (E)-3-(4-methoxybenzyloxy)prop-2-en-1-ol 
218k (1.17 g, 6.0 mmol) were combined according to general procedure IV (reaction 
time: 2 hours) to afford the title compound as a yellow oil (1.55 g, 64%). ሾαሿDଶ଴ -55.2 (c 
1.45, CHCl3); FTIR (film/cm-1) υmax: 2978, 2936, 2878, 1748, 1704, 1672, 1651; 1H 
NMR (500MHz, CDCl3) δH mixture of rotamers 1.36–1.50 (12H, m),3.78 (3H, s), 3.79–4.03 
(1H, m), 4.07–4.15 (1H, m), 4.46–4.67 (2H, m), 4.68 (2H, s), 4.73–4.85 (1H, m), 4.95–
5.24 (2H, m), 6.66 (1H, app. d, J = 12.0 Hz), 6.87 (2H, app. d, J = 8.5 Hz), 7.24 (2H, 
app. d, J = 8.5 Hz); 13C NMR (125MHz, CDCl3) δC rotamer A 18.5, 28.1, 55.2, 63.5, 64.1, 
66.9, 71.3, 78.5, 78.9, 79.3, 80.8, 98.1, 114.0, 129.3, 152.5, 159.6, 170.1; δC rotamer B 
18.6, 28.2, 55.2, 63.6, 64.1, 66.9, 71.3, 78.5, 78.9, 79.3, 80.8, 98.1, 114.0, 129.3, 152.8, 
159.6, 170.2; HRMS (ESI, +ve) m/z calcd. for C21H29NO7Na 430.1842, found: 
430.1852 (M+Na)+. 
 
(±)-(anti)-3-tert-Butyl 4-methyl 4-(1-methoxyallyl)oxazolidine-3,4-dicarboxylate 
(239a) 
 
 
 
To a solution of (R,E)-3-tert-butyl 4-(3-methoxyallyl) oxazolidine-3,4-dicarboxylate 
238a (50 mg, 0.174 mmol) in THF (0.5 mL) at -78 °C was added TMSCl (67 μL, 0.522 
mmol).  After 10 mins LHMDS (1M, 522 μl, 0.522 mmol) was added via syringe pump 
at an addition rate of 3 mL min-1 and reaction mixture allowed to warm to room 
  | 175 
Chapter 7  Experimental   
temperature after a period of 30 mins, and stirred for 18 hours.  The reaction was 
quenched by the addition of 1N HCl and brine solution (1:1, 5 mL) and extracted with 
DCM (3 × 15 mL), EtOAc (1 × 15 mL), dried over Na2SO4 and concentrated in vacuo 
to afford the crude acid.  Treatment with diazomethane according to general procedure 
VIII and purification by flash chromatography (8:1 Pet/EtOAc + 1% NEt3) affords the 
methyl ester as a colourless oil (26 mg, 50%, dr 6:1). FTIR (film/cm-1) υmax: 2981, 
2934, 1743, 1698; 1H NMR (500MHz, CDCl3) δH major diastereomer 1.47 (9H, s), 3.37 (3H, 
s), 3.75 (3H, s), 4.70–4.88 (2H, m), 4.28–4.65 (1H, m), 4.70–4.88 (1H, m), 5.07–5.44 
(3H, m), 5.90–6.08 (1H, m);  δH minor diastereomer 1.44 (9H, s), 3.35 (3H, s), 3.78 (3H, s), 
4.70–4.88 (2H, m), 4.28–4.65 (1H, m), 4.70–4.88 (1H, m), 5.07–5.44 (3H, m), 5.68–
5.78 (1H, m); 13C NMR (125MHz, CDCl3) δC major diastereomer 28.3, 52.4, 57.7, 67.7, 72.1, 
73.4, 80.7, 81.3, 118.4, 133.7, 151.4, 171.0; δC minor diastereomer 28.2, 52.5, 58.0, 68.3, 72.3, 
73.1, 80.3, 81.0, 118.4, 133.7, 151.8, 171.7; HRMS (ESI, +ve) m/z calcd. for 
C14H23NO6Na 324.1423, found: 324.1422 (M+Na)+. 
 
(±)-(anti)-3-tert-Butyl 4-methyl 4-(1-methoxyallyl)thiazolidine-3,4-dicarboxylate 
(239b) 
 
 
 
To a solution of (R,E)-3-tert-butyl 4-(3-methoxyallyl) thiazolidine-3,4-dicarboxylate 
238b (75 mg, 0.247 mmol) in THF (0.75 mL) at -78 °C was added TMSCl (95 μL, 
0.742 mmol).  After 10 mins LHMDS (1M, 742 μl, 0.742 mmol) was added via syringe 
pump at an addition rate of 3 mL min-1 and reaction mixture allowed to warm to room 
temperature after a period of 30 mins, and stirred for 18 hours.  The reaction was 
quenched by the addition of 1N HCl and brine solution (1:1, 5 mL) and extracted with 
DCM (3 × 15 mL), EtOAc (1 × 15 mL), dried over Na2SO4 and concentrated in vacuo 
to afford the crude acid.  Treatment with diazomethane according to general procedure 
VIII and purification by flash chromatography (8:1 Pet/EtOAc + 1% NEt3) affords the 
methyl ester as a colourless oil (34.4 mg, 44%, dr 12:1). FTIR (film/cm-1) υmax: 2979, 
2932, 2830, 1741, 1694; 1H NMR (500MHz, CDCl3) δH major diastereomer 1.47 (9H, s), 3.03 
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(1H, d, J = 12.4 Hz), 3.33 (3H, s), 3.40–3.58 (1H, m), 3.73 (3H, s), 4.39 (0.5H, bs), 4.42 
(1H, d, J = 9.1 Hz), 4.64 (0.5H, bs), 4.75 (0.5H, bs), 4.91 (0.5H, bs), 5.31 (1H, app. d, J 
= 9.5 Hz), 5.38 (1H, app. d, J = 16.8 Hz), 6.13 (1H, ddd, J = 16.8, 9.5, 6.1 Hz); δH minor 
diastereomer 1.44 (9H, s), 3.03 (1H, d, J = 12.4 Hz), 3.38 (3H, s), 3.40–3.58 (1H, m), 3.77 
(3H, s), 4.39 (0.5H, bs), 4.42 (1H, d, J = 9.1 Hz), 4.64 (0.5H, bs), 4.75 (0.5H, bs), 4.91 
(0.5H, bs), 5.31 (1H, app. d, J = 9.5 Hz), 5.38 (1H, app. d, J = 16.8 Hz), 5.83 (1H, ddd, 
J = 16.8, 9.5, 6.1 Hz); 13C NMR (125MHz, CDCl3) δC major diastereomer 28.2, 36.5, 51.2, 
52.4, 57.8, 72.9, 80.6, 81.8, 118.1, 134.4, 152.3, 171.3; HRMS (ESI, +ve) m/z calcd. for 
C14H23NO5SNa 340.1195, found: 340.1188 (M+Na)+. 
 
(4S,5R)-3-tert-Butyl 4-methyl 4-((R)-1-methoxyallyl)-5-methyloxazolidine-3,4-
dicarboxylate (239c) 
 
 
 
To a solution of (4S,5R)-3-tert-butyl 4-((E)-3-methoxyallyl) 5-methyloxazolidine-3,4-
dicarboxylate 238c (150 mg, 0.500 mmol) in THF (1.5 mL) at -78 °C was added 
TMSCl (191 μL, 1.50 mmol).  After 10 mins LHMDS (1M, 1.50 mL, 1.50 mmol) was 
added via syringe pump at an addition rate of 3 mL min-1 and reaction mixture allowed 
to warm to room temperature after a period of 30 mins, and stirred for 18 hours.  The 
reaction was quenched by the addition of 1N HCl and brine solution (1:1, 5 mL) and 
extracted with DCM (3 × 15 mL), EtOAc (1 × 15 mL), dried over Na2SO4 and 
concentrated in vacuo to afford the crude acid. Treatment with diazomethane according 
to general procedure VIII and purification by flash chromatography (10:1 Pet/EtOAc) 
affords the methyl ester as a colourless oil (74 mg, 47%, dr >99:1).   ሾαሿDଶ଴ -54.0 (c 1, 
CH2Cl2); FTIR (film/cm-1) υmax: 2981, 2942, 2871, 1742, 1705; 1H NMR (500MHz, 
CDCl3, 328K) δH rotamer A 1.18 (3H, d, J = 3.9 Hz), 1.46 (9H, s), 3.36 (3H, s), 3.74 (3H, 
s), 4.20–4.28 (1H, m), 4.39 (1H, app. d, J = 4.3 Hz), 4.67 (1H, d, J = 4.0 Hz), 5.16 (1H, 
d, J = 4.0 Hz), 5.26–5.35 (1H, m), 5.41 (1H, dd, J = 17.4, 1.7 Hz), 6.10–6.20 (1H, m); 
δH rotamer B 1.20 (3H, d, J = 3.9 Hz), 1.48 (9H, s), 3.38 (3H, s), 3.75 (3H, s), 4.20–4.28 
(1H, m), 4.62 (1H, app. d, J = 4.3 Hz), 4.70 (1H, d, J = 4.0 Hz), 5.26–5.35 (2H, m), 5.41 
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(1H, dd, J = 17.4, 1.7 Hz), 6.10–6.20 (1H, m); 13C NMR (75MHz, CDCl3) δC rotamer A 
15.3, 27.3, 50.8, 57.1, 76.2, 77.7, 78.4, 79.6, 115.9, 127.2, 133.1, 150.3, 169.5; δC rotamer 
B 15.4, 27.3, 50.9, 57.3, 76.8, 77.9, 78.5, 79.9, 116.2, 128.0, 133.2, 150.8, 169.6; HRMS 
(ESI, +ve) m/z calcd. for C15H25NO6Na 338.1580, found: 338.1551 (M+Na)+. 
 
(4S,5R)-3-tert-Butyl 4-methyl 4-((R)-1-ethoxyallyl)-5-methyloxazolidine-3,4-
dicarboxylate (239d) 
 
 
 
To a solution of (4S,5R)-3-tert-butyl 4-((E)-3-ethoxyallyl) 5-methyloxazolidine-3,4-
dicarboxylate 238d (191 mg, 0.61 mmol) in THF (4.0 mL) at -78 °C was added TMSCl 
(232 μL, 1.82 mmol).  After 10 mins LHMDS (1M, 1.82 mL, 1.82 mmol) was added 
via syringe pump at an addition rate of 3 mL min-1 and reaction mixture allowed to 
warm to room temperature after a period of 30 mins, and stirred for 18 hours.  The 
reaction was quenched by the addition of 1N HCl and brine solution (1:1, 5 mL) and 
extracted with DCM (3 × 15 mL), EtOAc (1 × 15 mL), dried over Na2SO4 and 
concentrated in vacuo to afford the crude acid. Treatment with diazomethane according 
to general procedure VIII and purification by flash chromatography (10:1 Pet/EtOAc) 
affords the methyl ester as a colourless oil (140 mg, 70%, dr >99:1). ሾαሿDଶ଴ -62.7 (c 1.9, 
CHCl3); FTIR (film/cm-1) υmax: 2977, 2874, 1742, 1704; 1H NMR (500MHz, CDCl3, 
328K) δH rotamer A 1.08–1.15 (6H, m), 1.39 (9H, s), 3.33–3.43 (1H, m), 3.51–3.61 (1H, 
m), 3.68 (3H, s), 4.21 (1H, app. sex, J = 6.0 Hz), 4.42–4.48 (1H, m), 4.61 (1H, d, J = 
3.9 Hz), 5.11 (1H, d, J = 3.9 Hz), 5.20 (1H, app. t, J = 10.8 Hz), 5.37 (1H, app. dd, J = 
17.2, 2.3 Hz), 6.11–6.21 (1H, m); δH rotamer B 1.08–1.15 (6H, m), 1.41 (9H, s), 3.33–3.43 
(1H, m), 3.51–3.61 (1H, m), 3.69 (3H, s), 4.21 (1H, app. sex, J = 6.0 Hz), 4.64 (1H, d, J 
= 3.9 Hz), 4.66–4.70 (1H, m), 5.20 (1H, app. t, J = 10.8 Hz), 5.28 (1H, d, J = 3.9 Hz), 
5.37 (1H, app. dd, J = 17.2, 2.3 Hz), 6.11–6.21 (1H, m); 13C NMR (125MHz, CDCl3) δC 
rotamer A 15.4, 16.3, 28.3, 51.8, 65.8, 70.8, 77.7, 78.8, 79.4, 80.5, 116.5, 134.8, 151.2, 
170.5; δC rotamer B 15.4, 16.4, 28.3, 51.9, 66.2, 70.8, 78.0, 78.8, 79.6, 80.8, 116.7, 135.0, 
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151.7, 170.7; HRMS (ESI, +ve) m/z calcd. for C16H27NO6Na 352.1736, found: 
352.1716 (M+Na)+. 
 
DL-Serine methyl ester hydrochloride (rac-247) 
 
 
 
DL-Serine (20.2 g, 193 mmol) in MeOH (400 mL) and thionyl chloride (28.0 mL, 385 
mmol, 2.0 eq) were combined according to general procedure V to afford DL-serine 
methyl ester hydrochloride as a white powder (29.6 g, 99%).  Mpt: 138-141 °C (lit.290 
135-136 °C); 1H NMR (500MHz, D2O) δH  3.81 (3H, s), 3.95 (1H, dd, J = 4.0, 12.5 Hz), 
4.05 (1H, dd, J = 4.0, 12.5 Hz), 4.24 (1H, app. t, J = 4.0 Hz), 4.69 (3H, s); 13C NMR 
(125MHz, D2O) δC 53.7, 54.7, 59.2, 168.9. All analytical data is in accordance with 
literature precedence.291 
 
L-Serine methyl ester hydrochloride hydrochloride (247) 
 
 
 
L-Serine (20.2 g, 193 mmol) in MeOH (400 mL) and thionyl chloride (28.0 mL, 385 
mmol, 2.0 eq) were combined according to general procedure V to afford L-serine 
methyl ester hydrochloride as a white powder (29.8 g, 99%). Mpt: 162-163 °C (lit.292 
162-165 °C); ሾαሿDଶ଴ +5 (c 1, MeOH), lit.
293 ሾαሿDଶ଴ +5 (c 2, MeOH). All other data as 
previously stated. 
 
D-Serine methyl ester hydrochloride hydrochloride (ent-247) 
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D-Serine (10.1 g, 96.5 mmol) in MeOH (200 mL) and thionyl chloride (14.0 mL, 193 
mmol, 2.0 eq) were combined according to general procedure V to afford D-serine 
methyl ester hydrochloride as a white powder (14.8 g, 99%). Mpt: 162-165 °C (lit.294 
163-164 °C); ሾαሿDଶ଴ -5 (c 1, MeOH), lit.
295 ሾαሿDଶ଴ -5.2 (c 0.4, MeOH).  All other data as 
previously stated. 
 
(±)-Methyl 2-tert-butyloxazolidine-4-carboxylate (rac-248) 
 
 
 
To a suspension of DL-serine methyl ester hydrochloride rac-247 (7.02 g, 45.1 mmol, 
1.0 eq) in pentane (125 mL) was added pivalaldehyde (7.35 mL, 67.7 mmol, 1.5 eq) and 
triethylamine (6.93 mL, 49.6 mmol, 1.1 eq) and the reaction refluxed at 55 °C for 72 
hours under Dean Stark conditions.  The resulting mixture was allowed to cool to room 
temperature, filtered, and the solid washed with pentane.  The combined filtrate was 
concentrated in vacuo to afford the title compound as a pale yellow liquid (7.50 g, 89%, 
dr 60:40). FTIR (film/cm-1) υmax: 3320, 2957, 2909, 2872, 1740; 1H NMR (500MHz, 
CDCl3) δH major diastereomer 1.00 (9H, s), 2.95 (1H, bs), 3.69–3.79 (1H, m), 3.77 (3H, s), 
3.89–4.15 (2H, m), 4.09 (1H, s);  δH minor diastereomer 0.92 (9H, s), 2.95 (1H, bs), 3.69–3.79 
(1H, m), 3.75 (3H, s), 3.89–4.15 (2H, m), 4.34 (1H, s); 13C NMR (125MHz, CDCl3) δC 
major diastereomer 25.2, 33.2, 52.5, 59.5, 68.3, 99.9, 172.8; δC minor diastereomer 24.9, 34.5, 52.3, 
59.4, 68.9, 99.2, 173.1; HRMS (ESI, +ve) m/z calcd. for C9H17NO3Na 210.1106, found: 
210.1096 (M+Na)+. 
 
(S)-Methyl 2-tert-butyloxazolidine-4-carboxylate (248) 
 
 
 
To a suspension of L-serine methyl ester hydrochloride 247 (6.0 g, 38.6 mmol, 1.0 eq) 
in pentane (150 mL) was added pivalaldehyde (6.30 mL, 57.9 mmol, 1.5 eq) and 
triethylamine (6.0 mL, 42.5 mmol, 1.1 eq) and the reaction refluxed at 55 °C for 72 
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hours under Dean Stark conditions.  The resulting mixture was allowed to cool to room 
temperature, filtered, and the solid washed with pentane.  The combined filtrate was 
concentrated in vacuo to afford the title compound as a pale yellow liquid (6.84 g, 95%, 
dr 63:37). All other data as previously stated, and in accordance with literature 
precedence.296 
 
(R)-Methyl 2-tert-butyloxazolidine-4-carboxylate (ent-248) 
 
 
 
To a suspension of D-serine methyl ester hydrochloride ent-247 (7.78 g, 50.0 mmol, 1.0 
eq) in pentane (150 mL) was added pivalaldehyde (8.14 mL, 75.0 mmol, 1.5 eq) and 
triethylamine (7.68 mL, 55.0 mmol, 1.1 eq) and the reaction refluxed at 55 °C for 72 
hours under Dean Stark conditions.  The resulting mixture was allowed to cool to room 
temperature, filtered, and the solid washed with pentane.  The combined filtrate was 
concentrated in vacuo to afford the title compound as a pale yellow liquid (8.76 g, 94%, 
dr 60:40). All other data as previously stated, and in accordance with literature 
precedence.201 
 
(±)-(syn)-3-tert-Butyl 4-methyl 2-tert-butyloxazolidine-3,4-dicarboxylate (rac-249) 
 
 
 
To a solution of (±)-methyl 2-tert-butyloxazolidine-4-carboxylate rac-248 (4.63 g, 24.7 
mmol, 1.0 eq) and NaHCO3 (5.19 g, 61.8 mmol, 2.5 eq) in MeOH (80 mL) was added 
Boc2O (5.37 g, 24.7 mmol, 1.0 eq) and allowed to stir vigorously at 50 °C for 18 hours.  
The resulting mixture was allowed to cool to room temperature, filtered and the filtrate 
concentrated in vacuo.  The residue was diluted with diethyl ether, washed with brine (1 
× 75 mL), dried over MgSO4 and concentrated in vacuo.  Purification by flash 
chromatography 4:1 Pet/EtOAc) afforded the title compound as a colourless liquid (4.67 
g, 66%, dr >99:1). FTIR (film/cm-1) υmax: 2975, 2908, 1762, 1741, 1704; 1H NMR 
(500MHz, CDCl3) δH 0.92 (9H, s), 1.46 (9H, s), 3.74 (3H, s), 4.10 (1H, app. t, J = 7.2 
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Hz), 4.26 (1H, app. t, J = 7.2 Hz), 4.68 (1H, bs), 5.01 (1H, s); 13C NMR (125MHz, 
CDCl3) δC 25.7, 28.2, 37.7, 52.2, 59.7, 68.3, 81.3, 97.6, 155.1, 171.0; HRMS (ESI, +ve) 
m/z calcd. for C14H25NO5Na 310.1630, found: 310.1626 (M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-methyl 2-tert-butyloxazolidine-3,4-dicarboxylate (249) 
 
 
 
To a solution of (S)-methyl 2-tert-butyloxazolidine-4-carboxylate 248 (a 60:40 mixture 
of diastereomers) (2.46 g, 13.1 mmol, 1.0 eq) and NaHCO3 (2.75 g, 32.8 mmol, 2.5 eq) 
in MeOH (40 mL) was added Boc2O (2.85 g, 13.1 mmol, 1.0 eq) and allowed to stir 
vigorously at 50 °C for 18 hours.  The resulting mixture was allowed to cool to room 
temperature, filtered and the filtrate concentrated in vacuo.  The residue was diluted 
with diethyl ether, washed with brine (1 × 50 mL), dried over MgSO4 and concentrated 
in vacuo to afford the crude compound with a dr >98:2.  Purification by flash 
chromatography (4:1 Pet/EtOAc) afforded the title compound as a colourless liquid 
(2.62 g, 70%, dr >99:1). ሾαሿDଶ଴ -30 (c 2, CH2Cl2), lit.
196 ሾαሿDଶ଴ -30 (c 0.3, MeOH). All 
other data as previously stated, and in accordance with literature precedence.196  
 
(2S,4R)-3-tert-Butyl 4-methyl 2-tert-butyloxazolidine-3,4-dicarboxylate (ent-249) 
 
 
 
To a solution of (R)-Methyl 2-tert-butyloxazolidine-4-carboxylate ent-248 (a 60:40 
mixture of diastereomers) (6.00 g, 32.0 mmol, 1.0 eq) and NaHCO3 (6.72 g, 80.0 mmol, 
2.5 eq) in MeOH (125 mL) was added Boc2O (6.95 g, 32.0 mmol, 1.0 eq) and allowed 
to stir vigorously at 50 °C for 18 hours.  The resulting mixture was allowed to cool to 
room temperature, filtered and the filtrate concentrated in vacuo.  The residue was 
diluted with diethyl ether, washed with brine (1 × 75 mL), dried over MgSO4 and 
concentrated in vacuo to afford the crude compound with a dr >98:2.  Purification by 
flash chromatography (4:1 Pet/EtOAc) afforded the title compound as a colourless 
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liquid (6.41 g, 70%, dr >99:1). ሾαሿDଶ଴ +29 (c 2.4, CH2Cl2). All other data as previously 
stated.  
 
(±)-(syn)-3-(tert-Butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid (rac-
250) 
 
 
 
To a solution of (±)-(syn)-3-tert-butyl 4-methyl 2-tert-butyloxazolidine-3,4-
dicarboxylate rac-249 (4.16 g, 14.5 mmol, 1.0 eq) in MeOH (29 mL) at 0 °C was added 
3N KOH (9.65 mL, 29.0 mmol, 2.0 eq) dropwise and the reaction mixture allowed to 
stir at room temperature for 4 hours.  The solvent was removed in vacuo and the residue 
diluted with ether, then acidified with 3N HCl till pH 1-2 and then extracted with ether.  
The combined organics were washed with brine (1 × 50 mL), dried over MgSO4 and 
concentrated in vacuo to afford the title compound as a white solid (3.55 g, 90%, dr 
>99:1). FTIR (film/cm-1) υmax: 3191, 2981, 2890, 1703; 1H NMR (500MHz, CDCl3) δH 
0.92 (9H, s), 1.50 (9H, s), 4.22 (1H, t, J = 8.8 Hz), 4.44 (1H, dd, J = 8.8, 6.5 Hz), 4.65 
(1H, dd, J = 8.8, 6.5 Hz), 5.06 (1H, s), 9.70 (1H, bs); 13C NMR (125MHz, CDCl3) δC 
25.6, 28.0, 37.7, 59.3, 67.7, 83.1, 97.3, 156.7, 172.6; HRMS (ESI, +ve) m/z calcd. for 
C13H23NO5Na 296.1474, found: 296.1468 (M+Na)+. 
 
(2R,4S)-3-(tert-Butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid (250) 
 
 
 
To a solution of (2R,4S)-3-tert-butyl 4-methyl 2-tert-butyloxazolidine-3,4-dicarboxylate 
249 (5.54 g, 19.3 mmol, 1.0 eq) in MeOH (20 mL) at 0 °C was added 3N KOH (12.9 
mL, 38.6 mmol, 2.0 eq) dropwise and the reaction mixture allowed to stir at room 
temperature for 4 hours.  The solvent was removed in vacuo and the residue diluted 
with ether, then acidified with 3N HCl till pH 1-2 and then extracted with ether.  The 
combined organics were washed with brine (1 × 50 mL), dried over MgSO4 and 
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concentrated in vacuo to afford the title compound as a white solid (4.68 g, 89%, dr 
>99:1). Mpt: 134-136 °C (lit.191 106-109 °C); ሾαሿDଶ଴ -98 (c 3.5, CH2Cl2), lit.
191 ሾαሿDଶ଴ -64 
(c 1, CHCl3). All other data as previously stated, and in accordance with literature 
precedence.191 
 
(2S,4R)-3-(tert-Butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid (ent-250) 
 
 
 
To a solution of (2S,4R)-3-tert-butyl 4-methyl 2-tert-butyloxazolidine-3,4-dicarboxylate 
ent-249 (5.76 g, 20.0 mmol, 1.0 eq) in MeOH (20 mL) at 0 °C was added 3N KOH (14 
mL, 40.0 mmol, 2.0 eq) dropwise and the reaction mixture allowed to stir at room 
temperature for 4 hours.  The solvent was removed in vacuo and the residue diluted 
with ether, then acidified with 3N HCl till pH 1-2 and then extracted with ether.  The 
combined organics were washed with brine (1 × 50 mL), dried over MgSO4 and 
concentrated in vacuo to afford the title compound as a white solid (4.97 g, 91%, dr 
>99:1). Mpt: 134-135 °C (lit.191 103-105 °C); ሾαሿDଶ଴ +99 (c 3, CH2Cl2). All other data as 
previously stated. 
 
(±)-(syn)-3-tert-Butyl 4-((E)-3-methoxyallyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate (rac-251a) 
 
 
 
EDCi.HCl (2.49 g, 13.0 mmol), triethylamine (1.82 mL, 13.0 mmol), (±)-(syn)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid rac-250 (3.54 g, 13.0 
mmol), DMAP (5 mol%), DCM (125 mL) and (E)-3-(methoxy)prop-2-enol 218a (9.19 
mmol, 810 mg) were combined according to general procedure IV (reaction time: 2 
hours) to afford the title compound as a yellow oil without the need for further 
purification (3.12 g, 99%). FTIR (film/cm-1) υmax: 2961, 2907, 1755, 1705, 1654; 1H 
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NMR (500MHz, CDCl3) δH 0.93 (9H, s), 1.46 (9H, s), 3.54 (3H, s), 4.15 (1H, app. t, J = 
8.4 Hz), 4.23 (1H, dd, J = 8.4, 6.0 Hz), 4.57 (2H, dd, J = 7.8, 3.8 Hz), 4.64 (1H, bs), 
4.91 (1H, dt, J = 12.7, 7.8 Hz), 5.02 (1H, s), 6.64 (1H, d, J = 12.7 Hz); 13C NMR 
(125MHz, CDCl3) δC 25.8, 28.2, 37.8, 56.0, 59.8, 63.5, 68.4, 81.2, 96.5, 97.6, 153.7, 
155.0, 170.4; HRMS (ESI, +ve) m/z calcd. for C17H29NO6Na 366.1893, found: 
366.1895 (M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-methoxyallyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate (251a) 
 
 
 
EDCi.HCl (456 mg, 2.38 mmol), triethylamine (335 μL, 2.38 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (650 mg, 2.38 mmol), 
DMAP (5 mol%), DCM (40 mL) and (E)-3-(methoxy)prop-2-enol 218a (140 mg, 1.59 
mmol) were combined according to general procedure IV (reaction time: 2 hours).  
Purified on a short pad of silica (2:1 Pet:EtOAc + 1% NEt3) to afford  the title 
compound as a colourless oil (495 mg, 91%). ሾαሿDଶ଴ -22.5 (c 2, CH2Cl2).  All other data 
as previously stated. 
 
(2S,4R)-3-tert-Butyl 4-((E)-3-methoxyallyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate (ent-251a) 
 
 
 
EDCi.HCl (383 mg, 2.00 mmol), triethylamine (280 μL, 2.00 mmol), (2S,4R)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid ent-250 (546 mg, 2.38 
mmol), DMAP (5 mol%), DCM (50 mL) and (E)-3-(methoxy)prop-2-enol 218a (88 mg, 
1.59 mmol) were combined according to general procedure IV (reaction time: 2 hours).  
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Purified on a short pad of silica (2:1 Pet:EtOAc + 1% NEt3) to afford  the title 
compound as a colourless oil (299 mg, 87%).  ሾαሿDଶ଴ +22.5 (c 2, CH2Cl2).  All other data 
as previously stated. 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-ethoxyallyl) 2-tert-butyloxazolidine-3,4-dicarboxylate 
(251b) 
 
 
 
EDCi.HCl (383 mg, 2.00 mmol), triethylamine (280 μL, 2.00 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (547 mg, 2.00 mmol), 
DMAP (5 mol%), DCM (50 mL) and (E)-3-(ethoxy)prop-2-enol 218b (102 mg, 1.00 
mmol) were combined according to general procedure IV (reaction time: 1 hour) to 
afford the title compound as a yellow oil without the need for further purification (331 
mg, 93%). ሾαሿDଶ଴ -26 (c 1, CH2Cl2); FTIR (film/cm-1) υmax: 2976, 2939, 2875, 1755, 
1705, 1673, 1653; 1H NMR (500MHz, d6-acetone) δH 0.93 (9H, s), 1.25 (3H, d, J = 7.0 
Hz), 1.46 (9H, s), 3.79 (2H, q, J = 7.0 Hz), 4.13–4.22 (2H, m), 4.57 (2H, d, J = 7.8 Hz), 
4.70 (1H, dd, J = 7.9, 6.2 Hz), 4.92–5.04 (2H, m), 6.70 (1H, d, J = 12.6 Hz); 13C NMR 
(125MHz, d6-acetone) δC 14.0, 25.4, 27.5, 37.5, 59.8, 63.1, 64.7, 68.2, 80.3, 97.2, 97.4, 
152.8, 154.8, 170.1; HRMS (ESI, +ve) m/z calcd. for C18H31NO6Na 380.2049, found: 
380.2040 (M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-isopropoxyallyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate 
 
 
 
EDCi.HCl (383 mg, 2.00 mmol), triethylamine (280 μL, 2.00 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (547 mg, 2.00 mmol), 
DMAP (5 mol%), DCM (50 mL) and (E)-3-(isopropoxy)prop-2-enol 218c (116 mg, 
1.00 mmol) were combined according to general procedure IV (reaction time: 20 
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minutes), purified by flash chromatography (4:1 Pet:EtOAc, Brockmann Grade I Basic 
Alumina) to afford the title compound as a colourless oil (133 mg, 36%). ሾαሿDଶ଴ -19 (c 1, 
CH2Cl2); FTIR (film/cm-1) υmax: 2978, 2936, 2875, 1751, 1702, 1671, 1652; 1H NMR 
(500MHz, d6-acetone) δH 0.93 (9H, s), 1.21 (6H, d, J = 6.2 Hz), 1.46 (9H, s), 4.08–4.21 
(3H, m), 4.56 (2H, d, J = 8.1 Hz), 4.70 (1H, app. t, J = 7.8 Hz), 4.94–5.03 (2H, m), 6.62 
(1H, d, J = 12.5 Hz); 13C NMR (125MHz, d6-acetone) δC 21.4, 25.4, 27.5, 37.5, 59.8, 
63.2, 68.2, 72.8, 80.2, 97.2, 98.6, 152.0, 154.8, 170.1; HRMS (ESI, +ve) m/z calcd. for 
C19H33NO6Na 394.2206, found: 394.2209 (M+Na)+. 
 
(2R,4S)-4-((E)-3-(Allyloxy)allyl) 3-tert-butyl 2-tert-butyloxazolidine-3,4-
dicarboxylate (251d) 
 
 
 
EDCi.HCl (767 mg, 4.00 mmol), triethylamine (560 μL, 4.00 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (1.09 g, 4.00 mmol), 
DMAP (5 mol%), DCM (100 mL) and (E)-3-(allyloxy)prop-2-en-1-ol 218d (228 mg, 
2.00 mmol) were combined according to general procedure IV (reaction time: 16 hours) 
to afford the title compound without the need for further purification as a pale yellow oil 
(552 mg, 75%). ሾαሿDଶ଴ -21 (c 3, CH2Cl2); FTIR (film/cm-1) υmax: 2974, 2936, 1754, 
1704, 1673, 1654; 1H NMR (500 MHz, d6-acetone) δH 0.92 (9H, s), 1.44 (9H, s), 4.14 
(1H, app. t, J = 8.5 Hz),  4.19–4.24 (3H, m), 4.54 (2H, d, J = 7.9 Hz), 4.63 (1H, bs), 
4.95 (1H, dt, J = 12.6, 7.8 Hz), 5.01 (1H, s), 5.22 (1H, dq, J = 10.6, 1.4 Hz), 5.29 (1H, 
dq, J = 17.3, 1.4 Hz), 5.89 (1H, ddt, J = 17.3, 10.6, 5.4 Hz), 6.57 (1H, d, J = 12.6 Hz); 
13C NMR (125 MHz, d6-acetone) δC 25.8, 28.2, 37.8, 59.7, 63.5, 68.4, 70.2, 81.2, 97.6, 
98.0, 117.9, 132.7, 152.4, 155.0, 170.3; HRMS (ESI, +ve) m/z calcd. for C19H31NO6Na 
392.2049, found: 392.2040 (M+Na)+. 
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(2R,4S)-3-tert-Butyl 4-((E)-3-(prop-2-ynyloxy)allyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate (251e) 
 
 
 
EDCi.HCl (767 mg, 4.00 mmol), triethylamine (560 μL, 4.00 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (1.09 g, 4.00 mmol), 
DMAP (5 mol%), DCM (100 mL) and (E)-3-(prop-2-ynyloxy)prop-2-en-1-ol 218e (224 
mg, 2.00 mmol) were combined according to general procedure IV (reaction time: 2 
hours). Purified on a short pad of silica (2:1 Pet:EtOAc + 1% Net3) to afford the title 
compound as a colourless oil (580 mg, 79%). ሾαሿDଶ଴ -21 (c 1, CH2Cl2); FTIR (film/cm-1) 
υmax: 3261, 2975, 2908, 2875, 1754, 1702, 1654; 1H NMR (500 MHz, d6-acetone) δH 
0.93 (9H, s), 1.46 (9H, s), 3.09 (1H, t, J = 2.4 Hz), 4.13–4.22 (2H, m), 4.50 (2H, d, J = 
2.4 Hz), 4.59 (2H, d, J = 7.8 Hz), 4.71 (1H, dd, J = 8.0, 6.2 Hz), 4.99 (1H, s), 5.11 (1H, 
dt, J = 12.5, 7.8 Hz), 6.71 (1H, d, J = 12.5 Hz); 13C NMR (125 MHz, d6-acetone) δC 
25.4, 27.5, 37.5, 56.9, 59.8, 62.6, 68.2, 76.4, 78.3, 80.3, 97.2, 99.5, 151.2, 154.8, 170.1; 
HRMS (ESI, +ve) m/z calcd. for C19H29NO6Na 390.1893, found: 390.1892 (M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-phenoxyallyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate (251f) 
 
 
 
EDCi.HCl (383 mg, 2.00 mmol), triethylamine (280 μL, 2.00 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (547 mg, 2.00 mmol), 
DMAP (5 mol%), DCM (50 mL) and (E)-3-phenoxyprop-2-en-1-ol 218f (150 mg, 1.00 
mmol) were combined according to general procedure IV (reaction time: 2 hours). 
Purified by flash chromatography on Brockmann Grade I Basic Alumina (4:1 
Pet:EtOAc) to afford the title compound as a colourless oil (337 mg, 83%).  ሾαሿDଶ଴ -17 (c 
1, CH2Cl2); FTIR (film/cm-1) υmax: 2975, 2907, 1756, 1704, 1674, 1592; 1H NMR (500 
MHz, CDCl3) δH 0.98 (9H, s), 1.49 (9H, s), 4.17 (1H, app. t, J = 8.0 Hz), 4.28 (1H, app. 
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t, J = 8.0 Hz), 4.65–4.72 (3H, m), 5.07 (1H, s), 5.39–5.48 (1H, m), 6.83 (1H, d, J = 12.2 
Hz), 7.00 (2H, d,  J = 7.7 Hz), 7.10 (1H, t, J = 7.7 Hz), 7.33 (2H, app. t, J = 7.7 Hz); 13C 
NMR (125 MHz, CDCl3) δC 25.9, 28.2, 37.8, 59.9, 62.2, 68.4, 81.2, 97.7, 105.1, 117.3, 
123.6, 129.6, 148.7, 155.0, 156.6, 170.2; HRMS (ESI, +ve) m/z calcd. for C22H31NO6Na 
428.2049, found: 428.2051 (M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-(4-methoxyphenoxy)allyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate (251g) 
 
 
 
EDCi.HCl (383 mg, 2.00 mmol), triethylamine (280 μL, 2.00 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (547 mg, 2.00 mmol), 
DMAP (5 mol%), DCM (50 mL) and (E)-3-(4-methoxyphenoxy)prop-2-en-1-ol 218g 
(180 mg, 1.00 mmol) were combined according to general procedure IV (reaction time: 
3 hours). Purified by flash chromatography (4:1 Pet:EtOAc, Brockmann Grade I Basic 
Alumina) to afford the title compound as a colourless oil (367 mg, 84%).  ሾαሿDଶ଴ -18 (c 
1, CH2Cl2); FTIR (film/cm-1) υmax: 2968, 2902, 2873, 1755, 1703, 1673, 1505; 1H 
NMR (500 MHz, d6-acetone) δH 0.95 (9H, s), 1.47 (9H, s), 3.78 (3H, s), 4.15–4.25 (2H, 
m), 4.67 (2H, d, J = 7.8 Hz), 4.74 (1H, dd, J = 8.1, 5.9 Hz), 5.01 (1H, s), 5.34 (1H, dt, J 
= 12.2, 7.8 Hz), 6.91–7.02 (5H, m); 13C NMR (125 MHz, d6-acetone) δC 25.5, 27.5, 
37.5, 55.0, 59.8, 62.1, 68.2, 80.4, 97.2, 104.0, 114.8, 118.3, 149.8, 150.3, 154.8, 156.1, 
170.1; HRMS (ESI, +ve) m/z calcd. for C23H33NO7Na 458.2155, found: 458.2139 
(M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-(4-(trifluoromethyl)phenoxy)allyl) 2-tert-
butyloxazolidine-3,4-dicarboxylate (251h) 
 
 
 
  | 189 
Chapter 7  Experimental   
EDCi.HCl (766 mg, 4.00 mmol), triethylamine (560 μL, 4.00 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (1.09 g, 4.00 mmol), 
DMAP (5 mol%), DCM (100 mL) and (E)-3-(4-(trifluoromethyl)phenoxy)prop-2-en-1-
ol 218h (436 mg, 2.00 mmol) were combined according to general procedure IV 
(reaction time: 2 hours) to afford the title compound without the need for further 
purification as a pale yellow oil (897 mg, 95%).  ሾαሿDଶ଴ -13 (c 3, CH2Cl2); FTIR 
(film/cm-1) υmax: 2972, 2912, 2878, 1757, 1702, 1613; 1H NMR (500MHz, d6-acetone) 
δH 0.95 (9H, s), 1.47 (9H, s), 4.16–4.26 (2H, m), 4.73–4.80 (3H, m), 5.01 (1H, s), 5.62 
(1H, dt, J = 12.0, 7.5 Hz), 7.17 (1H, d, J = 12.0 Hz), 7.28 (2H, app. d, J = 8.7 Hz), 7.74 
(2H, app. d, J = 8.7 Hz); 13C NMR (125MHz, d6-acetone) δC 25.4, 27.5, 37.5, 59.8, 
61.5, 68.1, 80.4, 97.3, 107.8, 116.8, 122.8 (q, J = 121.2 Hz), 124.7 (q, J = 33.2 Hz), 
127.3 (q, J = 3.8 Hz), 146.7, 154.8, 159.4, 170.1; HRMS (ESI, +ve) m/z calcd. for 
C23H30F3NO6Na 496.1923, found: 496.1911 (M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-(2-iodophenoxy)allyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate (251i) 
 
 
 
EDCi.HCl (383 mg, 2.00 mmol), triethylamine (280 μL, 2.00 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (547 mg, 2.00 mmol), 
DMAP (5 mol%), DCM (50 mL) and (E)-3-(2-iodophenoxy)prop-2-en-1-ol 218i (276 
mg, 1.00 mmol) were combined according to general procedure (reaction time: 2 hours). 
Purified by flash chromatography (4:1 Pet:EtOAc, Brockmann Grade I Basic Alumina) 
to afford the title compound as a colourless oil (370 mg, 72%). ሾαሿDଶ଴ -17 (c 2, CH2Cl2); 
FTIR (film/cm-1) υmax: 2974, 2937, 2912, 1756, 1702, 1674; 1H NMR (500MHz, d6-
acetone) δH 0.95 (9H, s), 1.46 (9H, s), 4.16–4.26 (2H, m), 4.72 (2H, dq, J = 7.5, 1.0 Hz), 
4.76 (1H, dd, J = 8.2, 5.8 Hz), 5.01 (1H, s), 5.49 (1H, dt, J = 12.1, 7.5 Hz), 6.96 (1H, td, 
J = 7.5, 1.3 Hz), 7.02 (1H, dt, J = 12.1, 1.0 Hz), 7.13 (1H, dd, J = 8.2, 1.3 Hz), 7.24–
7.47 (1H, m), 7.89 (1H, dd, J = 7.5, 1.6 Hz); 13C NMR (125MHz, d6-acetone) δC 25.4, 
27.5, 37.5, 59.8, 61.6, 68.2, 80.4, 86.4, 97.2, 106.4, 117.2, 125.6, 130.0, 139.8, 148.1, 
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154.8, 155.8, 170.1; HRMS (ESI, +ve) m/z calcd. for C22H30INO6Na 554.1016, found: 
554.0993 (M+Na)+. 
 
(±)- (syn)-4-((E)-3-(Benzyloxy)allyl) 3-tert-butyl 2-tert-butyloxazolidine-3,4-
dicarboxylate (rac-251j) 
 
 
 
EDCi.HCl (702 mg, 3.66 mmol), triethylamine (511 μL, 3.66 mmol), (±)-(syn)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid rac-250 (1.00 g, 3.66 
mmol), DMAP (5 mol%), DCM (70 mL) and (E)-3-(benzyloxy)prop-2-enol 218j (400 
mg, 2.44 mmol) were combined according to general procedure IV (reaction time: 2 
hours) to afford the title compound as a yellow oil without the need for further 
purification (955 mg, 94%). FTIR (film/cm-1) υmax: 2974, 2908, 1754, 1703, 1672, 
1651; 1H NMR (500MHz, CDCl3) δH 0.95 (9H, s), 1.47 (9H, s), 4.12–4.19 (1H, m), 
4.20–4.30 (1H, m), 4.58 (2H, d, J = 7.8 Hz), 4.65 (1H, bs), 4.75 (2H, s), 5.01–5.09 (2H, 
m), 6.69 (1H, d, J = 12.6 Hz), 7.29–7.39 (5H, m); 13C NMR (125MHz, CDCl3) δC 25.8, 
28.1, 37.9, 59.8, 63.5, 68.4, 71.4, 81.2, 97.6, 98.3, 127.5, 128.2, 128.5, 136.3, 152.6, 
155.0, 170.4; HRMS (ESI, +ve) m/z calcd. for C23H33NO6Na 442.2206, found: 
442.2201 (M+Na)+. 
 
(2R,4S)-4-((E)-3-(Benzyloxy)allyl) 3-tert-butyl 2-tert-butyloxazolidine-3,4-
dicarboxylate (251j) 
 
 
 
EDCi.HCl (702 mg, 3.66 mmol), triethylamine (511 μL, 3.66 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (1.00 g, 3.66 mmol), 
DMAP (5 mol%), DCM (70 mL) and (E)-3-(benzyloxy)prop-2-enol 218j (400 mg, 2.44 
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mmol) were combined according to general procedure IV (reaction time: 2 hours).  
Purified on a short pad of silica (2:1 Pet:EtOAc + 1% Net3) to afford the title compound 
as a colourless oil (753 mg, 74%).  ሾαሿDଶ଴ -19 (c 3, CH2Cl2). All other data as previously 
stated. 
 
(2S,4R)-4-((E)-3-(Benzyloxy)allyl) 3-tert-butyl 2-tert-butyloxazolidine-3,4-
dicarboxylate (ent-251j) 
 
 
 
EDCi.HCl (767 mg, 4.00 mmol), triethylamine (560 μL, 4.00 mmol), (2S,4R)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid ent-250 (1.09 g, 4.00 mmol), 
DMAP (5 mol%), DCM (100 mL) and (E)-3-(benzyloxy)prop-2-enol 218j (328 mg, 
2.00 mmol) were combined according to general procedure IV (reaction time: 2 hours).  
Purified on a short pad of silica (2:1 Pet:EtOAc + 1% Net3) to afford the title compound 
as a colourless oil (654 mg, 78%).  ሾαሿDଶ଴ +19 (c 2, CH2Cl2). All other data as previously 
stated. 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-(4-methoxybenzyloxy)allyl) 2-tert-butyloxazolidine-
3,4-dicarboxylate (251k) 
 
 
 
EDCi.HCl (383 mg, 2.00 mmol), triethylamine (280 μL, 2.00 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (547 mg, 2.00 mmol), 
DMAP (5 mol%), DCM (50 mL) and (E)-3-(4-methoxybenzyloxy)prop-2-en-1-ol 218k 
(194 mg, 1.00 mmol) were combined according to the general procedure IV (reaction 
time: 30 minutes), purified by flash chromatography (4:1 Pet:EtOAc, Brockmann Grade 
I Basic Alumina) to afford the title compound as a colourless oil (227 mg, 51%).  ሾαሿDଶ଴ 
-17.0 (c 2.0, CH2Cl2); FTIR (film/cm-1) υmax: 2959, 2915, 2849, 1753, 1703, 1672, 
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1651, 1614, 1515; 1H NMR (500MHz, CDCl3) δH 0.96 (9H, s), 1.48 (9H, s), 3.81 (3H, 
s), 4.15 (1H, app. t, J = 7.6 Hz), 4.22–4.28 (1H, m), 4.59 (2H, d, J = 7.7 Hz), 4.66 (1H, 
app. t, J = 7.6 Hz), 4.71 (2H, s), 5.02–5.12 (2H, m), 6.66 (1H, d, J = 12.6 Hz), 6.90 (2H, 
d, J = 8.5 Hz), 7.25 (2H, d, J = 8.5 Hz); 13C NMR (125MHz, CDCl3) δC 25.8, 28.2, 
37.8, 55.2, 59.9, 63.4, 68.4, 71.4, 81.1, 97.7, 98.5, 114.0, 128.6, 129.1, 152.5, 155.0, 
159.7, 170.3; HRMS (ESI, +ve) m/z calcd. for C24H35NO7Na 472.2311, found: 
472.2286 (M+Na)+. 
 
(2S,4R)-3-tert-Butyl 4-((E)-3-(4-methoxybenzyloxy)allyl) 2-tert-butyloxazolidine-
3,4-dicarboxylate (ent-251k) 
 
 
 
EDCi.HCl (612 mg, 3.19 mmol), triethylamine (445 μL, 3.19 mmol), (2S,4R)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid ent-250 (872 mg, 3.19 
mmol), DMAP (5 mol%), DCM (50 mL) and (E)-3-(4-methoxybenzyloxy)prop-2-en-1-
ol 218k (370 mg, 1.60 mmol) were combined according to general procedure IV 
(reaction time: 30 minutes). Purified by flash chromatography (2:1 Pet/EtOAc + 1% 
Et3N) to afford the title compound as a colourless oil (719 mg, 100%). ሾαሿDଶ଴ +17.1 (c 
2.1, CH2Cl2).  All other data as previously stated. 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-(2,6-dichlorobenzyloxy)allyl) 2-tert-butyloxazolidine-
3,4-dicarboxylate (251l) 
 
 
 
EDCi.HCl (383 mg, 2.00 mmol), triethylamine (280 μL, 2.00 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (547 mg, 2.00 mmol), 
DMAP (5 mol%), DCM (50 mL) and (E)-methyl 3-(2,6-dichlorobenzyloxy)acrylate 
218l (233 mg, 1.00 mmol) were combined according to general procedure IV (reaction 
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time: 50 minutes). Purified by flash chromatography (4:1 Pet:EtOAc) to afford the title 
compound as a colourless oil (291 mg, 60%). ሾαሿDଶ଴ -15 (c 2.0, CH2Cl2); FTIR (film/cm-
1) υmax: 2975, 2908, 1753, 1703, 1673, 1651, 1583, 1565; 1H NMR (500MHz, CDCl3) 
δH 0.95 (9H, s), 1.47 (9H, s), 4.15 (1H, app. t, J = 8.0 Hz), 4.25 (1H, dd, J = 8.0, 6.5 
Hz), 4.60 (2H, d, J = 7.7 Hz), 4.67 (1H, app. t, J = 8.0 Hz), 5.02 (2H, s), 5.04 (1H, s), 
5.09–5.17 (1H, m), 6.71 (1H, d, J = 12.5 Hz), 7.21 (1H, t, J = 8.1 Hz), 7.33 (2H, d, J = 
8.1 Hz); 13C NMR (125MHz, CDCl3) δC 25.9, 28.2, 37.8, 59.9, 63.1, 66.2, 68.4, 81.1, 
97.7, 98.7, 128.4, 130.4, 131.8, 136.9, 152.3, 154.9, 170.3; HRMS (ESI, +ve) m/z calcd. 
for C23H31NCl2O6Na 510.1426, found: 510.1405 (M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-(2-iodobenzyloxy)allyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate (251m) 
 
O
N
Boc
tBu O
O
O
I  
 
EDCi.HCl (383 mg, 2.00 mmol), triethylamine (280 μL, 2.00 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (547 mg, 2.00 mmol), 
DMAP (5 mol%), DCM (50 mL) and (E)-3-(2-iodobenzyloxy)prop-2-en-1-ol 218m 
(290 mg, 1.00 mmol) were combined according to general procedure IV (reaction time: 
1 hour) to afford the crude title compound as a pale yellow oil (quant.) which was taken 
forward in its crude form. 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-isobutoxyallyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate (251n) 
 
 
 
EDCi.HCl (383 mg, 2.00 mmol), triethylamine (280 μL, 2.00 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (547 mg, 2.00 mmol), 
DMAP (5 mol%), DCM (50 mL) and (E)-3-isobutoxyprop-2-en-1-ol 218n (130 mg, 
1.00 mmol) were combined according to general procedure IV (reaction time: 20 
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minutes) to afford the crude title compound as a pale yellow oil (quant.) which was 
taken forward in its crude form. 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-(cyclohexyloxy)allyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate (251o) 
 
 
 
EDCi.HCl (383 mg, 2.00 mmol), triethylamine (280 μL, 2.00 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (547 mg, 2.00 mmol), 
DMAP (5 mol%), DCM (50 mL) and (E)-3-(cyclohexyloxy)prop-2-en-1-ol 218o (156 
mg, 1.00 mmol) were combined according to general procedure IV (reaction time: 2 
hours) to afford the crude title compound as a yellow oil (quant.) which was taken 
forward in its crude form. 
 
(2R,4S)-4-((E)-3-(But-3-en-2-yloxy)allyl) 3-tert-butyl 2-tert-butyloxazolidine-3,4-
dicarboxylate (251p) 
 
 
 
EDCi.HCl (383 mg, 2.00 mmol), triethylamine (280 μL, 2.00 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (547 mg, 2.00 mmol), 
DMAP (5 mol%), DCM (50 mL) and (E)-3-(but-3-en-2-yloxy)prop-2-en-1-ol 218p 
(128 mg, 1.00 mmol) were combined according to general procedure IV (reaction time: 
10 minutes) to afford the title compound as a yellow oil (383 mg, 83%). ሾαሿDଶ଴ -23 (c 
2.0, CH2Cl2); FTIR (film/cm-1) υmax: 2977, 2933, 2872, 1758, 1709, 1672; 1H NMR 
(500MHz, d6-acetone) δH 0.94 (9H, s), 1.29 (3H, d, J = 6.5 Hz), 1.46 (9H, s), 4.12–4.21 
(2H, m), 4.43 (1H, quin., J = 6.4 Hz), 4.55 (2H, d, J = 7.8 Hz), 4.69 (1H, app. t, J = 7.0 
Hz), 4.98–5.06 (2H, m), 5.15 (1H, dd, J = 10.6, 1.0 Hz), 5.26 (1H, dd, J = 17.3, 1.0 Hz), 
5.83 (1H, ddd, J = 17.3, 10.6, 6.4 Hz), 6.61 (1H, d, J = 12.4 Hz); 13C NMR (125MHz, 
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d6-acetone) δC 20.2, 25.5, 27.5, 37.5, 59.8, 63.0, 68.2, 77.2, 80.3, 97.2, 99.2, 115.4, 
139.0, 151.7, 154.7, 170.1; HRMS (ESI, +ve) m/z calcd. for C20H33NO6Na 406.2206, 
found: 406.2212 (M+Na)+.  
 
(±)-(anti)-3-tert-Butyl 4-methyl 2-tert-butyl-4-(1-methoxyallyl)oxazolidine-3,4-
dicarboxylate (rac-252a) 
 
 
 
(±)-(syn)-3-tert-Butyl 4-((E)-3-methoxyallyl) 2-tert-butyloxazolidine-3,4-dicarboxylate 
rac-251a (500 mg, 1.46 mmol), TMSCl (556 μL, 4.37 mmol), LHMDS (1M, 4.37 mL, 
4.37 mmol) and THF (5.0 mL) were combined according to general procedure VII 
(reaction time: 18 hours). Purified by flash chromatography (8:1 Pet/EtOAc) to afford 
the methyl ester as a colourless oil (419 mg, 81%, dr >99:1). FTIR (film/cm-1) υmax: 
2979, 2957, 2907, 1743, 1702; 1H NMR (500MHz, CDCl3, 328K) δH 0.95 (9H, s), 1.52 
(9H, s), 3.29 (3H, s), 3.74 (3H, s), 4.18 (1H, d, J = 8.5 Hz), 4.35 (1H, d, J = 8.5 Hz), 
4.83 (1H, bs), 5.14 (1H, s), 5.32–5.40 (2H, m), 5.64–5.75 (1H, m);  13C NMR (125MHz, 
CDCl3) δC 26.1, 28.2, 38.1, 52.3, 56.8, 69.2, 72.3, 78.4, 80.8, 98.0, 120.1, 133.6, 153.8, 
171.0; HRMS (ESI, +ve) m/z calcd. for C18H31NO6Na 380.2049, found: 380.2032 
(M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-1-methoxyallyl)oxazolidine-3,4-
dicarboxylate (252a) 
 
 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-methoxyallyl) 2-tert-butyloxazolidine-3,4-dicarboxylate 
251a (476 mg, 1.39 mmol), TMSCl (529 μL, 4.16 mmol), LHMDS (1M, 4.16 mL, 4.16 
mmol) and THF (4.75 mL) were combined according to general procedure VII (reaction 
time: 18 hours). Purification by flash chromatography (8:1 Pet/EtOAc) affords the 
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methyl ester as a colourless oil (388 mg, 78%, dr >99:1). ሾαሿDଶ଴ -12.0 (c 2.0, CH2Cl2). 
All other data as previously stated. 
 
(2S,4S)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((R)-1-methoxyallyl)oxazolidine-3,4-
dicarboxylate (ent-252a) 
 
 
 
(2S,4R)-3-tert-Butyl 4-((E)-3-methoxyallyl) 2-tert-butyloxazolidine-3,4-dicarboxylate 
ent-251a (247 mg, 0.719 mmol), TMSCl (275 μL, 2.16 mmol), LHMDS (1M, 2.16 mL, 
2.16 mmol) and THF (2.5 mL) were combined according to general procedure VII 
(reaction time: 18 hours). Purification by flash chromatography (8:1 Pet/EtOAc) affords 
the methyl ester as a colourless oil (213 mg, 83%, dr >99:1). ሾαሿDଶ଴ +12.1 (c 1.9, 
CH2Cl2).  All other data as previously stated. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-1-ethoxyallyl)oxazolidine-3,4-
dicarboxylate (252b) 
 
 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-ethoxyallyl) 2-tert-butyloxazolidine-3,4-dicarboxylate 
251b (109 mg, 0.305 mmol), TMSCl (116 μL, 0.915 mmol), LHMDS (1M, 915 μL, 
0.915 mmol) and THF (1.10 mL) were combined according to general procedure VII 
(reaction time: 18 hours). Purification by flash chromatography (15:1 Pet/EtOAc) 
affords the methyl ester as a colourless oil (95 mg, 84%, dr >99:1). ሾαሿDଶ଴ +5 (c 2.0, 
CH2Cl2); FTIR (film/cm-1) υmax: 2978, 2903, 1743, 1710; 1H NMR (500 MHz, CDCl3, 
328K) δH 0.94 (9H, s), 1.16 (3H, t, J = 7.2 Hz), 1.49 (9H, s), 3.32 (1H, app. qu, J = 7.2 
Hz), 3.53 (1H, app. qu, J = 7.2 Hz), 3.72 (3H, s), 4.21 (1H, d, J = 8.3 Hz), 4.30 (1H, d, J 
= 8.3 Hz), 4.90 (1H, bs), 5.12 (1H, s), 5.29 (1H, d, J = 10.5 Hz), 5.34 (1H, d, J = 17.2 
Hz), 5.67–5.79 (1H, m); 13C NMR (125 MHz, CDCl3, 328K) δC 15.2, 26.2, 28.2, 38.3, 
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52.0, 64.5, 70.0, 72.2, 77.9, 80.6, 98.3, 119.0, 134.8, 153.6, 171.0; HRMS (ESI, +ve) 
m/z calcd. for C19H33NO6Na 394.2206, found: 394.2201 (M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-1-isopropoxyallyl)oxazolidine-3,4-
dicarboxylate (252c) 
 
 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-isopropoxyallyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate 251c (77 mg, 0.207 mmol), TMSCl (79 μL, 0.621 mmol), LHMDS (1M, 
621 μL, 0.621 mmol) and THF (0.77 mL) were combined according to general 
procedure VII (reaction time: 18 hours). Purification by flash chromatography (10:1 
Pet/EtOAc) affords the methyl ester as a colourless oil (56 mg, 70%, dr >99:1). ሾαሿDଶ଴ 
+12 (c 2.0, CH2Cl2); FTIR (film/cm-1) υmax: 2976, 2908, 1744, 1705; 1H NMR (500 
MHz, CDCl3, 328K) δH 0.97 (9H, s), 1.12 (3H, d, J = 6.1 Hz), 1.14 (3H, d, J = 6.1 Hz), 
1.50 (9H, s), 3.68–3.74 (4H, m), 4.26–4.32 (2H, m), 5.03 (1H, bs), 5.13 (1H, s), 5.27 
(1H, d, J = 10.6 Hz), 5.40 (1H, d, J = 17.3 Hz), 5.85 (1H, ddd, J = 17.3, 10.6, 6.9 Hz); 
13C NMR (125 MHz, CDCl3, 328K) δC 22.1, 23.2, 26.5, 28.3, 38.6, 51.9, 70.4, 70.7, 
72.3, 76.1, 80.9, 98.3, 118.9, 136.5, 153.1, 171.0; HRMS (ESI, +ve) m/z calcd. for 
C20H35NO6Na 408.2362, found: 408.2366 (M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-1-(allyloxy)allyl)oxazolidine-3,4-
dicarboxylate (252d) 
 
 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-(allyloxy)allyl) 2-tert-butyloxazolidine-3,4-dicarboxylate 
251d (227 mg, 0.610 mmol), TMSCl (234 μL, 1.84 mmol), LHMDS (1M, 1.84 mL, 
1.84 mmol) and THF (2.30 mL) were combined according to general procedure VII 
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(reaction time: 18 hours). Purification by flash chromatography (10:1 Pet/EtOAc) 
affords the methyl ester as a colourless oil (165 mg, 71%, dr >99:1). ሾαሿDଶ଴ +6 (c 2.0, 
CH2Cl2); FTIR (film/cm-1) υmax: 2979, 2960, 2909, 1743, 1709; 1H NMR (500 MHz, 
CDCl3, 328K) δH 0.94 (9H, s), 1.48 (9H, s), 3.73 (3H, s), 3.85 (1H, ddt, J = 12.6, 5.2, 
1.6 Hz), 4.01 (1H, dd, J = 12.6, 5.2 Hz), 4.24 (1H, d, J = 8.5 Hz), 4.34 (1H, d, J = 8.5 
Hz), 4.99 (1H, bs), 5.10 (1H, dq, J = 17.3, 1.4 Hz), 5.13 (1H, s), 5.24 (1H, dq, J = 10.4, 
1.4 Hz), 5.32 (1H, app. dt, J = 10.4, 1.4 Hz), 5.36 (1H, app. dt, J = 17.3, 1.4 Hz), 5.72 
(1H, ddd, J = 17.3, 10.4, 6.9 Hz), 5.88 (1H, ddt, J = 17.3, 10.5, 5.2 Hz); 13C NMR (125 
MHz, CDCl3, 328K) δC 26.2, 28.2, 38.3, 52.0, 69.6, 69.9, 72.3, 77.6, 80.8, 98.3, 115.7, 
119.7, 134.3, 134.7, 153.6, 170.9; HRMS (ESI, +ve) m/z calcd. for C20H33NO6Na 
406.2206, found: 406.2200 (M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-1(3-(trimethylsilyl)prop-2-
ynyloxy)allyl)oxazolidine-3,4-dicarboxylate (252e) 
 
 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-(prop-2-ynyloxy)allyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate 251e (100 mg, 0.272 mmol), TMSCl (104 μL, 0.816 mmol), LHMDS 
(1M, 816 μL, 0.816 mmol) and THF (1.00 mL) were combined according to general 
procedure VII (reaction time: 18 hours). Purification by flash chromatography (10:1 
Pet/EtOAc) affords the methyl ester as a colourless oil (94 mg, 76%, dr >99:1). ሾαሿDଶ଴ -7 
(c 2.0, CH2Cl2); FTIR (film/cm-1) υmax: 2981, 2959, 2905, 1744, 1707; 1H NMR (500 
MHz, CDCl3, 328K) δH 0.17 (9H, s), 0.94 (9H, s), 1.52 (9H, s), 3.73 (3H, s), 4.09 (2H, 
q, J = 15.1 Hz), 4.20 (1H, d, J = 8.4 Hz), 4.37 (1H, d, J = 8.4 Hz), 5.00 (1H, d, J = 6.3 
Hz), 5.14 (1H, s), 5.34 (1H, d, J = 10.4 Hz), 5.41 (1H, d, J = 17.2 Hz), 5.65–5.76 (1H, 
m); 13C NMR (125 MHz, CDCl3, 328K) δC -0.3, 26.2, 28.2, 38.2, 52.1, 57.5, 69.8, 72.3, 
78.0, 81.0, 91.1, 98.1, 101.8, 120.6, 133.5, 153.6, 170.7; HRMS (ESI, +ve) m/z calcd. 
for C23H39NO6SiNa 476.2444, found: 476.2434 (M+Na)+. 
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(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-1-phenoxyallyl)oxazolidine-3,4-
dicarboxylate (252f) 
 
 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-phenoxyallyl) 2-tert-butyloxazolidine-3,4-dicarboxylate 
251f (200 mg, 0.493 mmol), TMSCl (188 μL, 1.48 mmol), LHMDS (1M, 1.48 mL, 1.48 
mmol) and THF (2.00 mL) were combined according to general procedure VII (reaction 
time: 18 hours). Purification by flash chromatography (10:1 Pet/EtOAc) affords the 
methyl ester as a colourless oil (160 mg, 77%, dr >99:1). ሾαሿDଶ଴ +57 (c 2.0, CH2Cl2); 
FTIR (film/cm-1) υmax: 2979, 2957, 2908, 1743, 1721; 1H NMR (500 MHz, CDCl3, 
328K) δH 1.03 (9H, s), 1.14 (9H, s), 3.81 (3H, s), 4.34 (1H, d, J = 8.7 Hz), 4.45 (1H, d, J 
= 8.7 Hz), 5.29 (1H, s), 5.37 (1H, app. dt, J = 10.9, 1.4 Hz), 5.41 (1H, app. dt, J = 17.4, 
1.4 Hz), 5.82 (1H, bs), 6.05 (1H, ddd, J = 17.4, 10.9, 4.5 Hz), 6.88–6.94 (3H, m), 7.19–
7.24 (2H, m); 13C NMR (125 MHz, CDCl3, 328K) δC 26.4, 27.7, 38.7, 46.3, 52.3, 70.9, 
71.8, 81.2, 98.7, 115.8, 119.3, 121.1, 129.0, 133.7, 153.4, 157.9, 170.9; HRMS (ESI, 
+ve) m/z calcd. for C23H33NO6Na 442.2206, found: 442.2177 (M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-1-(4-methoxyphenoxy)allyl) 
oxazolidine-3,4-dicarboxylate (252g) 
 
 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-(4-methoxyphenoxy)allyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate 251g (200 mg, 0.459 mmol), TMSCl (176 μL, 1.38 mmol), LHMDS (1M, 
1.38 mL, 1.38 mmol) and THF (2.00 mL) were combined according to general 
procedure VII (reaction time: 18 hours). Purification by flash chromatography (10:1 
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Pet/EtOAc) affords the methyl ester as a colourless oil (141 mg, 68%, dr >99:1). ሾαሿDଶ଴ 
+31 (c 3.0, CH2Cl2); FTIR (film/cm-1) υmax: 2981, 2956, 2908, 2836, 1742, 1709, 1506; 
1H NMR (500 MHz, CDCl3, 328K) δH 1.01 (9H, s), 1.16 (9H, s), 3.73 (3H, s), 3.79 (3H, 
s), 4.32 (1H, d, J = 8.6 Hz), 4.42 (1H, d, J = 8.6 Hz), 5.27 (1H, s), 5.33 (1H, d, J = 10.8 
Hz), 5.39 (1H, d, J = 17.4 Hz), 5.70 (1H, bs), 6.05 (1H, ddd, J = 17.4, 10.8, 4.1 Hz), 
6.76 (2H, app. d, J = 9.1 Hz), 6.84 (2H, app. d, J = 9.1 Hz); 13C NMR (125 MHz, 
CDCl3, 328K) δC 26.4, 27.8, 38.7, 52.2, 55.7, 70.8, 71.8, 77.1, 81.1, 98.6, 114.4, 116.7, 
119.3, 134.0, 152.1, 153.4, 154.3, 170.9; HRMS (ESI, +ve) m/z calcd. for C24H35NO7Na 
472.2311, found: 472.2309 (M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-1-(4-(trifluoromethyl)phenoxy) 
allyl) oxazolidine-3,4-dicarboxylate (252h) 
 
 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-(4-(trifluoromethyl)phenoxy)allyl) 2-tert-butyloxazolidine 
-3,4-dicarboxylate 251h (150 mg, 0.317 mmol), TMSCl (121 μL, 0.951 mmol), 
LHMDS (1M, 951 μL, 0.951 mmol) and THF (1.50 mL) were combined according to 
general procedure VII (reaction time: 18 hours). Purification by flash chromatography 
(10:1 Pet/EtOAc) affords the methyl ester as a colourless oil (133 mg, 73%, dr >99:1). 
ሾαሿD
ଶ଴ +47 (c 2.0, CH2Cl2); FTIR (film/cm-1) υmax: 2980, 2956, 2913, 1741, 1710, 1614; 
1H NMR (500 MHz, CDCl3, 328K) δH 1.03 (9H, s), 1.14 (9H, s), 3.82 (3H, s), 4.35 (1H, 
d, J = 8.8 Hz), 4.44 (1H, d, J = 8.8 Hz), 5.26 (1H, s), 5.34–5.43 (2H, m), 5.91 (1H, bs), 
6.00–6.10 (1H, m), 6.99 (2H, app. d, J = 8.6 Hz), 7.50 (2H, app. d, J = 8.6 Hz); 13C 
NMR (125 MHz, CDCl3, 328K) δC 26.4, 27.7, 38.7, 52.4, 70.8, 71.7, 81.4, 98.7, 115.8, 
119.6, 123.2, 123.6 (q, J = 32.7 Hz), 125.4, 126.6 (q, J = 3.8 Hz), 132.9, 153.3, 160.3, 
170.6; HRMS (ESI, +ve) m/z calcd. for C24H32F3NO6Na 510.2079, found: 510.2085 
(M+Na)+. 
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(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-1-(2-iodophenoxy)allyl) 
oxazolidine-3,4-dicarboxylate (252i) 
 
 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-(2-iodophenoxy)allyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate 251i (166 mg, 0.312 mmol), TMSCl (120 μL, 0.937 mmol), LHMDS 
(1M, 937 μL, 0.937 mmol) and THF (1.70 mL) were combined according to general 
procedure VII (reaction time: 18 hours). Purification by flash chromatography (15:1 
Pet/EtOAc) affords the methyl ester as a colourless oil (99 mg, 58%, dr >99:1). ሾαሿDଶ଴ 
+19 (c 3.0, CH2Cl2); FTIR (film/cm-1) υmax: 2978, 2958, 2903, 1742, 1704; 1H NMR 
(500 MHz, CDCl3, 328K) δH 0.99 (9H, s), 1.20(9H, s), 3.82 (3H, s), 4.50 (1H, d, J = 8.6 
Hz), 4.55 (1H, d, J = 8.6 Hz), 5.27–5.35 (2H, m), 5.47 (1H, s), 5.86 (1H, ddd, J = 16.6, 
10.8, 5.2 Hz), 6.18 (1H, bs), 6.66 (1H, t, J = 7.6 Hz), 6.79 (1H, d, J = 8.3 Hz), 7.13–7.28 
(1H, m), 7.75 (1H, d, J = 7.6 Hz); 13C NMR (125 MHz, CDCl3, 328K) δC 26.3, 27.7, 
38.1, 52.3, 69.9, 71.8, 81.2, 86.4, 98.4, 113.3, 120.3, 122.6, 128.1, 129.0, 132.2, 139.3, 
153.4, 155.5, 170.7; HRMS (ESI, +ve) m/z calcd. for C23H32INO6Na 568.1172, found: 
568.1167 (M+Na)+. X-Ray: Structure deposited with CCDC (CCDC 812147) 
 
(±)-(anti)-3-tert-Butyl 4-methyl 4-(1-(benzyloxy)allyl)-2-tert-butyloxazolidine-3,4-
dicarboxylate (rac-252j) 
 
 
 
(±)- (syn)-4-((E)-3-(Benzyloxy)allyl) 3-tert-butyl 2-tert-butyloxazolidine-3,4-
dicarboxylate rac-251j (232 mg, 0.553 mmol), TMSCl (211 μL, 1.66 mmol), LHMDS 
(1M, 1.66 mL, 1.66 mmol) and THF (2.30 mL) were combined according to general 
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procedure VII (reaction time: 18 hours). Purification by flash chromatography (15:1 
Pet/EtOAc) affords the methyl ester as a colourless oil (185 mg, 73%, dr >99:1). FTIR 
(film/cm-1) υmax: 2981, 2958, 2903, 1741, 1708; 1H NMR (500 MHz, CDCl3, 328K) δH 
0.97 (9H, s), 1.41 (9H, s), 3.76 (3H, s), 4.30 (1H, d, J = 8.5 Hz), 4.36–4.49 (2H, m), 
4.54 (1H, d, J = 8.5 Hz), 5.12–5.20 (2H, m), 5.35 (1H, d, J = 10.4 Hz), 5.41 (1H, d, J = 
17.2 Hz), 5.78 (1H, ddd, J = 17.2, 10.4, 7.0 Hz), 7.22–7.28 (1H, m), 7.29–7.38 (4H, m); 
13C NMR (125 MHz, CDCl3, 328K) δC 26.2, 28.1, 38.3, 52.4, 70.1, 70.2, 72.4, 81.0, 
97.6, 98.1, 120.3, 126.8, 127.2, 128.4, 134.0, 138.5, 153.7, 171.1; HRMS (ESI, +ve) m/z 
calcd. for C24H35NO6Na 456.2362, found: 456.2340 (M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 4-((S)-1-(benzyloxy)allyl)-2-tert-butyloxazolidine-3,4-
dicarboxylate (252j) 
 
 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-(benzyloxy)allyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate 251j (247 mg, 0.589 mmol), TMSCl (225 μL, 1.77 mmol), LHMDS (1M, 
1.77 mL, 1.77 mmol) and THF (2.50 mL) were combined according to general 
procedure VII (reaction time: 18 hours). Purification by flash chromatography (15:1 
Pet/EtOAc) affords the methyl ester as a colourless oil (185 mg, 73%, dr >99:1). ሾαሿDଶ଴ 
±0 (c 1.0, CH2Cl2). All other data as previously stated. 
 
(2S,4S)-3-tert-Butyl 4-methyl 4-((R)-1-(benzyloxy)allyl)-2-tert-butyloxazolidine-3,4-
dicarboxylate (ent-252j) 
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(2S,4R)-3-tert-Butyl 4-((E)-3-(benzyloxy)allyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate ent-251j (200 mg, 0.480 mmol), TMSCl (183 μL, 1.44 mmol), LHMDS 
(1M, 1.44 mL, 1.44 mmol) and THF (2.00 mL) were combined according to general 
procedure VII (reaction time: 18 hours). Purification by flash chromatography (15:1 
Pet/EtOAc) affords the methyl ester as a colourless oil (149 mg, 72%, dr >99:1). ሾαሿDଶ଴ 
±0 (c 1.0, CH2Cl2). All other data as previously stated. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-1-(4-methoxybenzyloxy)allyl) 
oxazolidine-3,4-dicarboxylate (252k) 
 
 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-(4-methoxybenzyloxy)allyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate 251k (118 mg, 0.260 mmol), TMSCl (100 μL, 0.78 mmol), LHMDS 
(1M, 780 μL, 0.78 mmol) and THF (1.20 mL) were combined according to general 
procedure VII (reaction time: 18 hours). Purification by flash chromatography (8:1 
Pet/EtOAc) affords the methyl ester as a colourless oil (90 mg, 75%, dr >99:1). ሾαሿDଶ଴ -
6.0 (c 2.0, CH2Cl2); FTIR (film/cm-1) υmax: 2981, 2957, 2908, 1743, 1707; 1H NMR 
(500 MHz, CDCl3, 328K) δH 0.96 (9H, s), 1.44 (9H, s), 3.75 (3H, s), 3.80 (3H, s), 4.28 
(1H, d, J = 8.5 Hz), 4.34-4.39 (2H, m), 4.47 (1H, d, J = 11.1 Hz), 5.08-5.18 (2H, m), 
5.34 (1H, app. dt, J = 10.5, 1.4 Hz), 5.40 (1H, d, J = 17.2 Hz), 5.78 (1H, ddd, J = 17.2, 
10.5, 6.8 Hz), 6.86 (2H, app. d, J = 8.7 Hz), 7.23 (2H, app. d, J = 8.7 Hz); 13C NMR 
(125 MHz, CDCl3, 328K) δC 26.3, 28.2, 38.3, 52.0, 55.2, 70.3, 72.4, 78.0, 80.9, 98.3, 
113.7, 119.8, 128.4, 130.0, 130.7, 134.3, 153.6, 159.0, 171.0; HRMS (ESI, +ve) m/z 
calcd. for C25H37NO7Na 486.2468, found: 486.2442 (M+Na)+. 
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(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-1-(2,6-dichlorobenzyloxy)allyl) 
oxazolidine-3,4-dicarboxylate (252l) 
 
 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-(2,6-dichlorobenzyloxy)allyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate 251l (215 mg, 0.440 mmol), TMSCl (168 μL, 1.32 mmol), LHMDS (1M, 
1.32 mL, 1.32 mmol) and THF (2.20 mL) were combined according to general 
procedure VII (reaction time: 18 hours). Purification by flash chromatography (10:1 
Pet/EtOAc) affords the methyl ester as a colourless oil (154 mg, 70%, dr 93:7). FTIR 
(film/cm-1) υmax: 2979, 2957, 2908, 1743, 1707; 1H NMR (500MHz, CDCl3, 328K) δH 
Major Diastereomer 0.96 (9H, s), 1.48 (9H, s), 3.73 (3H, s), 4.27 (1H, d, J = 8.7 Hz), 4.33 (1H, 
d, J = 8.7 Hz), 4.76 (1H, d, J = 10.8 Hz), 4.81 (1H, d, J = 10.8 Hz), 5.10–5.19 (2H, m), 
5.24 (1H, d, J = 10.3 Hz), 5.38 (1H, d, J = 17.2 Hz), 5.77 (1H, ddd, J = 17.2, 10.3, 7.4 
Hz), 7.14 (1H, m), 7.27 (2H, d, J = 5.8 Hz); δH Minor Diastereomer 0.94 (9H, s), 1.43 (9H, s), 
3.73 (3H, s), 4.27 (1H, d, J = 8.7 Hz), 4.33 (1H, d, J = 8.7 Hz), 4.76 (1H, d, J = 10.8 
Hz), 4.81 (1H, d, J = 10.8 Hz), 5.10–5.19 (2H, m), 5.45 (1H, d, J = 10.3), 5.53 (1H, d, J 
= 17.2 Hz), 5.77 (1H, ddd, J = 17.2, 10.3, 7.4 Hz), 7.14 (1H, m), 7.36 (2H, d, J = 8.0 
Hz); 13C NMR (125MHz, CDCl3, 328K) δC 26.5, 28.3, 38.4, 51.9, 66.1, 70.3, 72.3, 
79.3, 80.8, 98.3, 119.9, 128.2, 129.5, 134.0, 134.3, 136.9, 153.2, 170.7; HRMS (ESI, 
+ve) m/z calcd. for C24H33Cl2NO6Na 524.1583, found: 5224.1571 (M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-1-(2-iodobenzyloxy)allyl) 
oxazolidine-3,4-dicarboxylate (252m) 
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Crude (2R,4S)-3-tert-butyl 4-((E)-3-(2-iodobenzyloxy)allyl) 2-tert-butyloxazolidine-
3,4-dicarboxylate 251m (200 mg, 0.367 mmol), TMSCl (140 μL, 1.10 mmol), LHMDS 
(1M, 1.10 mL, 1.10 mmol) and THF (2.00 mL) were combined according to general 
procedure VII (reaction time: 18 hours). Purification by flash chromatography (8:1 
Pet/EtOAc) affords the methyl ester as a colourless oil (104 mg, 51%, dr >99:1). ሾαሿDଶ଴ 
+5.3 (c 3.0, CH2Cl2); FTIR (film/cm-1) υmax: 2978, 2957, 2912, 1743, 1706; 1H NMR 
(500 MHz, CDCl3, 328K) δH 0.97 (9H, s), 1.35 (9H, s), 3.77 (3H, s), 4.35 (2H, d, J = 
10.5 Hz), 4.44 (1H, d, J = 8.5 Hz), 4.50 (1H, d, J = 11.2 Hz), 5.20 (1H, s), 5.25 (1H, bs), 
5.36 (1H, d, J = 10.3 Hz), 5.42 (1H, d, J = 17.2 Hz), 5.80 (1H, ddd, J = 17.2, 10.3, 6.9 
Hz), 6.95 (1H, t, J = 7.7 Hz), 7.36 (1H, t, J = 7.7 Hz), 7.52 (1H, d, J = 7.7 Hz), 7.76 
(1H, d, J = 7.7 Hz); 13C NMR (125 MHz, CDCl3, 328K) δC 26.2, 28.0, 38.3, 52.2, 70.0, 
72.4, 74.5, 78.0, 81.0, 95.8, 98.4, 120.1, 127.9, 128.0, 128.5, 133.7, 138.6, 140.8, 153.6, 
170.8; HRMS (ESI, +ve) m/z calcd. for C24H34INO6Na 582.1329, found: 582.1344 
(M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-1-isobutoxyallyl)oxazolidine-3,4-
dicarboxylate (252n) 
 
 
 
Crude (2R,4S)-3-tert-butyl 4-((E)-3-isobutoxyallyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate 251n (154 mg, 0.400 mmol), TMSCl (153 μL, 1.20 mmol), LHMDS 
(1M, 1.2 mL, 1.20 mmol) and THF (1.50 mL) were combined according to general 
procedure VII (reaction time: 18 hours). Purification by flash chromatography (10:1 
Pet/EtOAc) affords the methyl ester as a colourless oil (88 mg, 55%, dr >99:1). ሾαሿDଶ଴ +8 
(c 3.0, CH2Cl2); FTIR (film/cm-1) υmax: 2958, 2909, 2874, 1744, 1712; 1H NMR (500 
MHz, CDCl3, 328K) δH 0.88 (3H, d, J = 6.7 Hz), 0.90 (3H, d, J = 6.7 Hz), 0.95 (9H, s), 
1.49 (9H, s), 1.83 (1H, sept., J = 6.7 Hz), 3.09 (1H, dd, J = 8.2, 6.1 Hz), 3.19 (1H, t, J = 
8.2 Hz), 3.72 (3H, s), 4.25 (1H, d, J = 8.5 Hz), 4.31 (1H, d, J = 8.5 Hz), 4.89 (1H, bs), 
5.12 (1H, s), 5.29 (1H, d, J = 10.5 Hz), 5.34 (1H, d, J = 17.3 Hz), 5.72 (1H, ddd, J = 
17.3, 10.5, 6.8 Hz); 13C NMR (125 MHz, CDCl3, 328K) δC 19.2, 19.5, 26.3, 28.3, 28.7, 
  | 206 
Chapter 7  Experimental   
38.4, 51.9, 70.0, 72.3, 75.4, 77.7, 80.6, 98.3, 119.2, 134.8, 153.5, 171.0; HRMS (ESI, 
+ve) m/z calcd. for C21H37NO6Na 422.2519, found: 422.2509 (M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-1-(cyclohexyloxy)allyl)oxazolidine-
3,4-dicarboxylate (252o) 
 
 
 
Crude (2R,4S)-3-tert-butyl 4-((E)-3-(cyclohexyl)allyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate 252o (200 mg, 0.486 mmol), TMSCl (186 μL, 1.46 mmol), LHMDS (1M, 
1.46 mL, 1.46 mmol) and THF (2.00 mL) were combined according to general 
procedure VII (reaction time: 18 hours). Purification by flash chromatography (15:1 
Pet/EtOAc) affords the methyl ester as a colourless oil (97 mg, 47%, dr >99:1). ሾαሿDଶ଴ 
+20 (c 2.0, CH2Cl2); FTIR (film/cm-1) υmax: 2986, 2936, 2860, 1740, 1703; 1H NMR 
(500 MHz, CDCl3, 328K) δH 0.98 (9H, s), 1.11–1.35 (5H, m), 1.47–1.53 (10H, s), 1.64–
1.76 (2H, m), 1.80–1.93 (2H, m), 3.32–3.40 (1H, m), 3.72 (3H, s), 4.26 (1H, d, J = 8.4 
Hz), 4.31 (1H, d, J = 8.4 Hz), 5.06 (1H, bs), 5.13 (1H, s), 5.25 (1H, d, J = 10.6 Hz), 5.39 
(1H, d, J = 17.3 Hz), 5.88 (1H, ddd, J = 17.3, 10.6, 3.9 Hz); 13C NMR (125 MHz, 
CDCl3, 328K) δC 24.2, 24.3, 25.7, 26.6, 28.3, 32.4, 33.5, 38.7, 51.8, 70.5, 72.3, 80.9, 
98.4, 118.6, 136.8, 153.1, 171.0; HRMS (ESI, +ve) m/z calcd. for C23H39NO6Na 
448.2675, found: 448.2671 (M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 4-((S)-1-(but-3-en-2-yloxy)allyl)-2-tert-
butyloxazolidine-3,4-dicarboxylate (252p) 
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(2R,4S)-4-((E)-3-(But-3-en-2-yloxy)allyl) 3-tert-butyl 2-tert-butyloxazolidine-3,4-
dicarboxylate 251p (200 mg, 0.522 mmol), TMSCl (200 μL, 1.56 mmol), LHMDS 
(1M, 1.56 mL, 1.56 mmol) and THF (2.00 mL) were combined according to general 
procedure VII (reaction time: 18 hours). Purification by flash chromatography (10:1 
Pet/EtOAc) affords the methyl ester as a colourless oil (149 mg, 72%, dr 1:1). FTIR 
(film/cm-1) υmax: 2979, 2912, 2872, 1744, 1714; 1H NMR (500MHz, CDCl3, 328K) δH 
Diastereomer A 0.97 (9H, s), 1.20 (3H, d, J = 6.4 Hz), 1.49 (9H, s), 3.71 (3H, s), 4.01 (1H, 
app. quint., J = 6.4 Hz), 4.25–4.33 (2H, m), 4.95–5.15 (4H, m), 5.23–5.39 (2H, m), 
5.72–5.87 (2H, m); δH Diastereomer B 0.98 (9H, s), 1.22 (3H, d, J = 6.4 Hz), 1.50 (9H, s), 
3.73 (3H, s), 4.01 (1H, app. quint., J = 6.4 Hz) , 4.25–4.33 (2H, m), 4.95–5.15 (4H, m), 
5.23–5.39 (2H, m), 5.72–5.87 (2H, m); 13C NMR (125MHz, CDCl3, 328K) δC Diastereomer 
A 20.8, 26.5, 28.3, 38.6, 51.8, 70.5, 72.2, 74.4, 75.4, 80.8, 98.3, 114.2, 119.1, 135.3, 
140.3, 153.1, 170.9; δC Diastereomer B 21.6, 26.6, 28.3, 38.7, 51.9, 70.5, 72.3, 74.4, 75.9, 
81.0, 98.4, 115.9, 119.8, 136.1, 141.2, 153.2, 171.0; HRMS (ESI, +ve) m/z calcd. for 
C21H35NO6Na 420.2362, found: 420.2347 (M+Na)+. 
 
(2R,4R)-4-Benzyl 3-tert-butyl 4-((S)-1-(benzyloxy)allyl)-2-(tert-butyl)oxazolidine-
3,4-dicarboxylate (254j) 
 
 
 
To a solution of (2R,4S)-3-tert-butyl 4-((E)-3-(benzyloxy)allyl) 2-tert-butyloxazolidine-
3,4-dicarboxylate 251j  (200 mg, 0.480 mmol) in THF (2.00 mL) at -78 °C was added 
TMSCl (183 μL, 1.44 mmol).  After 10 mins LHMDS (1M, 1.44 mL, 1.44 mmol) was 
added via syringe pump at an addition rate of 0.5 mL min-1 and reaction mixture 
allowed to warm to room temperature after a period of 30 mins, and stirred for 18 hours.  
The reaction was quenched by the addition of 1N HCl and brine solution (1:1, 5 mL) 
and extracted with DCM (3 × 15 mL), EtOAc (1 × 15 mL), dried over Na2SO4 and 
concentrated in vacuo to afford the crude acid.  Residue dissolved in Acetone (5 mL) 
and K2CO3 (66 mg, 0.48 mmol) and BnBr (143 μL, 1.20 mmol) added and allowed to 
stir for 12 hours.  Partioned between EtOAc (25 mL) and sat. NaHCO3 (25 mL) and the 
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organic layer washed with brine (1× 25 mL), dried over Na2SO4 and concentrated in 
vacuo to afford the benzyl ester as a colourless oil (175 mg, 72%, dr >99:1). ሾαሿDଶ଴ -9.3 
(c 3.0, CH2Cl2); FTIR (film/cm-1) υmax: 2978, 2905, 2875, 1739, 1705; 1H NMR 
(500MHz, CDCl3, 328K) δH 0.94 (9H, s), 1.40 (9H, s), 4.35 (1H, d, J = 8.6 Hz), 4.38–
4.47 (2H, m), 4.56 (1H, d, J = 11.4 Hz), 5.12–5.27 (4H, m), 5.32 (1H, d, J = 10.5 Hz), 
5.36 (1H, d, J = 17.3 Hz), 5.80 (1H, ddd, J = 17.3, 10.5, 6.9 Hz), 7.22–7.29 (1H, m), 
7.29–7.39 (7H, m), 7.40–7.45 (2H, m); 13C NMR (125MHz, CDCl3, 328K) δC 26.3, 
28.1, 38.4, 67.1, 70.0, 70.6, 72.4, 78.1, 80.9, 98.4, 120.0, 126.9, 127.1, 128.1, 128.2, 
128.4, 128.4, 134.1, 135.5, 138.5, 153.7, 170.2; HRMS (ESI, +ve) m/z calcd. for 
C30H40NO6 510.2856, found: 510.2834 (M+H)+. 
 
(2S,4S)-4-Benzyl 3-tert-butyl 4-((R)-1-(benzyloxy)allyl)-2-tert-butyloxazolidine-3,4-
dicarboxylate (ent-254j) 
 
 
 
To a solution of (2S,4R)-3-tert-butyl 4-((E)-3-(benzyloxy)allyl) 2-tert-butyloxazolidine-
3,4-dicarboxylate ent-251j  (225 mg, 0.536 mmol) in THF (2.30 mL) at -78 °C was 
added TMSCl (205 μL, 1.61 mmol).  After 10 mins LHMDS (1M, 1.61 mL, 1.61 mmol) 
was added via syringe pump at an addition rate of 0.5 mL min-1 and reaction mixture 
allowed to warm to room temperature after a period of 30 mins, and stirred for 18 hours.  
The reaction was quenched by the addition of 1N HCl and brine solution (1:1, 5 mL) 
and extracted with DCM (3 × 15 mL), EtOAc (1 × 15 mL), dried over Na2SO4 and 
concentrated in vacuo to afford the crude acid.  Residue dissolved in Acetone (5 mL) 
and K2CO3 (74 mg, 0.536 mmol) and BnBr (160 μL, 1.34 mmol) added and allowed to 
stir for 12 hours.  Partioned between EtOAc (25 mL) and sat. NaHCO3 (25 mL) and the 
organic layer washed with brine (1× 25 mL), dried over Na2SO4 and concentrated in 
vacuo to afford the benzyl ester as a colourless oil (164 mg, 60%, dr >99:1). ሾαሿDଶ଴ +9.3 
(c 2.7, CH2Cl2).  All other data as previously stated. 
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(2R,4R)-4-Benzyl 3-tert-butyl 2-tert-butyl-4-((R)-1-(4-methoxybenzyloxy)allyl) 
oxazolidine-3,4-dicarboxylate (254k) 
 
 
 
To a solution of (2R,4S)-3-tert-butyl 4-((E)-3-(4-methoxybenzyloxy)allyl) 2-tert-
butyloxazolidine-3,4-dicarboxylate 251k (1.29 g, 2.87 mmol) in THF (13.0 mL) at -78 
°C was added TMSCl (1.10 mL, 8.61 mmol).  After 10 mins LHMDS (1M, 8.61 mL, 
8.61 mmol) was added via syringe pump at an addition rate of 0.5 mL min-1 and 
reaction mixture allowed to warm to room temperature after a period of 30 mins, and 
stirred for 18 hours.  The reaction was quenched by the addition of 1N HCl and brine 
solution (1:1, 5 mL) and extracted with DCM (3 × 15 mL), EtOAc (1 × 15 mL), dried 
over Na2SO4 and concentrated in vacuo to afford the crude acid.  Residue dissolved in 
Acetone (15 mL) and K2CO3 (397 mg, 2.87 mmol) and BnBr (854 μL, 7.18 mmol) 
added and allowed to stir for 3 hours.  Partioned between EtOAc (50 mL) and sat. 
NaHCO3 (50 mL) and the organic layer washed with brine (1× 50 mL), dried over 
Na2SO4 and concentrated in vacuo to afford the benzyl ester as a colourless oil (895 mg, 
58%, dr >99:1). ሾαሿDଶ଴ -11.5 (c 2.0, CH2Cl2); FTIR (film/cm-1) υmax: 2977, 2961, 2910, 
1737, 1706; 1H NMR (500MHz, CDCl3, 328K) δH 0.94 (9H, s), 1.42 (9H, s), 3.80 (3H, 
s), 4.32 (1H, d, J = 8.6 Hz), 4.35–4.41 (2H, m), 4.48 (1H, d, J = 11.0 Hz), 5.12–5.26 
(4H, m), 5.31 (1H, d, J = 10.5 Hz), 5.36 (1H, d, J = 17.3 Hz), 5.74–5.84 (1H, m), 6.87 
(2H, app. d, J = 8.7 Hz), 7.25 (2H, app. d, J = 8.7 Hz), 7.30–7.44 (5H, m); 13C NMR 
(125MHz, CDCl3, 328K) δC 26.3, 28.2, 38.4, 55.2, 67.1, 70.1, 70.4, 72.4, 78.1, 80.9, 
98.4, 113.7, 119.8, 128.2, 128.4, 128.5, 130.0, 130.7, 134.2, 135.5, 153.7, 159.1, 170.2; 
HRMS (ESI, +ve) m/z calcd. for C31H42NO7 540.2961, found: 540.2986 (M+H)+. 
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(2S,4S)-4-Benzyl 3-tert-butyl 2-tert-butyl-4-((R)-1-(4-methoxybenzyloxy)allyl) 
oxazolidine-3,4-dicarboxylate (ent-254k) 
 
 
 
To a solution of (2S,4R)-3-tert-butyl 4-((E)-3-(4-methoxybenzyloxy)allyl) 2-tert-
butyloxazolidine-3,4-dicarboxylate ent-251k (700 mg, 1.56 mmol) in THF (7.0 mL) at -
78 °C was added TMSCl (596 μL, 4.68 mmol).  After 10 mins LHMDS (1M, 4.68 mL, 
4.68 mmol) was added via syringe pump at an addition rate of 0.5 mL min-1 and 
reaction mixture allowed to warm to room temperature after a period of 30 mins, and 
stirred for 18 hours.  The reaction was quenched by the addition of 1N HCl and brine 
solution (1:1, 5 mL) and extracted with DCM (3 × 15 mL), EtOAc (1 × 15 mL), dried 
over Na2SO4 and concentrated in vacuo to afford the crude acid.  Residue dissolved in 
Acetone (15 mL) and K2CO3 (216 mg, 1.56 mmol) and B5nBr (464 μL, 3.90 mmol) 
added and allowed to stir for 3 hours.  Partioned between EtOAc (50 mL) and sat. 
NaHCO3 (50 mL) and the organic layer washed with brine (1× 50 mL), dried over 
Na2SO4 and concentrated in vacuo to afford the benzyl ester as a colourless oil (500 mg, 
60%, dr >99:1). ሾαሿDଶ଴ +10.6 (c 2.45, CH2Cl2). All other data as previously stated. 
 
(Z)-Methyl 3-methoxyacrylate (255) 
 
 
 
To solution of silver(I) trifluoromethane sulphonate (385 mg, 1.50 mmol, 10 mol%) in 
methanol (15 mL) was added methyl propiolate (1.33 mL, 15.0 mmol, 1.0 eq).  The 
reaction mixture was stirred at room temperature for 21 hours and concentrated in 
vacuo.  The residue was taken up in chloroform (50 mL), filtered through celite and the 
filtrate concentrated in vacuo to afford the pure vinylogous carbonate as a colourless oil 
(1.62 g, 93%). 1H NMR (500MHz, CDCl3) δH 3.66 (3H, s), 3.86 (3H, s), 4.82 (1H, d, J 
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= 7.1 Hz), 6.44 (1H, d, J = 7.1 Hz); 13C NMR (125MHz, CDCl3) δC 51.0, 62.6, 96.0, 
160.2, 165.7.  All analytical data is in accordance with literature precedence.297  
 
(Z)-3-Methoxyprop-2-en-1-ol (256) 
 
 
 
(Z)-Methyl 3-methoxyacrylate 255 (1.62 g, 14.0 mmol) was reduced according to 
general procedure II (reaction time 4 hours) to afford the product as a pale yellow oil 
(699 mg, 57%). 1H NMR (500MHz, d6-acetone) δH 3.37 (1H, t, J = 5.6 Hz), 3.57 (3H, 
s), 4.09 (2H, m), 4.52 (1H, q, J = 6.6 Hz), 5.96 (1H, dt, J = 6.6, 1.3 Hz); 13C NMR 
(125MHz, d6-acetone) δC 55.7, 59.8, 107.5, 147.7.  All analytical data is in accordance 
with literature precedence.298 
 
(2R,4S)-3-tert-Butyl 4-((Z)-3-methoxyallyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate (257) 
 
 
 
EDCi.HCl (767 mg, 4.00 mmol), triethylamine (560 μL, 4.00 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (1.09 g, 4.00 mmol), 
DMAP (5 mol%), DCM (100 mL) and (Z)-3-methoxyprop-2-en-1-ol 256 (176 mg, 2.00 
mmol) were combined according to general procedure IV (reaction time: 2 hours).  
Purified on a short pad of silica (2:1 Pet:EtOAc + 1% Net3) to afford  the title 
compound as a colourless oil (330 mg, 48%). ሾαሿDଶ଴ -19.6 (c 2.3, CHCl3); FTIR 
(film/cm-1) υmax: 2974, 2939, 2909, 2872, 1734, 1705, 1665; 1H NMR (500MHz, d6-
acetone) δH 0.93 (9H, s), 1.46 (9H, s), 3.66 (3H, s), 4.14–4.22 (2H, m), 4.51–4.61 (2H, 
m), 4.67 (1H, app d, J = 7.2 Hz), 4.71 (1H, t, J = 7.2 Hz), 4.99 (1H, s), 6.23 (1H, d, J = 
6.1 Hz); 13C NMR (125MHz, d6-acetone) δC 25.4, 27.5, 37.5, 57.3, 58.3, 59.8, 68.2, 
80.3, 97.2, 99.4, 150.8, 154.8, 170.2; HRMS (ESI, +ve) m/z calcd. for C17H30NO6 
344.2073, found: 344.2056 (M+H)+. 
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(E)-Methyl 3-methoxybut-2-enoate (259) 
 
 
 
To a stirred solution of methyl acetoacetate (4.00 mL, 37.0 mmol, 1.0 eq) and trimethyl 
orthoformate (4.12 mL, 37.6 mmol, 1.02 eq) at room temperature was added 3 drops of 
conc. H2SO4 and reaction mixture stirred at room temperature for 24 hours. Partitioned 
between NaHCO3 (sat) (50 mL) and DCM and extracted with DCM (3 × 50 mL).  The 
organics were combined, dried over MgSO4, filtered and concentrated in vacuo. Purified 
by flash chromatography (20:1 Pet/EtOAc) to afford the pure vinylogous carbonate as a 
colourless liquid (2.87 g, 60%).  1H NMR (500MHz, CDCl3) δH 2.30 (3H, s), 3.63 (3H, 
s), 3.68 (3H, s), 5.03 (1H, s); 13C NMR (125MHz, CDCl3) δC 18.9, 50.8, 55.4, 90.5, 
168.4, 173.3.  All analytical data is in accordance with literature precedence.206  
 
Methyl 3,3-dimethoxybutanoate (260) 
 
 
 
Undesired side product from synthesis of (E)-methyl 3-methoxybut-2-enoate 259. 1H 
NMR (500MHz, CDCl3) δH 1.47 (3H, s), 2.69 (2H, s), 3.23 (6H, s), 3.70 (3H, s); 13C 
NMR (125MHz, CDCl3) δC 21.8, 42.1, 48.4, 51.8, 99.8, 170.2. All analytical data is in 
accordance with literature precedence.299  
 
(E)-3-Methoxybut-2-en-1-ol (261) 
 
 
 
(E)-Methyl 3-methoxybut-2-enoate 259 (780 mg, 6 mmol) was reduced according to 
general procedure II (reaction time 4 hours) to afford the product as a colourless oil 
(484 mg, 79%). 1H NMR (500MHz, d6-acetone) δH 1.77 (3H, s), 3.26 (1H, t, J = 5.6 
Hz), 3.47 (3H, s), 4.04 (2H, dd, J = 7.4, 5.6 Hz), 4.67 (1H, t, J = 7.4 Hz); 13C NMR 
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(125MHz, d6-acetone) δC 16.3, 54.3, 58.8, 97.8, 157.0. All analytical data is in 
accordance with literature precedence.300 
 
(2R,4S)-3-tert-Butyl 4-((E)-3-methoxybut-2-enyl) 2-tert-butyloxazolidine-3,4-
dicarboxylate (262) 
 
 
 
EDCi.HCl (767 mg, 4.00 mmol), triethylamine (560 μL, 4.00 mmol), (2R,4S)-3-(tert-
butoxycarbonyl)-2-tert-butyloxazolidine-4-carboxylic acid 250 (1.09 g, 4.00 mmol), 
DMAP (5 mol%), DCM (100 mL) and (E)-3-methoxybut-2-en-1-ol 261 (204 mg, 2.00 
mmol) were combined according to general procedure IV (reaction time: 3 hours) to 
afford the title compound as a pale yellow oil (quant) which used in its crude form. 
 
(2R,4S)-4-Allyl 3-tert-butyl 2-tert-butyloxazolidine-3,4-dicarboxylate (265a) 
 
 
 
Allyl alcohol (58 μL, 0.85 mmol), (2R,4S)-3-(tert-butoxycarbonyl)-2-tert-
butyloxazolidine-4-carboxylic acid 250 (255 mg, 0.94 mmol), EDCi.HCl (180 mg, 0.94 
mmol), triethylamine (131 μL, 0.94 mmol), DMAP (5 mol%) and DCM (40 mL) were 
combined according to general procedure II to afford the title compound as a yellow oil 
(224 mg, 84%). ሾαሿDଶ଴ -19.5 (c 1.2, CH2Cl2); FTIR (film/cm
-1) νmax: 2975, 2906, 2871, 
1759, 1704, 1480; 1H NMR (500MHz, CDCl3) δH 0.94 (9H, s), 1.46 (9H, s), 4.18 (1H, t, 
J = 8.6 Hz), 4.26 (1H, dd, J = 8.6, 6.5 Hz), 4.64 (2H, qd, J = 13.4, 5.7 Hz), 4.70 (1H, 
bs), 5.04 (1H, s), 5.24 (1H, d, J = 10.5 Hz), 5.34 (1H, dd, J = 17.2, 1.3 Hz), 5.85-5.95 
(1H, m); 13C NMR (125MHz, CDCl3) δC 25.8, 28.2, 37.8, 59.7, 65.8, 68.4, 81.3, 97.6, 
118.6, 131.6, 155.0, 170.1; HRMS (ESI, +ve) m/z calcd. for C16H27NO5Na 336.1787, 
found: 336.1780 (M+Na)+. 
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(2R,4S)-4-((E)-But-2-enyl) 3-tert-butyl 2-tert-butyloxazolidine-3,4-dicarboxylate 
(265b) 
 
 
 
Crotyl alcohol (156 μL, 1.83 mmol), (2R,4S)-3-(tert-butoxycarbonyl)-2-tert-
butyloxazolidine-4-carboxylic acid 250 (550 mg, 2.01 mmol), EDCi.HCl (386 mg, 2.01 
mmol), triethylamine (282 μL, 2.01 mmol), DMAP (5 mol%) and DCM (90 mL) were 
combined according to general procedure II to afford the title compound as a pale 
yellow oil (157 mg, 84%). ሾαሿDଶ଴ -23.6 (c 1.1, CH2Cl2); FTIR (film/cm
-1) νmax: 2963, 
2912, 1758, 1706, 1479; 1H NMR (500MHz, CDCl3) δH 0.94 (9H, s), 1.46 (9H, s), 1.71 
(3H, d, J = 6.6 Hz), 4.17 (1H, t, J = 8.5 Hz), 4.24 (1H, t, J = 8.5 Hz), 4.57 (2H, d, J = 
6.5 Hz), 4.67 (1H, bs), 5.04 (1H, s), 5.58 (1H, dtd, J = 15.3, 6.6, 1.6 Hz), 5.81 (1H, dq, J 
= 15.3, 6.6 Hz); 13C NMR (125MHz, CDCl3) δC 17.7, 25.8, 28.2, 37.9, 59.8, 65.9, 68.5, 
81.2, 97.6, 124.6, 131.8, 155.0, 170.2; HRMS (ESI, +ve) m/z calcd. for C17H29NO5Na 
350.1943, found: 350.1935 (M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-(2-methylallyl) 2-tert-butyloxazolidine-3,4-dicarboxylate 
(265c) 
 
 
 
2-Methyl-2-propen-1-ol (154 μL, 1.83 mmol), (2R,4S)-3-(tert-butoxycarbonyl)-2-tert-
butyloxazolidine-4-carboxylic acid 250 (550 mg, 2.01 mmol), EDCi.HCl (386 mg, 2.01 
mmol), triethylamine (282 μL, 2.01 mmol), DMAP (5 mol%) and DCM (90 mL) were 
combined according to general procedure II to afford the title compound as a yellow oil 
(250 mg, 97%). ሾαሿDଶ଴ -20.8 (c 1.3, CH2Cl2); FTIR (film/cm
-1) νmax: 2976, 1760, 1709, 
1480; 1H NMR (500MHz, CDCl3) δH 0.94 (9H, s), 1.47 (9H, s), 1.76 (3H, s), 4.17 (1H, 
t, J = 8.6 Hz), 4.28 (1H, dd, J = 8.6, 6.2 Hz), 4.50 (1H, d, J = 13.1 Hz), 4.61 (1H, d, J = 
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13.1 Hz), 4.73 (1H, bs), 4.94 (1H, s), 5.01 (1H, s), 5.05 (1H, s); 13C NMR (125MHz, 
CDCl3) δC 19.4, 25.8, 28.2, 37.8, 59.7, 68.4, 68.5, 81.3, 97.6, 113.4, 139.3, 155.0, 
170.1; HRMS (ESI, +ve) m/z calcd. for C17H29NO5Na 350.1943, found: 350.1932 
(M+Na)+. 
 
(2R,4S)-4-But-2-ynyl 3-tert-butyl 2-tert-butyloxazolidine-3,4-dicarboxylate (265d) 
 
 
 
2-Butyn-1-ol (233 mg, 3.33 mmol), (2R,4S)-3-(tert-butoxycarbonyl)-2-tert-
butyloxazolidine-4-carboxylic acid 250 (1.00 g, 3.66 mmol), EDCi.HCl (638 mg, 3.33 
mmol), triethylamine (463 μL, 3.33 mmol), DMAP (5 mol%) and DCM (100 mL) were 
combined according to general procedure II to afford the title compound as a yellow oil 
(779 mg, 72%). ሾαሿDଶ଴ -19.3 (c 1.4, CH2Cl2); FTIR (film/cm
-1) νmax: 2973, 2874, 1764, 
1742, 1707, 1480; 1H NMR (500MHz, CDCl3) δH 0.96 (9H, s), 1.48 (9H, s), 1.84 (3H, t, 
J = 2.4 Hz), 4.20 (1H, t, J = 8.6 Hz), 4.27 (1H, t, J = 8.6 Hz), 4.72 (3H, app. q, J = 2.4 
Hz), 5.05 (1H, s); 13C NMR (125MHz, CDCl3) δC 3.6, 25.8, 28.2, 37.9, 53.5, 59.6, 68.4, 
72.7, 81.3, 83.6, 97.7, 155.0, 170.0; HRMS (ESI, +ve) m/z calcd. for C17H27NO5Na 
348.1787, found: 348.1768 (M+Na)+. 
 
(2R,4S)-4-((Z)-But-2-en-1-yl) 3-tert-butyl 2-(tert-butyl)oxazolidine-3,4-
dicarboxylate (265e) 
 
 
 
To a solution of (2R,4S)-4-But-2-ynyl 3-tert-butyl 2-tert-butyloxazolidine-3,4-
dicarboxylate 265d (300 mg, 0.92 mmol) in EtOAc (22 mL) was added Lindlar catalyst 
(5 mol%) and quinoline (5 mol%) and the reaction was stirred at room temperature 
under an atmosphere of hydrogen for 90 min. The reaction mixture was filtered through 
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celite and the filtrate concentrated in vacuo. Purification by flash chromatography (4:1 
Pet:EtOAc) afforded the title compound as a pale yellow oil (172 mg, 57%). ሾαሿDଶ଴ -27.5 
(c 1.2, CH2Cl2); FTIR (film/cm-1) νmax: 2975, 2939, 2909, 2875, 1759, 1706, 1479; 1H 
NMR (500MHz, CDCl3) δH 0.93 (9H, s), 1.45 (9H, s), 1.69 (3H, dd, J = 7.0, 0.8 Hz), 
4.20 (1H, t, J = 8.5 Hz), 4.27 (1H, dd, J = 8.5, 6.2 Hz), 4.66 (1H, bs), 4.70 (2H, d, J = 
7.0 Hz), 5.03 (1H, s), 5.36-5.44 (1H, m), 5.68-5.76 (1H, m); 13C NMR (125MHz, 
CDCl3) δC 13.1, 25.8, 28.2, 37.8, 59.7, 60.8, 68.5, 81.2, 97.6, 123.7, 130.1, 155.0, 
170.3; HRMS (ESI, +ve) m/z calcd. for C17H29NO5Na 350.1943, found: 350.1936 
(M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-methyl 4-allyl-2-tert-butyloxazolidine-3,4-dicarboxylate 
(266a) 
 
 
 
Synthesis via Ireland-Claisen Rearrangement (Section 3.4.2 Substrate Rearrangement): 
(2R,4S)-4-Allyl 3-tert-butyl 2-tert-butyloxazolidine-3,4-dicarboxylate 265a (295 mg, 
0.941 mmol), TMSCl (360 μL, 2.82 mmol), LiHMDS (1M, 2.82 mL, 2.82 mmol) and 
THF (3.00 mL) were combined according to general procedure VII (reaction time: 18 
hours). Purification by flash chromatography (15:1 Pet/EtOAc) affords the methyl ester 
as a pale yellow oil (176 mg, 57%). 
 
Synthesis via Alkylation (Section 5.2.3 Ligand Development): 
To a solution of (2R,4S)-3-tert-butyl 4-methyl 2-tert-butyloxazolidine-3,4-dicarboxylate 
249 (1.44 g, 5 mmol, 1 eq) and allyl bromide (4.33 mL, 50 mmol, 10 eq) in THF (15 
mL) at -84 °C was added LHMDS (1M in THF, 15 mL, 15 mmol, 3 eq) via syringe 
pump at a rate of 10 mL/hr and allowed to stir at -84 °C for 16 hours. Quenched with 
NH4Cl (sat.) (30 mL), diluted with water (30 mL) and extracted with EtOAc (1 × 50 
mL) and DCM (2 × 50 mL). The organics were combined, dried over MgSO4 and 
concentrated in vacuo. Purification by flash chromatography affords the title compound 
as a colourless oil (1.33 g, 81%). 
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ሾαሿD
ଶ଴ +11.7 (c 1.2, CH2Cl2); FTIR (film/cm-1) νmax: 2978, 2905, 1742, 1711, 1641, 
1478; 1H NMR (500MHz, CDCl3) δH 0.97 (9H, s), 1.42 (9H, s), 2.68 (1H, dd, J = 14.2, 
5.8 Hz), 3.08 (1H, s), 3.74 (3H, s), 4.05 (1H, d, J = 8.5 Hz), 4.22 (1H, dd, J = 8.5, 1.6 
Hz), 5.04 (1H, s), 5.08-5.18 (2H, m), 5.75-5.85 (1H, m); 13C NMR (125MHz, CDCl3) 
δC 26.5, 28.1, 39.3, 39.4, 52.4, 68.6, 75.2, 80.8, 98.0, 119.5, 132.0, 153.1, 172.1; HRMS 
(ESI, +ve) m/z calcd. for C17H29NO5Na 350.1943, found: 350.1937 (M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-methyl 4-((S)-but-3-en-2-yl)-2-tert-butyloxazolidine-3,4-
dicarboxylate (266b) 
 
 
 
(2R,4S)-4-((E)-But-2-enyl) 3-tert-butyl 2-tert-butyloxazolidine-3,4-dicarboxylate 265b 
(327 mg, 1.00 mmol), TMSCl (382 μL, 3.00 mmol), LiHMDS (1M, 3.00 mL, 3.00 
mmol) and THF (3.30 mL) were combined according to general procedure VII to afford 
the title compound as a colourless oil (149 mg, 44%). ሾαሿDଶ଴ -7.5 (c 1.2, CH2Cl2); FTIR 
(film/cm-1) νmax: 2981, 2953, 2910, 1744, 1709, 1639, 1565, 1478; 1H NMR (400MHz, 
CDCl3) δH 1.01 (9H, s), 1.05 (3H, d, J = 7.0 Hz), 1.51 (9H, s), 3.71 (1H, s), 3.78 (3H, s), 
4.16 (1H, d, J = 8.9 Hz), 4.33 (1H, d, J = 8.9 Hz), 5.15-5.21 (3H, m), 5.94-6.04 (1H, m); 
13C NMR (125MHz, CDCl3) δC 13.0, 26.5, 28.2, 39.2, 52.2, 60.4, 71.3, 71.6, 81.0, 98.2, 
116.4, 139.5, 153.5, 172.1; HRMS (ESI, +ve) m/z calcd. for C18H31NO5Na 364.2100, 
found: 364.2066 (M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-methyl 2-tert-butyl-4-(2-methylallyl)oxazolidine-3,4-
dicarboxylate (266c) 
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(2R,4S)-3-tert-Butyl 4-(2-methylallyl) 2-tert-butyloxazolidine-3,4-dicarboxylate 265c 
(160 mg, 0.49 mmol), TMSCl (187 μL, 1.47 mmol), LiHMDS (1M, 1.47 mL, 1.47 
mmol) and THF (1.2 mL) were combined according to general procedure VII to afford 
the title compound as a colourless oil (43 mg, 26%). ሾαሿDଶ଴ +14.5 (c 1.1, CH2Cl2); FTIR 
(film/cm-1) νmax: 2986, 2956, 2907, 2871, 1743, 1709, 1643, 1478; 1H NMR (500MHz, 
CDCl3) δH 1.02 (9H, s), 1.47 (9H, s), 1.81 (3H, s), 2.69 (1H, d, J = 14.1 Hz), 3.13 (1H, 
bs), 3.77 (3H, s), 4.16 (1H, d, J = 8.6 Hz), 4.22 (1H, dd, J = 8.6, 1.2 Hz), 4.81 (1H, s), 
4.96 (1H, s), 5.08 (1H, s); 13C NMR (125MHz, CDCl3) δC 23.6, 26.8, 28.2, 39.5, 40.9, 
52.4, 68.9, 74.0, 80.9, 97.9, 116.4, 140.8, 153.0, 172.5; HRMS (ESI, +ve) m/z calcd. for 
C18H31NO5Na 364.2100, found: 364.2095 (M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-methyl 4-(buta-2,3-dien-2-yl)-2-tert-butyloxazolidine-3,4-
dicarboxylate (266d) 
 
 
 
(2R,4S)-4-But-2-ynyl 3-tert-butyl 2-tert-butyloxazolidine-3,4-dicarboxylate 265d (200 
mg, 0.62 mmol), TMSCl (235 μL, 1.85 mmol), LiHMDS (1M, 1.85 mL, 1.85 mmol) 
and THF (2.00 mL) were combined according to general procedure VII to afford the 
title compound as colourless crystals (117 mg, 56%). ሾαሿDଶ଴ -54.5
 (c 1.1, CH2Cl2); FTIR 
(film/cm-1) νmax: 2977, 2910, 2871, 1964, 1763, 1737, 1700, 1479; 1H NMR (500MHz, 
CDCl3) δH 0.95 (s, 9H), 1.45 (s, 9H), 1.72 (3H, t, J = 3.1 Hz), 3.72 (3H, s), 4.16 (1H, d, 
J = 9.2 Hz), 4.48 (1H, d, J = 9.2 Hz), 4.71-4.81 (2H, m), 5.23 (1H, s); 13C NMR 
(125MHz, CDCl3) δC 14.3, 26.2, 27.9, 39.1, 51.9, 71.7, 75.7, 77.2, 80.4, 98.4, 99.8, 
153.5, 170.3, 206.4; HRMS (ESI, +ve) m/z calcd. for C18H29NO5Na 362.1943, found: 
362.1925 (M+Na)+. X-Ray Crystal structure obtained. 
 
(±)-(syn)-Methyl 2-amino-2-(hydroxymethyl)-3-methoxypent-4-enoate (rac-267) 
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(±)-(anti)-3-tert-Butyl 4-methyl 2-tert-butyl-4-(1-methoxyallyl)oxazolidine-3,4-
dicarboxylate rac-252a (65 mg, 0.181 mmol), MeOH (1 mL) and 6N HCl (0.6 mL, 3.62 
mmol) were combined according to general procedure IX. Purified by flash 
chromatography (95:5 DCM:MeOH) to afford the title compound as a colourless oil 
(16.1 mg, 47%).  FTIR (film/cm-1) υmax: 3365, 3310, 2951, 2897, 2826; 1H NMR 
(500MHz, CDCl3) δH 2.24 (3H, s), 3.24 (3H, s), 3.50 (1H, d, J = 10.9 Hz), 3.76 (1H, d, 
J = 10.9 Hz), 3.79 (3H, s), 3.87 (1H, d, J = 7.9 Hz), 5.35 (1H, ddd, J = 17.3, 1.4, 0.9 
Hz), 5.42 (1H, dd, J = 10.3, 1.4 Hz), 5.71–5.81 (1H, m); 13C NMR (125MHz, CDCl3) δC 
52.6, 56.7, 65.5, 66.1, 84.7, 121.0, 132.9, 174.6; HRMS (ESI, +ve) m/z calcd. for 
C8H15NO4Na 212.0899, found: 212.0881 (M+Na)+. 
 
(2R,3S)-Methyl 2-amino-2-(hydroxymethyl)-3-methoxypent-4-enoate (267) 
 
 
 
 (2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-1-methoxyallyl)oxazolidine-3,4-
dicarboxylate 252a (100 mg, 0.291 mmol), MeOH (2 mL) and 6N HCl (970 μL, 5.82 
mmol) were combined according to general procedure IX (reaction time: 8 hours) to 
afford the title compound as a colourless oil (42 mg, 76%).  ሾαሿDଶ଴ -31.3 (c 1.5, CH2Cl2). 
All other data as previously stated. 
 
(2S,3R)-Methyl 2-amino-2-(hydroxymethyl)-3-methoxypent-4-enoate (ent-267) 
 
 
 
 (2S,4S)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((R)-1-methoxyallyl)oxazolidine-3,4-
dicarboxylate ent-252a (100 mg, 0.291 mmol), MeOH (2 mL) and 6N HCl (970 μL, 
5.82 mmol) were combined according to general procedure IX (reaction time: 8 hours) 
to afford the title compound as a colourless oil (43 mg, 78%).  ሾαሿDଶ଴ +31.6 (c 1.9, 
CH2Cl2).  All other data as previously stated. 
 
  | 220 
Chapter 7  Experimental   
(2R,4R)-tert-Butyl 2-tert-butyl-4-(hydroxymethyl)-4-((S)-1-methoxyallyl) 
oxazolidine-3-carboxylate (268) 
 
 
 
To a stirred solution of lithium aluminium hydride in THF (1M, 840 μL, 0.840 mmol, 
2.0 eq) at 0 °C was added a solution of (2R,4R)-3-tert-butyl 4-methyl 2-tert-butyl-4-
((S)-1-methoxyallyl)oxazolidine-3,4-dicarboxylate 252a (150 mg, 0.420 mmol, 1.0 eq) 
in THF (4 mL) dropwise.  The reaction mixture was allowed to warm to room 
temperature and stirred for 4 hours.  Reaction mixture poured into an ice-cold solution 
of saturated Rochelle salt (15 mL) and EtOAc (10 mL).  The biphasic mixture was 
stirred vigorously at room temperature for 2 hours before extracting with EtOAc (3 × 25 
mL).  The organics were combined, dried over MgSO4, filtered and concentrated in 
vacuo to afford the pure title compound without the need for further purification as a 
colourless oil (138 mg, 100%).  ሾαሿDଶ଴ +24.6 (c 1.26, CH2Cl2); FTIR (film/cm-1) υmax: 
3390, 2978, 2935, 2825, 1694, 1664; 1H NMR (500MHz, CDCl3) δH 0.97 (9H, s), 1.53 
(9H, s), 3.30 (3H, s), 3.47 (1H, d, J = 8.7 Hz), 3.53 (1H, d, J = 11.7 Hz), 3.79 (1H, d, J 
= 11.7 Hz), 4.20 (1H, d, J = 8.7 Hz), 4.69 (1H, bs), 5.14 (1H, s), 5.40 (1H, d, J = 10.5 
Hz), 5.50 (1H, d, J = 17.4 Hz), 5.71–5.81 (1H, m); 13C NMR (125MHz, CDCl3) δC 26.6, 
28.2, 38.6, 57.2, 65.9, 69.5, 70.8, 78.9, 82.0, 98.5, 119.5, 134.2, 156.4; HRMS (ESI, 
+ve) m/z calcd. for C17H31NO5Na 352.2100, found: 352.2104 (M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-2,5-dihydrofuran-2-yl)oxazolidine-
3,4-dicarboxylate (270) 
 
 
 
To a solution of (2R,4R)-3-tert-butyl 4-methyl 2-tert-butyl-4-((S)-1-
(allyloxy)allyl)oxazolidine-3,4-dicarboxylate 252d (69 mg, 0.180 mmol, 1.0 eq) in 
DCM (500 μL) was added Hoveyda-Grubbs II (5 mol%, 6 mg, 0.009 mmol) and stirred 
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at room temperature for 24 hours.  Reaction mixture concentrated in vacuo and the 
residue purified by column chromatography (15:1 Pet/EtOAc) to afford the title 
compound as a colourless oil (47 mg, 73%).  ሾαሿDଶ଴ +4.0 (c 1.0, CH2Cl2); FTIR 
(film/cm-1) υmax: 2978, 2957, 2908, 1709; 1H NMR (500MHz, CDCl3) δH 0.99 (9H, s), 
1.46 (9H, s), 3.78 (3H, s), 4.07 (2H, s), 4.59 (1H, d, J = 13.1 Hz), 4.67 (1H, dd, J = 
13.1, 6.2 Hz), 5.14 (1H, s), 5.66 (1H, bs), 5.97 (1H, d, J = 5.9 Hz), 6.08 (1H, d, J = 5.9 
Hz); 13C NMR (125MHz, CDCl3) δC 26.4, 28.2, 39.0, 52.4, 71.2, 71.7, 75.7, 80.8, 85.9, 
98.2, 127.8, 129.5, 153.9, 171.7; HRMS (ESI, +ve) m/z calcd. for C18H29NO6Na 
378.1893, found: 378.1883 (M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-1-(prop-2-ynyloxy)allyl) 
oxazolidine-3,4-dicarboxylate (272) 
 
 
 
To a solution of (2R,4R)-3-tert-butyl 4-methyl 2-tert-butyl-4-((S)-1-(prop-2-
ynyloxy)allyl)oxazolidine-3,4-dicarboxylate 252e (474 mg, 1.04 mmol, 1.0 eq) in 
MeOH (10 mL) was added K2CO3 (360 mg, 2.61 mmol, 2.5 eq) and stirred at room 
temperature for 30 minutes.  Reaction mixture filtered and partioned between brine and 
DCM, and extracted with DCM (3 × 15 mL), dried over anhydrous Na2SO4 and 
concentrated in vacuo to afford the terminal alkyne as a pale yellow oil (359 mg, 91%).  
ሾαሿD
ଶ଴ -3.0 (c 2.0, CH2Cl2); FTIR (film/cm-1) υmax: 3259, 2979, 2960, 2908, 2872, 1743, 
1704; 1H NMR (500MHz, CDCl3) δH  0.94 (9H, s), 1.52 (9H, s), 2.37 (1H, t, J = 2.4 
Hz), 3.73 (3H, s), 4.06 (1H, dd, J = 15.0, 2.4 Hz), 4.13 (1H, dd, J = 15.0, 2.4 Hz), 4.20 
(1H, d, J = 8.5 Hz), 4.36 (1H, d, J = 8.5 Hz), 5.05 (1H, d, J = 7.0 Hz), 5.14 (1H, s), 5.36 
(1H, d, J = 10.4 Hz), 5.42 (1H, d, J = 17.2 Hz), 5.71 (1H, ddd, J = 17.2, 10.4, 7.0 Hz); 
13C NMR (125MHz, CDCl3) δC 26.2, 28.2, 38.2, 52.1, 56.4, 69.8, 72.2, 74.2, 77.8, 79.7, 
81.0, 98.2, 120.8, 133.3, 153.6, 170.7; HRMS (ESI, +ve) m/z calcd. for C20H31NO6Na 
404.2049, found: 404.2044 (M+Na)+. 
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(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S)-4-vinyl-2,5-dihydrofuran-2-
yl)oxazolidine-3,4-dicarboxylate (273) 
 
 
 
To a solution of (2R,4R)-3-tert-butyl 4-methyl 2-tert-butyl-4-((S)-1-(prop-2-
ynyloxy)allyl)oxazolidine-3,4-dicarboxylate (40 mg, 0.105 mmol, 1 eq) in DCM (1.75 
mL, [0.06M]) under 1 bar ethylene was added Hoveyda-Grubbs II (3.3 mg, 5.24 μmol, 
5 mol%) and the resulting solution allowed to stir for 24 hours.  Reaction mixture 
concentrated in vacuo and purified by flash chromatography (10:1 Pet/EtOAc) to afford 
the title compound 8 as a colourless oil (20 mg, 50%). ሾαሿDଶ଴ +36.5 (c 2.3, CH2Cl2); 
FTIR (film/cm-1) υmax: 2976, 2963, 2936, 2905, 2875, 1717; 1H NMR (500MHz, 
CDCl3) δH 1.02 (9H, s), 1.48 (9H, s), 3.78 (3H, s), 4.04–4.11 (2H, m), 4.66–4.73 (1H, 
m), 4.79–4.86 (1H, m), 5.05 (1H, d, J = 17.7 Hz), 5.18 (1H, s), 5.21 (1H, d, J = 10.8 
Hz), 5.75 (1H, bs), 5.95 (1H, s), 6.53 (1H, dd, J = 17.7, 10.8 Hz); 13C NMR (125MHz, 
CDCl3) δC 26.4, 28.2, 38.9, 52.1, 71.4, 72.1, 74.2, 80.8, 86.0, 98.4, 116.9, 126.2, 129.2, 
141.4, 153.8, 171.5; HRMS (ESI, +ve) m/z calcd. for C20H31NO6Na 404.2049, found: 
404.2038 (M+Na)+. 
 
(2R,2'R,4R,4'R)-3-tert-Butyl 4-dimethyl 4,4'-((2S,2'S)-4,4'-((E)-ethene-1,2-
diyl)bis(2,5-dihydrofuran-4,2-diyl))bis(2-tert-butyloxazolidine-3,4-dicarboxylate) 
(274) 
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((S)-4-vinyl-2,5-dihydrofuran-2-yl)oxazolidine-3,4-dicarboxylate 273 (20 mg, 50%). 
ሾαሿD
ଶ଴ +72.0 (c 2, CH2Cl2); FTIR (film/cm-1) υmax: 2976, 2960, 2912, 2875, 1713; 1H 
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NMR (500MHz, CDCl3) δH 1.01 (18H, s), 1.47 (18H, s), 3.79 (6H, s), 4.00–4.10 (4H, 
m), 4.71 (2H, app. dt, J = 11.9, 2.1 Hz), 4.83 (2H, app. ddd, J = 11.9, 5.6, 2.1 Hz), 5.16 
(2H, s), 5.74 (2H, bs), 6.02 (2H, s), 6.17 (2H, s); HRMS (ESI, +ve) m/z calcd. for 
C38H58N2O12Na 757.3887, found: 757.3874 (M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-(3-methylbenzofuran-2-yl)oxazolidine-
3,4-dicarboxylate (275) 
 
 
 
To a solution of palladium(II) acetate (0.6 mg, 2.66 μmol), triphenylphosphine (0.7 mg, 
2.66 μmol), and silver carbonate (22 mg, 79.8 μmol) in MeCN was added (2R,4R)-3-
tert-butyl 4-methyl 2-tert-butyl-4-((S)-1-(2-iodophenoxy)allyl)oxazolidine-3,4-
dicarboxylate 252i (29 mg, 53.2 μmol) and reaction stirred for 18 hours. Concentrated 
in vacuo and purified by flash chromatography (10:1 Pet/EtOAc) to afford a mixture of 
5-endo and 5-exo products. Upon standing in CDCl3 a single isomer of the 5-endo is 
obtained as a colourless oil (22 mg, 100%). ሾαሿDଶ଴ -1.8 (c 1.1, CH2Cl2); FTIR (film/cm-
1) υmax: 2976, 2957, 2909, 2875, 1766, 1741, 1704; 1H NMR (500MHz, CDCl3) δH 1.02 
(9H, s), 1.11 (9H, s), 2.18 (3H, s), 3.92 (3H, s), 4.48 (1H, d, J = 8.9 Hz), 4.74 (1H, d, J 
= 8.9 Hz), 5.49 (1H, s), 7.21–7.30 (2H, m), 7.39 (1H, app. d, J = 8.2 Hz), 7.48 (1H, app. 
d, J = 7.5 Hz); 13C NMR (125MHz, CDCl3) δC 7.8, 26.2, 27.6, 38.8, 52.8, 68.7, 76.9, 
80.4, 98.7, 111.0, 112.0, 119.1, 122.5, 124.4, 130.3, 148.7, 152.8, 153.7, 169.8; HRMS 
(ESI, +ve) m/z calcd. for C23H32NO6 418.2230, found: 418.2239 (M+H)+. 
 
(2S,5S,9R)-tert-Butyl 2-tert-butyl-8-(hydroxymethyl)-9-(4-methoxybenzyloxy)-6-
oxo-3,7-dioxa-1-azaspiro[4.4]nonane-1-carboxylate (278) 
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To a solution of (2S,4S)-4-benzyl 3-tert-butyl 2-tert-butyl-4-((R)-1-(4-
methoxybenzyloxy)allyl)oxazolidine-3,4-dicarboxylate ent-254k (40 mg, 74.1 μmol, 1 
eq) in water/acetone (0.9 mL, 1:8) was added NMO (20 mg, 0.148 mmol, 2 eq) and a 
tBuOH solution of OsO4 (47 μL, 3.7 μmol, 5 mol%) and allowed to stir at room 
temperature for 24 hours. Quenched with sat. NaHCO3 solution and allowed to stir for 
10 mins. Extracted with EtOAc (2 × 15 mL), washed with brine (1 × 25 mL), dried over 
Na2SO4 and concentrated in vacuo and purified by flash chromatography (8:1 – 2:1 
Pet/EtOAc) to afford the pure title compound as a colourless oil (42 mg, 100%). ሾαሿDଶ଴ 
+33.7 (c 1.75, CHCl3); FTIR (film/cm-1) υmax: 3514, 2934, 2873, 1793, 1714, 1693, 
1613; 1H NMR (500MHz, CDCl3, 328K) δH 1.12 (9H, s), 1.46 (9H, s), 1.72 (1H, bs), 
3.73 (1 H, app. d, J = 9.7 Hz), 3.82 (3H, s), 3.91 (1H, dd, J = 12.7, 2.4 Hz), 4.00 (1H, 
bs), 4.13 (1H, d, J = 8.2 Hz), 4.38 (1H, app. d, J = 10.8 Hz), 4.60–4.93 (3H, m), 5.21 
(1H, bs), 6.90 (2H, d, J = 8.7 Hz), 7.26 (2H, d, J = 8.7 Hz); 13C NMR (125MHz, CDCl3, 
328K) δC 26.7, 28.1, 39.4, 55.2, 60.9, 69.1, 73.2, 75.4, 79.7, 82.5, 97.4, 114.1, 117.6, 
129.1, 129.8, 152.4, 159.9, 171.9; HRMS (ESI, +ve) m/z calcd. for C24H36NO8 
466.2441, found: 466.2452 (M+H)+. 
 
(2S,5S,9R)-tert-Butyl 2-tert-butyl-9-(4-methoxybenzyloxy)-8-((4-
nitrobenzoyloxy)methyl)-6-oxo-3,7-dioxa-1-azaspiro[4.4]nonane-1-carboxylate 
(280) 
 
 
 
To a solution of (2S,5S,9R)-tert-butyl 2-tert-butyl-8-(hydroxymethyl)-9-(4-
methoxybenzyloxy)-6-oxo-3,7-dioxa-1-azaspiro[4.4]nonane-1-carboxylate 278 (34 mg, 
59.2 μmol, 1 eq) in DCM (10 mL) at room temperature was added DMAP (5 mol%), 
NEt3 (13 μL, 88.9 μmol, 1.5 eq) and 4-nitrobenzoyl chloride (11 mg, 59.2 μmol, 1 eq) 
and the reaction mixture stirred overnight. Quenched with water. Extracted with DCM 
(2 × 10 mL) and the organics washed with 1M HCl (1 × 25 mL), sat. NaHCO3 (1 × 25 
mL), brine (1 × 25 mL), dried over MgSO4 and concentrated in vacuo and purified by 
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flash chromatography (2:1 Pet/EtOAc) to afford a white solid (23 mg, 64%). 
Recrystallised using DCM/Petrol 60-80 °C to afford clear crystals. Mpt: 173-174 °C; 
ሾαሿD
ଶ଴ +70.1 (c 0.87, CHCl3); FTIR (film/cm-1) υmax: 2965, 2936, 2909, 2878, 1798, 
1728, 1687, 1611; 1H NMR (400 MHz, CDCl3, 328K) δH 1.17 (9H, s), 1.51 (9H, s), 
3.80 (3H, s), 4.20 (1H, d, J = 8.2 Hz), 4.24 (1H, m), 4.37 (1H, d, J = 11.2 Hz), 4.49 (1H, 
app. d, J = 7.5 Hz), 4.66 (1H, dd, J = 12.4, 2.5 Hz), 4.71–4.83 (2H, m), 4.89–5.43 (2H, 
m), 6.85 (2H, app. d, J = 8.0 Hz), 7.26 (2H, d, J = 8.0 Hz), 8.29 (4H, bs); 13C NMR (125 
MHz, CDCl3) δC 26.9, 28.2, 39.3, 55.2, 62.6, 68.7, 69.8, 73.3, 74.1, 82.6, 97.2, 114.1, 
117.6, 123.3, 128.8, 129.8, 131.1, 134.8, 150.9, 152.4, 159.9, 164.2, 171.4; MS (ESI, 
+ve) m/z calcd. for C31H38N2O11Na 637.2373, found: 637.2388 (M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-methyl 2-tert-butyl-4-propyloxazolidine-3,4-dicarboxylate 
(281a) 
 
 
 
A mixture of (2R,4S)-3-tert-Butyl 4-methyl 4-allyl-2-tert-butyloxazolidine-3,4-
dicarboxylate 266a (192 mg, 0.59 mmol, 1 eq) and 10 mol% Pd/C (10 mg, 5 wt%) in 
MeOH (22 mL) was hydrogenated at atmospheric pressure for 90 minutes.  Reaction 
mixture filtered through celite® and concentrated in vacuo to afford the title compound 
as a pale yellow oil (168 mg, 87%). [α]D -7.5 (c1.2, CH2Cl2); FTIR (film/cm-1) νmax: 
2967, 2874, 1742, 1709; 1H NMR (500MHz, CDCl3) δH 0.89 (3H, t, J = 7.3 Hz), 0.95 
(9H, s), 1.04-1.10 (1H, m), 1.40 (9H, s), 1.44-1.50 (1H, m), 1.89 (1H, td, J = 13.3, 4.3 
Hz), 2.33 (1H, bs), 3.70 (3H, s), 3.94 (1H, d, J = 8.6 Hz), 4.21 (1H, dd, J = 1.5, 8.6 Hz), 
5.08 (1H, s); 13C NMR (125MHz, CDCl3) δC 14.2, 16.3, 26.2, 27.9, 37.4, 39.4, 52.2, 
68.9, 76.0, 80.5, 98.3, 153.4, 172.7; HRMS (ESI, +ve) m/z calcd. for C17H31NO5Na 
352.2100, found: 352.2106 (M+Na)+. 
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(2R,4S)-3-tert-Butyl 4-methyl 4-(sec-butyl)-2-(tert-butyl)oxazolidine-3,4-
dicarboxylate (281b) 
 
 
 
A mixture of (2R,4S)-3-tert-butyl 4-methyl 4-((S)-but-3-en-2-yl)-2-tert-
butyloxazolidine-3,4-dicarboxylate 266b (175 mg, 0.51 mmol, 1 eq) and 10 mol% Pd/C 
(9mg, 5 wt%) in MeOH (20 mL) was hydrogenated at atmospheric pressure for 90 
minutes.  Reaction mixture filtered through celite® and concentrated in vacuo to afford 
the title compound as a pale yellow oil (90 mg, 51%). [α]D -9.2 (c 1.2, CH2Cl2); FTIR 
(film/cm-1) νmax: 2963, 2912, 2877, 1743, 1707, 1478; 1H NMR (500MHz, CDCl3) δH 
0.87 (3H, d, J = 6.7 Hz), 0.91-1.01 (12H, m), 1.39-1.49 (11H, m), 2.68 (1H, bs), 3.73 
(3H, s), 4.04 (1H, d, J = 8.8 Hz), 4.33 (1H, d, J = 8.8 Hz), 5.08 (1H, s); 13C NMR 
(125MHz, CDCl3) δC 13.1, 13.5, 26.5, 26.9, 28.1, 37.2, 39.0, 52.2, 71.1, 72.4, 80.7, 
97.8, 153.5, 172.7; HRMS (ESI, +ve) m/z calcd. for C18H33NO5Na 366.2256, found: 
366.2231 (M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-methyl 2-(tert-butyl)-4-isobutyloxazolidine-3,4-dicarboxylate 
(281c) 
 
 
 
A mixture of (2R,4S)-3-tert-butyl 4-methyl 2-tert-butyl-4-(2-methylallyl)oxazolidine-
3,4-dicarboxylate 266c (85 mg, 0.25 mmol, 1 eq) and 10 mol% Pd/C (5mg, 5 wt%) in 
MeOH (9 mL) was hydrogenated at atmospheric pressure for 90 minutes.  Reaction 
mixture filtered through celite® and concentrated in vacuo to afford the title compound 
as a pale yellow oil (56 mg, 66%). [α]D -3.6 (c 1.1, CH2Cl2); FTIR (film/cm-1) νmax: 
2958, 2915, 2873, 1744, 1706, 1478; 1H NMR (500MHz, CDCl3) δH 0.91 (3H, d, J = 
6.6 Hz), 0.97-1.03 (12H, m), 1.44 (9H, s), 1.69-1.75 (1H, m), 1.90 (1H, dd, J = 14.2, 5.7 
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Hz), 2.27 (1H, d, J = 9.6 Hz), 3.73 (3H, s), 4.03 (1H, d, J = 8.7 Hz), 4.23 (1H, dd, J = 
8.7, 1.5 Hz), 5.15 (1H, s); 13C NMR (125MHz, CDCl3) δC 23.6, 24.3, 24.6, 26.7, 28.2, 
39.6, 42.3, 52.3, 69.0, 75.0, 80.7, 98.0, 153.0, 172.9; HRMS (ESI, +ve) m/z calcd. for 
C18H33NO5Na 366.2256, found: 366.2249 (M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-methyl 4-((Z)-but-2-en-2-yl)-2-tert-butyloxazolidine-3,4-
dicarboxylate (281d) 
 
 
 
A mixture of (2R,4S)-3-tert-butyl 4-methyl 4-(buta-2,3-dien-2-yl)-2-tert-
butyloxazolidine-3,4-dicarboxylate 266d (41 mg, 0.121 mmol, 1 eq) and 10 mol% Pd/C 
(4mg, 10 wt%) in MeOH (2mL) was hydrogenated at atmospheric pressure for 20 
minutes.  Reaction mixture filtered through celite® and concentrated in vacuo. Purified 
by flash chromatography (20:1 Pet/EtOAc) to afford the title compound as a colourless 
oil (33 mg, 80%). [α]D -71.1 (c 1.35, CHCl3); FTIR (film/cm-1) νmax: 2976, 2960, 2933, 
2875, 1760, 1732, 1698; 1H NMR (500MHz, CDCl3) δH 0.93 (9H, s), 1.44 (9H, s), 1.57 
(3H, dd, J = 7.5, 1.4 Hz)), 1.71 (3H, app. t, J = 1.4 Hz), 3.76 (3H, s), 4.23 (1H, d, J = 
9.1 Hz), 4.58 (1H, d, J = 9.1 Hz), 5.34 (1H, s), 5.46 (1H, qd, J = 7.5, 1.4 Hz); 13C NMR 
(125MHz, CDCl3) δC 13.8, 22.6, 26.2, 28.2, 39.0, 52.2, 70.8, 77.8, 80.4, 98.8, 124.2, 
133.4, 153.5, 172.8; HRMS (ESI, +ve) m/z calcd. for C18H32NO5 342.2280, found: 
342.2287 (M+H)+. 
 
(R)-Methyl 2-amino-2-(hydroxymethyl)pent-4-enoate (282a) 
 
 
 
(2R,4S)-3-tert-Butyl 4-methyl 4-allyl-2-tert-butyloxazolidine-3,4-dicarboxylate 266a 
(110 mg, 0.336 mmol), MeOH (1.6 mL) and 6N HCl (1.12 mL, 6.72 mmol) were 
combined according to general procedure IX to afford the title compound as a 
colourless oil (43 mg, 80%). [α]D -5.6 (c 0.8, CH2Cl2); FTIR (film/cm-1) νmax: 3367, 
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2954, 2254, 1733, 1642, 1594; 1H NMR (500MHz, CDCl3) δH 2.23 (1H, dd, J = 13.7, 
7.4 Hz), 2.47 (1H, dd, J = 13.7, 7.4 Hz), 2.55 (3H, bs), 3.49 (1H, d, J = 10.7 Hz), 3.73 
(3H, s), 3.78 (1H, d, J = 10.7 Hz), 5.12 (1H, d, J = 5.8 Hz), 5.15 (1H, s), 5.59-5.69 (1H, 
m); 13C NMR (125MHz, CDCl3) δC 40.4, 52.4, 62.3, 67.8, 120.0, 131.6, 175.7; HRMS 
(ESI, +ve) m/z calcd. for C7H13NO3Na 182.0793, found: 182.0781 (M+Na)+. 
 
(2R,3S)-Methyl 2-amino-2-(hydroxymethyl)-3-methylpent-4-enoate (282b) 
 
 
 
(2R,4S)-3-tert-Butyl 4-methyl 4-((S)-but-3-en-2-yl)-2-tert-butyloxazolidine-3,4-
dicarboxylate 266b (110 mg, 0.322 mmol), MeOH (1.5 mL) and 6N HCl (1.07 mL, 6.44 
mmol) were combined according to general procedure IX to afford the title compound 
as a yellow oil (25 mg, 45%). [α]D -49 (c 1.1, CH2Cl2); FTIR (film/cm-1) νmax: 2970, 
2957, 2253, 1730, 1595; 1H NMR (500MHz, CDCl3) δH 0.97 (3H, d, J = 7.0 Hz), 2.22 
(3H, bs), 2.56 (1H, quint, J = 7.3 Hz), 3.52 (1H, d, J = 10.8 Hz), 3.77 (3H, s), 3.83 (1H, 
d, J = 10.8 Hz), 5.06-5.16 (2H, m), 5.72 (1H, ddd, J = 16.9, 10.5, 8.6 Hz); 13C NMR 
(125MHz, CDCl3) δC 14.8, 42.9, 52.4, 65.2, 67.1, 117.2, 137.9, 175.4; HRMS (ESI, 
+ve) m/z calcd. for C8H15NO3Na 196.0950, found: 196.0939 (M+Na)+. 
 
(R)-Methyl 2-amino-2-(hydroxymethyl)-3-methylpenta-3,4-dienoate (282c) 
 
 
 
(2R,4S)-3-tert-Butyl 4-methyl 4-(buta-2,3-dien-2-yl)-2-tert-butyloxazolidine-3,4-
dicarboxylate 266d (100 mg, 0.295 mmol), MeOH (1.5 mL) and 6N HCl (1.17 mL, 5.90 
mmol) were combined according to general procedure IX to afford the title compound 
as a yellow oil (22 mg, 44%). [α]D -32 (c 0.7, CH2Cl2); FTIR (film/cm-1) νmax: 3365, 
2954, 2252, 1957, 1731, 1584; 1H NMR (500MHz, CDCl3) δH 1.73 (3H, t, J = 3.4 Hz), 
2.59 (3H, bs), 3.60 (1H, d, J = 10.7 Hz), 3.78 (3H, s), 3.98 (1H, d, J = 10.7 Hz) 4.82-
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4.92 (2H, m); 13C NMR (125MHz, CDCl3) δC 14.6, 52.7, 63.4, 66.0, 78.2, 99.9, 173.7, 
205.6; HRMS (ESI, +ve) m/z calcd. for C8H13NO3Na 194.0793, found: 194.0778 
(M+Na)+. 
 
(R)-Methyl 2-amino-2-(hydroxymethyl)pentanoate (282d) 
 
 
 
(2R,4S)-3-tert-Butyl 4-methyl 2-tert-butyl-4-propyloxazolidine-3,4-dicarboxylate 281a 
(110 mg, 0.334 mmol), MeOH (1.6 mL) and 6N HCl (1.32 mL, 6.68 mmol) were 
combined according to general procedure IX to afford the title compound as a yellow oil 
(39 mg, 73%). [α]D -25.7 (c 0.7, CH2Cl2); FTIR (film/cm-1) νmax: 3358, 3304, 2960, 
2876, 1737, 1564; 1H NMR (500MHz, CDCl3) δH 0.92 (3H, t, J = 7.3 Hz), 1.14-1.22 
(1H, m), 1.34-1.42 (1H, m), 1.48 (1H, td, J = 13.0, 4.4 Hz), 1.69 (1H, bs), 2.19 (3H, bs), 
3.47 (1H, d, J = 8.9 Hz), 3.76 (3H, s), 3.82 (1H, bs); 13C NMR (125MHz, CDCl3) δC 
14.2, 16.9, 38.1, 52.5, 63.1, 67.7, 175.6; HRMS (ESI, +ve) m/z calcd. for C7H15NO3Na 
184.0950, found: 184.0943 (M+Na)+. 
 
(2R,3S)-Methyl 2-amino-2-(hydroxymethyl)-3-methylpentanoate (282e) 
 
 
 
(2R,4S)-3-tert-Butyl 4-methyl 4-(sec-butyl)-2-(tert-butyl)oxazolidine-3,4-dicarboxylate 
281b (75 mg, 0.218 mmol), MeOH (1.5 mL) and 6N HCl (867 μL, 4.37 mmol) were 
combined according to general procedure IX to afford the title compound as a yellow oil 
(23 mg, 59%). [α]D -43.6 (c 1.1, CH2Cl2); FTIR (film/cm-1) νmax: 3301, 2965, 2939, 
2878, 1730, 1596; 1H NMR (500MHz, CDCl3) δH 0.87 (3H, d, J = 6.9 Hz), 0.92 (3H, t, 
J = 7.2 Hz), 0.98-1.04 (1H, m), 1.52-1.58 (1H, m), 1.64-1.70 (1H, m), 2.48 (3H, bs), 
3.57 (1H, d, J = 10.7 Hz), 3.75 (3H, s), 3.87 (1H, d, J = 10.7 Hz); 13C NMR (125MHz, 
CDCl3) δC 12.3, 13.5, 23.4, 40.4, 52.3, 66.3, 66.5, 175.8; HRMS (ESI, +ve) m/z calcd. 
for C8H17NO3Na 198.1106, found: 198.1077 (M+Na)+. 
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(R)-Methyl 2-amino-2-(hydroxymethyl)-4-methylpentanoate (282f) 
 
 
 
(2R,4S)-3-tert-Butyl 4-methyl 2-(tert-butyl)-4-isobutyloxazolidine-3,4-dicarboxylate 
281c (56 mg, 0.163 mmol), MeOH (0.8 mL) and 6N HCl (647 μL, 3.26 mmol) were 
combined according to general procedure IX to afford the title compound as a pale 
yellow oil (20 mg, 71%). [α]D -36 (c 1.0, CH2Cl2); FTIR (film/cm-1) νmax: 3367, 3302, 
2955, 2873, 1732, 1598; 1H NMR (500MHz, CDCl3) δH 0.84 (3H, d, J = 6.5 Hz), 0.94 
(3H, d, J = 6.5 Hz), 1.47 (1H, dd, J = 13.9, 5.0 Hz), 1.61-1.75 (2H, m), 2.41 (3H, bs), 
3.41 (1H, d, J = 10.4 Hz), 3.74 (3H, s), 3.77 (1H, d, J = 10.4 Hz); 13C NMR (125MHz, 
CDCl3) δC 22.8, 23.9, 24.4, 44.6, 52.3, 62.3, 69.1, 176.6; HRMS (ESI, +ve) m/z calcd. 
for C8H17NO3Na 198.1106, found: 198.1113 (M+Na)+. 
 
Heptadec-16-en-7-one (286) 
 
 
 
To the orange/red solution of Fe(acac)3 (110 mg, 0.300 mmol, 3 mol%) in THF (100 
mL) at -78 °C was added hexyl magnesium bromide (2.0M, 6.50 mL, 13.0 mmol) and 
the solution turned dark brown.  The reaction mixture was allowed to stir for 30 minutes 
before undecanoyl chloride (2.15 mL, 10.0 mmol) was added via syringe and stirred at -
78 °C for 1 hour. Quenched with NH4Cl (sat.) (75 mL) and allowed to warm to room 
temperature and extracted with Et2O (3 × 75 mL), dried over MgSO4 and concentrated 
in vacuo to afford the crude ketone.  Purification by flash chromatography (20:1 
Pet/EtOAc) affords the title compound as a white solid (2.44 g, 97%). Mpt: 32-34 °C 
(lit.239 33-34 °C); FTIR (film/cm-1) υmax: 2957, 2918, 2848, 1698; 1H NMR (500 MHz, 
CDCl3) δH  0.88 (3H, t, J = 6.5 Hz), 1.28 (14H, s), 1.35–1.43 (2H, m), 1.51–1.61 (4H, 
m), 2.04 (2H, q, J = 6.8 Hz), 2.38 (4H, t, J = 7.4 Hz), 4.93 (1H, d, J = 10.1 Hz), 4.99 
(1H, d, J = 17.2 Hz), 5.76–7.86 (1H, m); 13C NMR (125 MHz, CDCl3) δC 14.0, 22.5, 
23.8, 23.9, 28.9 (×2), 29.0, 29.2, 29.3 (×2), 31.6, 33.8, 42.8 (×2), 114.1, 139.1, 211.6; 
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MS (ESI, +ve) m/z calcd. for C17H32ONa 275.2351, found: 275.2353 (M+Na)+. All data 
in accordance with literature precedence.239 
 
(E)-Dotriacont-16-ene-7,26-dione (289) 
 
 
 
To a solution of heptadec-16-en-7-one 286 (250 mg, 1 mmol, 2 eq) in DCM (5 mL) was 
added Grubbs II (11 mg, 0.0125 mmol, 2.5 mol%) and heated at reflux for 3 days.  
Reaction mixture concentrated in vacuo and the residue purified by flash 
chromatography (20:1 Pet/EtOAc) to afford the title compound as a white solid (197 
mg, 83%). Mpt: 66-67 °C; FTIR (film/cm-1) υmax: 2956, 2918, 2848, 1699; 1H NMR 
(500 MHz, CDCl3) δH 0.88 (6H, t, J = 6.9 Hz), 1.22–1.36 (32H, m), 1.52–1.61 (8H, m), 
1.92–2.00 (4H, m), 2.36–2.41 (8H, m), 5.36–5.39 (2H, m); 13C NMR (125 MHz, 
CDCl3) δC 14.0, 22.5, 23.8, 23.9, 28.9, 29.1, 29.3 (×3), 29.4, 29.6, 31.6, 32.6, 42.8, 
130.3, 211.7; MS (ESI, +ve) m/z calcd. for C32H60O2Na 499.4491, found: 499.4474 
(M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S,E)-1-methoxy-12-oxooctadec-2-
enyl) oxazolidine-3,4-dicarboxylate (288a) 
 
 
 
To a solution of (2R,4R)-3-tert-butyl 4-methyl 2-tert-butyl-4-((S)-1-
methoxyallyl)oxazolidine-3,4-dicarboxylate 252a (64 mg, 0.178 mmol) and (E)-
dotriacont-16-ene-7,26-dione 289 (85 mg, 0.178 mmol) in DCM (500 μL) was added 
Hoveyda-Grubbs II (6 mg, 0.009 mmol, 5 mol%) and heated at reflux for 72 hours.  
Reaction mixture concentrated in vacuo and the residue purified by flash 
chromatography (15:1 Pet/EtOAc) to afford the title compound as a colourless oil (51 
mg, 48%). ሾαሿDଶ଴ -12.5 (c 0.8, CH2Cl2); FTIR (film/cm-1) υmax: 2957, 2932, 2858, 1740, 
1702; 1H NMR (500MHz, CDCl3) δH 0.87–0.98 (12H, m), 1.24–1.42 (16H, m), 1.51 
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(9H, s), 1.54–1.63 (4H, m), 2.06 (2H, q, J = 6.8 Hz), 2.38 (4H, t, J = 7.4 Hz), 3.24 (3H, 
s), 3.71 (3H, s), 4.15 (1H, d, J = 8.3 Hz), 4.41 (1H, d, J = 8.3 Hz), 4.79 (1H, d, J = 6.5 
Hz), 5.13 (1H, s), 5.21 (1H, dd, J = 15.5, 6.5 Hz), 5.76 (1H, dt, J = 15.5, 6.8 Hz); 13C 
NMR (125MHz, CDCl3) δC 13.8, 22.4, 23.8 (×2), 26.1, 28.2, 28.9, 29.1 (×2), 29.2 (×3), 
31.5, 32.2, 38.1, 42.7 (×2), 52.0, 56.1, 69.6, 72.7, 78.8, 80.6, 98.1, 125.3, 137.4, 153.8, 
171.0, 211.0; MS (ESI, +ve) m/z calcd. for C33H59NO7Na 604.4189, found: 604.4131 
(M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S,E)-1-(benzyloxy)-12-oxooctadec-2-
enyl) oxazolidine-3,4-dicarboxylate (288j) 
 
 
 
To a solution of (2R,4R)-3-tert-butyl 4-methyl 2-tert-butyl-4-((S)-1-
benzyloxyallyl)oxazolidine-3,4-dicarboxylate 252j (87 mg, 0.200 mmol) and (E)-
dotriacont-16-ene-7,26-dione 289 (76 mg, 0.160 mmol) in DCM (500 μL) was added 
Hoveyda-Grubbs II (6 mg, 0.010 mmol, 5 mol%) and heated at reflux for 4 days.  
Reaction mixture concentrated in vacuo and the residue purified by flash 
chromatography (15:1 Pet/EtOAc) to afford the title compound as a colourless oil (29 
mg, 22%). N.B. Unable to isolate cleanly due to co-elution of 252j and 288j. 
Furthermore, due to poor solubility of 289, and poor consumption during the reaction, 
this co-elutes across entire column despite large Rf difference. 
 
(2R,4R)-4-Benzyl 3-tert-butyl 2-tert-butyl-4-((S)-1-hydroxyallyl)oxazolidine-3,4-
dicarboxylate (290) 
 
 
 
To a solution of (2R,4R)-3-tert-butyl 4-methyl 2-tert-butyl-4-((S)-1-(4-
methoxybenzyloxy)allyl)oxazolidine-3,4-dicarboxylate 252k (185 mg, 0.400 mmol, 1 
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eq) in DCM/H2O (18:1, 4.0 mL) was added DDQ (114 mg, 0.50 mmol, 1.25 eq) and 
stirred at room temperature for 2 hours.  The precipitate formed was removed by 
filtration, and the filtrate was concentrated in vacuo to afford the crude allylic alcohol. 
Purified by flash chromatography (8:1 Pet/EtOAC) to afford the title compound (106 
mg, 77% NMR corrected yield*). FTIR (film/cm-1) υmax: 3352, 2972, 2877, 1761, 1735, 
1680; 1H NMR (500 MHz, CDCl3) δH 0.94 (9H, s), 1.46 (9H, s), 3.83 (3H, s), 4.05 (1H, 
d, J = 9.7 Hz), 4.48 (1H, d, J = 9.7 Hz), 4.54 (1H, app. dt, J = 11.2, 1.8 Hz), 5.19 (1H, 
s), 5.33 (1H, dt, J = 10.7, 1.8 Hz), 5.52 (1H, dt, J = 17.1, 1.8 Hz), 5.83 (1H, bs), 5.95 
(1H, ddd, J = 17.1, 10.7, 4.0 Hz); HRMS (ESI, +ve) m/z calcd. for C17H29NO6Na 
366.1893, found: 366.1885 (M+Na)+. 
 
(2R,4R)-3-tert-Butyl 4-methyl 2-tert-butyl-4-((S,E)-1-hydroxy-12-oxooctadec-2-
enyl)oxazolidine-3,4-dicarboxylate (291) 
 
 
 
To a solution of (2R,4R)-3-tert-butyl 4-methyl 2-tert-butyl-4-((S)-1-
hydroxyallyl)oxazolidine-3,4-dicarboxylate 290 (45mg, 0.103 mmol) and (E)-
dotriacont-16-ene-7,26-dione 289 (49 mg, 0.103 mmol) in DCM (500 μL) was added 
Hoveyda-Grubbs II (3.2 mg, 0.0052 mmol, 5 mol%) and heated at reflux for 30 hours.  
Reaction mixture concentrated in vacuo and the residue purified by column 
chromatography (15:1 to 4:1 Pet/EtOAc) to afford the title compound as a colourless oil 
(48 mg, 83%). ሾαሿDଶ଴ -10.7 (c 0.75, CH2Cl2); FTIR (film/cm-1) υmax: 3377, 2954, 2930, 
2857, 1762, 1737, 1714, 1686; 1H NMR (500MHz, CDCl3) δH 0.88 (3H, t, J = 6.9 Hz), 
0.94 (9H, s), 1.24–1.34 (14H, m), 1.34–1.43 (2H, m), 1.49 (9H, s), 1.53–1.60 (4H, m), 
2.02–2.09 (2H, m), 2.39 (4H, t, J = 7.5 Hz), 3.82 (3H, s), 4.00 (1H, d, J = 9.4 Hz), 4.46 
(2H, app. d, J = 9.4 Hz), 5.17 (1H, s), 5.46 (1H, dd, J = 15.4, 5.3 Hz), 5.70 (1H, bs), 
5.83–5.91 (1H, m); 13C NMR (125MHz, CDCl3) δC 14.0, 22.5, 23.8, 26.6, 28.2, 28.9 
(×2), 29.1, 29.2, 29.3 (×2), 29.4, 31.6, 32.4, 39.3, 42.8 (×2), 52.6, 74.2, 75.1, 77.8, 82.2, 
                                                 
* p-Anisaldehyde still present. Used in cross-metathesis in this crude form. 
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99.4, 125.2, 135.0, 155.5, 171.2, 211.7; MS (ESI, +ve) m/z calcd. for C32H57NO7Na 
590.4032, found: 590.4039 (M+Na)+. 
 
(2R,4R)-4-Benzyl 3-tert-butyl 2-tert-butyl-4-((S)-1-(4-methoxybenzyloxy)allyl) 
oxazolidine-3,4-dicarboxylate (254 by Preparative Scale Synthesis) 
 
 
 
To a stirred solution of L-Boc oxazolidine carboxylic acid 250 (2.19 g, 8.00 mmol, 2 eq) 
in DCM (125 mL) was added EDCi.HCl (1.53 g, 8.00 mmol, 2 eq), triethylamine (1.12 
mL, 8.00 mmol, 2 eq), catalytic DMAP (5 mol%) and (E)-3-(4-
methoxybenzyloxy)prop-2-en-1-ol 218k (925 mg, 4.00 mmol, 1 eq).  The reaction was 
stirred at room temperature for 2 hours then washed with NaHCO3 (sat) (3 × 50 mL), 
10% citric acid (1 × 50 mL), brine (1 × 50 mL) and dried over Na2SO4.  Concentration 
in vacuo affords the crude oxazolidine ester (1.80g, quant). 
 
To a stirred solution of the crude oxazolidine ester (1.80 g, 4.00 mmol, 1 eq) in THF 
(18.0 mL) at -78 °C was added TMSCl (1.53 mL, 12.0 mmol, 3 eq).  After 10 mins 
LHMDS (1M, 12.0 mL, 12.0 mmol, 3 eq) was added via syringe pump at an addition 
rate of 10 mL hr-1 and reaction mixture allowed to warm to room temperature after a 
period of 30 mins, and stirred for 18 hours.  The reaction was quenched by the addition 
of 1N HCl and brine solution (1:1) and extracted with DCM (3 × 50 mL), dried over 
Na2SO4 and concentrated in vacuo to afford the crude acid.  Residue dissolved in 
acetone (35.0 mL), and K2CO3 (552 mg, 4.00 mmol, 1 eq) and BnBr (1.19 mL, 10.0 
mmol, 2.5 eq) added and reaction mixture stirred for 4 hours. Partitioned between 
between EtOAc and NaHCO3 (sat) and washed with NaHCO3 (sat) (3 × 50 mL), brine 
(1 × 50 mL) and dried over Na2SO4.  Concentration in vacuo affords the crude ester. 
Purification by flash chromatography (10:1 Pet/EtOAc) affords the title compound ent-
254k as a colourless oil (1.70 g, 79%, dr >99:1). All data as previously stated. 
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(2S,4S)-4-Benzyl 3-tert-butyl 2-tert-butyl-4-((R)-1-(4-methoxybenzyloxy)allyl) 
oxazolidine-3,4-dicarboxylate (ent-254k by Preparative Scale Synthesis) 
 
 
 
To a stirred solution of D-Boc oxazolidine carboxylic acid ent-250 (2.19 g, 8.00 mmol, 
2 eq) in DCM (125 mL) was added EDCi.HCl (1.53 g, 8.00 mmol, 2 eq), triethylamine 
(1.12 mL, 8.00 mmol, 2 eq), catalytic DMAP (5 mol%) and (E)-3-(4-
methoxybenzyloxy)prop-2-en-1-ol 218k (925 mg, 4.00 mmol, 1 eq).  The reaction was 
stirred at room temperature for 2 hours then washed with NaHCO3 (sat) (3 × 50 mL), 
10% citric acid (1 × 50 mL), brine (1 × 50 mL) and dried over Na2SO4.  Concentration 
in vacuo affords the crude oxazolidine ester (1.80g, quant). 
 
To a stirred solution of the crude oxazolidine ester (1.80 g, 4.00 mmol, 1 eq) in THF 
(18.0 mL) at -78 °C was added TMSCl (1.53 mL, 12.0 mmol, 3 eq).  After 10 mins 
LHMDS (1M, 12.0 mL, 12.0 mmol, 3 eq) was added via syringe pump at an addition 
rate of 10 mL hr-1 and reaction mixture allowed to warm to room temperature after a 
period of 30 mins, and stirred for 18 hours.  The reaction was quenched by the addition 
of 1N HCl and brine solution (1:1) and extracted with DCM (3 × 50 mL), dried over 
Na2SO4 and concentrated in vacuo to afford the crude acid.  Residue dissolved in 
acetone (35.0 mL), and K2CO3 (552 mg, 4.00 mmol, 1 eq) and BnBr (1.19 mL, 10.0 
mmol, 2.5 eq) added and reaction mixture stirred for 4 hours. Partitioned between 
between EtOAc and NaHCO3 (sat) and washed with NaHCO3 (sat) (3 × 50 mL), brine 
(1 × 50 mL) and dried over Na2SO4.  Concentration in vacuo affords the crude ester. 
Purification by flash chromatography (10:1 Pet/EtOAc) affords the title compound ent-
254k as a colourless oil (1.75 g, 81%, dr >99:1). All data as previously stated. 
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(2R,4R)-4-Benzyl 3-tert-butyl 2-tert-butyl-4-((S)-1-hydroxyallyl)oxazolidine-3,4-
dicarboxylate (292) 
 
 
 
To a solution of (2R,4R)-4-benzyl 3-tert-butyl 2-tert-butyl-4-((S)-1-(4-
methoxybenzyloxy)allyl)oxazolidine-3,4-dicarboxylate 254k (393 mg, 0.728 mmol, 1 
eq) in DCM/H2O (18:1, 6.1 mL) was added DDQ (207 mg, 0.910 mmol, 1.25 eq) and 
stirred at room temperature for 2 hours.  The precipitate formed was removed by 
filtration, and the filtrate was concentrated in vacuo to afford the crude allylic alcohol 
(390 mg, 89% NMR corrected yield†).  Residue dissolved in MeOH (5 mL) and added 
dropwise to an ice-cold solution of sodium borohydride (82 mg, 2.18 mmol, 3 eq) in 
MeOH (20 mL) and reaction allowed to stir at 0 °C for 2 hours.  Partitioned between 
water and DCM and the aqueous extracted with DCM (3 × 25 mL).  The organics were 
combined and washed with brine, dried over Na2SO4 and concentrated in vacuo.  
Purified by flash chromatography (10:1 Pet/EtOAc) to afford the pure title compound as 
a colourless oil (225 mg, 74%). ሾαሿDଶ଴ -33.8 (c 2.1, CH2Cl2); FTIR (film/cm-1) υmax: 
3349, 2973, 2910, 2876, 1760, 1734, 1682; 1H NMR (500 MHz, CDCl3) δH 0.89 (9H, 
s), 1.47 (9H, s), 4.06 (1H, d, J = 9.7 Hz), 4.48 (1H, d, J = 9.7 Hz), 4.57–4.62 (1H, m), 
5.19 (1H, s), 5.22 (1H, d, J = 12.4 Hz), 5.31–5.37 (2H, m), 5.54 (1H, dt, J = 17.0, 1.8 
Hz), 5.89 (1H, bs), 5.96 (1H, ddd, J = 17.0, 10.7, 4.0 Hz), 7.29–7.39 (3H, m), 7.39–7.43 
(2H, m); 13C NMR (125 MHz, CDCl3) δC 26.6, 28.1, 39.3, 67.4, 74.0, 75.2, 78.2, 82.4, 
99.4, 118.0, 128.2, 128.3, 128.5, 133.6, 135.4, 155.5, 170.2; HRMS (ESI, +ve) m/z 
calcd. for C23H33NO6Na 442.2206, found: 442.2207 (M+Na)+. 
 
(2S,4S)-4-Benzyl 3-tert-butyl 2-tert-butyl-4-((R)-1-hydroxyallyl)oxazolidine-3,4-
dicarboxylate (ent-292) 
 
 
                                                 
† p-Anisaldehyde still present. Subsequent sodium borohydride reduction to 4-methoxybenzyl alcohol 
allows purification by flash chromatography. 
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To a solution of (2S,4S)-4-benzyl 3-tert-butyl 2-tert-butyl-4-((R)-1-(4-
methoxybenzyloxy)allyl)oxazolidine-3,4-dicarboxylate ent-254k (562 mg, 1.04 mmol, 
1 eq) in DCM/H2O (18:1, 8.0 mL) was added DDQ (295 mg, 1.30 mmol, 1.25 eq) and 
stirred at room temperature for 2 hours.  The precipitate formed was removed by 
filtration, and the filtrate was concentrated in vacuo to afford the crude allylic alcohol 
(390 mg, 89% NMR corrected yield‡).  Residue dissolved in MeOH (5 mL) and added 
dropwise to an ice-cold solution of sodium borohydride (118 mg, 3.12 mmol, 3 eq) in 
MeOH (30 mL) and reaction allowed to stir at 0 °C for 2 hours.  Partitioned between 
water and DCM and the aqueous extracted with DCM (3 × 25 mL).  The organics were 
combined and washed with brine, dried over Na2SO4 and concentrated in vacuo.  
Purified by flash chromatography (10:1 Pet/EtOAc) to afford the pure title compound as 
a colourless oil (324 mg, 74%). ሾαሿDଶ଴ +32.5 (c 2.1, CH2Cl2); FTIR (film/cm-1) υmax: 
3349, 2973, 2910, 2876, 1760, 1734, 1682; 1H NMR (500 MHz, CDCl3) δH 0.89 (9H, 
s), 1.47 (9H, s), 4.06 (1H, d, J = 9.7 Hz), 4.48 (1H, d, J = 9.7 Hz), 4.57–4.62 (1H, m), 
5.19 (1H, s), 5.22 (1H, d, J = 12.4 Hz), 5.31–5.37 (2H, m), 5.54 (1H, dt, J = 17.0, 1.8 
Hz), 5.89 (1H, bs), 5.96 (1H, ddd, J = 17.0, 10.7, 4.0 Hz) , 7.29–7.39 (3H, m), 7.39–
7.43 (2H, m); 13C NMR (125 MHz, CDCl3) δC 26.6, 28.1, 39.3, 67.4, 74.0, 75.2, 78.2, 
82.4, 99.4, 118.0, 128.2, 128.3, 128.5, 133.6, 135.4, 155.5, 170.2; HRMS (ESI, +ve) m/z 
calcd. for C23H33NO6Na 442.2206, found: 442.2207 (M+Na)+. 
 
(2R,4R)-4-Benzyl 3-tert-butyl 2-tert-butyl-4-((S,E)-1-hydroxy-12-oxooctadec-2-
enyl)oxazolidine-3,4-dicarboxylate (293) 
 
 
 
To a solution of (2R,4R)-4-benzyl 3-tert-butyl 2-tert-butyl-4-((S)-1-
hydroxyallyl)oxazolidine-3,4-dicarboxylate 254k (324 mg, 0.772 mmol, 1 eq) and (E)-
dotriacont-16-ene-7,26-dione 289 (368 mg, 0.772 mmol, 1 eq) in DCM (1.0 mL) was 
added Hoveyda-Grubbs II (24.2 mg, 0.0386 mmol, 5 mol%) and heated at reflux for 24 
hours.  Reaction mixture concentrated in vacuo and the residue purified by flash 
                                                 
‡ p-Anisaldehyde still present. Subsequent sodium borohydride reduction to 4-methoxybenzyl alcohol 
allows purification by flash chromatography. 
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chromatography (15:1 Pet/EtOAc) to afford the title compound as a colourless oil (328 
mg, 66%). ሾαሿDଶ଴ -12.3 (c 2.2, CH2Cl2); FTIR (film/cm-1) υmax: 3378, 2957, 2929, 2854, 
1760, 1731, 1707, 1683; 1H NMR (500 MHz, CDCl3) δH 0.82–0.92 (12H, m), 1.22–1.33 
(14H, m), 1.33–1.42 (2H, m), 1.47 (9H, s), 1.52–1.61 (4H, m), 2.00–2.08 (2H, m), 2.38 
(4H, t, J = 7.4 Hz), 4.00 (1H, d, J = 9.5 Hz), 4.46 (1H, d, J = 9.4 Hz), 4.51 (1H, bs), 
5.16 (1H, s), 5.20 (1H, d, J = 12.1 Hz), 5.31 (1H, d, J = 12.1 Hz), 5.47 (1H, dd, J = 
15.4, 5.2 Hz), 5.77 (1H, bs), 5.83–5.92 (1H, m) , 7.28–7.37 (3H, m), 7.37–7.42 (2H, m); 
13C NMR (125 MHz, CDCl3) δC 14.0, 22.5, 23.8, 26.5 (×2), 28.2, 28.9 (×2), 29.0, 29.3 
(×2), 29.4, 31.6, 32.4, 39.2, 42.8 (×2), 67.3, 74.1, 75.1, 77.3, 77.8, 82.1, 99.4, 125.1, 
128.2, 128.4, 134.0, 135.5, 155.4, 170.6, 211.6; MS (ESI, +ve) m/z calcd. for 
C38H62NO7 644.4526, found: 644.4533 (M+H)+. 
 
(2S,4S)-4-Benzyl 3-tert-butyl 2-tert-butyl-4-((R,E)-1-hydroxy-12-oxooctadec-2-
enyl)oxazolidine-3,4-dicarboxylate (ent-293) 
 
 
 
To a solution of (2S,4S)-4-benzyl 3-tert-butyl 2-tert-butyl-4-((R)-1-
hydroxyallyl)oxazolidine-3,4-dicarboxylate ent-293 (125 mg, 0.297 mmol, 1 eq) and 
(E)-Dotriacont-16-ene-7,26-dione 289 (142 mg, 0.297 mmol, 1 eq) in DCM (1.0 mL) 
was added Hoveyda-Grubbs II (9.3 mg, 0.0149 mmol, 5 mol%) and heated at reflux for 
24 hours.  Reaction mixture concentrated in vacuo and the residue purified by flash 
chromatography (15:1 Pet/EtOAc) to afford the title compound as a colourless oil (144 
mg, 75%). ሾαሿDଶ଴ +12.0 (c 2, CH2Cl2). All other data as previously stated. 
 
(2S,3R,E)-Benzyl 2-amino-3-hydroxy-2-(hydroxymethyl)-14-oxoicos-4-enoate (ent-
294) 
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 (2S,4S)-4-Benzyl 3-tert-butyl 2-tert-butyl-4-((R,E)-1-hydroxy-12-oxooctadec-2-
enyl)oxazolidine-3,4-dicarboxylate ent-293 (73 mg, 0.113 mmol, 1.0 eq), MeOH (2.0 
mL) and 6N HCl (378 μL, 2.27 mmol, 20 eq) were combined according to general 
procedure IX (reaction time: 6 hours) to afford the title compound as a pale yellow oil 
(40.4 mg, 75%). ሾαሿDଶ଴ +16.0 (c 1, CH2Cl2); FTIR (film/cm-1) υmax: 3359, 2926, 2854, 
1739, 1711, 1587; 1H NMR (500MHz, CDCl3) δH 0.89 (3H, t, J = 6.7 Hz), 1.22–1.38 
(16H, m), 1.50–1.62 (4H, m), 2.01 (2H, q, J = 7.0 Hz), 2.39 (4H, t, J = 7.4 Hz), 2.93 
(4H, bs), 3.65 (1H, d, J = 11.2 Hz), 3.89 (1H, d, J = 11.2 Hz), 4.28 (1H, d, J = 7.4 Hz), 
5.23 (2H, s), 5.45 (1H, dd, J = 15.4, 7.4 Hz), 5.73 (1H, dt, J = 15.4, 7.0 Hz), 7.31–7.41 
(5H, m); 13C NMR (125MHz, CDCl3) δC 14.0, 22.5, 23.8 (×2), 28.9 (×2), 29.0, 29.2 
(×2), 29.3, 31.6, 32.2, 42.8 (×2), 65.0, 66.5, 67.4, 75.0, 126.3, 128.2, 128.5, 128.6, 
135.4, 136.3, 173.6, 211.9; HRMS (ESI, +ve) m/z calcd. for C28H45NO5Na 498.3195, 
found: 498.3173 (M+Na)+. 
 
(2R,4R)-3-(tert-Butoxycarbonyl)-2-tert-butyl-4-((S)-1-hydroxy-12-
oxooctadecyl)oxazolidine-4-carboxylic acid (295) 
 
 
 
A mixture of (2R,4R)-4-benzyl 3-tert-butyl 2-tert-butyl-4-((S,E)-1-hydroxy-12-
oxooctadec-2-enyl)oxazolidine-3,4-dicarboxylate 293 (120 mg, 0.186 mmol) and 10 
mol% Pd/C (12 mg, 10 wt%) in EtOH (5.0 mL) was hydrogenated at atmospheric 
pressure for 1 hours.  Reaction mixture filtered through celite® and concentrated in 
vacuo to afford the title compound as a pale yellow oil (103 mg, 100%). ሾαሿDଶ଴ -35.0 (c 
2, CH2Cl2); FTIR (film/cm-1) υmax: 3408, 2954, 2926, 2855, 1760, 1712, 1679, 1615; 
1H NMR (500 MHz, CDCl3) δH 0.88 (3H, t, J = 6.9 Hz), 0.94 (9H, s), 1.21–1.41 (20H, 
m), 1.47–1.66 (15H, m), 2.39 (4H, t, J = 7.5 Hz), 4.05 (1H, d, J = 9.7 Hz), 4.27 (1H, d, J 
= 9.6 Hz), 4.58 (1H, d, J = 9.7 Hz), 5.20 (1H, s); 13C NMR (125 MHz, CDCl3) δC 14.0, 
22.5, 23.9 (×2), 26.4, 28.1, 28.9, 29.2, 29.3, 29.4 (×4), 31.5 (×2), 31.6, 39.0, 42.8 (×2), 
72.4, 73.5, 74.2, 84.0, 98.6, 157.3, 171.4, 211.9; HRMS (ESI, +ve) m/z calcd. for 
C31H56NO7 554.4057, found: 554.4051 (M-H)-. 
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(2S,4S)-3-(tert-Butoxycarbonyl)-2-tert-butyl-4-((R)-1-hydroxy-12-
oxooctadecyl)oxazolidine-4-carboxylic acid (ent-295) 
 
 
 
A mixture of (2S,4S)-4-benzyl 3-tert-butyl 2-tert-butyl-4-((R,E)-1-hydroxy-12-
oxooctadec-2-enyl)oxazolidine-3,4-dicarboxylate ent-293 (100 mg, 0.155 mmol) and 10 
mol% Pd/C (10 mg, 10 wt%) in EtOH (5.0 mL) was hydrogenated at atmospheric 
pressure for 1 hours.  Reaction mixture filtered through celite® and concentrated in 
vacuo to afford the title compound as a pale yellow oil (84 mg, 98%). ሾαሿDଶ଴ +34.2 (c 
1.87, CH2Cl2). All other data as previously stated. 
 
(2S,3R)-2-Amino-3-hydroxy-2-(hydroxymethyl)-14-oxoicosanoic acid ((−)-
Mycestericin G) (30) 
 
 
 
 To a solution of (2S,4S)-3-tert-butoxycarbonyl)-2-tert-butyl-4-((R)-1-hydroxy-12-
oxooctadecyl)oxazolidine-4-carboxylic acid ent-295 (47 mg, 84.6 μmol, 1.0 eq) in 
MeOH (1.5 mL) was added 6N HCl (250 μL, 1.69 mmol, 20 eq) and the reaction 
mixture refluxed for 18 hours. Reaction mixture was allowed to cool to room 
temperature and concentrated in vacuo to afford the crude hydrochloride salt.  Residue 
dissolved in MeOH (2.5 mL) and neutralised to pH 5-6 with 2N NaOH and concentrated 
in vacuo before the residue dissolved in water (5 mL) and the white precipitate filtered 
to afford (−)-mycestericin G 30 (13.9 mg, 43%). Mpt: 188-190 °C (lit.50 190-191.5 °C); 
ሾαሿD
ଶ଴ +13.3 (c 0.3, MeOH), lit.50 ሾαሿDଶ଴ -6.81 (c 0.106, MeOH); FTIR (film/cm-1) υmax: 
3384, 3084, 2920, 2851, 1707, 1595; 1H NMR (500 MHz, MeOD) δH 0.90 (3H, t, J = 
6.9 Hz), 1.23–1.45 (20H, m), 1.54 (4H, app. quint, J = 7.0 Hz), 1.58–1.70 (2H, m), 2.44 
(4H, t, J = 7.3 Hz), 3.82 (1H, d, J = 11.3 Hz), 3.84 (1H, bs), 3.94 (1H, d, J = 11.3 Hz); 
13C NMR (125 MHz, MeOD) δC 13.0, 22.2, 23.5 (×2), 25.9, 28.6, 28.9, 29.1, 29.2 (×2), 
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29.3 (×2), 31.3, 31.4, 42.1 (×2), 61.1, 68.5, 70.9, 172.6, 213.0; HRMS (ESI, -ve) m/z 
calcd. for C21H40NO5 386.2906, found: 386.2913 (M-H)-. 
 
(2R,3S)-2-Amino-3-hydroxy-2-(hydroxymethyl)-14-oxoicosanoic acid ((+)-
Mycestericin G) (ent-5) 
 
 
 
To a solution of (2R,4R)-3-tert-butoxycarbonyl)-2-tert-butyl-4-((S)-1-hydroxy-12-
oxooctadecyl)oxazolidine-4-carboxylic acid 295 (103 mg, 0.186 mmol) in MeOH (3.0 
mL) was added 6N HCl (620 μL, 3.72 mmol) and the reaction mixture refluxed for 18 
hours.  Reaction mixture was allowed to cool to room temperature and concentrated in 
vacuo to afford the crude hydrochloride salt.  Residue dissolved in MeOH (2.5 mL) and 
neutralised to pH 5-6 with 2N NaOH and concentrated in vacuo before the residue 
dissolved in water (5 mL) and the white precipitate filtered to afford crude mycestericin 
G. Passed through a column of amberlite IRC-76 ion exchange resin (MeOH) and 
purified by flash chromatography (10:3:1 CHCl3/MeOH/H2O, bottom layer used) to 
afford pure mycestericin G ent-5 (25 mg, 35%). Mpt: 188-189 °C; ሾαሿDଶ଴ -14.0 (c 1.2, 
MeOH). All other data as previously stated. 
 
position synthetic sample isolated sample (reported)50 
H20 (CH3) 0.90 (3H, t, J = 6.9 Hz) 0.90 (3H, t, J = 6.6 Hz) 
H5-11, H17-19 (CH2) 1.23–1.45 (20H, m) 1.30 (20H, m) 
H4 not observed, seen with neighbouring multiplet 1.36 (1H, m) 
H12, H16 (CH2) 
1.54 (4H, app. quint, J = 7.0 
Hz) 1.54 (4H, quint, J = 6.5 Hz)
H4 1.58–1.70 (2H, m) 1.62 (1H, m) 
H13, H15 (CH2) 2.44 (4H, t, J = 7.3 Hz) 2.44 (4H, t, J = 7.1 Hz) 
H21 3.82 (1H, d, J = 11.3 Hz) 3.81 (1H, J = 11.1 Hz) 
H3 3.84 (1H, bs) 3.83 (1H, m) 
H21 3.94 (1H, d, J = 11.3 Hz) 3.93 (1H, d, J = 11.1 Hz) 
ሾહሿ۲
૛૙ -15.0 (c 1.2, MeOH) -6.81 (c 0.106, MeOH) 
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No previous 13C data has been reported for either the naturally isolated sample, or any 
synthetic sample. 
 
(4S,5R)- 4-Benzyl 3-tert-butyl 4-((R)-1-(4-methoxybenzyloxy)allyl)-5-
methyloxazolidine-3,4-dicarboxylate (297) 
 
 
 
To a solution of (4S,5R)-3-tert-butyl 4-((E)-3-(4-methoxybenzyloxy)allyl) 5-
methyloxazolidine-3,4-dicarboxylate 238e (885 mg, 1.97 mmol) in THF (8.9 mL) at -78 
°C was added TMSCl (752 μL, 5.91 mmol).  After 10 mins LHMDS (1M, 5.91 mL, 
5.91 mmol) was added via syringe pump at an addition rate of 3 mL min-1 and reaction 
mixture allowed to warm to room temperature after a period of 30 mins, and stirred for 
18 hours.  The reaction was quenched by the addition of 1N HCl and brine solution 
(1:1, 5 mL) and extracted with DCM (3 × 15 mL), EtOAc (1 × 15 mL), dried over 
Na2SO4 and concentrated in vacuo to afford the crude acid. Treatment with 
diazomethane according to general procedure VIII and purification by flash 
chromatography (10:1 Pet/EtOAc) affords the methyl ester as a colourless oil (723 mg, 
68%, dr >99:1). ሾαሿDଶ଴ -30.7 (c 2.15, CHCl3); FTIR (film/cm
-1) υmax: 2979, 2935, 2868, 
1738, 1699; 1H NMR (500MHz, CDCl3, 328K) δH rotamer A 1.14 (3H, d, J = 6.4 Hz), 1.37 
(9H, s), 3.81 (3H, s), 4.34 (1H, quin, J = 6.1 Hz), 4.37–4.43 (1H, m), 4.50–4.57 (1H, 
m), 4.70 (1H, app. d, J = 4.2 Hz), 4.73 (1H, app. d, J = 4.2 Hz), 5.10–5.39 (4H, m), 5.48 
(1H, app. dd, J = 17.4, 1.8 Hz), 6.19–6.31 (1H, m), 6.86–6.92 (2H, m), 7.25 (2H, app. d, 
J = 8.5 Hz), 7.29–7.44 (5H, m); δH rotamer B 1.18 (3H, d, J = 6.4 Hz), 1.42 (9H, s), 3.82 
(3H, s), 4.34 (1H, quin, J = 6.1 Hz), 4.37–4.43 (1H, m), 4.50–4.57 (1H, m), 4.73 (1H, 
app. d, J = 4.2 Hz), 4.97 (1H, app. d, J = 4.2 Hz),  5.10–5.39 (4H, m), 5.48 (1H, app. dd, 
J = 17.4, 1.8 Hz), 6.19–6.31 (1H, m), 6.86–6.92 (2H, m), 7.25 (2H, app. d, J = 8.5 Hz), 
7.29–7.44 (5H, m); 13C NMR (125MHz, CDCl3) δC rotamer A 16.3, 28.3, 55.3, 66.7, 70.9, 
72.0, 76.7, 77.9, 79.5, 80.6, 113.7, 117.2, 128.1, 128.4 (×2), 129.2, 130.2, 134.4, 135.1, 
151.3, 159.1, 169.9; δC rotamer B 16.3, 28.4, 55.3, 66.8, 71.0, 72.2, 77.3, 77.9, 79.8, 81.0, 
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113.9, 117.5, 128.3, 128.4, 128.6, 129.3, 130.6, 134.6, 135.6, 151.8, 159.3, 170.0; 
HRMS (ESI, +ve) m/z calcd. for C28H36NO7 498.2492, found: 498.2508 (M+H)+. 
 
(4R,5R)-4-Benzyl 3-tert-butyl 4-((R)-1-hydroxyallyl)-5-methyloxazolidine-3,4-
dicarboxylate (298) 
 
 
 
To a solution of (4S,5R)- 4-benzyl 3-tert-butyl 4-((R)-1-(4-methoxybenzyloxy)allyl)-5-
methyloxazolidine-3,4-dicarboxylate 297 (475 mg, 0.955 mmol, 1 eq) in DCM/H2O 
(18:1, 9.0 mL) was added DDQ (270 mg, 1.19 mmol, 1.25 eq) and stirred at room 
temperature for 3 hours.  The precipitate formed was removed by filtration, and the 
filtrate was concentrated in vacuo and purified by flash chromatography (10:1 – 8:1 
Pet/EtOAc) to afford the title compound as a colourless oil (347 mg, 96%). ሾαሿDଶ଴ +31.5 
(c 2.0, CHCl3); FTIR (film/cm-1) υmax: 3345, 2980, 2936, 2884, 1740, 1683; 1H NMR 
(500MHz, CDCl3) δH 1.27 (3H, d, J = 6.4 Hz), 1.45 (9H, s), 4.06 (1H, q, J = 6.4 Hz), 
4.47 (1H, app. t, J = 8.4 Hz), 4.73 (1H, d, J = 3.7 Hz), 5.06 (1H, d, J = 3.7 Hz), 5.22 
(1H, d, J = 12.5 Hz), 5.26–5.39 (3H, m), 5.82 (1H, d, J = 10.3 Hz), 5.89 (1H, ddd, J = 
17.3, 10.3, 7.1 Hz), 7.30–7.42 (5H, m); 13C NMR (125MHz, CDCl3) δC 15.6, 28.2, 67.4, 
73.4, 74.5, 79.5, 80.3, 82.1, 118.7, 128.2, 128.3, 128.5, 135.4, 135.7, 154.3, 168.4; 
HRMS (ESI, +ve) m/z calcd. for C20H27NO6Na 400.1736, found: 400.1743 (M+Na)+. 
 
(4R,5R)-3-(tert-Butoxycarbonyl)-4-((R)-1-hydroxy-5-oxoheptyl)-5-
methyloxazolidine-4-carboxylic acid (299) 
 
 
 
To a solution of (4R,5R)-4-benzyl 3-tert-butyl 4-((R)-1-hydroxyallyl)-5-
methyloxazolidine-3,4-dicarboxylate 298 (200 mg, 0.530 mmol, 1 eq) and (E)-
Dotriacont-16-ene-7,26-dione 289 (253 mg, 0.530 mmol, 1 eq) in DCM (1.5 mL) was 
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added Hoveyda-Grubbs II (16.6 mg, 26.5 μmol, 5 mol%) and heated at reflux for 24 
hours. Reaction mixture concentrated in vacuo and some residual impurities removed 
by flash chromatography (10:1 Pet/EtOAc) to afford the crude allylic alcohol as a pale 
yellow oil. 
 
Allylic alcohol (123 mg, 0.204 mmol, 1.0 eq) and 10 mol% Pd/C (12 mg, 10 wt%) in 
EtOH (5.0 mL) was hydrogenated at atmospheric pressure for 1 hours.  Reaction 
mixture filtered through celite® and concentrated in vacuo. Purified by flash 
chromatography (8:1 – 2:1 Pet/EtOAc) to afford the title compound as a colourless oil 
(88 mg, 34%, 8:1 mix of rotamers). ሾαሿDଶ଴ +18.1 (c 2.65, CHCl3); FTIR (film/cm
-1) υmax: 
3156, 2927, 2856, 1707, 1684; 1H NMR (500MHz, CDCl3) δH major rotamer 0.88 (3H, t, J = 
6.9 Hz), 1.21–1.36 (20H, m), 1.39 (3H, d, J = 6.4 Hz), 1.48 (9H, s), 1.50–1.61 (5H, m), 
1.62–1.73 (1H, m), 2.38 (4H, t, J = 7.5 Hz), 3.92 (1H, d, J = 9.6 Hz), 4.07 (1H, q, J = 
6.4 Hz), 4.79 (1H, d, J = 3.7 Hz), 5.06 (1H, d, J = 3.7 Hz), 5.65 (1H, bs), 8.88 (1H, bs); 
δH minor rotamer 0.88 (3H, t, J = 6.9 Hz), 1.21–1.36 (20H, m), 1.39 (3H, d, J = 6.4 Hz), 1.45 
(9H, s), 1.50–1.61 (5H, m), 1.62–1.73 (1H, m), 2.38 (4H, t, J = 7.5 Hz), 3.92 (1H, d, J = 
9.6 Hz), 4.33 (1H, q, J = 5.9 Hz), 4.71 (1H, d, J = 3.5 Hz), 5.37 (1H, d, J = 3.5 Hz), 
5.65 (1H, bs), 8.88 (1H, bs); 13C NMR (125MHz, CDCl3) δC mixture of rotamers 14.0, 16.0, 
16.4, 22.5, 23.8, 23.9, 26.1, 27.0, 28.2, 28.3, 28.9, 29.3, 29.4 (× 3), 29.5 (× 3), 29.6 (× 
2), 31.6, 32.2, 42.8, 71.9, 72.2, 72.8, 75.1, 77.2, 79.5, 79.9, 80.0, 82.1, 82.7, 152.5, 
154.3, 172.0, 212.0; HRMS (ESI, +ve) m/z calcd. for C28H51NO7Na 536.3563, found: 
536.3567 (M+Na)+. 
 
(2S,3R)-2-Amino-3-hydroxy-2-((R)-1-hydroxyethyl)-14-oxoicosanoic acid (296) 
 
 
 
To a solution of (4R,5R)-3-(tert-butoxycarbonyl)-4-((R)-1-hydroxy-5-oxoheptyl)-5-
methyloxazolidine-4-carboxylic acid 299 (53 mg, 0.103 mmol, 1.0 eq) in MeOH (1.5 
mL) was added 6N HCl (350 μL, 2.06 mmol, 20 eq) and the reaction mixture refluxed 
for 2 hours. Reaction mixture was allowed to cool to room temperature and 
concentrated in vacuo to afford the crude hydrochloride salt. Residue dissolved in 
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MeOH (2.5 mL) and neutralised to pH 5-6 with 2N NaOH and concentrated in vacuo 
before the residue dissolved in water (5 mL) and the white precipitate filtered. Filtrate 
concentrated in vacuo and purified by flash chromatography (10:3:1 
CHCl3/MeOH/H2O; bottom layer used) to afford the title compound as a white 
amorphous solid (5.0 mg, 12%). ሾαሿDଶ଴ +24.0 (c 0.25, MeOH); FTIR (film/cm-1) υmax: 
3308, 2920, 2851, 1710, 1640; 1H NMR (500 MHz, MeOD) δH 0.92 (3H, t, J = 7.0 Hz), 
1.24 (3H, d, J = 6.6 Hz), 1.27–1.48 (20H, m), 1.52–1.60 (4H, m), 1.61–1.79 (2H, m), 
2.46 (4H, t, J = 7.3 Hz), 3.14 (1H, s), 3.90 (1H, d, J = 10.3 Hz), 4.40 (1H, q, J = 6.6 
Hz); 13C NMR (125MHz, CDCl3) δC 13.0, 17.2, 22.2, 23.3, 23.5 (× 2), 25.9, 28.6, 28.9, 
29.2 (× 2), 29.3, 29.4, 31.4 (× 2), 32.0, 42.1, 65.4, 70.2, 71.1, 172.1, 213.0; HRMS (ESI, 
+ve) m/z calcd. for C22H44NO5 402.3219, found: 402.3218 (M+H)+. 
 
(2R,4R)-tert-Butyl 2-tert-butyl-4-((S)-1-ethoxyallyl)-4-(hydroxymethyl)oxazolidine-
3-carboxylate (323a) 
 
 
 
To a stirred solution of lithium aluminium hydride (16 mg, 0.415 mmol, 2.0 eq) in THF 
(0.4 mL) at 0 °C was added a solution of (2R,4R)-3-tert-butyl 4-methyl 2-tert-butyl-4-
((S)-1-ethoxyallyl)oxazolidine-3,4-dicarboxylate 252b (77 mg, 0.207 mmol, 1.0 eq) in 
THF (2.0 mL) dropwise. The reaction mixture was allowed to warm to room 
temperature and stirred for 2 hours.  Reaction mixture poured into an ice-cold solution 
of saturated Rochelle salt (15 mL) and EtOAc (10 mL).  The biphasic mixture was 
stirred vigorously at room temperature for 2 hours before extracting with EtOAc (3 × 25 
mL).  The organics were combined, dried over MgSO4, filtered and concentrated in 
vacuo to afford the pure title compound as a colourless oil without the need for further 
purification (71 mg, 100%).  ሾαሿDଶ଴ +39.4 (c 1.6, CH2Cl2); FTIR (film/cm-1) υmax: 3396, 
2978, 2936, 2878, 1695, 1665; 1H NMR (500MHz, CDCl3) δH 0.95 (9H, s), 1.20 (3H, t, 
J = 7.0 Hz), 1.52 (9H, s), 3.24 (1H, dq, J = 9.1, 7.0 Hz), 3.42 (1H, d, J = 8.5 Hz), 3.50 
(1H, d, J = 11.8 Hz), 3.61 (1H, dq, J = 9.1, 7.0 Hz), 3.79 (1H, d, J = 11.8 Hz), 4.21 (1H, 
d, J = 8.5 Hz), 4.79 (1H, bs), 5.10 (1H, s), 5.35 (1H, app. dt, J = 10.5, 1.5 Hz), 5.50 (1H, 
d, J = 17.3 Hz), 5.80 (1H, ddd, J = 17.3, 10.5, 6.2 Hz); 13C NMR (125MHz, CDCl3) δC 
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15.6, 26.6, 28.2, 38.8, 65.2, 65.9, 69.5, 70.9, 76.6, 82.1, 98.5, 118.8, 134.9, 156.5; 
HRMS (ESI, +ve) m/z calcd. for C18H33NO5 344.2437, found: 344.2424 (M+H)+. 
 
(2R,4R)-tert-Butyl 2-tert-butyl-4-(hydroxymethyl)-4-((S)-1-(4-
methoxyphenoxy)allyl)oxazolidine-3-carboxylate (323b) 
 
 
 
To a stirred solution of lithium aluminium hydride (16 mg, 0.428 mmol, 2.0 eq) in THF 
(0.4 mL) at 0 °C was added a solution of (2R,4R)-3-tert-butyl 4-methyl 2-tert-butyl-4-
((S)-1-methoxyphenoxyallyl)oxazolidine-3,4-dicarboxylate 252g (96 mg, 0.214 mmol, 
1.0 eq) in THF (2.0 mL) dropwise. The reaction mixture was allowed to warm to room 
temperature and stirred for 2 hours.  Reaction mixture poured into an ice-cold solution 
of saturated Rochelle salt (15 mL) and EtOAc (10 mL).  The biphasic mixture was 
stirred vigorously at room temperature for 2 hours before extracting with EtOAc (3 × 25 
mL).  The organics were combined, dried over MgSO4, filtered and concentrated in 
vacuo to afford the pure title compound as a colourless oil without the need for further 
purification (80 mg, 89%).  ሾαሿDଶ଴ +59.4 (c 2.39, CH2Cl2); FTIR (film/cm-1) υmax: 3381, 
2977, 2960, 2875, 1661; 1H NMR (500MHz, CDCl3) δH 0.96 (9H, s), 1.16 (9H, s), 3.51 
(1H, d, J = 9.0 Hz), 3.58 (1H, t, J = 11.5 Hz), 3.74 (3H, s), 3.88 (1H, d, J = 12.1 Hz), 
4.36 (1H, d, J = 9.0 Hz), 5.20 (1H, bs), 5.38 (1H, d, J = 10.8 Hz), 5.51 (1H, app. dt, J = 
17.4, 1.6 Hz), 5.54–5.64 (2H, m), 6.00 (1H, ddd, J = 17.4, 10.8, 4.2 Hz), 6.74–6.79 (2H, 
m), 6.81–6.85 (2H, m); 13C NMR (125MHz, CDCl3) δC 26.5, 27.7, 38.9, 55.7, 65.9, 
69.8, 70.9, 75.7, 82.5, 98.8, 114.4, 116.5, 119.1, 133.7, 152.6, 154.0, 156.3; HRMS 
(ESI, +ve) m/z calcd. for C23H36NO6 422.2543, found: 422.2546 (M+H)+. 
 
(2R,4R)-tert-Butyl 4-allyl-2-tert-butyl-4-(hydroxymethyl)oxazolidine-3-carboxylate 
(323c) 
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To a stirred solution of lithium aluminium hydride (23 mg, 0.610 mmol, 2.0 eq) in THF 
(0.6 mL) at 0 °C was added a solution of (2R,4S)-3-tert-butyl 4-methyl 4-allyl-2-tert-
butyloxazolidine-3,4-dicarboxylate 266a (100 mg, 0.305 mmol, 1.0 eq) in THF (2.8 
mL) dropwise. The reaction mixture was allowed to warm to room temperature and 
stirred for 2 hours.  Reaction mixture poured into an ice-cold solution of saturated 
Rochelle salt (15 mL) and EtOAc (10 mL).  The biphasic mixture was stirred vigorously 
at room temperature for 2 hours before extracting with EtOAc (3 × 25 mL).  The 
organics were combined, dried over MgSO4, filtered and concentrated in vacuo to afford 
the pure title compound as a colourless oil without the need for further purification (91 
mg, 100%).  ሾαሿDଶ଴ +17.5 (c 3.03, CH2Cl2); FTIR (film/cm-1) υmax: 3397, 2976, 2932, 
1699, 1666; 1H NMR (500MHz, CDCl3, 328K) δH 0.95 (9H, s), 1.45 (9H, s), 2.47 (1H, 
dd, J = 14.0, 6.0 Hz), 2.84 (1H, dd, J = 14.0, 8.8 Hz), 3.55 (1H, app. t, J = 9.3 Hz), 3.75 
(1H, d, J = 8.6 Hz), 3.82 (1H, d, J = 11.5 Hz), 3.96 (1H, d, J = 8.9 Hz), 5.05 (1H, s), 
5.10–5.18 (2H, m), 5.78–5.88 (1H, m); 13C NMR (125MHz, CDCl3) δC 26.7, 28.1, 36.2, 
38.9, 66.8, 67.9, 73.4, 82.1, 97.9, 119.1, 133.1, 155.9; HRMS (ESI, +ve) m/z calcd. for 
C16H30NO4 300.2175, found: 300.2178 (M+H)+. 
 
(2R,4R)-tert-Butyl 4-((S)-but-3-en-2-yl)-2-tert-butyl-4-(hydroxymethyl)oxazolidine-
3-carboxylate (323d) 
 
 
 
To a stirred solution of lithium aluminium hydride (33 mg, 0.862 mmol, 2.0 eq) in THF 
(0.9 mL) at 0 °C was added a solution of (2R,4S)-3-tert-butyl 4-methyl 4-((S)-but-3-en-
2-yl)-2-tert-butyloxazolidine-3,4-dicarboxylate 266b (147 mg, 0.431 mmol, 1.0 eq) in 
THF (12.5 mL) dropwise. The reaction mixture was allowed to warm to room 
temperature and stirred for 4 hours.  Reaction mixture poured into an ice-cold solution 
of saturated Rochelle salt (15 mL) and EtOAc (10 mL).  The biphasic mixture was 
stirred vigorously at room temperature for 2 hours before extracting with EtOAc (3 × 25 
mL).  The organics were combined, dried over MgSO4, filtered and concentrated in 
vacuo to afford the pure title compound as a colourless oil without the need for further 
purification (131 mg, 98%). FTIR (film/cm-1) υmax: 3397, 2975, 2916, 1699, 1666; 1H 
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NMR (500MHz, CDCl3) δH 0.96 (9H, s), 0.98 (3H, d, J = 7.0 Hz), 1.51 (9H, s), 3.51 
(2H, bs), 3.60 (1H, d, J = 11.6 Hz), 3.79 (1H, d, J = 11.6 Hz), 4.01 (1H, d, J = 9.2 Hz), 
4.83–5.50 (1H, bs), 5.05 (1H, s), 5.13 (1H, d, J = 10.4 Hz), 5.24 (1H, d, J = 17.3 Hz), 
5.86 (1H, ddd, J = 17.3, 10.4, 6.8 Hz); 13C NMR (125MHz, CDCl3) δC 12.7, 26.7, 28.1, 
35.4, 39.0, 66.5, 70.1, 70.3, 82.0, 98.2, 116.5, 139.3, 155.7; HRMS (ESI, +ve) m/z 
calcd. for C17H31NO4Na 336.2151, found: 336.2153 (M+Na)+. 
 
(2R,4R)-tert-Butyl 4-((E)-but-2-enyl)-2-tert-butyl-4-(hydroxymethyl)oxazolidine-3-
carboxylate (323e) 
 
 
 
To a stirred solution of lithium aluminium hydride (130 mg, 3.42 mmol, 2.0 eq) in THF 
(12.5 mL) at 0 °C was added a solution of (2R,4S)-3-tert-butyl 4-methyl 4-((E)-but-2-
enyl)-2-tert-butyloxazolidine-3,4-dicarboxylate 333a (584 mg, 1.71 mmol, 1.0 eq) in 
THF (12.5 mL) dropwise. The reaction mixture was allowed to warm to room 
temperature and stirred for 4 hours.  Reaction mixture poured into an ice-cold solution 
of saturated Rochelle salt (15 mL) and EtOAc (10 mL).  The biphasic mixture was 
stirred vigorously at room temperature for 2 hours before extracting with EtOAc (3 × 25 
mL).  The organics were combined, dried over MgSO4, filtered and concentrated in 
vacuo to afford the pure title compound as a colourless oil without the need for further 
purification (536 mg, 100%, 5:1 mix of rotamers). FTIR (film/cm-1) υmax: 3388, 2973, 
2934, 2911; 1H NMR (500MHz, CDCl3) δH major rotamer 0.94 (9H, s), 1.48 (9H, s), 1.69 
(3H, d, J = 5.9 Hz), 2.36–2.53 (1H, m), 2.76 (1H, bs), 3.51 (1H, bs), 3.68 (1H, bs), 3.81 
(1H, d, J = 11.0 Hz), 3.96 (1H, d, J = 8.8 Hz), 5.02 (1H, s), 5.21–5.70 (3H, m); δH minor 
rotamer 0.94 (9H, s), 1.48 (9H, s), 1.69 (3H, d, J = 5.9 Hz), 2.36–2.53 (1H, m), 2.88 (1H, 
bs), 3.51 (1H, bs), 3.68 (1H, bs), 3.81 (1H, d, J = 11.0 Hz), 3.89 (1H, d, J = 8.8 Hz), 
5.09 (1H, s), 5.21–5.70 (3H, m); 13C NMR (125MHz, CDCl3) δC 18.1, 26.7, 28.1, 34.9, 
38.9, 66.7, 68.0, 73.5, 82.0, 97.9, 125.4, 129.8, 156.0; HRMS (ESI, +ve) m/z calcd. for 
C17H31NO4Na 336.2151, found: 336.2157 (M+Na)+. 
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(2R,4R)-tert-Butyl 2-tert-butyl-4-(hydroxymethyl)-4-(2-methylallyl)oxazolidine-3-
carboxylate (323f) 
 
O
NtBu
Boc
Me
OH
 
 
To a stirred solution of lithium aluminium hydride in THF (2.4M, 560 μL, 1.32 mmol, 
2.0 eq) at 0 °C was added a solution of (2R,4S)-3-tert-butyl 4-methyl 2-tert-butyl-4-(2-
methylallyl)oxazolidine-3,4-dicarboxylate 333b (226 mg, 0.662 mmol, 1.0 eq) in THF 
(6.0 mL) dropwise. The reaction mixture was allowed to warm to room temperature and 
stirred for 1 hours.  Reaction mixture poured into an ice-cold solution of saturated 
Rochelle salt (15 mL) and EtOAc (10 mL).  The biphasic mixture was stirred vigorously 
at room temperature for 2 hours before extracting with EtOAc (3 × 25 mL).  The 
organics were combined, dried over MgSO4, filtered and concentrated in vacuo to afford 
the pure title compound as a colourless oil without the need for further purification (169 
mg, 82%). ሾαሿDଶ଴ +25.5 (c 2.2, CHCl3); FTIR (film/cm-1) υmax: 3382, 2969, 2928, 1697, 
1665; 1H NMR (500MHz, CDCl3) δH 0.95 (9H, s), 1.48 (9H, s), 1.81 (3H, s), 2.39 (1H, 
d, J = 13.8 Hz), 2.87 (1H, app. d, J = 8.1 Hz), 3.51 (1H, bs), 3.65 (1H, bs), 3.84 (1H, d, 
J = 11.3 Hz), 4.09 (1H, d, J = 9.0 Hz), 4.80 (1H, s), 4.93 (1H, s), 5.03 (1H, bs), 5.40 
(1H, bs); 13C NMR (125MHz, CDCl3) δC 23.6, 26.9, 28.2, 38.6, 39.0, 67.7, 67.9, 72.4, 
82.2, 97.6, 116.1, 141.8, 155.8; HRMS (ESI, +ve) m/z calcd. for C17H32NO4 314.2331, 
found: 314.2323 (M+H)+. 
 
(4S,5R)-tert-Butyl 4-((R)-1-ethoxyallyl)-4-(hydroxymethyl)-5-methyloxazolidine-3-
carboxylate (324) 
 
 
 
To a stirred solution of lithium aluminium hydride (57 mg, 1.51 mmol, 2.0 eq) in THF 
(1.5 mL) at 0 °C was added a solution of (4S,5R)-3-tert-butyl 4-methyl 4-((R)-1-
ethoxyallyl)-5-methyloxazolidine-3,4-dicarboxylate 239d (249 mg, 0.756 mmol, 1.0 eq) 
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in THF (7.0 mL) dropwise. The reaction mixture was allowed to warm to room 
temperature and stirred for 2 hours.  Reaction mixture poured into an ice-cold solution 
of saturated Rochelle salt (15 mL) and EtOAc (10 mL).  The biphasic mixture was 
stirred vigorously at room temperature for 2 hours before extracting with EtOAc (3 × 25 
mL).  The organics were combined, dried over MgSO4, filtered and concentrated in 
vacuo to afford the pure title compound as a colourless oil without the need for further 
purification (192 mg, 84%, 10:1 mix of rotamers). ሾαሿDଶ଴ -36.2 (c 2.35, CHCl3); FTIR 
(film/cm-1) υmax: 3378, 2976, 2931, 2875, 1673; 1H NMR (500MHz, CDCl3) δH major 
rotamer 1.14 (3H, t, J = 7.0 Hz), 1.20 (3H, d, J = 6.6 Hz), 1.47 (9H, s), 3.28–3.38 (1H, m), 
3.49–3.62 (1H, m), 3.75 (2H, bs), 4.38 (1H, q, J = 6.6 Hz), 4.61 (1H, d, J = 3.9 Hz), 
4.71 (1H, bs), 4.80 (1H, d, J = 6.3 Hz), 4.91 (1H, d, J = 3.9 Hz), 5.29 (1H, d, J = 10.6 
Hz), 5.42 (1H, d, J = 17.3 Hz), 5.75 (1H, ddd, J = 17.3, 10.6, 6.5 Hz); δH minor rotamer 1.14 
(3H, t, J = 7.0 Hz), 1.20 (3H, d, J = 6.6 Hz), 1.50 (9H, s), 3.28–3.38 (1H, m), 3.49–3.62 
(1H, m), 3.75 (2H, bs), 4.46 (1H, q, J = 6.6 Hz), 4.53 (1H, d, J = 3.9 Hz), 4.71 (1H, bs), 
4.80 (1H, d, J = 6.3 Hz), 4.85 (1H, d, J = 3.9 Hz), 5.29 (1H, d, J = 10.6 Hz), 5.42 (1H, 
d, J = 17.3 Hz), 5.53 (1H, ddd, J = 17.3, 10.6, 6.5 Hz); 13C NMR (125MHz, CDCl3) δC 
major rotamer 15.4, 15.6, 28.3, 64.6, 64.8, 68.2, 76.3, 76.8, 79.2, 81.0, 118.5, 134.2, 154.5; 
δC minor rotamer 15.3, 16.9, 29.6, 59.9, 63.2, 66.3, 76.3, 77.2, 82.5, 85.7, 119.4, 133.7, 
154.5; HRMS (ESI, +ve) m/z calcd. for C15H27NO5Na 324.1787, found: 324.1768 
(M+Na)+. 
 
(2R,4R)-tert-Butyl 2-tert-butyl-4-((S)-1-ethoxyallyl)-4-formyloxazolidine-3-
carboxylate (325a) 
 
 
 
DMSO (78 μL, 1.10 mmol, 5.4 eq) in DCM (400 μL) was added dropwise to a solution 
of oxalyl chloride (47 μL, 0.551 mmol, 2.7 eq) in DCM (1.0 mL) at -78 °C and stirred 
for 30 minutes. (2R,4R)-tert-butyl 2-tert-butyl-4-((S)-1-ethoxyallyl)-4-
(hydroxymethyl)oxazolidine-3-carboxylate 323a (70 mg, 0.204 mmol, 1 eq) in DCM 
(1.2 mL) was added dropwise to the reaction mixture and stirred for a further 15 
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minutes. NEt3 (182 μL, 1.31 mmol, 6.4 eq) in DCM (400 μL) was added dropwise and 
the reaction mixture allowed to warm to room temperature and stirred for 2 hours. 
Reaction mixture diluted with DCM (15 mL) and washed with water (3 × 10 mL) and 
NaHCO3 (sat) (3 × 10 mL). The organic layer was dried over Na2SO4, filtered and 
concentrated in vacuo to afford the pure title compound as a colourless oil without the 
need for further purification (54 mg, 78%). ሾαሿDଶ଴ -15.2 (c 1.05, CH2Cl2); FTIR 
(film/cm-1) υmax: 2978, 2937, 2906, 2876, 1724, 1695; 1H NMR (500MHz, CDCl3) δH 
0.94 (9H, s), 1.20 (3H, t, J = 7.0 Hz), 1.51 (9H, s), 3.30 (1H, app. quin., J = 7.0 Hz), 
3.61 (1H, app. t, J = 7.0 Hz), 4.06–4.23 (2H, m), 4.87 (1H, bs), 5.16 (1H, s), 5.34 (1H, 
d, J = 10.6 Hz), 5.38 (1H, d, J = 17.3 Hz), 5.71 (1H, bs), 9.73 (1H, s); 13C NMR 
(125MHz, CDCl3) δC 15.4, 26.4, 28.2, 38.8, 64.8, 67.3, 74.8, 78.6, 81.6, 97.9, 119.4, 
134.2, 154.2, 197.3; HRMS (ESI, +ve) m/z calcd. for C18H31NO5Na 364.2094, found: 
364.2113 (M+Na)+. 
 
(2R,4R)-tert-Butyl 2-tert-butyl-4-formyl-4-((S)-1-(4-methoxyphenoxy)allyl) 
oxazolidine-3-carboxylate (325b) 
 
 
 
DMSO (64 μL, 0.897 mmol, 5.4 eq) in DCM (400 μL) was added dropwise to a 
solution of oxalyl chloride (39 μL, 0.448 mmol, 2.7 eq) in DCM (1.0 mL) at -78 °C and 
stirred for 30 minutes. (2R,4R)-tert-butyl 2-tert-butyl-4-(hydroxymethyl)-4-((S)-1-(4-
methoxyphenoxy)allyl)oxazolidine-3-carboxylate 323b (70 mg, 0.166 mmol, 1 eq) in 
DCM (1.2 mL) was added dropwise to the reaction mixture and stirred for a further 15 
minutes. NEt3 (148 μL, 1.31 mmol, 6.4 eq) in DCM (400 μL) was added dropwise and 
the reaction mixture allowed to warm to room temperature and stirred for 2 hours. 
Reaction mixture diluted with DCM (15 mL) and washed with water (3 × 10 mL) and 
NaHCO3 (sat) (3 × 10 mL). The organic layer was dried over Na2SO4, filtered and 
concentrated in vacuo to afford the pure title compound as a colourless oil without the 
need for further purification (55 mg, 80%). ሾαሿDଶ଴ +46.5 (c 2.0, CH2Cl2); FTIR (film/cm-
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1) υmax: 2977, 2939, 2912, 2876, 1726, 1694; 1H NMR (500MHz, CDCl3, 328K) δH 
1.01 (9H, s), 1.20 (9H, s), 3.75 (3H, s), 4.19 (1H, d, J = 9.2 Hz), 4.37 (1H, d, J = 9.2 
Hz), 5.28–5.44 (3H, m), 5.60 (1H, bs), 5.95 (1H, ddd, J = 16.2, 10.8, 4.2 Hz), 6.78 (2H, 
app. d, J = 9.2 Hz), 6.86 (2H, app. d, J = 9.2 Hz), 9.80 (1H, s); 13C NMR (125MHz, 
CDCl3, 328K) δC 26.4, 27.8, 38.9, 55.7, 67.8, 74.7, 77.1, 82.0, 98.4, 114.6, 116.8, 119.3, 
133.5, 152.1, 153.7, 154.5, 196.8; HRMS (ESI, +ve) m/z calcd. for C23H33NO6Na 
442.2200, found: 442.2219 (M+Na)+. 
 
(2R,4S)-tert-Butyl 4-allyl-2-tert-butyl-4-formyloxazolidine-3-carboxylate (325c) 
 
 
 
DMSO (110 μL, 1.55 mmol, 5.4 eq) in DCM (400 μL) was added dropwise to a 
solution of oxalyl chloride (67 μL, 0.776 mmol, 2.7 eq) in DCM (1.0 mL) at -78 °C and 
stirred for 30 minutes. (2R,4R)-tert-butyl 4-allyl-2-tert-butyl-4-
(hydroxymethyl)oxazolidine-3-carboxylate 323c (86 mg, 0.287 mmol, 1 eq) in DCM 
(1.2 mL) was added dropwise to the reaction mixture and stirred for a further 15 
minutes. NEt3 (257 μL, 1.84 mmol, 6.4 eq) in DCM (400 μL) was added dropwise and 
the reaction mixture allowed to warm to room temperature and stirred for 2 hours. 
Reaction mixture diluted with DCM (15 mL) and washed with water (3 × 10 mL) and 
NaHCO3 (sat) (3 × 10 mL). The organic layer was dried over Na2SO4, filtered and 
concentrated in vacuo to afford the pure title compound as a colourless oil without the 
need for further purification (64 mg, 75%). ሾαሿDଶ଴ +36.5 (c 2.0, CH2Cl2); FTIR (film/cm-
1) υmax: 2977, 2935, 2875, 1719, 1697; 1H NMR (500MHz, CDCl3) δH 0.97 (9H, s), 
1.45 (9H, s), 2.56 (1H, app. d, J = 9.0 Hz), 2.90 (1H, s), 3.93 (1H, d, J = 9.1 Hz), 4.14 
(1H, d, J = 9.1 Hz), 5.11 (1H, s), 5.14–5.20 (2H, m), 5.75–5.87 (1H, m), 9.75 (1H, s); 
13C NMR (125MHz, CDCl3) δC 26.5, 28.1, 36.2, 39.3, 71.3, 71.9, 81.7, 97.7, 119.9, 
131.4, 153.6, 199.2; HRMS (ESI, +ve) m/z calcd. for C16H27NO4Na 320.1838, found: 
320.1835 (M+Na)+. 
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(2R,4S)-tert-Butyl 4-((S)-but-3-en-2-yl)-2-tert-butyl-4-formyloxazolidine-3-
carboxylate (325d) 
 
 
 
DMSO (98 μL, 1.38 mmol, 5.4 eq) in DCM (400 μL) was added dropwise to a solution 
of oxalyl chloride (59 μL, 0.689 mmol, 2.7 eq) in DCM (1.0 mL) at -78 °C and stirred 
for 30 minutes. (2R,4R)-tert-butyl 4-((S)-but-3-en-2-yl)-2-tert-butyl-4-
(hydroxymethyl)oxazolidine-3-carboxylate 323d (80 mg, 0.255 mmol, 1 eq) in DCM 
(1.2 mL) was added dropwise to the reaction mixture and stirred for a further 15 
minutes. NEt3 (228 μL, 1.63 mmol, 6.4 eq) in DCM (400 μL) was added dropwise and 
the reaction mixture allowed to warm to room temperature and stirred for 2 hours. 
Reaction mixture diluted with DCM (15 mL) and washed with water (3 × 10 mL) and 
NaHCO3 (sat) (3 × 10 mL). The organic layer was dried over Na2SO4, filtered and 
concentrated in vacuo to afford the pure title compound as a colourless oil without the 
need for further purification (65 mg, 82%). ሾαሿDଶ଴ -60.5 (c 2.0, CH2Cl2); FTIR (film/cm-
1) υmax: 2976, 2913, 2871, 1713, 1697; 1H NMR (500MHz, CDCl3) δH 0.93 (9H, s), 
1.03 (3H, d, J = 6.9 Hz), 1.49 (9H, s), 3.59 (1H, bs) 3.99 (1H, d, J = 9.4 Hz), 4.21 (1H, 
d, J = 9.4 Hz), 5.11–5.16 (2H, m), 5.17 (1H, s), 5.72 (1H, bs), 9.75 (1H, s); 13C NMR 
(125MHz, CDCl3) δC 12.4, 26.4, 28.1, 36.9, 39.2, 68.2, 73.0, 81.7, 97.7, 117.5, 137.9, 
153.6, 198.3; HRMS (ESI, +ve) m/z calcd. for C17H29NO4Na 334.1994, found: 
334.1982 (M+Na)+. 
 
(2R,4S)-tert-Butyl 4-((E)-but-2-enyl)-2-tert-butyl-4-formyloxazolidine-3-
carboxylate (325e) 
 
 
 
DMSO (656 μL, 9.23 mmol, 5.4 eq) in DCM (2.67 mL) was added dropwise to a 
solution of oxalyl chloride (397 μL, 4.62 mmol, 2.7 eq) in DCM (6.67 mL) at -78 °C 
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and stirred for 30 minutes. (2R,4R)-tert-butyl 4-((E)-but-2-enyl)-2-tert-butyl-4-
(hydroxymethyl)oxazolidine-3-carboxylate 323e (536 mg, 1.71 mmol, 1 eq) in DCM 
(8.0 mL) was added dropwise to the reaction mixture and stirred for a further 15 
minutes. NEt3 (1.53 mL, 10.9 mmol, 6.4 eq) in DCM (2.67 mL) was added dropwise 
and the reaction mixture allowed to warm to room temperature and stirred for 2 hours. 
Reaction mixture diluted with DCM (25 mL) and washed with water (3 × 20 mL) and 
NaHCO3 (sat) (3 × 20 mL). The organic layer was dried over Na2SO4, filtered and 
concentrated in vacuo to afford the pure title compound as a colourless oil without the 
need for further purification (434 mg, 81%, 6:1 mix of rotamers). FTIR (film/cm-1) 
υmax: 2973, 2934, 2875, 1718, 1698; 1H NMR (500MHz, CDCl3) δH major rotamer 0.98 (9H, 
s), 1.48 (9H, s), 1.70 (3H, app. dq, J = 6.4, 1.2 Hz), 2.51 (1H, app. d, J = 8.7 Hz), 2.85 
(1H, bs), 3.94 (1H, d, J = 9.0 Hz), 4.15 (1H, d, J = 9.0 Hz), 5.11 (1H, s), 5.38–5.47 (1H, 
m), 5.55–5.64 (1H, m), 9.79 (1H, s); δH minor rotamer 0.99 (9H, s), 1.47 (9H, s), 1.66 (3H, 
app. dq, J = 6.4, 1.2 Hz), 2.51 (1H, app. d, J = 8.7 Hz), 2.85 (1H, bs), 3.88 (1H, d, J = 
9.0 Hz), 4.15 (1H, d, J = 9.0 Hz), 5.18 (1H, s), 5.38–5.47 (1H, m), 5.66–5.73 (1H, m), 
9.79 (1H, s); 13C NMR (125MHz, CDCl3) δC 13.1, 18.2, 26.5, 28.1, 39.3, 71.5, 81.6, 
97.7, 122.6, 123.5, 130.6, 153.7, 200.0; HRMS (ESI, +ve) m/z calcd. for C17H29NO4Na 
334.1994, found: 334.1996 (M+Na)+. 
 
(2R,4S)-tert-Butyl 2-tert-butyl-4-formyl-4-(2-methylallyl)oxazolidine-3-carboxylate 
(325f) 
 
O
NtBu
Boc
Me
O
 
 
DMSO (202 μL, 2.84 mmol, 5.4 eq) in DCM (800 μL) was added dropwise to a 
solution of oxalyl chloride (122 μL, 1.42 mmol, 2.7 eq) in DCM (2.0 mL) at -78 °C and 
stirred for 30 minutes. (2R,4R)-tert-butyl 2-tert-butyl-4-(hydroxymethyl)-4-(2-
methylallyl)oxazolidine-3-carboxylate 323f (165 mg, 0.526 mmol, 1 eq) in DCM (2.4 
mL) was added dropwise to the reaction mixture and stirred for a further 15 minutes. 
NEt3 (470 μL, 3.37 mmol, 6.4 eq) in DCM (800 μL) was added dropwise and the 
reaction mixture allowed to warm to room temperature and stirred for 2 hours. Reaction 
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mixture diluted with DCM (25 mL) and washed with water (3 × 20 mL) and NaHCO3 
(sat) (3 × 20 mL). The organic layer was dried over Na2SO4, filtered and concentrated in 
vacuo to afford the pure title compound as a colourless oil without the need for further 
purification (116 mg, 71%). ሾαሿDଶ଴ +37.7 (c 2.15, CHCl3); FTIR (film/cm-1) υmax: 2976, 
2936, 2875, 1717, 1695; 1H NMR (500MHz, CDCl3) δH 0.98 (9H, s), 1.46 (9H, s), 1.78 
(3H, s), 2.54 (1H, d, J = 14.2 Hz), 2.87 (1H, bs), 4.01 (1H, d, J = 9.3 Hz), 4.08 (1H, d, J 
= 9.3 Hz), 4.49 (1H, s), 4.95 (1H, s), 5.11 (1H, s), 9.74 (1H, s); 13C NMR (125MHz, 
CDCl3) δC 23.5, 26.7, 28.1, 38.4, 39.3, 70.1, 71.9, 81.8, 97.4, 116.4, 140.4, 153.4, 
199.2; HRMS (ESI, +ve) m/z calcd. for C17H29NO4Na 334.1994, found: 334.1987 
(M+Na)+. 
 
(4S,5R)-tert-Butyl 4-((R)-1-ethoxyallyl)-4-(hydroxymethyl)-5-methyloxazolidine-3-
carboxylate (326) 
 
 
 
DMSO (219 μL, 3.08 mmol, 5.4 eq) in DCM (800 μL) was added dropwise to a 
solution of oxalyl chloride (132 μL, 1.54 mmol, 2.7 eq) in DCM (2.0 mL) at -78 °C and 
stirred for 30 minutes. (4S,5R)-tert-butyl 4-((R)-1-ethoxyallyl)-4-(hydroxymethyl)-5-
methyloxazolidine-3-carboxylate 324 (172 mg, 0.571 mmol, 1 eq) in DCM (2.4 mL) 
was added dropwise to the reaction mixture and stirred for a further 15 minutes. NEt3 
(510 μL, 3.65 mmol, 6.4 eq) in DCM (800 μL) was added dropwise and the reaction 
mixture allowed to warm to room temperature and stirred for 2 hours. Reaction mixture 
diluted with DCM (25 mL) and washed with water (3 × 20 mL) and NaHCO3 (sat) (3 × 
20 mL). The organic layer was dried over Na2SO4, filtered and concentrated in vacuo to 
afford the pure title compound as a colourless oil without the need for further 
purification (143 mg, 84%, 4:3 mix of rotamers). FTIR (film/cm-1) υmax: 2977, 2933, 
2871, 1736, 1699; 1H NMR (500MHz, CDCl3) δH major rotamer 1.16 (3H, t, J = 6.9 Hz), 
1.24 (3H, d, J = 4.4 Hz), 1.48 (9H, s), 3.39 (1H, q, J = 7.1 Hz), 3.57–3.66 (1H, m), 
4.31–4.39 (1H, m), 4.68 (1H, d, J = 4.3 Hz), 4.71 (1H, d, J = 3.9 Hz), 5.17–5.44 (3H, 
m), 6.00–6.13 (1H, m), 9.56 (1H, s); δH minor rotamer 1.18 (3H, t, J = 6.9 Hz), 1.23 (3H, d, J 
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= 4.4 Hz), 1.44 (9H, s), 3.37 (1H, q, J = 7.1 Hz), 3.57–3.66 (1H, m), 4.31–4.39 (1H, m), 
4.42 (1H, d, J = 4.3 Hz), 4.76 (1H, d, J = 3.9 Hz), 5.17–5.44 (3H, m), 6.00–6.13 (1H, 
m), 9.49 (1H, s); 13C NMR (125MHz, CDCl3) δC major rotamer 15.4, 16.1, 28.3, 65.4, 72.6, 
76.0, 78.4, 79.7, 81.0, 117.1, 134.3, 152.0, 199.4; δC minor rotamer 15.4, 16.0, 28.2, 65.7, 
72.5, 77.4, 79.6, 79.9, 81.7, 117.2, 134.2, 151.3, 198.8; HRMS (ESI, +ve) m/z calcd. for 
C15H25NO5Na 322.1630, found: 322.1614 (M+Na)+. 
 
(2R,4R)-tert-Butyl 2-tert-butyl-4-((S)-1-ethoxyallyl)-4-vinyloxazolidine-3-
carboxylate (327a) 
 
 
 
To a solution of methyltriphenylphosphonium bromide (22 mg, 61.5 μmol, 1.5 eq) in 
THF (0.5 mL) at 0 °C was added n-butyl lithium (1.6M in hexane, 38 μL, 61.5 μmol, 
1.5 eq) and the solution turned a dark yellow. After 15 minutes a solution of (2R,4R)-
tert-butyl 2-tert-butyl-4-((S)-1-ethoxyallyl)-4-formyloxazolidine-3-carboxylate 325a 
(14 mg, 41.0 μmol, 1 eq) in THF (0.5 mL) was added and stirred at reflux for 16 hours. 
The reaction mixture was allowed to cool to room temperature before concentrated in 
vacuo and purified by flash chromatography (20:1 Pet/EtOAc) to afford the title 
compound as a colourless oil (12.1 mg, 87%). ሾαሿDଶ଴ -19.1 (c 0.47, CH2Cl2); FTIR 
(film/cm-1) υmax: 2976, 2932, 2905, 2875, 1694; 1H NMR (500MHz, CDCl3) δH 0.94 
(9H, s), 1.19 (3H, t, J = 7.0 Hz), 1.51 (9H, s), 3.28 (1H, bs), 3.56 (1H, bs), 3.94 (1H, d, 
J = 8.6 Hz), 4.29 (1H, d, J = 8.6 Hz), 4.76 (1H, bs), 5.09–5.36 (5H, m), 5.70 (1H, ddd, J 
= 17.0, 10.7, 6.5 Hz), 6.10 (1H, bs); 13C NMR (125MHz, CDCl3) δC 15.4, 26.7, 28.2, 
38.8, 64.4, 70.2, 71.0, 78.9, 80.4, 97.9, 115.9, 118.9, 135.1, 137.5, 154.3; HRMS (ESI, 
+ve) m/z calcd. for C19H34NO4 340.2488, found: 340.2485 (M+H)+.  
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(2R,4R)-tert-Butyl 2-tert-butyl-4-((S)-1-(4-methoxyphenoxy)allyl)-4-
vinyloxazolidine-3-carboxylate (327b) 
 
 
 
To a solution of methyltriphenylphosphonium bromide (60 mg, 0.168 mmol, 1.5 eq) in 
THF (1.5 mL) at 0 °C was added n-butyl lithium (1.6M in hexane, 105 μL, 0.168 mmol, 
1.5 eq) and the reaction turned a dark yellow. After 15 minutes a solution of (2R,4R)-
tert-butyl 2-tert-butyl-4-((S)-1-(4-methoxyphenoxy)allyl)-4-formyloxazolidine-3-
carboxylate 325b (47 mg, 0.112 mmol, 1 eq) in THF (1.5 mL) was added and stirred at 
reflux for 16 hours. The reaction mixture was allowed to cool to room temperature 
before concentrated in vacuo and purified by flash chromatography (20:1 Pet/EtOAc) to 
afford the title compound as a colourless oil (34 mg, 74%). ሾαሿDଶ଴ +10.8 (c 0.74, CHCl3); 
FTIR (film/cm-1) υmax: 2975, 2934, 2906, 2875, 1695; 1H NMR (500MHz, CDCl3, 
328K) δH 0.98 (9H, s), 1.20 (9H, s), 3.74 (3H, s), 4.07 (1H, d, J = 8.7 Hz), 4.46 (1H, d, J 
= 8.7 Hz), 5.24–5.40 (5H, m), 4.58 (1H, bs), 5.88 (1H, ddd, J = 16.1, 10.8, 4.7 Hz), 
6.13–6.31 (1H, m), 6.73–6.79 (2H, m), 6.81–6.86 (2H, m); 13C NMR (125MHz, CDCl3, 
328K) δC 26.7, 27.9, 38.8, 55.8, 69.9, 71.5, 77.1, 80.7, 98.4, 114.5, 116.6, 116.8, 119.1, 
133.9, 137.3, 152.4, 153.9, 154.1; HRMS (ESI, +ve) m/z calcd. for C24H35NO5 
417.2515, found: 417.2519 (M+H)+. 
 
(2R,4R)-tert-Butyl 4-allyl-2-tert-butyl-4-vinyloxazolidine-3-carboxylate (327c) 
 
 
 
To a solution of methyltriphenylphosphonium bromide (106 mg, 0.298 mmol, 1.5 eq) in 
THF (1.5 mL) at 0 °C was added n-butyl lithium (1.6M in hexane, 186 μL, 0.298 mmol, 
1.5 eq) and the reaction turned a dark yellow. After 15 minutes a solution of (2R,4S)-
tert-butyl 4-allyl-2-tert-butyl-4-formyloxazolidine-3-carboxylate 325c (59 mg, 0.198 
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mmol, 1 eq) in THF (1.5 mL) was added and stirred at reflux for 16 hours. The reaction 
mixture was allowed to cool to room temperature before concentrated in vacuo and 
purified by flash chromatography (20:1 Pet/EtOAc) to afford the title compound as a 
colourless oil (45 mg, 78%). ሾαሿDଶ଴ +12.4 (c 2.25, CHCl3); FTIR (film/cm-1) υmax: 2976, 
2909, 2872, 1699; 1H NMR (500MHz, CDCl3) δH 0.95 (9H, s), 1.46 (9H, s), 2.39 (1H, 
dd, J = 13.9, 6.1 Hz), 3.09 (1H, bs), 4.00 (1H, d, J = 8.8 Hz), 4.07 (1H, d, J = 8.8 Hz), 
5.06–5.20 (5H, m), 5.77–5.87 (1H, m), 6.18 (1H, bs); 13C NMR (125MHz, CDCl3) δC 
26.7, 28.3, 39.1, 40.2, 66.6, 76.4, 80.4, 97.8, 113.9, 118.8, 133.0, 140.7, 154.3; HRMS 
(ESI, +ve) m/z calcd. for C17H29NO3Na 318.2045, found: 318.2042 (M+Na)+. 
 
(2R,4S)-tert-Butyl 4-((S)-but-3-en-2-yl)-2-tert-butyl-4-vinyloxazolidine-3-
carboxylate (327d) 
 
 
 
To a solution of methyltriphenylphosphonium bromide (112 mg, 0.314 mmol, 1.5 eq) in 
THF (1.5 mL) at 0 °C was added n-butyl lithium (1.6M in hexane, 196 μL, 0.314 mmol, 
1.5 eq) and the reaction turned a dark yellow. After 15 minutes a solution of (2R,4S)-
tert-butyl 4-((S)-but-3-en-2-yl)-2-tert-butyl-4-formyloxazolidine-3-carboxylate 325d 
(65 mg, 0.209 mmol, 1 eq) in THF (1.5 mL) was added and stirred at reflux for 18 
hours. The reaction mixture was allowed to cool to room temperature before 
concentrated in vacuo and purified by flash chromatography (20:1 Pet/EtOAc) to afford 
the title compound as a colourless oil (44 mg, 69%). ሾαሿDଶ଴ -52.6 (c 1.35, CH2Cl2); FTIR 
(film/cm-1) υmax: 2975, 2936, 2875, 1698; 1H NMR (500MHz, CDCl3, 328K) δH 0.96 
(9H, s), 1.01 (3H, d, J = 6.9 Hz), 1.51 (9H, s), 3.39 (1H, bs), 4.02 (1H, d, J = 8.8 Hz), 
4.08 (1H, d, J = 8.8 Hz), 5.03–5.13 (3H, m), 5.15–5.21 (2H, m), 5.79 (1H, ddd, J = 
17.2, 10.5, 6.5 Hz), 6.20–6.33 (1H, m); 13C NMR (125MHz, CDCl3, 328K) δC 13.1, 
26.7, 28.3, 39.1, 40.6, 69.1, 71.6, 80.3, 97.9, 114.3, 116.1, 139.2, 139.9, 154.0; HRMS 
(ESI, +ve) m/z calcd. for C18H31NO3Na 332.2202, found: 332.2203 (M+Na)+. 
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(2R,4R)-tert-Butyl 4-((E)-but-2-enyl)-2-tert-butyl-4-vinyloxazolidine-3-carboxylate 
(327e) 
 
 
 
To a solution of methyltriphenylphosphonium bromide (629 mg, 1.76 mmol, 1.5 eq) in 
THF (7.5 mL) at 0 °C was added n-butyl lithium (1.6M in hexane, 1.10 mL, 1.76 mmol, 
1.5 eq) and the reaction turned a dark yellow. After 15 minutes a solution of (2R,4S)-
tert-butyl 4-((E)-but-2-enyl)-2-tert-butyl-4-formyloxazolidine-3-carboxylate 325e (365 
mg, 1.17 mmol, 1 eq) in THF (7.5 mL) was added and stirred at reflux for 3 hours. The 
reaction mixture was allowed to cool to room temperature before concentrated in vacuo 
and purified by flash chromatography (20:1 Pet/EtOAc) to afford the title compound as 
a colourless oil (267 mg, 74%, 7:1 mix of rotamers). ሾαሿDଶ଴ +30.7 (c 1.4, CHCl3); FTIR 
(film/cm-1) υmax: 2975, 2937, 2908, 2872, 1699; 1H NMR (500MHz, CDCl3) δH major 
rotamer 0.93 (9H, s), 1.44 (9H, s), 1.66 (3H, d, J = 6.6 Hz), 2.27–2.37 (1H, m), 2.95 (1H, 
bs), 3.97 (1H, d, J = 8.8 Hz), 4.03 (1H, dd, J = 8.8, 1.2 Hz), 5.01–5.18 (3H, m), 5.35–
5.45 (1H, m), 5.48–5.57 (1H, m), 6.16 (1H, bs); δH minor rotamer 0.94 (9H, s), 1.44 (9H, s), 
1.63 (3H, d, J = 6.6 Hz), 2.27–2.37 (1H, m), 2.95 (1H, bs), 3.92 (1H, d, J = 8.8 Hz), 
4.03 (1H, dd, J = 8.8, 1.2 Hz), 5.01–5.18 (3H, m), 5.35–5.45 (1H, m), 5.57–5.65 (1H, 
m), 6.16 (1H, bs); 13C NMR (125MHz, CDCl3) δC major rotamer 18.1, 26.7, 28.3, 39.1, 39.7, 
66.7, 76.5, 80.2, 97.7, 113.7, 125.2, 129.4, 140.8, 154.2; δC minor rotamer 13.1, 26.7, 28.3, 
39.1, 39.7, 66.7, 76.5, 80.3, 97.7, 113.8, 124.5, 127.1, 140.6, 154.2; HRMS (ESI, +ve) 
m/z calcd. for C18H31NO3Na 332.2202, found: 332.2209 (M+Na)+. 
 
(2R,4R)-tert-Butyl 2-tert-butyl-4-(2-methylallyl)-4-vinyloxazolidine-3-carboxylate 
(327f) 
 
O
NtBu
Boc
Me
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To a solution of methyltriphenylphosphonium bromide (198 mg, 0.554 mmol, 1.5 eq) in 
THF (3.0 mL) at 0 °C was added n-butyl lithium (1.6M in hexane, 346 μL, 0.554 mmol, 
1.5 eq) and the reaction turned a dark yellow. After 15 minutes a solution of (2R,4S)-
tert-butyl 2-tert-butyl-4-formyl-4-(2-methylallyl)oxazolidine-3-carboxylate 325f (115 
mg, 0.369 mmol, 1 eq) in THF (3.0 mL) was added and stirred at reflux for 2 hours. The 
reaction mixture was allowed to cool to room temperature before concentrated in vacuo 
and purified by flash chromatography (10:1 Pet/EtOAc) to afford the title compound as 
a colourless oil (80 mg, 70%). ሾαሿDଶ଴ +2.3 (c 3.45, CHCl3); FTIR (film/cm-1) υmax: 2975, 
2930, 2872, 1698; 1H NMR (500MHz, CDCl3) δH 0.96 (9H, s), 1.48 (9H, s), 1.80 (3H, 
s), 2.35 (1H, d, J = 13.6 Hz), 3.04 (1H, bs), 4.03 (1H, d, J = 8.7 Hz), 4.13 (1H, d, J = 
8.7 Hz), 4.78 (1H, s), 4.93 (1H, s), 5.09 (1H, d, J = 17.7 Hz), 5.10 (1H, bs), 5.14 (1H, d, 
J = 11.0 Hz), 6.21 (1H, bs); 13C NMR (125MHz, CDCl3) δC 23.8, 27.0, 28.3, 39.1, 43.0, 
66.6, 74.8, 80.5, 97.4, 113.7, 115.8, 141.1, 142.0, 153.9; HRMS (ESI, +ve) m/z calcd. 
for C18H31NO3Na 332.2202, found: 332.2193 (M+Na)+. 
 
(4S,5R)-tert-Butyl 4-((R)-1-ethoxyallyl)-5-methyl-4-vinyloxazolidine-3-carboxylate 
(328) 
 
 
 
To a solution of methyltriphenylphosphonium bromide (215 mg, 0.602 mmol, 1.5 eq) in 
THF (3.0 mL) at 0 °C was added n-butyl lithium (1.6M in hexane, 376 μL, 0.602 mmol, 
1.5 eq) and the reaction turned a dark yellow. After 15 minutes a solution of (4S,5R)-
tert-butyl 4-((R)-1-ethoxyallyl)-4-(hydroxymethyl)-5-methyloxazolidine-3-carboxylate 
326 (120 mg, 0.401 mmol, 1 eq) in THF (3.0 mL) was added and stirred at reflux for 16 
hours. The reaction mixture was allowed to cool to room temperature before 
concentrated in vacuo and purified by flash chromatography (10:1 Pet/EtOAc) to afford 
the title compound as a colourless oil (87 mg, 73%, 5:2 mix of rotamers). ሾαሿDଶ଴ +67.9 (c 
1.40, CHCl3); FTIR (film/cm-1) υmax: 2977, 2936, 2857, 1710, 1692; 1H NMR 
(500MHz, CDCl3) δH major rotamer 1.10–1.18 (6H, m), 1.45 (9H, s), 3.26–3.38 (1H, m), 
3.48–3.61 (1H, m), 4.30–4.42 (1H, m), 4.63–4.67 (1H, m), 4.97 (1H, d, J = 3.3 Hz), 
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5.13–5.39 (5H, m), 5.60–5.76 (2H, m); δH minor rotamer 1.10–1.18 (6H, m), 1.43 (9H, s), 
3.26–3.38 (1H, m), 3.48–3.61 (1H, m), 4.30–4.42 (1H, m), 4.63–4.67 (1H, m), 4.73 
(1H, d, J = 3.3 Hz), 5.13–5.39 (5H, m), 5.60–5.76 (2H, m); 13C NMR (125MHz, CDCl3) 
δC major rotamer 15.4, 16.7, 28.4, 64.3, 68.9, 77.6, 79.1, 79.3, 79.5, 116.6, 119.4, 132.8, 
134.8, 151.4; δC minor rotamer 15.4, 16.8, 28.4, 64.7, 68.6, 78.7, 79.6, 80.0, 80.8, 116.3, 
119.5, 133.5, 135.0, 152.2; HRMS (ESI, +ve) m/z calcd. for C16H27NO4Na 320.1838, 
found: 320.1856 (M+Na)+. 
 
(2R,4S)-3-tert-Butyl 4-methyl 4-((E)-but-2-enyl)-2-tert-butyloxazolidine-3,4-
dicarboxylate (333a) 
 
 
 
To a solution of (2R,4S)-3-tert-butyl 4-methyl 2-tert-butyloxazolidine-3,4-dicarboxylate 
249 (1.44 g, 5 mmol, 1 eq) and crotyl bromide (5.14 mL, 50 mmol, 10 eq) in THF (15 
mL) at -84 °C was added LHMDS (1M in THF, 15 mL, 15 mmol, 3 eq) via syringe 
pump at a rate of 10 mL/hr and allowed to stir at -84 °C for 16 hours. Quenched with 
NH4Cl (sat.) (30 mL), diluted with water (30 mL) and extracted with EtOAc (1 × 50 
mL) and DCM (2 × 50 mL). The organics were combined, dried over MgSO4 and 
concentrated in vacuo. Purification by flash chromatography affords the title compound 
as a colourless oil (1.54 g, 90%, 6:1 mix of rotamers). ሾαሿDଶ଴ +26.7 (c 1.35, CHCl3); 
FTIR (film/cm-1) υmax: 2961, 2911, 2881, 1743, 1708; 1H NMR (500MHz, CDCl3) δH 
major rotamer 0.98 (9H, s), 1.44 (9H, s), 1.67 (3H, dd, J = 6.3, 1.0 Hz),  2.62 (1H, app. d, J = 
15.1 Hz), 3.01 (1H, bs), 3.75 (3H, s), 4.05 (1H, d, J = 8.5 Hz), 4.22 (1H, dd, J = 8.5, 1.5 
Hz), 5.04 (1H, s), 5.36–5.47 (1H, m), 5.51–5.59 (1H, m); δH minor rotamer 0.99 (9H, s), 1.43 
(9H, s), 1.64 (3H, dd, J = 6.3, 1.0 Hz),  2.74 (1H, app. d, J = 15.1 Hz), 3.01 (1H, bs), 
3.76 (3H, s), 3.99 (1H, d, J = 8.5 Hz), 4.24 (1H, dd, J = 8.5, 1.5 Hz), 5.11 (1H, s), 5.36–
5.47 (1H, m), 5.60–5.69 (1H, m); 13C NMR (125MHz, CDCl3) δC major rotamer 18.1, 26.5, 
28.2, 37.9, 39.4, 52.3, 68.8, 75.3, 80.7, 98.0, 124.2, 130.2, 153.2, 172.4; δC minor rotamer 
13.1, 26.5, 28.2, 37.9, 39.4, 52.3, 68.8, 75.3, 80.8, 98.0, 123.4, 127.9, 153.2, 172.5; 
HRMS (ESI, +ve) m/z calcd. for C18H31NO5Na 364.2100, found: 364.2116 (M+Na)+. 
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(2R,4S)-3-tert-Butyl 4-methyl 2-tert-butyl-4-(2-methylallyl)oxazolidine-3,4-
dicarboxylate (333b) 
 
 
 
To a solution of (2R,4S)-3-tert-butyl 4-methyl 2-tert-butyloxazolidine-3,4-dicarboxylate 
249 (1.44 g, 5 mmol, 1 eq) and crotyl bromide (5.14 mL, 50 mmol, 10 eq) in THF (15 
mL) at -84 °C was added LHMDS (1M in THF, 15 mL, 15 mmol, 3 eq) via syringe 
pump at a rate of 10 mL/hr and allowed to stir at -84 °C for 16 hours. Quenched with 
NH4Cl (sat.) (30 mL), diluted with water (30 mL) and extracted with EtOAc (1 × 50 
mL) and DCM (2 × 50 mL). The organics were combined, dried over MgSO4 and 
concentrated in vacuo. Purification by flash chromatography affords the title compound 
as a colourless oil (1.54 g, 90%). ሾαሿDଶ଴ +11.5 (c 1.92, CHCl3); FTIR (film/cm-1) υmax: 
2975, 2957, 2908, 2878, 1743, 1708; 1H NMR (500MHz, CDCl3) δH 0.99 (9H, s), 1.45 
(9H, s), 1.79 (3H, s), 2.66 (1H, d, J = 14.2 Hz), 3.12 (1H, bs), 3.75 (3H, s), 4.14 (1H, d, 
J = 8.2 Hz), 4.20 (1H, d, J = 8.2 Hz), 4.79 (1H, s), 4.93 (1H, s), 5.06 (1H, s); 13C NMR 
(125MHz, CDCl3) δC 23.6, 26.7, 28.2, 39.5, 40.9, 52.4, 68.9, 74.0, 80.9, 97.8, 116.4, 
140.8, 152.9, 172.4; HRMS (ESI, +ve) m/z calcd. for C18H31NO5Na 364.2100, found: 
364.2102 (M+Na)+. 
 
(R)-3-Phenylcyclohexanone (ent-304) 
 
 
 
Phenylboronic acid (60 mg, 0.50 mmol), bis(ethylene)rhodium(I) chloride dimer (3.2 
mg, 8.25 μmol), (2R,4R)-tert-butyl 4-allyl-2-tert-butyl-4-vinyloxazolidine-3-
carboxylate 327c (5.8 mg, 19.8 μmol), 2-cyclohexenone (32 μL, 0.330 mmol) and KOH 
(0.075M in water, 0.45 mL, 33 μmol) were combined according to General Procedure 
X. Purification by flash chromatography (10:1 Pet/EtOAc) affords the methyl ester as a 
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colourless oil (58 mg, 100%, 88% ee). Chiral HPLC analysis performed using Chiralpak 
AD column (hexane/2-propanol, 99:1, 0.5 mL/min, 214 nm); tR: 23.3 min (minor), 27.8 
min (major). ሾαሿDଶ଴ +16.0 (c 1.88, CHCl3), lit.
268 ሾαሿDଶ଴ +17.2 (c 1.0, CHCl3, 94% ee); 
1H 
NMR (500MHz, CDCl3) δH 1.74–1.93 (2H, m), 2.07–2.14 (1H, m), 2.17 (1H, ddd, J = 
13.0, 6.3, 3.2 Hz), 2.35–2.65 (4H, m), 3.03 (1H, tt, J = 11.8, 3.9 Hz), 7.22–7.28 (3H, 
m), 7.35 (2H, app. t, J = 7.5 Hz); 13C NMR (125MHz, CDCl3) δC 25.6, 32.8, 41.2, 44.8, 
49.0, 126.6, 126.7, 128.7, 144.4, 211.0. All analytical data in accordance with reported 
literature values.268  
 
(R)-3-(4-Fluorophenyl)cyclohexanone (334a) 
 
 
 
4-Fluorophenyl boronic acid (70 mg, 0.50 mmol), bis(ethylene)rhodium(I) chloride 
dimer (3.2 mg, 8.25 μmol), (2R,4R)-tert-butyl 4-allyl-2-tert-butyl-4-vinyloxazolidine-3-
carboxylate 327c (5.8 mg, 19.8 μmol), 2-cyclohexenone (32 μL, 0.330 mmol) and KOH 
(0.075M in water, 0.45 mL, 33 μmol) were combined according to General Procedure 
X. Purification by flash chromatography (10:1 Pet/EtOAc) affords the methyl ester as a 
colourless oil (60 mg, 95%, 91% ee). Chiral HPLC analysis performed using Chiralpak 
AD column (hexane/2-propanol, 97:3, 1 mL/min, 214 nm); tR: 9.6 min (minor), 12.0 
min (major). ሾαሿDଶ଴ +12.4 (c 2.5, CHCl3), lit.
268 ሾαሿDଶ଴ +16.0 (c 1.05, CHCl3, 93% ee); 
1H 
NMR (500MHz, CDCl3) δH 1.71–1.90 (2H, m), 2.01–2.11 (1H, m), 2.11–2.21 (1H, m), 
2.32–2.43 (1H, m), 2.43–2.54 (2H, m), 2.54–2.63 (1H, m), 2.94–3.08 (1H, m), 6.97–
7.06 (2H, m), 7.14–7.23 (2H, m); 13C NMR (125MHz, CDCl3) δC 25.4, 32.9, 41.1, 44.0, 
49.1, 115.4 (d, J = 21.4 Hz), 128.0 (d, J = 8.0 Hz), 140.1 (d, J = 3.0 Hz), 161.5 (d, J = 
243.7 Hz), 210.6. All analytical data in accordance with reported literature values.268  
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(R)-3-(4-Methoxyphenyl)cyclohexanone (334b) 
 
 
 
4-Methoxyphenyl boronic acid (76 mg, 0.50 mmol), bis(ethylene)rhodium(I) chloride 
dimer (3.2 mg, 8.25 μmol), (2R,4R)-tert-butyl 4-allyl-2-tert-butyl-4-vinyloxazolidine-3-
carboxylate 327c (5.8 mg, 19.8 μmol), 2-cyclohexenone (32 μL, 0.330 mmol) and KOH 
(0.075M in water, 0.45 mL, 33 μmol) were combined according to General Procedure 
X. Purification by flash chromatography (10:1 Pet/EtOAc) affords the methyl ester as a 
colourless oil (62 mg, 93%, 84% ee). Chiral HPLC analysis performed using Chiralcel 
OJ column (hexane/2-propanol, 97:3, 0.8 mL/min, 214 nm); tR: 26.4 min (major), 31.5 
min (minor). ሾαሿDଶ଴ +13.8 (c 2.4, CHCl3), lit.
268 ሾαሿDଶ଴ +14.0 (c 0.95, CHCl3, 93% ee); 
1H 
NMR (500MHz, CDCl3) δH 1.73–1.89 (2H, m), 2.04–2.11 (1H, m), 2.12–2.20 (1H, m), 
2.33–2.64 (4H, m), 2.99 (1H, tt, J = 11.8, 3.9 Hz), 3.81 (3H, s), 6.89 (2H, app. d, J = 8.6 
Hz), 7.16 (2H, app. d, J = 8.6 Hz); 13C NMR (125MHz, CDCl3) δC 25.5, 33.0, 41.2, 
44.0, 49.2, 55.3, 114.0, 127.5, 136.6, 158.3, 211.2. All analytical data in accordance 
with reported literature values.268 
 
(R)-3-(Naphthalen-1-yl)cyclohexanone (334c) 
 
 
 
1-Naphthaleneboronic acid (86 mg, 0.50 mmol), bis(ethylene)rhodium(I) chloride dimer 
(3.2 mg, 8.25 μmol), (2R,4R)-tert-butyl 4-allyl-2-tert-butyl-4-vinyloxazolidine-3-
carboxylate 327c (5.8 mg, 19.8 μmol), 2-cyclohexenone (32 μL, 0.330 mmol) and KOH 
(0.075M in water, 0.45 mL, 33 μmol) were combined according to General Procedure 
X. Purification by flash chromatography (10:1 Pet/EtOAc) affords the methyl ester as a 
colourless oil (74 mg, 100%, 73% ee). Chiral HPLC analysis performed using Chiralcel 
OD-H column (hexane/2-propanol, 90:10, 0.8 mL/min, 214 nm); tR: 17.4 min (major), 
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24.7 min (minor). ሾαሿDଶ଴ +31.0 (c 2.97, CHCl3), lit.
259 ሾαሿDଶ଴ +48.4 (c 1.05, CHCl3, 82% 
ee); 1H NMR (500MHz, CDCl3) δH 1.88–2.09 (2H, m), 2.16–2.32 (2H, m), 2.42–2.84 
(4H, m), 3.88 (1H, app. t, J = 11.3 Hz), 7.42 (1H, d, J = 7.4 Hz), 7.45–7.59 (3H, m), 
7.78 (1H, d, J = 8.1 Hz), 7.90 (1H, d, J = 8.1 Hz), 8.06 (1H, d, J = 8.1 Hz); 13C NMR 
(125MHz, CDCl3) δC 25.6, 32.3, 39.4, 41.5, 48.6, 122.5, 122.7, 125.6, 125.7, 126.2, 
127.3, 129.1, 130.9, 134.0, 140.1, 211.2. All analytical data in accordance with reported 
literature values.259 
 
(R)-3-(4-Acetylphenyl)cyclohexanone (334d) 
 
 
 
4-Acetylphenylboronic acid (82 mg, 0.50 mmol), bis(ethylene)rhodium(I) chloride 
dimer (3.2 mg, 8.25 μmol), (2R,4R)-tert-butyl 4-allyl-2-tert-butyl-4-vinyloxazolidine-3-
carboxylate 327c (5.8 mg, 19.8 μmol), 2-cyclohexenone (32 μL, 0.330 mmol) and KOH 
(0.075M in water, 0.45 mL, 33 μmol) were combined according to General Procedure 
X. Purification by flash chromatography (10:1 Pet/EtOAc) affords the methyl ester as a 
colourless oil (17 mg, 24%, 79% ee). Chiral HPLC analysis performed using Chiralpak 
AD column (hexane/2-propanol, 90:10, 0.6 mL/min, 214 nm); tR: 33.73 min (major), 
39.5 min (minor). ሾαሿDଶ଴ +5.9 (c 0.85, CHCl3), lit.
257 ሾαሿDଶ଴ -7.3 (c 1.0, CHCl3, 92% ee 
for S-isomer); 1H NMR (500MHz, CDCl3) δH 1.74–1.97 (2H, m), 2.04–2.25 (2H, m), 
2.35–2.69 (7H, m), 3.03–3.16 (1H, m), 7.33 (2H, app. d, J = 8.0 Hz), 7.94 (2H, app. d, J 
= 8.0 Hz); 13C NMR (125MHz, CDCl3) δC 25.4, 26.6, 32.4, 41.1, 44.6, 48.4, 126.9, 
128.9, 135.8, 149.7, 197.7, 210.3. All analytical data in accordance with reported 
literature values.257  
 
 
 
 
 
  | 266 
Chapter 7  Experimental   
(R)-3-(4-Chlorophenyl)cyclohexanone (334e) 
 
 
 
4-Chlorophenylboronic acid (78 mg, 0.50 mmol), bis(ethylene)rhodium(I) chloride 
dimer (3.2 mg, 8.25 μmol), (2R,4R)-tert-butyl 4-allyl-2-tert-butyl-4-vinyloxazolidine-3-
carboxylate 327c (5.8 mg, 19.8 μmol), 2-cyclohexenone (32 μL, 0.330 mmol) and KOH 
(0.075M in water, 0.45 mL, 33 μmol) were combined according to General Procedure 
X. Purification by flash chromatography (10:1 Pet/EtOAc) affords the methyl ester as a 
colourless oil (60 mg, 87%). Chiral HPLC analysis performed using Chiralpak AD, 
Chiralcel OD, OD-H or OJ columns unable to afford resolution of enantiomeric peaks. 
ሾαሿD
ଶ଴ +8.2 (c 2.45, CHCl3), lit.301 ሾαሿDଶ଴ +12.0 (c 0.20, CHCl3, 99% ee); 
1H NMR 
(500MHz, CDCl3) δH 1.70–1.90 (2H, m), 2.01–2.23 (2H, m), 2.32–2.63 (4H, m), 2.92–
3.07 (1H, m), 7.16 (2H, app. d, J = 8.3 Hz), 7.30 (2H, app. d, J = 8.3 Hz); 13C NMR 
(125MHz, CDCl3) δC 25.4, 32.7, 41.1, 44.1, 48.8, 128.0, 128.8, 132.4, 142.8, 210.5. All 
analytical data in accordance with reported literature values.301  
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8. APPENDICES 
8.1 X-Ray Crystallography Data 
 
8.1.1 X-Ray Data for 252i 
 
Table 1 - Crystal data and structure refinement for 252i 
Identification code p10dc3 
 Empirical formula C47 H66 Cl2 I2 N2 O12 
 Formula weight 1175.72 
 Temperature 240(2) K  
 Wavelength 1.54184 Å 
 Crystal system Hexagonal 
 Space group P61 
 Unit cell dimensions a = 10.9498(2)Å α = 90o 
       b = 10.9498(2)Å β = 90o 
       c = 77.5761(19)Å γ = 120o 
 Volume 8055.1(3) Å3 
 Z 6 
 Density (calculated) 1.454 Mg/m3 
 Absorption coefficient 10.588 mm-1 
 F(000) 3588 
 Crystal size 0.20 x 0.20 x 0.12 mm 
 Theta range for data collection 3.42 to 67.47o 
 Index ranges -11<=h<=13; -12<=k<=13; -92<=l<=92 
 Reflections collected 61225 
 Independent reflections 9351 [R(int) = 0.0644] 
 Reflections observed (>2σ) 8819 
 Data Completeness 0.998 
 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 1.00000 and 0.42759 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 9351 / 30 / 628 
 Goodness-of-fit on F2 1.037 
 Final R indices [I>2σ(I)] R1 = 0.0498   wR2 = 0.1255 
 R indices (all data) R1 = 0.0533  wR2 = 0.1283 
 Absolute structure parameter 0.015(5) 
 Largest diff. peak and hole 0.875 and -0.970 eÅ-3 
  
Notes: 
 
The asymmetric unit consists of two molecules of the target compound, plus a disordered region 
of solvent. The latter was modeled as two dichloromethane fragments, present in a 60:40 ratio. 
C-Cl, Cl…Cl and some ADP restraints were applied in the solvent region, in order to assist 
convergence.  
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Table 2 - Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 103) for 252i. 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor 
Atom x y z U(eq) 
I(1) 9800(1) 15856(1) -239(1) 66(1) 
I(1A) 6571(1) 3144(1) 9(1) 60(1) 
Cl(1) 10641(11) 6294(10) 1115(1) 122(3) 
Cl(2) 10214(18) 8438(13) 973(1) 168(4) 
Cl(3) 10314(9) 6631(6) 939(1) 142(2) 
Cl(4) 12195(6) 9262(6) 824(1) 109(2) 
O(1) 9164(5) 11140(5) -50(1) 50(1) 
O(2) 9789(5) 12070(5) -626(1) 48(1) 
O(3) 7799(4) 11731(5) -495(1) 44(1) 
O(4) 11263(6) 10358(6) -426(1) 58(1) 
O(5) 11899(5) 10844(5) -149(1) 52(1) 
O(6) 11289(5) 14281(4) -360(1) 46(1) 
O(7) 6879(4) 2295(5) 377(1) 41(1) 
O(2A) 8048(5) 4947(5) 591(1) 54(1) 
O(3A) 9262(5) 6221(4) 358(1) 45(1) 
O(4A) 9776(5) 3659(5) 806(1) 54(1) 
O(5A) 10283(4) 2144(5) 678(1) 46(1) 
O(6A) 10757(4) 3609(4) 293(1) 40(1) 
N(1) 9316(5) 11358(5) -344(1) 34(1) 
N(1A) 9644(4) 4518(5) 454(1) 32(1) 
C(1) 8285(6) 10863(7) -199(1) 43(1) 
C(2) 10525(7) 12294(6) -89(1) 46(1) 
C(3) 10771(5) 11994(6) -277(1) 34(1) 
C(4) 7202(7) 9295(7) -196(1) 55(2) 
C(5) 7930(9) 8399(8) -211(1) 66(2) 
C(6) 6449(10) 9005(11) -20(1) 87(3) 
C(7) 6122(9) 8900(9) -340(1) 83(3) 
C(8) 9045(6) 11761(6) -501(1) 37(1) 
C(9) 7228(7) 12049(7) -652(1) 52(2) 
C(10) 8197(9) 13533(8) -708(1) 66(2) 
C(11) 6975(11) 10973(9) -790(1) 75(2) 
C(12) 5857(9) 11897(13) -584(1) 84(3) 
C(13) 11310(6) 10957(6) -295(1) 39(1) 
C(14) 12591(9) 10019(9) -159(1) 69(2) 
C(15) 11854(6) 13359(5) -370(1) 39(1) 
C(16) 13287(7) 14007(7) -282(1) 55(2) 
C(17) 14353(13) 14123(14) -358(2) 109(4) 
C(18) 11803(6) 15427(6) -466(1) 41(1) 
C(19) 11288(7) 16341(6) -436(1) 46(1) 
C(20) 11710(9) 17522(7) -538(1) 57(2) 
C(21) 12697(9) 17812(7) -666(1) 61(2) 
C(22) 13209(7) 16940(7) -696(1) 53(2) 
C(23) 12789(7) 15744(7) -596(1) 46(1) 
C(1A) 10702(5) 4863(6) 317(1) 37(1) 
C(2A) 9487(5) 2454(6) 354(1) 35(1) 
C(3A) 9081(5) 3040(5) 509(1) 30(1) 
C(4A) 12225(6) 6059(7) 360(1) 51(2) 
C(5A) 12757(7) 5712(10) 525(1) 70(2) 
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C(6A) 13160(7) 6104(10) 211(1) 72(2) 
C(7A) 12318(8) 7488(9) 378(2) 90(3) 
C(8A) 8894(6) 5214(6) 478(1) 38(1) 
C(9A) 8693(8) 7205(8) 369(1) 58(2) 
C(10A) 7125(10) 6408(10) 337(2) 88(3) 
C(11A) 9468(13) 8195(10) 218(1) 86(3) 
C(12A) 9059(10) 7974(9) 534(1) 69(2) 
C(13A) 9761(5) 3000(6) 681(1) 34(1) 
C(14A) 10808(8) 1945(9) 841(1) 58(2) 
C(15A) 7457(5) 2180(6) 538(1) 34(1) 
C(16A) 7017(6) 695(7) 583(1) 47(1) 
C(17A) 6314(7) -399(8) 481(1) 63(2) 
C(18A) 5592(5) 2220(6) 375(1) 39(1) 
C(19A) 5212(6) 2576(7) 221(1) 43(1) 
C(20A) 3931(8) 2549(9) 207(1) 62(2) 
C(21A) 3058(8) 2197(12) 344(1) 80(3) 
C(22A) 3412(7) 1819(11) 498(1) 75(2) 
C(23A) 4681(7) 1833(9) 514(1) 59(2) 
C(1S) 9570(30) 6691(13) 1001(5) 145(6) 
C(2S) 11081(16) 8366(7) 987(2) 114(4) 
                                      
   
  | 270 
Chapter 8  Appendices   
Table 3 - Bond lengths [Å] and angles [o] for 252i 
I(1)-C(19) 2.101(6) I(1A)-C(19A) 2.090(6) 
Cl(1)-C(1S) 1.690(2) Cl(2)-C(1S) 1.690(2) 
Cl(3)-C(2S) 1.690(2) Cl(4)-C(2S) 1.688(2) 
O(1)-C(2) 1.424(8) O(1)-C(1) 1.434(7) 
O(2)-C(8) 1.204(7) O(3)-C(8) 1.348(7) 
O(3)-C(9) 1.485(7) O(4)-C(13) 1.194(8) 
O(5)-C(13) 1.340(7) O(5)-C(14) 1.442(8) 
O(6)-C(18) 1.363(7) O(6)-C(15) 1.427(7) 
O(7)-C(18A) 1.369(6) O(7)-C(15A) 1.431(6) 
O(2A)-C(8A) 1.203(7) O(3A)-C(8A) 1.337(7) 
O(3A)-C(9A) 1.492(7) O(4A)-C(13A) 1.203(7) 
O(5A)-C(13A) 1.320(7) O(5A)-C(14A) 1.448(7) 
O(6A)-C(2A) 1.413(6) O(6A)-C(1A) 1.416(7) 
N(1)-C(8) 1.379(7) N(1)-C(3) 1.476(7) 
N(1)-C(1) 1.492(7) N(1A)-C(8A) 1.383(7) 
N(1A)-C(1A) 1.475(7) N(1A)-C(3A) 1.477(7) 
C(1)-C(4) 1.522(9) C(1)-H(1) 0.9900 
C(2)-C(3) 1.548(7) C(2)-H(2A) 0.9800 
C(2)-H(2B) 0.9800 C(3)-C(13) 1.525(7) 
C(3)-C(15) 1.545(7) C(4)-C(7) 1.522(11) 
C(4)-C(6) 1.546(10) C(4)-C(5) 1.548(11) 
C(5)-H(5A) 0.9700 C(5)-H(5B) 0.9700 
C(5)-H(5C) 0.9700 C(6)-H(6A) 0.9700 
C(6)-H(6B) 0.9700 C(6)-H(6C) 0.9700 
C(7)-H(7A) 0.9700 C(7)-H(7B) 0.9700 
C(7)-H(7C) 0.9700 C(9)-C(10) 1.494(11) 
C(9)-C(11) 1.513(11) C(9)-C(12) 1.520(11) 
C(10)-H(10A) 0.9700 C(10)-H(10B) 0.9700 
C(10)-H(10C) 0.9700 C(11)-H(11A) 0.9700 
C(11)-H(11B) 0.9700 C(11)-H(11C) 0.9700 
C(12)-H(12A) 0.9700 C(12)-H(12B) 0.9700 
C(12)-H(12C) 0.9700 C(14)-H(14A) 0.9700 
C(14)-H(14B) 0.9700 C(14)-H(14C) 0.9700 
C(15)-C(16) 1.521(9) C(15)-H(15) 0.9900 
C(16)-C(17) 1.254(15) C(16)-H(16) 0.9400 
C(17)-H(17A) 0.9400 C(17)-H(17B) 0.9400 
C(18)-C(23) 1.391(8) C(18)-C(19) 1.391(8) 
C(19)-C(20) 1.381(9) C(20)-C(21) 1.386(11) 
C(20)-H(20) 0.9400 C(21)-C(22) 1.348(11) 
C(21)-H(21) 0.9400 C(22)-C(23) 1.389(10) 
C(22)-H(22) 0.9400 C(23)-H(23) 0.9400 
C(1A)-C(4A) 1.555(8) C(1A)-H(1A) 0.9900 
C(2A)-C(3A) 1.533(7) C(2A)-H(2A1) 0.9800 
C(2A)-H(2A2) 0.9800 C(3A)-C(13A) 1.536(7) 
C(3A)-C(15A) 1.556(6) C(4A)-C(7A) 1.523(11) 
C(4A)-C(6A) 1.527(10) C(4A)-C(5A) 1.532(11) 
C(5A)-H(5A1) 0.9700 C(5A)-H(5A2) 0.9700 
C(5A)-H(5A3) 0.9700 C(6A)-H(6A1) 0.9700 
C(6A)-H(6A2) 0.9700 C(6A)-H(6A3) 0.9700 
C(7A)-H(7A1) 0.9700 C(7A)-H(7A2) 0.9700 
C(7A)-H(7A3) 0.9700 C(9A)-C(12A) 1.476(11) 
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C(9A)-C(10A) 1.508(11) C(9A)-C(11A) 1.531(13) 
C(10A)-H(10D) 0.9700 C(10A)-H(10E) 0.9700 
C(10A)-H(10F) 0.9700 C(11A)-H(11D) 0.9700 
C(11A)-H(11E) 0.9700 C(11A)-H(11F) 0.9700 
C(12A)-H(12D) 0.9700 C(12A)-H(12E) 0.9700 
C(12A)-H(12F) 0.9700 C(14A)-H(14D) 0.9700 
C(14A)-H(14E) 0.9700 C(14A)-H(14F) 0.9700 
C(15A)-C(16A) 1.490(8) C(15A)-H(15A) 0.9900 
C(16A)-C(17A) 1.316(10) C(16A)-H(16A) 0.9400 
C(17A)-H(17C) 0.9400 C(17A)-H(17D) 0.9400 
C(18A)-C(23A) 1.383(8) C(18A)-C(19A) 1.389(9) 
C(19A)-C(20A) 1.391(8) C(20A)-C(21A) 1.355(12) 
C(20A)-H(20A) 0.9400 C(21A)-C(22A) 1.382(14) 
C(21A)-H(21A) 0.9400 C(22A)-C(23A) 1.388(10) 
C(22A)-H(22A) 0.9400 C(23A)-H(23A) 0.9400 
C(1S)-H(1S1) 0.9800 C(1S)-H(1S2) 0.9800 
C(2S)-H(2S1) 0.9800 C(2S)-H(2S2) 0.9800 
    
C(2)-O(1)-C(1) 108.0(4) C(8)-O(3)-C(9) 120.5(5) 
C(13)-O(5)-C(14) 116.3(5) C(18)-O(6)-C(15) 119.6(4) 
C(18A)-O(7)-C(15A) 119.3(4) C(8A)-O(3A)-C(9A) 119.8(5) 
C(13A)-O(5A)-C(14A) 116.1(5) C(2A)-O(6A)-C(1A) 108.9(4) 
C(8)-N(1)-C(3) 120.8(4) C(8)-N(1)-C(1) 122.6(4) 
C(3)-N(1)-C(1) 110.5(4) C(8A)-N(1A)-C(1A) 124.0(4) 
C(8A)-N(1A)-C(3A) 121.9(4) C(1A)-N(1A)-C(3A) 109.4(4) 
O(1)-C(1)-N(1) 103.0(4) O(1)-C(1)-C(4) 106.8(5) 
N(1)-C(1)-C(4) 116.2(5) O(1)-C(1)-H(1) 110.2 
N(1)-C(1)-H(1) 110.2 C(4)-C(1)-H(1) 110.2 
O(1)-C(2)-C(3) 103.3(4) O(1)-C(2)-H(2A) 111.1 
C(3)-C(2)-H(2A) 111.1 O(1)-C(2)-H(2B) 111.1 
C(3)-C(2)-H(2B) 111.1 H(2A)-C(2)-H(2B) 109.1 
N(1)-C(3)-C(13) 110.2(4) N(1)-C(3)-C(15) 114.7(4) 
C(13)-C(3)-C(15) 106.3(4) N(1)-C(3)-C(2) 99.7(4) 
C(13)-C(3)-C(2) 114.7(5) C(15)-C(3)-C(2) 111.4(4) 
C(1)-C(4)-C(7) 111.5(6) C(1)-C(4)-C(6) 106.2(6) 
C(7)-C(4)-C(6) 109.3(7) C(1)-C(4)-C(5) 110.9(6) 
C(7)-C(4)-C(5) 109.7(7) C(6)-C(4)-C(5) 109.1(7) 
C(4)-C(5)-H(5A) 109.5 C(4)-C(5)-H(5B) 109.5 
H(5A)-C(5)-H(5B) 109.5 C(4)-C(5)-H(5C) 109.5 
H(5A)-C(5)-H(5C) 109.5 H(5B)-C(5)-H(5C) 109.5 
C(4)-C(6)-H(6A) 109.5 C(4)-C(6)-H(6B) 109.5 
H(6A)-C(6)-H(6B) 109.5 C(4)-C(6)-H(6C) 109.5 
H(6A)-C(6)-H(6C) 109.5 H(6B)-C(6)-H(6C) 109.5 
C(4)-C(7)-H(7A) 109.5 C(4)-C(7)-H(7B) 109.5 
H(7A)-C(7)-H(7B) 109.5 C(4)-C(7)-H(7C) 109.5 
H(7A)-C(7)-H(7C) 109.5 H(7B)-C(7)-H(7C) 109.5 
O(2)-C(8)-O(3) 124.5(5) O(2)-C(8)-N(1) 125.6(5) 
O(3)-C(8)-N(1) 109.9(4) O(3)-C(9)-C(10) 109.9(6) 
O(3)-C(9)-C(11) 109.4(5) C(10)-C(9)-C(11) 113.2(7) 
O(3)-C(9)-C(12) 101.5(6) C(10)-C(9)-C(12) 110.2(7) 
C(11)-C(9)-C(12) 111.9(7) C(9)-C(10)-H(10A) 109.5 
C(9)-C(10)-H(10B) 109.5 H(10A)-C(10)-H(10B) 109.5 
C(9)-C(10)-H(10C) 109.5 H(10A)-C(10)-H(10C) 109.5 
H(10B)-C(10)-H(10C) 109.5 C(9)-C(11)-H(11A) 109.5 
C(9)-C(11)-H(11B) 109.5 H(11A)-C(11)-H(11B) 109.5 
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C(9)-C(11)-H(11C) 109.5 H(11A)-C(11)-H(11C) 109.5 
H(11B)-C(11)-H(11C) 109.5 C(9)-C(12)-H(12A) 109.5 
C(9)-C(12)-H(12B) 109.5 H(12A)-C(12)-H(12B) 109.5 
C(9)-C(12)-H(12C) 109.5 H(12A)-C(12)-H(12C) 109.5 
H(12B)-C(12)-H(12C) 109.5 O(4)-C(13)-O(5) 123.9(5) 
O(4)-C(13)-C(3) 124.1(5) O(5)-C(13)-C(3) 112.0(5) 
O(5)-C(14)-H(14A) 109.5 O(5)-C(14)-H(14B) 109.5 
H(14A)-C(14)-H(14B) 109.5 O(5)-C(14)-H(14C) 109.5 
H(14A)-C(14)-H(14C) 109.5 H(14B)-C(14)-H(14C) 109.5 
O(6)-C(15)-C(16) 110.9(5) O(6)-C(15)-C(3) 105.3(4) 
C(16)-C(15)-C(3) 110.9(5) O(6)-C(15)-H(15) 109.9 
C(16)-C(15)-H(15) 109.9 C(3)-C(15)-H(15) 109.9 
C(17)-C(16)-C(15) 122.0(9) C(17)-C(16)-H(16) 119.0 
C(15)-C(16)-H(16) 119.0 C(16)-C(17)-H(17A) 120.0 
C(16)-C(17)-H(17B) 120.0 H(17A)-C(17)-H(17B) 120.0 
O(6)-C(18)-C(23) 125.4(5) O(6)-C(18)-C(19) 115.8(5) 
C(23)-C(18)-C(19) 118.8(5) C(20)-C(19)-C(18) 120.9(6) 
C(20)-C(19)-I(1) 120.4(5) C(18)-C(19)-I(1) 118.6(4) 
C(19)-C(20)-C(21) 118.9(6) C(19)-C(20)-H(20) 120.6 
C(21)-C(20)-H(20) 120.6 C(22)-C(21)-C(20) 120.9(6) 
C(22)-C(21)-H(21) 119.5 C(20)-C(21)-H(21) 119.5 
C(21)-C(22)-C(23) 120.8(7) C(21)-C(22)-H(22) 119.6 
C(23)-C(22)-H(22) 119.6 C(22)-C(23)-C(18) 119.6(6) 
C(22)-C(23)-H(23) 120.2 C(18)-C(23)-H(23) 120.2 
O(6A)-C(1A)-N(1A) 104.8(4) O(6A)-C(1A)-C(4A) 107.3(4) 
N(1A)-C(1A)-C(4A) 116.0(5) O(6A)-C(1A)-H(1A) 109.5 
N(1A)-C(1A)-H(1A) 109.5 C(4A)-C(1A)-H(1A) 109.5 
O(6A)-C(2A)-C(3A) 104.4(4) O(6A)-C(2A)-H(2A1) 110.9 
C(3A)-C(2A)-H(2A1) 110.9 O(6A)-C(2A)-H(2A2) 110.9 
C(3A)-C(2A)-H(2A2) 110.9 H(2A1)-C(2A)-H(2A2) 108.9 
N(1A)-C(3A)-C(2A) 100.5(4) N(1A)-C(3A)-C(13A) 109.8(4) 
C(2A)-C(3A)-C(13A) 115.0(4) N(1A)-C(3A)-C(15A) 115.4(4) 
C(2A)-C(3A)-C(15A) 109.9(4) C(13A)-C(3A)-C(15A) 106.5(4) 
C(7A)-C(4A)-C(6A) 109.9(7) C(7A)-C(4A)-C(5A) 109.7(8) 
C(6A)-C(4A)-C(5A) 107.9(6) C(7A)-C(4A)-C(1A) 112.2(5) 
C(6A)-C(4A)-C(1A) 106.7(6) C(5A)-C(4A)-C(1A) 110.3(5) 
C(4A)-C(5A)-H(5A1) 109.5 C(4A)-C(5A)-H(5A2) 109.5 
H(5A1)-C(5A)-H(5A2) 109.5 C(4A)-C(5A)-H(5A3) 109.5 
H(5A1)-C(5A)-H(5A3) 109.5 H(5A2)-C(5A)-H(5A3) 109.5 
C(4A)-C(6A)-H(6A1) 109.5 C(4A)-C(6A)-H(6A2) 109.5 
H(6A1)-C(6A)-H(6A2) 109.5 C(4A)-C(6A)-H(6A3) 109.5 
H(6A1)-C(6A)-H(6A3) 109.5 H(6A2)-C(6A)-H(6A3) 109.5 
C(4A)-C(7A)-H(7A1) 109.5 C(4A)-C(7A)-H(7A2) 109.5 
H(7A1)-C(7A)-H(7A2) 109.5 C(4A)-C(7A)-H(7A3) 109.5 
H(7A1)-C(7A)-H(7A3) 109.5 H(7A2)-C(7A)-H(7A3) 109.5 
O(2A)-C(8A)-O(3A) 125.7(5) O(2A)-C(8A)-N(1A) 123.9(5) 
O(3A)-C(8A)-N(1A) 110.3(5) C(12A)-C(9A)-O(3A) 111.4(5) 
C(12A)-C(9A)-C(10A) 112.3(8) O(3A)-C(9A)-C(10A) 109.8(6) 
C(12A)-C(9A)-C(11A) 111.4(7) O(3A)-C(9A)-C(11A) 100.8(6) 
C(10A)-C(9A)-C(11A) 110.6(8) C(9A)-C(10A)-H(10D) 109.5 
C(9A)-C(10A)-H(10E) 109.5 H(10D)-C(10A)-H(10E) 109.5 
C(9A)-C(10A)-H(10F) 109.5 H(10D)-C(10A)-H(10F) 109.5 
H(10E)-C(10A)-H(10F) 109.5 C(9A)-C(11A)-H(11D) 109.5 
C(9A)-C(11A)-H(11E) 109.5 H(11D)-C(11A)-H(11E) 109.5 
C(9A)-C(11A)-H(11F) 109.5 H(11D)-C(11A)-H(11F) 109.5 
  | 273 
Chapter 8  Appendices   
H(11E)-C(11A)-H(11F) 109.5 C(9A)-C(12A)-H(12D) 109.5 
C(9A)-C(12A)-H(12E) 109.5 H(12D)-C(12A)-H(12E) 109.5 
C(9A)-C(12A)-H(12F) 109.5 H(12D)-C(12A)-H(12F) 109.5 
H(12E)-C(12A)-H(12F) 109.5 O(4A)-C(13A)-O(5A) 123.8(5) 
O(4A)-C(13A)-C(3A) 122.8(5) O(5A)-C(13A)-C(3A) 113.3(4) 
O(5A)-C(14A)-H(14D) 109.5 O(5A)-C(14A)-H(14E) 109.5 
H(14D)-C(14A)-H(14E) 109.5 O(5A)-C(14A)-H(14F) 109.5 
H(14D)-C(14A)-H(14F) 109.5 H(14E)-C(14A)-H(14F) 109.5 
O(7)-C(15A)-C(16A) 112.8(5) O(7)-C(15A)-C(3A) 104.3(4) 
C(16A)-C(15A)-C(3A) 110.0(4) O(7)-C(15A)-H(15A) 109.9 
C(16A)-C(15A)-H(15A) 109.9 C(3A)-C(15A)-H(15A) 109.9 
C(17A)-C(16A)-C(15A) 124.9(7) C(17A)-C(16A)-H(16A) 117.5 
C(15A)-C(16A)-H(16A) 117.5 C(16A)-C(17A)-H(17C) 120.0 
C(16A)-C(17A)-H(17D) 120.0 H(17C)-C(17A)-H(17D) 120.0 
O(7)-C(18A)-C(23A) 125.0(6) O(7)-C(18A)-C(19A) 115.8(5) 
C(23A)-C(18A)-C(19A) 119.2(5) C(18A)-C(19A)-C(20A) 120.1(6) 
C(18A)-C(19A)-I(1A) 119.5(4) C(20A)-C(19A)-I(1A) 120.3(5) 
C(21A)-C(20A)-C(19A) 120.3(7) C(21A)-C(20A)-H(20A) 119.8 
C(19A)-C(20A)-H(20A) 119.8 C(20A)-C(21A)-C(22A) 120.2(6) 
C(20A)-C(21A)-H(21A) 119.9 C(22A)-C(21A)-H(21A) 119.9 
C(21A)-C(22A)-C(23A) 120.2(7) C(21A)-C(22A)-H(22A) 119.9 
C(23A)-C(22A)-H(22A) 119.9 C(18A)-C(23A)-C(22A) 119.9(7) 
C(18A)-C(23A)-H(23A) 120.0 C(22A)-C(23A)-H(23A) 120.0 
Cl(2)-C(1S)-Cl(1) 114.1(9) Cl(2)-C(1S)-H(1S1) 108.7 
Cl(1)-C(1S)-H(1S1) 108.7 Cl(2)-C(1S)-H(1S2) 108.7 
Cl(1)-C(1S)-H(1S2) 108.7 H(1S1)-C(1S)-H(1S2) 107.6 
Cl(4)-C(2S)-Cl(3) 107.4(5) Cl(4)-C(2S)-H(2S1) 110.2 
Cl(3)-C(2S)-H(2S1) 110.2 Cl(4)-C(2S)-H(2S2) 110.2 
Cl(3)-C(2S)-H(2S2) 110.2 H(2S1)-C(2S)-H(2S2) 108.5 
 
Symmetry transformations used to generate equivalent atoms:                                                    
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Table 4 - Anisotropic displacement parameters (Å2 x 103) for 252i. The anisotropic displacement factor 
exponent takes the form: -2 gpi2 [ h2 a*2 U11 + ... + 2 h k a* b* U 
Atom U11 U22 U33 U23 U13 U12 
I(1) 77(1) 56(1) 75(1) -2(1) 28(1) 41(1) 
I(1A) 61(1) 85(1) 43(1) 3(1) 2(1) 42(1) 
Cl(1) 155(7) 125(6) 97(5) -20(4) 3(5) 78(5) 
Cl(2) 253(11) 141(7) 101(6) -11(5) -29(7) 90(8) 
Cl(3) 161(5) 91(3) 141(5) 10(3) -32(4) 39(3) 
Cl(4) 104(3) 127(4) 110(4) -12(3) -36(3) 69(3) 
O(1) 59(3) 65(3) 25(2) 4(2) 5(2) 30(2) 
O(2) 53(2) 67(3) 29(2) 6(2) 8(2) 34(2) 
O(3) 42(2) 62(2) 37(2) 6(2) 0(2) 32(2) 
O(4) 90(3) 74(3) 41(2) -9(2) -4(2) 64(3) 
O(5) 67(3) 52(2) 49(3) -6(2) -19(2) 39(2) 
O(6) 60(2) 36(2) 51(2) 5(2) 17(2) 30(2) 
O(7) 25(2) 70(3) 32(2) 2(2) 0(1) 26(2) 
O(2A) 60(3) 63(3) 54(3) 5(2) 17(2) 42(2) 
O(3A) 57(2) 50(2) 43(2) 6(2) 0(2) 38(2) 
O(4A) 69(3) 71(3) 34(2) -7(2) -7(2) 43(2) 
O(5A) 49(2) 63(3) 41(2) 7(2) 1(2) 39(2) 
O(6A) 28(2) 48(2) 44(2) 1(2) 9(2) 20(2) 
N(1) 36(2) 41(2) 27(2) 1(2) 1(2) 21(2) 
N(1A) 25(2) 39(2) 36(2) 1(2) 3(2) 18(2) 
C(1) 48(3) 59(3) 31(3) 3(2) 7(2) 34(3) 
C(2) 60(4) 47(3) 32(3) -8(2) 1(2) 28(3) 
C(3) 38(3) 41(3) 27(3) -5(2) -1(2) 22(2) 
C(4) 49(3) 56(4) 51(4) 18(3) 11(3) 21(3) 
C(5) 78(5) 51(4) 65(5) 11(3) -3(4) 28(4) 
C(6) 79(6) 91(6) 80(7) 38(5) 39(5) 35(5) 
C(7) 60(5) 64(5) 87(7) 21(4) -12(4) 1(4) 
C(8) 43(3) 45(3) 31(3) -1(2) 0(2) 29(2) 
C(9) 54(4) 61(4) 47(4) 4(3) -12(3) 35(3) 
C(10) 76(5) 66(4) 64(5) 5(3) -13(4) 42(4) 
C(11) 100(6) 64(4) 51(4) 0(3) -27(4) 34(4) 
C(12) 64(5) 129(8) 86(6) 12(6) -9(4) 69(6) 
C(13) 40(3) 40(3) 38(3) 3(2) -2(2) 21(2) 
C(14) 80(5) 68(4) 85(6) -12(4) -31(4) 57(4) 
C(15) 48(3) 33(3) 40(3) -1(2) 4(2) 23(2) 
C(16) 46(3) 52(3) 54(4) -3(3) -5(3) 14(3) 
C(17) 84(7) 107(9) 140(12) -2(8) -8(7) 51(6) 
C(18) 49(3) 32(3) 41(3) -1(2) 5(2) 20(2) 
C(19) 55(3) 36(3) 44(3) -5(2) 1(3) 21(3) 
C(20) 84(5) 39(3) 55(4) -3(3) 2(3) 36(3) 
C(21) 82(5) 47(3) 50(4) 7(3) 5(3) 30(3) 
C(22) 59(4) 49(3) 39(4) 0(3) 7(3) 18(3) 
C(23) 52(3) 43(3) 42(3) -5(2) 5(3) 23(3) 
C(1A) 30(2) 43(3) 38(3) 6(2) 6(2) 19(2) 
C(2A) 23(2) 40(3) 35(3) -5(2) 2(2) 11(2) 
C(3A) 23(2) 39(3) 31(3) 2(2) 3(2) 17(2) 
C(4A) 27(3) 51(3) 66(4) 7(3) 5(3) 13(2) 
C(5A) 40(3) 81(5) 66(5) -3(4) -15(3) 13(3) 
  | 275 
Chapter 8  Appendices   
C(6A) 37(3) 84(5) 75(6) 25(4) 22(3) 15(3) 
C(7A) 41(4) 50(4) 158(10) 3(5) 6(5) 8(3) 
C(8A) 36(3) 42(3) 39(3) 1(2) 1(2) 23(2) 
C(9A) 77(5) 58(4) 64(4) -5(3) -14(3) 52(4) 
C(10A) 74(5) 80(6) 138(9) -29(6) -43(5) 60(5) 
C(11A) 135(9) 81(6) 79(6) 20(5) 1(6) 81(6) 
C(12A) 83(5) 62(4) 82(6) -9(4) -13(4) 52(4) 
C(13A) 26(2) 42(3) 32(3) 2(2) 4(2) 15(2) 
C(14A) 55(4) 94(5) 41(3) 15(3) -2(3) 49(4) 
C(15A) 23(2) 45(3) 33(3) 2(2) 0(2) 15(2) 
C(16A) 33(3) 49(3) 53(4) 7(3) 5(2) 16(2) 
C(17A) 44(3) 48(4) 78(5) -3(3) -7(3) 10(3) 
C(18A) 25(2) 55(3) 41(3) -1(2) 4(2) 23(2) 
C(19A) 32(3) 55(3) 46(3) -13(3) -10(2) 26(2) 
C(20A) 53(4) 90(5) 65(5) -16(4) -20(3) 52(4) 
C(21A) 42(4) 122(7) 92(7) -19(5) -1(4) 54(5) 
C(22A) 37(3) 120(7) 71(6) -10(5) 7(3) 41(4) 
C(23A) 34(3) 97(5) 49(4) 4(3) 13(3) 35(3) 
C(1S) 203(10) 132(9) 104(8) -17(8) -10(8) 86(9) 
C(2S) 117(7) 109(7) 132(7) -14(6) -52(6) 68(6) 
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Table 5 - Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 103) for 252i 
Atom x y z U(eq) 
H(1) 7805 11425 -193 51 
H(2A) 11242 12315 -12 55 
H(2B) 10538 13194 -81 55 
H(5A) 8281 8465 -327 99 
H(5B) 7255 7423 -184 99 
H(5C) 8710 8748 -130 99 
H(6A) 7119 9173 72 130 
H(6B) 5690 8033 -15 130 
H(6C) 6066 9629 -5 130 
H(7A) 6586 9045 -450 125 
H(7B) 5690 9485 -332 125 
H(7C) 5401 7916 -328 125 
H(10A) 8372 14167 -612 98 
H(10B) 7765 13770 -802 98 
H(10C) 9081 13626 -747 98 
H(11A) 7867 11057 -824 112 
H(11B) 6539 11139 -890 112 
H(11C) 6355 10032 -746 112 
H(12A) 5245 10935 -546 126 
H(12B) 5394 12122 -675 126 
H(12C) 6057 12537 -488 126 
H(14A) 11889 9029 -171 104 
H(14B) 13133 10155 -54 104 
H(14C) 13218 10318 -258 104 
H(15) 11941 13152 -492 47 
H(16) 13375 14331 -168 66 
H(17A) 14282 13804 -472 131 
H(17B) 15224 14528 -300 131 
H(20) 11336 18119 -520 68 
H(21) 13013 18629 -734 73 
H(22) 13859 17142 -786 64 
H(23) 13168 15154 -616 55 
H(1A) 10375 5095 210 44 
H(2A1) 9631 1674 388 41 
H(2A2) 8754 2118 265 41 
H(5A1) 12690 4799 512 105 
H(5A2) 12185 5689 621 105 
H(5A3) 13732 6427 544 105 
H(6A1) 14129 6824 233 108 
H(6A2) 12843 6321 104 108 
H(6A3) 13103 5194 200 108 
H(7A1) 13102 8087 453 135 
H(7A2) 11448 7361 428 135 
H(7A3) 12462 7926 266 135 
H(10D) 6656 5747 430 132 
H(10E) 6931 5898 228 132 
H(10F) 6778 7067 331 132 
H(11D) 9239 8943 214 129 
H(11E) 9178 7668 110 129 
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H(11F) 10477 8600 232 129 
H(12D) 8584 7315 627 104 
H(12E) 8764 8674 532 104 
H(12F) 10071 8438 551 104 
H(14D) 11085 1236 827 87 
H(14E) 10073 1636 928 87 
H(14F) 11617 2828 877 87 
H(15A) 7185 2615 631 41 
H(16A) 7260 526 693 56 
H(17C) 6053 -272 370 76 
H(17D) 6074 -1307 519 76 
H(20A) 3671 2776 101 74 
H(21A) 2208 2210 335 96 
H(22A) 2791 1552 593 91 
H(23A) 4922 1580 619 71 
H(1S1) 9391 6237 888 174 
H(1S2) 8660 6295 1061 174 
H(2S1) 10364 8646 998 137 
H(2S2) 11601 8566 1096 137 
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Table 6 - Dihedral angles [o] for 252i 
Atom1 - Atom2 - Atom3 - Atom4 Dihedral 
C(2) - O(1) - C(1) - N(1) 27.7(6) 
C(2) - O(1) - C(1) - C(4) 150.7(5) 
C(8) - N(1) - C(1) - O(1) -156.4(5) 
C(3) - N(1) - C(1) - O(1) -3.6(6) 
C(8) - N(1) - C(1) - C(4) 87.3(7) 
C(3) - N(1) - C(1) - C(4) -120.0(5) 
C(1) - O(1) - C(2) - C(3) -40.5(6) 
C(8) - N(1) - C(3) - C(13) -104.7(5) 
C(1) - N(1) - C(3) - C(13) 102.0(5) 
C(8) - N(1) - C(3) - C(15) 15.2(6) 
C(1) - N(1) - C(3) - C(15) -138.1(5) 
C(8) - N(1) - C(3) - C(2) 134.3(5) 
C(1) - N(1) - C(3) - C(2) -19.0(5) 
O(1) - C(2) - C(3) - N(1) 35.0(5) 
O(1) - C(2) - C(3) - C(13) -82.7(6) 
O(1) - C(2) - C(3) - C(15) 156.5(5) 
O(1) - C(1) - C(4) - C(7) 174.8(7) 
N(1) - C(1) - C(4) - C(7) -71.0(8) 
O(1) - C(1) - C(4) - C(6) 55.8(7) 
N(1) - C(1) - C(4) - C(6) 170.0(6) 
O(1) - C(1) - C(4) - C(5) -62.6(7) 
N(1) - C(1) - C(4) - C(5) 51.6(8) 
C(9) - O(3) - C(8) - O(2) 1.9(9) 
C(9) - O(3) - C(8) - N(1) -176.8(5) 
C(3) - N(1) - C(8) - O(2) 35.7(8) 
C(1) - N(1) - C(8) - O(2) -174.3(6) 
C(3) - N(1) - C(8) - O(3) -145.5(5) 
C(1) - N(1) - C(8) - O(3) 4.5(7) 
C(8) - O(3) - C(9) - C(10) -63.0(8) 
C(8) - O(3) - C(9) - C(11) 61.9(8) 
C(8) - O(3) - C(9) - C(12) -179.6(6) 
C(14) - O(5) - C(13) - O(4) 4.4(9) 
C(14) - O(5) - C(13) - C(3) -172.9(6) 
N(1) - C(3) - C(13) - O(4) 51.0(8) 
C(15) - C(3) - C(13) - O(4) -73.9(7) 
C(2) - C(3) - C(13) - O(4) 162.5(6) 
N(1) - C(3) - C(13) - O(5) -131.7(5) 
C(15) - C(3) - C(13) - O(5) 103.4(5) 
C(2) - C(3) - C(13) - O(5) -20.1(7) 
C(18) - O(6) - C(15) - C(16) 76.4(7) 
C(18) - O(6) - C(15) - C(3) -163.6(5) 
N(1) - C(3) - C(15) - O(6) 54.8(6) 
C(13) - C(3) - C(15) - O(6) 176.8(4) 
C(2) - C(3) - C(15) - O(6) -57.5(6) 
N(1) - C(3) - C(15) - C(16) 174.7(5) 
C(13) - C(3) - C(15) - C(16) -63.2(6) 
C(2) - C(3) - C(15) - C(16) 62.4(6) 
O(6) - C(15) - C(16) - C(17) -127.1(9) 
C(3) - C(15) - C(16) - C(17) 116.3(9) 
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C(15) - O(6) - C(18) - C(23) 5.2(9) 
C(15) - O(6) - C(18) - C(19) -174.2(5) 
O(6) - C(18) - C(19) - C(20) -178.6(6) 
C(23) - C(18) - C(19) - C(20) 1.9(10) 
O(6) - C(18) - C(19) - I(1) -0.5(7) 
C(23) - C(18) - C(19) - I(1) -179.9(5) 
C(18) - C(19) - C(20) - C(21) -2.1(11) 
I(1) - C(19) - C(20) - C(21) 179.8(6) 
C(19) - C(20) - C(21) - C(22) 2.0(12) 
C(20) - C(21) - C(22) - C(23) -1.7(12) 
C(21) - C(22) - C(23) - C(18) 1.5(11) 
O(6) - C(18) - C(23) - C(22) 179.0(6) 
C(19) - C(18) - C(23) - C(22) -1.6(9) 
C(2A) - O(6A) - C(1A) - N(1A) 22.1(5) 
C(2A) - O(6A) - C(1A) - C(4A) 146.0(5) 
C(8A) - N(1A) - C(1A) - O(6A) -156.1(5) 
C(3A) - N(1A) - C(1A) - O(6A) -0.1(5) 
C(8A) - N(1A) - C(1A) - C(4A) 85.7(6) 
C(3A) - N(1A) - C(1A) - C(4A) -118.2(5) 
C(1A) - O(6A) - C(2A) - C(3A) -34.7(5) 
C(8A) - N(1A) - C(3A) - C(2A) 137.3(5) 
C(1A) - N(1A) - C(3A) - C(2A) -19.4(5) 
C(8A) - N(1A) - C(3A) - C(13A) -101.1(5) 
C(1A) - N(1A) - C(3A) - C(13A) 102.2(5) 
C(8A) - N(1A) - C(3A) - C(15A) 19.2(7) 
C(1A) - N(1A) - C(3A) - C(15A) -137.4(5) 
O(6A) - C(2A) - C(3A) - N(1A) 32.1(5) 
O(6A) - C(2A) - C(3A) - C(13A) -85.8(5) 
O(6A) - C(2A) - C(3A) - C(15A) 154.1(4) 
O(6A) - C(1A) - C(4A) - C(7A) 176.6(7) 
N(1A) - C(1A) - C(4A) - C(7A) -66.6(8) 
O(6A) - C(1A) - C(4A) - C(6A) 56.2(7) 
N(1A) - C(1A) - C(4A) - C(6A) 173.0(5) 
O(6A) - C(1A) - C(4A) - C(5A) -60.7(7) 
N(1A) - C(1A) - C(4A) - C(5A) 56.1(7) 
C(9A) - O(3A) - C(8A) - O(2A) 5.1(9) 
C(9A) - O(3A) - C(8A) - N(1A) -174.0(5) 
C(1A) - N(1A) - C(8A) - O(2A) -178.7(6) 
C(3A) - N(1A) - C(8A) - O(2A) 28.1(9) 
C(1A) - N(1A) - C(8A) - O(3A) 0.4(7) 
C(3A) - N(1A) - C(8A) - O(3A) -152.8(5) 
C(8A) - O(3A) - C(9A) - C(12A) 58.0(9) 
C(8A) - O(3A) - C(9A) - C(10A) -67.0(9) 
C(8A) - O(3A) - C(9A) - C(11A) 176.3(6) 
C(14A) - O(5A) - C(13A) - O(4A) 4.3(8) 
C(14A) - O(5A) - C(13A) - C(3A) -173.8(5) 
N(1A) - C(3A) - C(13A) - O(4A) 52.5(6) 
C(2A) - C(3A) - C(13A) - O(4A) 164.9(5) 
C(15A) - C(3A) - C(13A) - O(4A) -73.0(7) 
N(1A) - C(3A) - C(13A) - O(5A) -129.3(4) 
C(2A) - C(3A) - C(13A) - O(5A) -16.9(6) 
C(15A) - C(3A) - C(13A) - O(5A) 105.1(5) 
C(18A) - O(7) - C(15A) - C(16A) 88.9(6) 
C(18A) - O(7) - C(15A) - C(3A) -151.7(5) 
N(1A) - C(3A) - C(15A) - O(7) 55.8(6) 
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C(2A) - C(3A) - C(15A) - O(7) -56.9(5) 
C(13A) - C(3A) - C(15A) - O(7) 177.9(4) 
N(1A) - C(3A) - C(15A) - C(16A) 177.0(5) 
C(2A) - C(3A) - C(15A) - C(16A) 64.3(6) 
C(13A) - C(3A) - C(15A) - C(16A) -60.9(6) 
O(7) - C(15A) - C(16A) - C(17A) 7.7(8) 
C(3A) - C(15A) - C(16A) - C(17A) -108.3(7) 
C(15A) - O(7) - C(18A) - C(23A) -10.0(9) 
C(15A) - O(7) - C(18A) - C(19A) 169.5(5) 
O(7) - C(18A) - C(19A) - C(20A) -179.2(6) 
C(23A) - C(18A) - C(19A) - C(20A) 0.3(10) 
O(7) - C(18A) - C(19A) - I(1A) 1.0(7) 
C(23A) - C(18A) - C(19A) - I(1A) -179.4(5) 
C(18A) - C(19A) - C(20A) - C(21A) 1.0(11) 
I(1A) - C(19A) - C(20A) - C(21A) -179.2(7) 
C(19A) - C(20A) - C(21A) - C(22A) -2.0(14) 
C(20A) - C(21A) - C(22A) - C(23A) 1.7(15) 
O(7) - C(18A) - C(23A) - C(22A) 178.9(7) 
C(19A) - C(18A) - C(23A) - C(22A) -0.7(11) 
C(21A) - C(22A) - C(23A) - C(18A) -0.3(14) 
 
Symmetry transformations used to generate equivalent atoms:  
  
  | 281 
Chapter 8  Appendices   
8.1.2 X-Ray Data for 266d 
 
Table 1 - Crystal data and structure refinement for 266d 
Identification code k10dc1 
 Empirical formula C18 H29 N O5 
 Formula weight 339.42 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Orthorhombic 
 Space group P212121 
 Unit cell dimensions a = 11.7360(1)Å α = 90o 
       b = 9.9090(1)Å β = 90o 
       c = 16.7050(2)Å γ = 90o 
 Volume 1942.66(3) Å3 
 Z 4 
 Density (calculated) 1.161 Mg/m3 
 Absorption coefficient 0.084 mm-1 
 F(000) 736 
 Crystal size 0.28 x 0.28 x 0.2 mm 
 Theta range for data collection 3.63 to 27.44o 
 Index ranges -15<=h<=15; -12<=k<=12; -21<=l<=21 
 Reflections collected 37055 
 Independent reflections 4426 [R(int) = 0.0368] 
 Reflections observed (>2σ) 4098 
 Data Completeness 0.995 
 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 0.984 and 0.908 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 4426 / 2 / 234 
 Goodness-of-fit on F2 1.007 
 Final R indices [I>2σ(I)] R1 = 0.0293   wR2 = 0.0752 
 R indices (all data) R1 = 0.0351  wR2 = 0.0793 
 Absolute structure parameter -0.2(6) 
 Largest diff. peak and hole 0.196 and -0.189 eÅ-3 
 
Notes: 
 
Allene hydrogens located and refined at 0.98 Å from C13.   
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Table 2 - Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 103) for 266d. 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor 
Atom x y z U(eq) 
O(1) 8445(1) 8802(1) 1698(1) 32(1) 
O(2) 7094(1) 10157(1) 4017(1) 41(1) 
O(3) 7966(1) 11822(1) 3346(1) 31(1) 
O(4) 8275(1) 6057(1) 3443(1) 37(1) 
O(5) 8703(1) 7821(1) 4256(1) 36(1) 
N(1) 8148(1) 8227(1) 3004(1) 26(1) 
C(1) 7909(1) 7799(1) 2176(1) 27(1) 
C(2) 8501(1) 10031(1) 2137(1) 32(1) 
C(3) 8564(1) 9625(1) 3037(1) 25(1) 
C(4) 6636(1) 7620(1) 1969(1) 32(1) 
C(5) 6163(1) 6386(1) 2404(1) 44(1) 
C(6) 6565(1) 7372(1) 1064(1) 42(1) 
C(7) 5918(1) 8849(1) 2190(1) 42(1) 
C(8) 7779(1) 10525(1) 3536(1) 26(1) 
C(9) 7346(1) 12803(1) 3813(1) 38(1) 
C(10) 9801(1) 9729(1) 3331(1) 28(1) 
C(11) 10656(1) 8833(1) 2908(1) 38(1) 
C(12) 10090(1) 10553(1) 3903(1) 30(1) 
C(13) 10368(1) 11371(1) 4480(1) 38(1) 
C(14) 8379(1) 7257(1) 3569(1) 29(1) 
C(15) 8881(1) 6992(1) 4980(1) 36(1) 
C(16) 7766(1) 6331(2) 5212(1) 47(1) 
C(17) 9825(1) 5970(2) 4850(1) 52(1) 
C(18) 9225(2) 8056(2) 5585(1) 59(1) 
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Table 3 - Bond lengths [Å] and angles [o] for 266d 
O(1)-C(1) 1.4219(13) O(1)-C(2) 1.4223(13) 
O(2)-C(8) 1.1936(14) O(3)-C(8) 1.3420(13) 
O(3)-C(9) 1.4429(14) O(4)-C(14) 1.2137(13) 
O(5)-C(14) 1.3322(14) O(5)-C(15) 1.4762(13) 
N(1)-C(14) 1.3738(14) N(1)-C(3) 1.4692(13) 
N(1)-C(1) 1.4743(14) C(1)-C(4) 1.5431(17) 
C(1)-H(1) 1.0000 C(2)-C(3) 1.5582(15) 
C(2)-H(2A) 0.9900 C(2)-H(2B) 0.9900 
C(3)-C(8) 1.5293(15) C(3)-C(10) 1.5358(16) 
C(4)-C(7) 1.5265(17) C(4)-C(5) 1.5270(17) 
C(4)-C(6) 1.5350(16) C(5)-H(5A) 0.9800 
C(5)-H(5B) 0.9800 C(5)-H(5C) 0.9800 
C(6)-H(6A) 0.9800 C(6)-H(6B) 0.9800 
C(6)-H(6C) 0.9800 C(7)-H(7A) 0.9800 
C(7)-H(7B) 0.9800 C(7)-H(7C) 0.9800 
C(9)-H(9A) 0.9800 C(9)-H(9B) 0.9800 
C(9)-H(9C) 0.9800 C(10)-C(12) 1.3024(17) 
C(10)-C(11) 1.5144(16) C(11)-H(11A) 0.9800 
C(11)-H(11B) 0.9800 C(11)-H(11C) 0.9800 
C(12)-C(13) 1.3013(18) C(13)-H(13A) 0.979(5) 
C(13)-H(13B) 0.981(5) C(15)-C(18) 1.5155(19) 
C(15)-C(16) 1.5143(19) C(15)-C(17) 1.516(2) 
C(16)-H(16A) 0.9800 C(16)-H(16B) 0.9800 
C(16)-H(16C) 0.9800 C(17)-H(17A) 0.9800 
C(17)-H(17B) 0.9800 C(17)-H(17C) 0.9800 
C(18)-H(18A) 0.9800 C(18)-H(18B) 0.9800 
C(18)-H(18C) 0.9800   
     
C(1)-O(1)-C(2) 109.21(8) C(8)-O(3)-C(9) 115.79(9) 
C(14)-O(5)-C(15) 120.82(8) C(14)-N(1)-C(3) 124.63(9) 
C(14)-N(1)-C(1) 118.75(9) C(3)-N(1)-C(1) 111.66(8) 
O(1)-C(1)-N(1) 104.00(8) O(1)-C(1)-C(4) 112.53(9) 
N(1)-C(1)-C(4) 115.29(9) O(1)-C(1)-H(1) 108.2 
N(1)-C(1)-H(1) 108.2 C(4)-C(1)-H(1) 108.2 
O(1)-C(2)-C(3) 106.18(8) O(1)-C(2)-H(2A) 110.5 
C(3)-C(2)-H(2A) 110.5 O(1)-C(2)-H(2B) 110.5 
C(3)-C(2)-H(2B) 110.5 H(2A)-C(2)-H(2B) 108.7 
N(1)-C(3)-C(8) 111.69(9) N(1)-C(3)-C(10) 112.91(9) 
C(8)-C(3)-C(10) 110.85(9) N(1)-C(3)-C(2) 101.06(8) 
C(8)-C(3)-C(2) 110.29(9) C(10)-C(3)-C(2) 109.63(9) 
C(7)-C(4)-C(5) 108.89(11) C(7)-C(4)-C(6) 109.65(11) 
C(5)-C(4)-C(6) 108.66(11) C(7)-C(4)-C(1) 112.89(10) 
C(5)-C(4)-C(1) 109.72(10) C(6)-C(4)-C(1) 106.94(10) 
C(4)-C(5)-H(5A) 109.5 C(4)-C(5)-H(5B) 109.5 
H(5A)-C(5)-H(5B) 109.5 C(4)-C(5)-H(5C) 109.5 
H(5A)-C(5)-H(5C) 109.5 H(5B)-C(5)-H(5C) 109.5 
C(4)-C(6)-H(6A) 109.5 C(4)-C(6)-H(6B) 109.5 
H(6A)-C(6)-H(6B) 109.5 C(4)-C(6)-H(6C) 109.5 
H(6A)-C(6)-H(6C) 109.5 H(6B)-C(6)-H(6C) 109.5 
C(4)-C(7)-H(7A) 109.5 C(4)-C(7)-H(7B) 109.5 
H(7A)-C(7)-H(7B) 109.5 C(4)-C(7)-H(7C) 109.5 
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H(7A)-C(7)-H(7C) 109.5 H(7B)-C(7)-H(7C) 109.5 
O(2)-C(8)-O(3) 124.18(10) O(2)-C(8)-C(3) 126.47(10) 
O(3)-C(8)-C(3) 109.35(9) O(3)-C(9)-H(9A) 109.5 
O(3)-C(9)-H(9B) 109.5 H(9A)-C(9)-H(9B) 109.5 
O(3)-C(9)-H(9C) 109.5 H(9A)-C(9)-H(9C) 109.5 
H(9B)-C(9)-H(9C) 109.5 C(12)-C(10)-C(11) 122.48(11) 
C(12)-C(10)-C(3) 121.56(10) C(11)-C(10)-C(3) 115.95(10) 
C(10)-C(11)-H(11A) 109.5 C(10)-C(11)-H(11B) 109.5 
H(11A)-C(11)-H(11B) 109.5 C(10)-C(11)-H(11C) 109.5 
H(11A)-C(11)-H(11C) 109.5 H(11B)-C(11)-H(11C) 109.5 
C(10)-C(12)-C(13) 179.20(13) C(12)-C(13)-H(13A) 119.9(10) 
C(12)-C(13)-H(13B) 121.3(9) H(13A)-C(13)-H(13B) 118.7(14) 
O(4)-C(14)-O(5) 126.08(10) O(4)-C(14)-N(1) 123.13(10) 
O(5)-C(14)-N(1) 110.79(9) O(5)-C(15)-C(18) 101.30(9) 
O(5)-C(15)-C(16) 109.16(11) C(18)-C(15)-C(16) 111.07(12) 
O(5)-C(15)-C(17) 111.03(11) C(18)-C(15)-C(17) 111.42(13) 
C(16)-C(15)-C(17) 112.32(11) C(15)-C(16)-H(16A) 109.5 
C(15)-C(16)-H(16B) 109.5 H(16A)-C(16)-H(16B) 109.5 
C(15)-C(16)-H(16C) 109.5 H(16A)-C(16)-H(16C) 109.5 
H(16B)-C(16)-H(16C) 109.5 C(15)-C(17)-H(17A) 109.5 
C(15)-C(17)-H(17B) 109.5 H(17A)-C(17)-H(17B) 109.5 
C(15)-C(17)-H(17C) 109.5 H(17A)-C(17)-H(17C) 109.5 
H(17B)-C(17)-H(17C) 109.5 C(15)-C(18)-H(18A) 109.5 
C(15)-C(18)-H(18B) 109.5 H(18A)-C(18)-H(18B) 109.5 
C(15)-C(18)-H(18C) 109.5 H(18A)-C(18)-H(18C) 109.5 
H(18B)-C(18)-H(18C) 109.5   
  
Symmetry transformations used to generate equivalent atoms: 
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Table 4 - Anisotropic displacement parameters (Å2 x 103) for 266d. The anisotropic displacement factor 
exponent takes the form: -2 gpi2 [ h2 a*2 U11 + ... + 2 h k a* b* U 
Atom U11 U22 U33 U23 U13 U12 
O(1) 46(1) 24(1) 25(1) -2(1) 6(1) -5(1) 
O(2) 48(1) 31(1) 44(1) -2(1) 21(1) -7(1) 
O(3) 38(1) 18(1) 37(1) -1(1) 8(1) 1(1) 
O(4) 56(1) 19(1) 36(1) 2(1) -5(1) -3(1) 
O(5) 57(1) 24(1) 26(1) 5(1) -6(1) -8(1) 
N(1) 37(1) 17(1) 25(1) 0(1) 0(1) -4(1) 
C(1) 36(1) 20(1) 24(1) 0(1) 2(1) 0(1) 
C(2) 48(1) 20(1) 27(1) 1(1) 3(1) -3(1) 
C(3) 33(1) 17(1) 26(1) 1(1) 3(1) -2(1) 
C(4) 36(1) 26(1) 33(1) -3(1) -2(1) 0(1) 
C(5) 39(1) 39(1) 54(1) 6(1) -5(1) -9(1) 
C(6) 47(1) 43(1) 37(1) -7(1) -8(1) 1(1) 
C(7) 38(1) 38(1) 49(1) -7(1) -4(1) 5(1) 
C(8) 30(1) 22(1) 27(1) 0(1) 0(1) -3(1) 
C(9) 45(1) 25(1) 43(1) -6(1) 7(1) 6(1) 
C(10) 31(1) 21(1) 31(1) 2(1) 5(1) -2(1) 
C(11) 36(1) 30(1) 49(1) -4(1) 11(1) 2(1) 
C(12) 27(1) 29(1) 35(1) 2(1) 4(1) -1(1) 
C(13) 37(1) 39(1) 40(1) -8(1) 1(1) -5(1) 
C(14) 37(1) 22(1) 29(1) 2(1) 1(1) -3(1) 
C(15) 46(1) 34(1) 27(1) 9(1) -3(1) -4(1) 
C(16) 50(1) 46(1) 45(1) 12(1) 9(1) -2(1) 
C(17) 44(1) 58(1) 54(1) 9(1) -6(1) 6(1) 
C(18) 95(1) 53(1) 31(1) 3(1) -15(1) -12(1) 
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Table 5 - Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 103) for 266d 
Atom x y z U(eq) 
H(1) 8304 6920 2080 32 
H(2A) 7816 10588 2034 38 
H(2B) 9185 10554 1981 38 
H(5A) 6201 6533 2983 66 
H(5B) 6616 5590 2262 66 
H(5C) 5369 6241 2244 66 
H(6A) 7063 6616 919 63 
H(6B) 6810 8185 777 63 
H(6C) 5778 7156 917 63 
H(7A) 5119 8677 2054 63 
H(7B) 6190 9638 1893 63 
H(7C) 5983 9022 2766 63 
H(9A) 6526 12644 3755 56 
H(9B) 7531 13713 3624 56 
H(9C) 7560 12717 4378 56 
H(11A) 11425 9046 3098 57 
H(11B) 10612 8989 2329 57 
H(11C) 10483 7885 3023 57 
H(16A) 7171 7022 5255 71 
H(16B) 7855 5875 5729 71 
H(16C) 7550 5670 4803 71 
H(17A) 9562 5269 4480 78 
H(17B) 10029 5556 5364 78 
H(17C) 10494 6424 4624 78 
H(18A) 9921 8509 5402 89 
H(18B) 9366 7627 6104 89 
H(18C) 8611 8720 5639 89 
H(13A) 10377(15) 11047(16) 5034(4) 50(4) 
H(13B) 10605(13) 12303(7) 4372(9) 44(4) 
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Table 6 - Dihedral angles [o] for 266d 
Atom1  -  Atom2  -  Atom3  -  Atom4 Dihedral 
C(2) - O(1) - C(1) - N(1) -26.75(11) 
C(2) - O(1) - C(1) - C(4) 98.71(11) 
C(14) - N(1) - C(1) - O(1) -142.06(10) 
C(3) - N(1) - C(1) - O(1) 14.18(12) 
C(14) - N(1) - C(1) - C(4) 94.26(12) 
C(3) - N(1) - C(1) - C(4) -109.51(11) 
C(1) - O(1) - C(2) - C(3) 29.03(12) 
C(14) - N(1) - C(3) - C(8) -85.69(13) 
C(1) - N(1) - C(3) - C(8) 119.74(10) 
C(14) - N(1) - C(3) - C(10) 40.03(14) 
C(1) - N(1) - C(3) - C(10) -114.54(10) 
C(14) - N(1) - C(3) - C(2) 157.05(11) 
C(1) - N(1) - C(3) - C(2) 2.47(12) 
O(1) - C(2) - C(3) - N(1) -18.43(12) 
O(1) - C(2) - C(3) - C(8) -136.71(9) 
O(1) - C(2) - C(3) - C(10) 100.96(10) 
O(1) - C(1) - C(4) - C(7) -67.46(13) 
N(1) - C(1) - C(4) - C(7) 51.60(14) 
O(1) - C(1) - C(4) - C(5) 170.90(10) 
N(1) - C(1) - C(4) - C(5) -70.05(12) 
O(1) - C(1) - C(4) - C(6) 53.22(12) 
N(1) - C(1) - C(4) - C(6) 172.28(10) 
C(9) - O(3) - C(8) - O(2) 5.09(17) 
C(9) - O(3) - C(8) - C(3) -175.49(10) 
N(1) - C(3) - C(8) - O(2) 19.03(16) 
C(10) - C(3) - C(8) - O(2) -107.82(13) 
C(2) - C(3) - C(8) - O(2) 130.57(12) 
N(1) - C(3) - C(8) - O(3) -160.37(9) 
C(10) - C(3) - C(8) - O(3) 72.78(11) 
C(2) - C(3) - C(8) - O(3) -48.83(12) 
N(1) - C(3) - C(10) - C(12) -129.69(11) 
C(8) - C(3) - C(10) - C(12) -3.52(14) 
C(2) - C(3) - C(10) - C(12) 118.47(11) 
N(1) - C(3) - C(10) - C(11) 51.14(13) 
C(8) - C(3) - C(10) - C(11) 177.31(9) 
C(2) - C(3) - C(10) - C(11) -60.69(12) 
C(11) - C(10) - C(12) - C(13) -135(11) 
C(3) - C(10) - C(12) - C(13) 46(11) 
C(15) - O(5) - C(14) - O(4) -5.36(19) 
C(15) - O(5) - C(14) - N(1) 173.52(10) 
C(3) - N(1) - C(14) - O(4) -161.24(11) 
C(1) - N(1) - C(14) - O(4) -8.32(17) 
C(3) - N(1) - C(14) - O(5) 19.84(15) 
C(1) - N(1) - C(14) - O(5) 172.76(10) 
C(14) - O(5) - C(15) - C(18) -179.70(13) 
C(14) - O(5) - C(15) - C(16) -62.47(15) 
C(14) - O(5) - C(15) - C(17) 61.88(15) 
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8.1.3 X-Ray Data for 280 
 
Table 1 - Crystal data and structure refinement for 280 
Identification code k11dc2 
 Empirical formula C31 H38 N2 O11 
 Formula weight 614.63 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group P21 
 Unit cell dimensions a = 8.9630(1)Å α = 90o 
       b = 10.6200(1)Å β = 103.620(1)o 
       c = 16.8130(3)Å γ = 90o 
 Volume 1555.38(4) Å3 
 Z 2 
 Density (calculated) 1.312 Mg/m3 
 Absorption coefficient 0.100 mm-1 
 F(000) 652 
 Crystal size 0.50 x 0.35 x 0.30 mm 
 Theta range for data collection 3.80 to 27.47o 
 Index ranges -11<=h<=11; -13<=k<=13; -21<=l<=21 
 Reflections collected 30623 
 Independent reflections 6989 [R(int) = 0.0300] 
 Reflections observed (>2sigma) 6183 
 Data Completeness 0.994 
 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 0.981 and 0.949 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 6989 / 16 / 436 
 Goodness-of-fit on F2 1.027 
 Final R indices [I>2σ(I)] R1 = 0.0325   wR2 = 0.0761 
 R indices (all data) R1 = 0.0404  wR2 = 0.0808 
 Absolute structure parameter 0.0(5) 
 Largest diff. peak and hole 0.143 and -0.159 eÅ-3 
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Table 2 - Atomic coordinates ( x 104) and equivalent isotropic  displacement parameters (Å2 x 103) for 280. 
U(eq) is defined  as one third of the trace of the orthogonalized Uij tensor 
Atom x y z U(eq) 
O(1) 221(1) 816(1) 874(1) 35(1) 
O(2) 5153(1) 814(1) 623(1) 31(1) 
O(3) 4537(1) -921(1) 1220(1) 32(1) 
O(4) 2293(1) 3138(1) 580(1) 39(1) 
O(5) 6594(1) 3044(1) 1361(1) 39(1) 
O(6) 7549(1) 4949(1) 1167(1) 43(1) 
O(7) 5403(2) 6985(1) 3413(1) 51(1) 
O(8) 10033(2) 3088(2) 5424(1) 65(1) 
O(9) 11152(2) 4857(1) 5294(1) 66(1) 
O(10) 4777(1) 1171(1) 2637(1) 33(1) 
O(11) 2717(1) 1042(1) 3204(1) 34(1) 
N(1) 2424(1) 683(1) 1863(1) 27(1) 
N(2) 10284(2) 3988(2) 5018(1) 49(1) 
C(1) 2892(2) 943(1) 1105(1) 26(1) 
C(2) 1420(2) 596(1) 464(1) 31(1) 
C(3) 750(2) 451(2) 1709(1) 32(1) 
C(4) 4259(2) 147(1) 1015(1) 26(1) 
C(5) 4519(2) 2067(1) 420(1) 33(1) 
C(6) 3437(2) 2288(1) 982(1) 28(1) 
C(7) 5802(2) 3000(2) 506(1) 40(1) 
C(8) 7402(2) 4090(2) 1611(1) 33(1) 
C(9) 8107(2) 4050(2) 2510(1) 32(1) 
C(10) 7903(2) 3017(2) 2986(1) 43(1) 
C(11) 8617(2) 3002(2) 3815(1) 47(1) 
C(12) 9495(2) 4027(2) 4141(1) 39(1) 
C(13) 9688(2) 5064(2) 3688(1) 42(1) 
C(14) 8988(2) 5064(2) 2861(1) 39(1) 
C(15) 230(2) -903(2) 1858(1) 37(1) 
C(16) -1532(2) -878(2) 1630(1) 57(1) 
C(17) 776(2) -1899(2) 1336(1) 41(1) 
C(18) 798(2) -1262(2) 2759(1) 54(1) 
C(19) 1538(2) 3798(2) 1119(1) 43(1) 
C(20) 2608(2) 4635(1) 1717(1) 34(1) 
C(21) 3581(2) 5481(2) 1461(1) 41(1) 
C(22) 4549(2) 6271(1) 2004(1) 36(1) 
C(23) 4527(2) 6233(1) 2826(1) 36(1) 
C(24) 3567(2) 5398(2) 3090(1) 49(1) 
C(25) 2634(2) 4594(2) 2542(1) 43(1) 
C(26) 6425(2) 7840(2) 3156(1) 48(1) 
C(27) 3425(2) 982(1) 2591(1) 26(1) 
C(28) 3621(2) 1147(2) 4066(1) 36(1) 
C(29) 2480(4) 781(3) 4580(2) 43(1) 
C(30) 4925(5) 173(4) 4247(4) 39(1) 
C(31) 4214(6) 2450(4) 4251(3) 42(1) 
C(29A) 2325(9) 1586(12) 4447(4) 91(3) 
C(30A) 4347(14) -33(9) 4297(7) 80(4) 
C(31A) 4754(14) 2275(11) 4134(7) 73(3) 
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Table 3 - Bond lengths [Å] and angles [o] for 280 
O(1)-C(3) 1.4256(17) O(1)-C(2) 1.4261(18) 
O(2)-C(4) 1.3518(16) O(2)-C(5) 1.4563(18) 
O(3)-C(4) 1.1950(17) O(4)-C(6) 1.4127(17) 
O(4)-C(19) 1.436(2) O(5)-C(8) 1.3383(18) 
O(5)-C(7) 1.4459(17) O(6)-C(8) 1.2052(18) 
O(7)-C(23) 1.3644(19) O(7)-C(26) 1.427(2) 
O(8)-N(2) 1.225(2) O(9)-N(2) 1.225(2) 
O(10)-C(27) 1.2131(16) O(11)-C(27) 1.3338(16) 
O(11)-C(28) 1.4881(16) N(1)-C(27) 1.3731(16) 
N(1)-C(1) 1.4582(17) N(1)-C(3) 1.4820(18) 
N(2)-C(12) 1.478(2) C(1)-C(4) 1.5246(19) 
C(1)-C(6) 1.5395(19) C(1)-C(2) 1.5394(17) 
C(2)-H(2A) 0.9900 C(2)-H(2B) 0.9900 
C(3)-C(15) 1.550(2) C(3)-H(3) 1.0000 
C(5)-C(7) 1.499(2) C(5)-C(6) 1.522(2) 
C(5)-H(5) 1.0000 C(6)-H(6) 1.0000 
C(7)-H(7A) 0.9900 C(7)-H(7B) 0.9900 
C(8)-C(9) 1.495(2) C(9)-C(14) 1.383(2) 
C(9)-C(10) 1.395(2) C(10)-C(11) 1.390(2) 
C(10)-H(10) 0.9500 C(11)-C(12) 1.380(2) 
C(11)-H(11) 0.9500 C(12)-C(13) 1.372(2) 
C(13)-C(14) 1.386(2) C(13)-H(13) 0.9500 
C(14)-H(14) 0.9500 C(15)-C(17) 1.526(2) 
C(15)-C(18) 1.529(2) C(15)-C(16) 1.535(2) 
C(16)-H(16A) 0.9800 C(16)-H(16B) 0.9800 
C(16)-H(16C) 0.9800 C(17)-H(17A) 0.9800 
C(17)-H(17B) 0.9800 C(17)-H(17C) 0.9800 
C(18)-H(18A) 0.9800 C(18)-H(18B) 0.9800 
C(18)-H(18C) 0.9800 C(19)-C(20) 1.505(2) 
C(19)-H(19A) 0.9900 C(19)-H(19B) 0.9900 
C(20)-C(25) 1.383(2) C(20)-C(21) 1.389(2) 
C(21)-C(22) 1.384(2) C(21)-H(21) 0.9500 
C(22)-C(23) 1.387(2) C(22)-H(22) 0.9500 
C(23)-C(24) 1.380(2) C(24)-C(25) 1.384(3) 
C(24)-H(24) 0.9500 C(25)-H(25) 0.9500 
C(26)-H(26A) 0.9800 C(26)-H(26B) 0.9800 
C(26)-H(26C) 0.9800 C(28)-C(30A) 1.424(10) 
C(28)-C(31) 1.489(5) C(28)-C(29A) 1.526(7) 
C(28)-C(29) 1.536(3) C(28)-C(30) 1.537(5) 
C(28)-C(31A) 1.557(10) C(29)-H(29A) 0.9800 
C(29)-H(29B) 0.9800 C(29)-H(29C) 0.9800 
C(30)-H(30A) 0.9800 C(30)-H(30B) 0.9800 
C(30)-H(30C) 0.9800 C(31)-H(31A) 0.9800 
C(31)-H(31B) 0.9800 C(31)-H(31C) 0.9800 
C(29A)-H(29D) 0.9800 C(29A)-H(29E) 0.9800 
C(29A)-H(29F) 0.9800 C(30A)-H(30D) 0.9800 
C(30A)-H(30E) 0.9800 C(30A)-H(30F) 0.9800 
C(31A)-H(31D) 0.9800 C(31A)-H(31E) 0.9800 
C(31A)-H(31F) 0.9800   
    
C(3)-O(1)-C(2) 108.52(10) C(4)-O(2)-C(5) 110.43(11) 
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C(6)-O(4)-C(19) 114.02(11) C(8)-O(5)-C(7) 116.19(11) 
C(23)-O(7)-C(26) 117.04(13) C(27)-O(11)-C(28) 120.48(10) 
C(27)-N(1)-C(1) 118.20(11) C(27)-N(1)-C(3) 128.03(11) 
C(1)-N(1)-C(3) 111.52(10) O(9)-N(2)-O(8) 124.03(16) 
O(9)-N(2)-C(12) 117.96(16) O(8)-N(2)-C(12) 118.01(15) 
N(1)-C(1)-C(4) 112.61(10) N(1)-C(1)-C(6) 117.34(11) 
C(4)-C(1)-C(6) 102.32(11) N(1)-C(1)-C(2) 101.00(10) 
C(4)-C(1)-C(2) 111.96(11) C(6)-C(1)-C(2) 112.01(11) 
O(1)-C(2)-C(1) 103.97(10) O(1)-C(2)-H(2A) 111.0 
C(1)-C(2)-H(2A) 111.0 O(1)-C(2)-H(2B) 111.0 
C(1)-C(2)-H(2B) 111.0 H(2A)-C(2)-H(2B) 109.0 
O(1)-C(3)-N(1) 102.41(11) O(1)-C(3)-C(15) 111.62(11) 
N(1)-C(3)-C(15) 117.18(12) O(1)-C(3)-H(3) 108.4 
N(1)-C(3)-H(3) 108.4 C(15)-C(3)-H(3) 108.4 
O(3)-C(4)-O(2) 122.01(13) O(3)-C(4)-C(1) 128.03(12) 
O(2)-C(4)-C(1) 109.92(11) O(2)-C(5)-C(7) 109.47(12) 
O(2)-C(5)-C(6) 105.44(10) C(7)-C(5)-C(6) 115.14(12) 
O(2)-C(5)-H(5) 108.9 C(7)-C(5)-H(5) 108.9 
C(6)-C(5)-H(5) 108.9 O(4)-C(6)-C(5) 107.37(11) 
O(4)-C(6)-C(1) 116.08(11) C(5)-C(6)-C(1) 102.07(11) 
O(4)-C(6)-H(6) 110.3 C(5)-C(6)-H(6) 110.3 
C(1)-C(6)-H(6) 110.3 O(5)-C(7)-C(5) 107.62(11) 
O(5)-C(7)-H(7A) 110.2 C(5)-C(7)-H(7A) 110.2 
O(5)-C(7)-H(7B) 110.2 C(5)-C(7)-H(7B) 110.2 
H(7A)-C(7)-H(7B) 108.5 O(6)-C(8)-O(5) 124.31(13) 
O(6)-C(8)-C(9) 124.43(14) O(5)-C(8)-C(9) 111.26(12) 
C(14)-C(9)-C(10) 120.43(13) C(14)-C(9)-C(8) 118.16(13) 
C(10)-C(9)-C(8) 121.40(13) C(11)-C(10)-C(9) 119.52(15) 
C(11)-C(10)-H(10) 120.2 C(9)-C(10)-H(10) 120.2 
C(12)-C(11)-C(10) 118.34(16) C(12)-C(11)-H(11) 120.8 
C(10)-C(11)-H(11) 120.8 C(13)-C(12)-C(11) 123.16(14) 
C(13)-C(12)-N(2) 118.87(15) C(11)-C(12)-N(2) 117.96(15) 
C(12)-C(13)-C(14) 118.11(14) C(12)-C(13)-H(13) 120.9 
C(14)-C(13)-H(13) 120.9 C(9)-C(14)-C(13) 120.41(15) 
C(9)-C(14)-H(14) 119.8 C(13)-C(14)-H(14) 119.8 
C(17)-C(15)-C(18) 108.68(15) C(17)-C(15)-C(16) 108.59(14) 
C(18)-C(15)-C(16) 109.54(14) C(17)-C(15)-C(3) 113.60(12) 
C(18)-C(15)-C(3) 110.40(12) C(16)-C(15)-C(3) 105.94(14) 
C(15)-C(16)-H(16A) 109.5 C(15)-C(16)-H(16B) 109.5 
H(16A)-C(16)-H(16B) 109.5 C(15)-C(16)-H(16C) 109.5 
H(16A)-C(16)-H(16C) 109.5 H(16B)-C(16)-H(16C) 109.5 
C(15)-C(17)-H(17A) 109.5 C(15)-C(17)-H(17B) 109.5 
H(17A)-C(17)-H(17B) 109.5 C(15)-C(17)-H(17C) 109.5 
H(17A)-C(17)-H(17C) 109.5 H(17B)-C(17)-H(17C) 109.5 
C(15)-C(18)-H(18A) 109.5 C(15)-C(18)-H(18B) 109.5 
H(18A)-C(18)-H(18B) 109.5 C(15)-C(18)-H(18C) 109.5 
H(18A)-C(18)-H(18C) 109.5 H(18B)-C(18)-H(18C) 109.5 
O(4)-C(19)-C(20) 112.92(13) O(4)-C(19)-H(19A) 109.0 
C(20)-C(19)-H(19A) 109.0 O(4)-C(19)-H(19B) 109.0 
C(20)-C(19)-H(19B) 109.0 H(19A)-C(19)-H(19B) 107.8 
C(25)-C(20)-C(21) 117.87(14) C(25)-C(20)-C(19) 120.60(15) 
C(21)-C(20)-C(19) 121.53(14) C(22)-C(21)-C(20) 121.95(14) 
C(22)-C(21)-H(21) 119.0 C(20)-C(21)-H(21) 119.0 
C(21)-C(22)-C(23) 119.08(15) C(21)-C(22)-H(22) 120.5 
C(23)-C(22)-H(22) 120.5 O(7)-C(23)-C(24) 116.05(13) 
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O(7)-C(23)-C(22) 124.25(14) C(24)-C(23)-C(22) 119.70(14) 
C(23)-C(24)-C(25) 120.43(15) C(23)-C(24)-H(24) 119.8 
C(25)-C(24)-H(24) 119.8 C(20)-C(25)-C(24) 120.93(16) 
C(20)-C(25)-H(25) 119.5 C(24)-C(25)-H(25) 119.5 
O(7)-C(26)-H(26A) 109.5 O(7)-C(26)-H(26B) 109.5 
H(26A)-C(26)-H(26B) 109.5 O(7)-C(26)-H(26C) 109.5 
H(26A)-C(26)-H(26C) 109.5 H(26B)-C(26)-H(26C) 109.5 
O(10)-C(27)-O(11) 126.35(11) O(10)-C(27)-N(1) 121.91(12) 
O(11)-C(27)-N(1) 111.74(11) C(30A)-C(28)-O(11) 108.0(5) 
C(30A)-C(28)-C(31) 130.1(5) O(11)-C(28)-C(31) 111.0(2) 
C(30A)-C(28)-C(29A) 119.9(7) O(11)-C(28)-C(29A) 98.0(3) 
C(31)-C(28)-C(29A) 84.1(5) C(30A)-C(28)-C(29) 86.9(5) 
O(11)-C(28)-C(29) 104.32(16) C(31)-C(28)-C(29) 111.7(2) 
C(29A)-C(28)-C(29) 33.6(4) C(30A)-C(28)-C(30) 22.4(5) 
O(11)-C(28)-C(30) 110.9(2) C(31)-C(28)-C(30) 111.5(3) 
C(29A)-C(28)-C(30) 137.8(5) C(29)-C(28)-C(30) 107.1(2) 
C(30A)-C(28)-C(31A) 114.1(7) O(11)-C(28)-C(31A) 109.0(5) 
C(31)-C(28)-C(31A) 22.3(4) C(29A)-C(28)-C(31A) 106.4(6) 
C(29)-C(28)-C(31A) 131.4(4) C(30)-C(28)-C(31A) 92.9(5) 
C(28)-C(29)-H(29A) 109.5 C(28)-C(29)-H(29B) 109.5 
C(28)-C(29)-H(29C) 109.5 C(28)-C(30)-H(30A) 109.5 
C(28)-C(30)-H(30B) 109.5 C(28)-C(30)-H(30C) 109.5 
C(28)-C(31)-H(31A) 109.5 C(28)-C(31)-H(31B) 109.5 
C(28)-C(31)-H(31C) 109.5 C(28)-C(29A)-H(29D) 109.5 
C(28)-C(29A)-H(29E) 109.5 H(29D)-C(29A)-H(29E) 109.5 
C(28)-C(29A)-H(29F) 109.5 H(29D)-C(29A)-H(29F) 109.5 
H(29E)-C(29A)-H(29F) 109.5 C(28)-C(30A)-H(30D) 109.5 
C(28)-C(30A)-H(30E) 109.5 H(30D)-C(30A)-H(30E) 109.5 
C(28)-C(30A)-H(30F) 109.5 H(30D)-C(30A)-H(30F) 109.5 
H(30E)-C(30A)-H(30F) 109.5 C(28)-C(31A)-H(31D) 109.5 
C(28)-C(31A)-H(31E) 109.5 H(31D)-C(31A)-H(31E) 109.5 
C(28)-C(31A)-H(31F) 109.5 H(31D)-C(31A)-H(31F) 109.5 
H(31E)-C(31A)-H(31F) 109.5   
  
Symmetry transformations used to generate equivalent atoms: 
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Table 4 - Anisotropic displacement parameters (Å2 x 103) for 280. The anisotropic displacement factor 
exponent takes the form: -2 gpi2 [ h2 a*2 U11 + ... + 2 h k a* b* U 
  Atom  U11  U22  U33  U23  U13  U12 
O(1) 28(1) 43(1) 29(1) -2(1) -3(1) 2(1) 
O(2) 38(1) 31(1) 26(1) 0(1) 10(1) -3(1) 
O(3) 37(1) 27(1) 31(1) 1(1) 6(1) 3(1) 
O(4) 50(1) 30(1) 29(1) 2(1) -9(1) 7(1) 
O(5) 50(1) 37(1) 27(1) 6(1) 2(1) -15(1) 
O(6) 54(1) 37(1) 39(1) 5(1) 12(1) -13(1) 
O(7) 69(1) 46(1) 32(1) -5(1) 2(1) -13(1) 
O(8) 83(1) 70(1) 35(1) 4(1) 2(1) -3(1) 
O(9) 63(1) 64(1) 55(1) -13(1) -16(1) -5(1) 
O(10) 29(1) 44(1) 23(1) 2(1) 1(1) -7(1) 
O(11) 32(1) 48(1) 21(1) -10(1) 3(1) 0(1) 
N(1) 26(1) 32(1) 21(1) -2(1) 2(1) -1(1) 
N(2) 50(1) 53(1) 37(1) -8(1) -1(1) 3(1) 
C(1) 30(1) 27(1) 20(1) -1(1) 0(1) 0(1) 
C(2) 32(1) 34(1) 24(1) -2(1) -1(1) -2(1) 
C(3) 25(1) 41(1) 27(1) -5(1) 1(1) 1(1) 
C(4) 31(1) 29(1) 17(1) -3(1) 2(1) -3(1) 
C(5) 45(1) 30(1) 20(1) 3(1) 2(1) -4(1) 
C(6) 36(1) 25(1) 20(1) 1(1) -4(1) -1(1) 
C(7) 53(1) 40(1) 24(1) 5(1) 5(1) -13(1) 
C(8) 34(1) 31(1) 34(1) 0(1) 9(1) -6(1) 
C(9) 31(1) 34(1) 33(1) 0(1) 7(1) -3(1) 
C(10) 47(1) 42(1) 35(1) 4(1) 0(1) -14(1) 
C(11) 54(1) 49(1) 35(1) 6(1) 3(1) -11(1) 
C(12) 37(1) 47(1) 31(1) -5(1) 1(1) -1(1) 
C(13) 40(1) 37(1) 46(1) -9(1) 4(1) -6(1) 
C(14) 41(1) 33(1) 42(1) -2(1) 8(1) -5(1) 
C(15) 32(1) 47(1) 31(1) -3(1) 3(1) -10(1) 
C(16) 34(1) 76(1) 61(1) -10(1) 12(1) -14(1) 
C(17) 45(1) 37(1) 40(1) -1(1) 6(1) -11(1) 
C(18) 70(1) 57(1) 33(1) 2(1) 5(1) -26(1) 
C(19) 39(1) 33(1) 49(1) -3(1) -6(1) 9(1) 
C(20) 35(1) 26(1) 37(1) 1(1) 0(1) 9(1) 
C(21) 62(1) 31(1) 27(1) 2(1) 7(1) 2(1) 
C(22) 50(1) 26(1) 34(1) 1(1) 13(1) -1(1) 
C(23) 46(1) 30(1) 30(1) -2(1) 5(1) 2(1) 
C(24) 70(1) 48(1) 32(1) -3(1) 19(1) -9(1) 
C(25) 47(1) 39(1) 45(1) -1(1) 17(1) -2(1) 
C(26) 47(1) 38(1) 53(1) -6(1) 2(1) -3(1) 
C(27) 30(1) 24(1) 21(1) 0(1) 2(1) 1(1) 
C(28) 41(1) 47(1) 18(1) -8(1) 2(1) -2(1) 
C(29) 50(2) 56(2) 25(1) -4(1) 13(1) -5(1) 
C(30) 52(2) 37(2) 24(2) 6(1) 2(1) 3(1) 
C(31) 65(2) 32(2) 25(2) -8(1) 5(2) -4(2) 
C(29A) 61(4) 186(11) 27(3) -22(5) 9(3) 20(6) 
C(30A) 157(12) 44(4) 25(3) 10(3) -7(7) -5(6) 
C(31A) 111(9) 78(6) 24(3) -27(3) 4(5) -20(7) 
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Table 5 - Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 103) for 280 
Atom x y z U(eq) 
H(2A) 1293 1134 -28 37 
H(2B) 1439 -298 299 37 
H(3) 309 1044 2055 38 
H(5) 3909 2068 -160 39 
H(6) 4011 2649 1516 34 
H(7A) 6518 2739 169 48 
H(7B) 5389 3842 320 48 
H(10) 7280 2329 2745 51 
H(11) 8504 2303 4148 57 
H(13) 10285 5761 3935 50 
H(14) 9113 5766 2532 46 
H(16A) -1927 -1720 1703 85 
H(16B) -1895 -618 1058 85 
H(16C) -1900 -280 1984 85 
H(17A) 1891 -1835 1411 62 
H(17B) 275 -1762 758 62 
H(17C) 512 -2738 1503 62 
H(18A) 346 -2069 2859 81 
H(18B) 492 -610 3102 81 
H(18C) 1919 -1335 2894 81 
H(19A) 1070 3178 1427 52 
H(19B) 700 4318 788 52 
H(21) 3583 5519 897 49 
H(22) 5218 6831 1816 43 
H(24) 3548 5374 3653 59 
H(25) 2002 4006 2735 51 
H(26A) 7150 7367 2917 71 
H(26B) 6991 8321 3629 71 
H(26C) 5835 8419 2747 71 
H(29A) 1543 1283 4407 64 
H(29B) 2944 942 5160 64 
H(29C) 2228 -115 4502 64 
H(30A) 4526 -652 4036 58 
H(30B) 5343 116 4839 58 
H(30C) 5739 432 3981 58 
H(31A) 4852 2683 3874 62 
H(31B) 4830 2489 4815 62 
H(31C) 3349 3037 4185 62 
H(29D) 1910 2384 4197 137 
H(29E) 2724 1706 5037 137 
H(29F) 1510 950 4353 137 
H(30D) 3598 -713 4135 120 
H(30E) 4752 -53 4892 120 
H(30F) 5191 -146 4024 120 
H(31D) 5584 2053 3870 110 
H(31E) 5188 2467 4712 110 
H(31F) 4204 3013 3863 110 
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Table 6 - Dihedral angles [o] for 280 
Atom1 - Atom2 - Atom3 - Atom4 Dihedral 
C(27) - N(1) - C(1) - C(4) 65.55(15) 
C(3) - N(1) - C(1) - C(4) -130.12(12) 
C(27) - N(1) - C(1) - C(6) -52.85(16) 
C(3) - N(1) - C(1) - C(6) 111.48(13) 
C(27) - N(1) - C(1) - C(2) -174.87(11) 
C(3) - N(1) - C(1) - C(2) -10.55(14) 
C(3) - O(1) - C(2) - C(1) -37.24(14) 
N(1) - C(1) - C(2) - O(1) 27.92(13) 
C(4) - C(1) - C(2) - O(1) 147.96(11) 
C(6) - C(1) - C(2) - O(1) -97.76(13) 
C(2) - O(1) - C(3) - N(1) 29.77(14) 
C(2) - O(1) - C(3) - C(15) -96.41(13) 
C(27) - N(1) - C(3) - O(1) 151.82(13) 
C(1) - N(1) - C(3) - O(1) -10.58(14) 
C(27) - N(1) - C(3) - C(15) -85.69(17) 
C(1) - N(1) - C(3) - C(15) 111.91(13) 
C(5) - O(2) - C(4) - O(3) 177.91(12) 
C(5) - O(2) - C(4) - C(1) 0.19(13) 
N(1) - C(1) - C(4) - O(3) 36.41(18) 
C(6) - C(1) - C(4) - O(3) 163.30(13) 
C(2) - C(1) - C(4) - O(3) -76.59(17) 
N(1) - C(1) - C(4) - O(2) -146.04(10) 
C(6) - C(1) - C(4) - O(2) -19.15(13) 
C(2) - C(1) - C(4) - O(2) 100.96(12) 
C(4) - O(2) - C(5) - C(7) 143.76(11) 
C(4) - O(2) - C(5) - C(6) 19.35(13) 
C(19) - O(4) - C(6) - C(5) -158.16(12) 
C(19) - O(4) - C(6) - C(1) 88.44(15) 
O(2) - C(5) - C(6) - O(4) -152.48(10) 
C(7) - C(5) - C(6) - O(4) 86.74(14) 
O(2) - C(5) - C(6) - C(1) -29.93(12) 
C(7) - C(5) - C(6) - C(1) -150.71(12) 
N(1) - C(1) - C(6) - O(4) -90.80(14) 
C(4) - C(1) - C(6) - O(4) 145.42(11) 
C(2) - C(1) - C(6) - O(4) 25.35(16) 
N(1) - C(1) - C(6) - C(5) 152.80(11) 
C(4) - C(1) - C(6) - C(5) 29.02(12) 
C(2) - C(1) - C(6) - C(5) -91.05(13) 
C(8) - O(5) - C(7) - C(5) -157.68(13) 
O(2) - C(5) - C(7) - O(5) -65.14(15) 
C(6) - C(5) - C(7) - O(5) 53.41(17) 
C(7) - O(5) - C(8) - O(6) -3.1(2) 
C(7) - O(5) - C(8) - C(9) 177.43(13) 
O(6) - C(8) - C(9) - C(14) 0.2(2) 
O(5) - C(8) - C(9) - C(14) 179.67(14) 
O(6) - C(8) - C(9) - C(10) -179.26(16) 
O(5) - C(8) - C(9) - C(10) 0.3(2) 
C(14) - C(9) - C(10) - C(11) -1.3(3) 
C(8) - C(9) - C(10) - C(11) 178.08(16) 
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C(9) - C(10) - C(11) - C(12) 0.8(3) 
C(10) - C(11) - C(12) - C(13) 0.4(3) 
C(10) - C(11) - C(12) - N(2) -178.39(17) 
O(9) - N(2) - C(12) - C(13) -4.1(2) 
O(8) - N(2) - C(12) - C(13) 176.08(16) 
O(9) - N(2) - C(12) - C(11) 174.81(17) 
O(8) - N(2) - C(12) - C(11) -5.0(2) 
C(11) - C(12) - C(13) - C(14) -1.2(3) 
N(2) - C(12) - C(13) - C(14) 177.58(15) 
C(10) - C(9) - C(14) - C(13) 0.5(2) 
C(8) - C(9) - C(14) - C(13) -178.91(15) 
C(12) - C(13) - C(14) - C(9) 0.7(2) 
O(1) - C(3) - C(15) - C(17) 58.28(16) 
N(1) - C(3) - C(15) - C(17) -59.33(16) 
O(1) - C(3) - C(15) - C(18) -179.34(14) 
N(1) - C(3) - C(15) - C(18) 63.05(18) 
O(1) - C(3) - C(15) - C(16) -60.83(16) 
N(1) - C(3) - C(15) - C(16) -178.44(13) 
C(6) - O(4) - C(19) - C(20) 63.37(17) 
O(4) - C(19) - C(20) - C(25) -131.07(15) 
O(4) - C(19) - C(20) - C(21) 49.79(19) 
C(25) - C(20) - C(21) - C(22) -0.4(2) 
C(19) - C(20) - C(21) - C(22) 178.80(14) 
C(20) - C(21) - C(22) - C(23) -1.2(2) 
C(26) - O(7) - C(23) - C(24) 178.90(15) 
C(26) - O(7) - C(23) - C(22) -1.4(2) 
C(21) - C(22) - C(23) - O(7) -178.52(15) 
C(21) - C(22) - C(23) - C(24) 1.2(2) 
O(7) - C(23) - C(24) - C(25) -179.95(16) 
C(22) - C(23) - C(24) - C(25) 0.3(3) 
C(21) - C(20) - C(25) - C(24) 1.9(2) 
C(19) - C(20) - C(25) - C(24) -177.27(16) 
C(23) - C(24) - C(25) - C(20) -1.9(3) 
C(28) - O(11) - C(27) - O(10) -10.6(2) 
C(28) - O(11) - C(27) - N(1) 170.06(12) 
C(1) - N(1) - C(27) - O(10) -17.35(19) 
C(3) - N(1) - C(27) - O(10) -178.74(13) 
C(1) - N(1) - C(27) - O(11) 161.99(11) 
C(3) - N(1) - C(27) - O(11) 0.60(19) 
C(27) - O(11) - C(28) - C(30A) -71.7(5) 
C(27) - O(11) - C(28) - C(31) 76.6(2) 
C(27) - O(11) - C(28) - C(29A) 163.3(5) 
C(27) - O(11) - C(28) - C(29) -163.03(17) 
C(27) - O(11) - C(28) - C(30) -48.0(2) 
C(27) - O(11) - C(28) - C(31A) 52.9(5) 
  
  | 297 
Chapter 8  Appendices   
8.2 2D-NOE Spectra 
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